Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease  by Michel, Martin C. et al.
Pharmacology & Therapeutics 164 (2016) 1–81
Contents lists available at ScienceDirect
Pharmacology & Therapeutics
j ourna l homepage: www.e lsev ie r .com/ locate /pharmtheraAssociate editor: P. MolenaarAngiotensin II type 1 receptor antagonists in animal models of vascular,
cardiac, metabolic and renal diseaseMartin C. Michel a,b,⁎, Hans R. Brunner c, Carolyn Foster d, Yong Huo e
a Dept. Pharmacology, Johannes Gutenberg University, Mainz, Germany
b Dept. Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim, Ingelheim, Germany
c Emeritus of Lausanne University, Riehen, Switzerland
d Retiree from Dept. of Research Networking, Boehringer Ingelheim Pharmaceuticals Inc., Ridgeﬁeld, CT, USA
e Dept. Cardiology & Heart Center, Peking University First Hospital, Beijing, PR Chinaangiotensin II type 1 receptor; AT2R, angiotensin II type
regulated kinase; GFR, glomerular ﬁltration rate; HUVEC
NAME, L-nitro-arginine methyl ester; MCP, monocyte ch
product; RAS, renin–angiotensin system; RBF, renal bloo
factor; TNF, tumor necrosis factor; VCAM, vascular cell ad
⁎ Corresponding author at: Dept. of Pharmacology, Joha
E-mail address:marmiche@uni-mainz.de (M.C. Miche
http://dx.doi.org/10.1016/j.pharmthera.2016.03.019
0163-7258/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 27 April 2016 We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hy-
pertension, atherosclerosis, cardiac function, hypertrophy and ﬁbrosis, glucose and lipid metabolism, and renal
function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas
those of other ARBs have been included systematically but without intention of completeness. ARBs as a class
lower blood pressure in established hypertension and prevent hypertension development in all applicable animal
models except those with a markedly suppressed renin–angiotensin system; blood pressure lowering even per-
sists for a considerable timeafter discontinuation of treatment. This translates into a reducedmortality, particularly
in models exhibiting marked hypertension. The retrieved data on vascular, cardiac and renal function and mor-
phology as well as on glucose and lipid metabolism are discussed to address three main questions: 1. Can ARB ef-
fects on blood vessels, heart, kidney and metabolic function be explained by blood pressure lowering alone or are
they additionally directly related to blockade of the renin–angiotensin system? 2. Are they shared by other inhib-
itors of the renin–angiotensin system, e.g. angiotensin converting enzyme inhibitors? 3. Are some effects speciﬁc
for one or more compounds within the ARB class? Taken together these data proﬁle ARBs as a drug class with
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Angiotensin II (ANG) has an important function in the regulation of
the cardiovascular system. This largely occurs via its role as a circulating
hormone in the renin–angiotensin system (RAS), but itmay also involve
locally formed ANGas part of a tissue RAS (Tamura et al., 1997b; Fukuda
et al., 1999; Bader, 2010; Siragy & Carey, 2010) or, in the central nervous
system, as a neurotransmitter (Culman et al., 2002). Angiotensin II type
1 receptors (AT1Rs) mediate many of the physiological and pathophys-
iological effects of ANG. Thus, AT1R antagonists, also known as angio-
tensin receptor blockers (ARBs), have become an important drug class
in the treatment of arterial hypertension and congestive heart failure
(CHF) and for nephroprotection. Following the discovery of the ﬁrst
non-peptidic ARB, losartan (also known as DUP-753 or MK-954, or
EXP 3174 for the active metabolite) (Chiu et al., 1990b; Wong et al.,
1990b), several other representatives of this drug class have become
clinically available. These include azilsartan (also known as TAK-491
or as TAK-536 for its prodrug), candesartan (also known as TCV-116
for the prodrug or CV-11974 for the active metabolite), eprosartan
(also known as SK&F 108566), irbesartan (also known as SR 47436 or
BMS 186295), olmesartan (also known as CS-866 for the prodrug and
RNH-6270 for the active metabolite), telmisartan (also known as BIBR
277) and valsartan (also known as CGP 48,933).
As reviewed previously, the various ARBs have different chemical
structures and accordingly use different binding pockets in the receptor,
which are associatedwith differences in dissociation times and, in most
cases, apparently insurmountable antagonism (Michel et al., 2013). The
physicochemical differences between ARBs also manifest in different
tissue penetration, including passage through the blood–brain-barrier.
The combination of these factors is associated with differences in phar-
macokinetic proﬁle, particularly duration of action. While generally
being highly speciﬁc for AT1R, some ARBs, particularly telmisartan, are
partial agonists at peroxisome proliferator-activated receptor (PARP)-
γ. More recently, it was discovered that ARBs, similar to ligands for
many other receptors (Kenakin & Christopoulos, 2013), exhibit a prop-
erty called ‘biased agonism’ or ‘ligand-directed signaling’ (Tilley, 2011;
Wilson et al., 2013). This means that some AT1R antagonists can inhibit
canonical signaling via the Gq/phospholipase C pathway but may be ag-
onists for other signaling pathways such asβ-arrestin pathways. Emerg-
ing examples of a potential clinical relevance of this phenomenon are
discussed in Section 4.3.3.
While ARBs are mostly known for their effects in the cardiovascular
system, they can also affect the function of other organ systems. Such
additional effects may occur as a result of vasodilation, often assessed
as blood pressure (BP) lowering or, at least in part, independently of
it. All clinically used ARBs have high selectivity for AT1R over angioten-
sin II type 2 receptors (AT2R) as shown for azilsartan (Ojima et al.,
2011), candesartan (Shibouta et al., 1993), eprosartan (Keiser et al.,
1995), irbesartan (Cazaubon et al., 1993), losartan (Chiu et al., 1990a),
olmesartan (Mizuno et al., 1995), telmisartan (Wienen et al., 1993) or
valsartan (Criscione et al., 1993). Most ARBs have also high selectivity
for AT1R as compared to molecular targets outside the RAS. Notable
exceptions include interaction with some types of potassium channels
reported for candesartan, eprosartan, losartan and telmisartan, but all
of these occur at much higher concentrations than those needed for
AT1R occupancy and in none of these cases clinical correlates have
been reported (Michel et al., 2013). Some ARBs, i.e. irbesartan, losartan
and telmisartan, can inhibit thromboxane A2 receptor-mediated effects
in blood vessels and platelets, and some data suggest that this may be
explained by direct interaction with that receptor (Monton et al.,
2000). Based on molecular modeling studies, it has been proposed
that some ARBs may also bind to vitamin D receptors and chemokine
CCR2 receptors (Marshall et al., 2006) but this has not been substantiat-
ed experimentally. Several ARBs are substrates of transporter molecules
such as P-glycoprotein or members of the Organic Acid Transporting
Polypeptide family, which may play a role in their pharmacokineticproﬁle including penetration into the brain (Michel et al., 2013). For in-
stance telmisartanmay inhibit P-glycoprotein, whichmay lead to drug-
drug-interactions (Stangier et al., 2000), and losartan (but not EXP
3174) and candesartan can interact with uric acid transporters, leading
to decreases or increases in serum uric acid levels by losartan and
candesartan, respectively (Nakashima et al., 1992; Manolis et al.,
2000). Uric acid is a substrate of several transporters including OAT1,
OAT3, OAT4, and MRP4 (Sato et al., 2008) and the glucose transporter,
GLUT9 (also known as URATv1) (Anzai et al., 2008). Although the re-
sults for any given transporter have not been fully consistent across
ARBs and individual transporters, effects on uric acid transporters
have been shown for candesartan (Yamashita et al., 2006; Sato et al.,
2008; Nakamura et al., 2010), eprosartan (Edwards et al., 1996),
irbesartan (Nakamura et al., 2010), losartan (Edwards et al., 1996;
Yamashita et al., 2006; Iwanaga et al., 2007; Anzai et al., 2008; Sato
et al., 2008), olmesartan (Iwanaga et al., 2007; Sato et al., 2008),
telmisartan (Iwanaga et al., 2007; Sato et al., 2008; Nakamura et al.,
2010) and valsartan (Yamashita et al., 2006; Iwanaga et al., 2007;
Anzai et al., 2008; Sato et al., 2008). Such interactions of most members
of this drug class apparently contribute to clinical effects of at least some
ARBs on serum uric acid (Nakashima et al., 1992; Manolis et al., 2000;
Sato et al., 2008).
The potentially most relevant molecular interaction of some
ARBs with a target other than the AT1R is that with PPARs, specif-
ically PPAR-γ. The most direct evidence for the interaction of some
ARBs with PPAR-γ comes from studies demonstrating direct bind-
ing of azilsartan, candesartan, irbesartan, losartan and telmisartan
to this receptor (Erbe et al., 2006; Storka et al., 2008; Kakuta
et al., 2014). This molecular interaction can be associated with
partial PPAR-γ agonism, for which telmisartan appears to show
the most potent effects (Michel et al., 2013; Kakuta et al., 2014).
The potential involvement of PPAR-γ in ARB effects is often studied
using inhibition by the PPAR-γ antagonist GW9662 (Willson et al.,
2000) or PPAR-γ knock-out (Rong et al., 2010) or knock-down ap-
proaches (Nakaya et al., 2007; Scalera et al., 2008; Walcher et al.,
2008).
Thus, alteration of a given cell or tissue function by an ARB suggests
but does not prove AT1R involvement in the regulation of that function,
unless such effects have been demonstrated for multiple members of
this drug class. On the other hand, lack of effect of an ARB does not nec-
essarily exclude a role for ANG acting via other receptor subtypes such
as AT2R. Based on the typically observed increase in ANG upon treat-
ment with an ARB, ARB treatment may actually enhance AT2R activa-
tion. Against this background we have aimed to systematically review
the effects of ARBs in non-clinical models, particularly related to disease
states of the cardiovascular system, metabolism and the kidney. Based
on a cataloguing of these effects we wished to address three main
questions:
1. Do ARB effects occur secondary to BP lowering, i.e. are mimicked by
other BP-lowering approaches?
2. If not, are they shared by RAS inhibitors as a class, or speciﬁc for ARBs
as compared to angiotensin-converting enzyme (ACE) inhibitors
(Bernstein et al., 2013)?
3. If not, do the effects of some ARBs occur independent of AT1R, i.e. are
mediated by other targets?
These ﬁndings provide insight into the widespread pathophysiolog-
ical role of ANG and AT1R activation and also highlight the therapeutic
promise of the ARB drug class via and beyond BP lowering.
In the overall interpretation of the data reviewed here it needs to be
considered that not all ﬁndings can be extrapolated between species,
speciﬁcally from experimental animals to humans. Reasonsmay include
a species-dependent pathophysiology of a given condition and a differ-
ent responsiveness to ARBs in some species. For example rabbitsmay be
more sensitive to BP-lowering effects of ARBs than other species as
doses typically used in rats may already cause profound hypotension
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be less responsive to at least some ARBs because the AT1R orthologs in
those species have lower afﬁnity for ARBs, e.g. in dogs for losartan and
valsartan (de Gasparo & Whitebread, 1995).
1.1. Literature search strategy
We have primarily explored ARB effects in non-clinical models, i.e.
studies in experimental animals, including isolated animal or human
tissues and animal or human isolated cells or cell lines. In vivo studies
in humans, particularly patient treatment studies, were not systemati-
cally considered and only in selected cases examples are referenced to
illustrate that a given non-clinical observation indeed has established
clinical correlates.
Our initial search strategy involving all clinically usedARBs indicated
that about 16,000 articles have been published in the scientiﬁc literature
on this drug class as listed in PubMed, of which approximately 4000 ap-
pear to be original full papers on ARB effects in non-clinicalmodels with
possible relevance to the topic reviewed here. The enormous wealth of
scientiﬁc literature documents the interest in this drug class; however,
it also led us to conclude that a truly comprehensive review of effects
of all clinically used ARBs in non-clinical models was unfeasible. There-
fore, we shifted to an alternative strategy focussing on two ARBs as an
example. We have picked telmisartan as one example, for which N500
non-clinical articles have been published which were comprehensively
catalogued in a proprietary database available to the authors. Moreover,
we considered telmisartan very suitable for our third objective, as it has
been associated with AT1R-independent effects more often than any
other ARB. The second ARB used as an example was azilsartan, as it is
the most recent member of this drug class. For each major effect of
azilsartan or telmisartanwe have identiﬁed during our literature search,
we performed dedicated searches to explore whether this effect was
shared by other ARBs or even BP-lowering drugs in general. Thus, our
manuscript represents a comprehensive analysis of fully published
non-clinical azilsartan and telmisartan data (systematic search com-
pleted in July 2015; data published in abstract form only were not con-
sidered), whereas data on other ARBs or anti-hypertensive drugs acting
independently of the RAS were only included as examples to document
the absence or presence of class effects. This search strategy implies that
articles on azilsartan and telmisartan are over-represented in our
analysis. However, as the vast majority of reported azilsartan and
telmisartan effects are shared by one or more other ARBs, in the follow-
ing all reported azilsartan and telmisartan data are assumed to be appli-
cable to ARBs as a class. Thus, mentioning of more studies with
azilsartan or telmisartan as compared to other ARBs should not be
interpreted as a claim for a larger database for these ARBs or as support
for effects unique to these two; support for the latter can only be derived
in speciﬁcally mentioned instances where this is supported by corre-
spondingdata. Studieswith overtly unethical designs, such as killing an-
imals by intravenous (i.v.) KCl injection (Gu et al., 2011), were excluded
from the analysis.
For ease of reading we do not consistently discriminate between
parent prodrugs and active metabolites in the case of azilsartan,
candesartan and olmesartan, as with oral administration of their
prodrugs only active metabolite is detectable in the circulation
(Michel et al., 2013); this means that, unless otherwise speciﬁed, the
mentioning of a given ARB implies that for in vivo studies with oral ad-
ministration the respective prodrug had been used (azilsartan has
sometimes also been used for oral administration). On the other hand,
upon oral administration of losartan, both parent compound and the
active metabolite EXP3174 are detectable and contribute to observed
effects but the ratio of both differs markedly between species (Stearns
et al., 1992; Suzuki et al., 2001). This is important because EXP3174 is
not only more potent than losartan (Wong et al., 1990e; Lin et al.,
1992; Wienen et al., 1992; Noda et al., 1993; Nishikawa et al., 1994;
Mizuno et al., 1995; Virone-Oddos et al., 1997; Tamura et al., 1997a;Vanderheyden et al., 1999; Koike et al., 2001; Sudoh et al., 2003;
Nussberger & Koike, 2004; Miura et al., 2011) but also, in contrast to
losartan, more consistently exhibits insurmountable antagonism
(Wienen et al., 1992; Cazaubon et al., 1993; Shibouta et al., 1993;
Dickinson et al., 1994; Mizuno et al., 1995; Jin et al., 1997; Morsing
et al., 1999). A comprehensive review of the antagonistic properties of
all ARBs at the molecular, cellular, tissue and organism level has been
published elsewhere (Michel et al., 2013).
2. Blood pressure reduction
Arterial hypertension is a highly prevalent condition which, if un-
treated or treated insufﬁciently, can lead tomorbidity such asmyocardi-
al infarction and stroke, kidney failure and, eventually, premature death,
making a profound understanding and effective treatment necessary.
There are many different animal models of hypertension which can be
used to test the antihypertensive properties of ARBs. Obviously, animal
models involving a strong RAS activation, e.g. the classic 2-kidney-1-clip
Goldblatt model of renovascular hypertension or the related 1-kidney-
1-clip model, are most sensitive in this regard. The spontaneously
hypertensive rat (SHR) is the most frequently studied animal model of
hypertension, but many other models in various species are available
and have been used to study ARBs. In this sectionwe review ARB effects
on BP in various animal models of hypertension (for summary see
Table 1). ARB effects on end-organ damage associated with such hyper-
tensionwill be discussed in the sections related to the respective organs.
An important consideration applies to the interpretation of data in all
animalmodels of hypertension. If treatment starts at an early phase of hy-
pertension or even before BP elevation occurs, e.g. in 4-week old SHR, this
implies a prevention and not a treatment approach. While prevention of
hypertension is a theoretically attractive concept, it should be noted
that neither ARBs nor any other class of anti-hypertensive drugs have
been approved for the prevention of hypertension. Use of ARBs and
other anti-hypertensive drugs in patients typically starts when elevated
BP is already present and, according to guidelines (Weber et al., 2014;
James et al., 2014), when non-pharmacological approaches have been in-
sufﬁciently effective. As presence of hypertension often remains undiag-
nosed for many years, it can be assumed that treatment often starts in
settings where the chronically elevated BP has already structurally affect-
ed the cardiovascular system. Obviously, this is only reﬂected in animal
models that have started treatment with ARBs or other drugs in late
phases of the condition. Therefore, we speciﬁcally highlight studies with
such late start of treatment throughout this section, as these studies
may be the most representative ones for the clinical situation.
2.1. Normotensive animals
Normotensive animals do not have the suppressed RAS activity seen
in models of mineralocorticoid-induced hypertension but typically ex-
hibit a much lower RAS activity than SHR or models of renal hyperten-
sion. Hence, one would expect that ARBs typically have limited BP
effects in normotensive animals. Many studies have characterized ARB
effects in normotensive animals, often as internal control group in stud-
ies of hypertensive animals. Most of these studies have been performed
in rats but some have also used other species including mice
(Bivalacqua et al., 1999; Mazzolai et al., 2000; Sakai et al., 2008; Bo
et al., 2010; Ohshima et al., 2012; Nakamura et al., 2013; Matsumoto
et al., 2014; Penna-de-Carvalho et al., 2014), rabbits (Azuma et al.,
1992; Hajj-Ali & Wong, 1993), sheep (Peers et al., 2001), dogs (Chan
et al., 1992; Keiser et al., 1992; MacFadyen et al., 1992; Hayashi et al.,
1997b) and monkeys (Criscione et al., 1993; Lacour et al., 1993;
Roccon et al., 1994).
Studies in normotensive animals were reported for all ARBs includ-
ing azilsartan (Iwai et al., 2007; Kusumoto et al., 2011; Nakamura
et al., 2013; Sueta et al., 2013; Matsumoto et al., 2014; Carroll et al.,
2015), candesartan (Kobayashi et al., 1993; Shibouta et al., 1993;
Table 1
ARB effects on BP in normotensive and hypertensive animalmodels. *: claim based on lim-
ited data, for instance a single study or a single ARB only. For details and references, see
Section 2.
Animal models in which ARBs effectively lower BP
– Normotensive animals
o Monkey
– Normotensive but sodium-depleted animals
o Rat
o Dog*




o SHR with concomitant type 1 diabetes
o SHR with cyclosporin A treatment and high-salt diet
o New Zealand genetically hypertensive rat*
– Renal hypertensive models






o Hypertension with reduced renal mass or parenchymal renal disease
▪ Rats with various degrees of nephrectomy
▪ Rats injected with anti-Thy-1 monoclonal antibody
▪ Rats with polycystic kidney disease




o High-fructose diet in rat




▪ Cohen-Rosenthal diabetic hypertensive rat
▪ Koletsky rat (fak/fak) rat*
▪ SHRcp rat
▪ Otsuka Long–Evans Tokushima fatty rat
▪ Zucker diabetic fatty rat
– Hypertension caused by STZ injection (type 1 diabetes) in rat
– Hypertension in genetically modiﬁed animals
o Mouse
▪ Transgenic harboring human renin and angiotensinogen*
▪ Transgenic harboring C-reactive protein*
▪ Endothelial NO synthase knock-out*
▪ Endothelin-1 knock-out*
▪ Hypoxia-inducible factor-1α knock-out*
o (mRen-2)27 rat
– Chronic cold exposure in rat*
– Cardiac pressure overload (aortic banding) in rat
– Sino-aortic denervation in rat*
– Kidney allograft transplantation in rat*
– Pharmacological intervention
o L-NAME treatment in rat
o Cylcosporin A treatment in rat*
o Chronic isoprenaline infusion in rat*
Animal models in which ARBs have only small if any effects on BP






– Animals on high-salt diet
o SHR and stroke-prone SHR
o DOCA-treated
o Diabetic Goto–Kakizaki rat*
– Monoamine uptake inhibitor treatment (tesofensine)
Animal models with equivocal data
– KK-Ay mouse
– Dahl S rats on high-salt diet
4 M.C. Michel et al. / Pharmacology & Therapeutics 164 (2016) 1–81Inada et al., 1994; Li & Widdop, 1996; Cervenka et al., 1998; Nishimura
et al., 1998b; Bivalacqua et al., 1999; Demeilliers et al., 1999), eprosartan
(Edwards et al., 1992a), irbesartan (Soltis et al., 1993), losartan and
EXP3174 (Wong et al., 1990d, 1990e; Azuma et al., 1992; MacFadyen
et al., 1992; Mizuno et al., 1992a; Criscione et al., 1993; Soltis et al.,
1993; Inada et al., 1994; Li & Widdop, 1996; Mazzolai et al., 2000;
Harada et al., 2009; Ohshima et al., 2012), olmesartan (Mizuno et al.,
1995; Koike et al., 2001; Harada et al., 2009; DeMarco et al., 2011),
telmisartan (Wienen & Entzeroth, 1994; Harada et al., 2009; DeMarco
et al., 2011; Ohshima et al., 2012; Toba et al., 2012;
Penna-de-Carvalho et al., 2014;Müller-Fielitz et al., 2015) and valsartan
(Criscione et al., 1993; Hayashi et al., 1997b; Yamamoto et al., 1997b;
Siragy et al., 2000; Sakai et al., 2008; Harada et al., 2009). They included
acute (Wong et al., 1990d, 1990e; MacFadyen et al., 1992; Edwards
et al., 1992a; Criscione et al., 1993; Shibouta et al., 1993; Soltis et al.,
1993; Inada et al., 1994; Wienen & Entzeroth, 1994; Mizuno et al.,
1995; Li & Widdop, 1996; Hayashi et al., 1997b; Cervenka et al., 1998;
Bivalacqua et al., 1999; Demeilliers et al., 1999; Harada et al., 2009;
Kusumoto et al., 2011) and chronic treatment (Mizuno et al., 1992a;
Kobayashi et al., 1993; Soltis et al., 1993; Mizuno et al., 1995; Ohshima
et al., 2012; Toba et al., 2012; Müller-Fielitz et al., 2015), and oral
(Mizuno et al., 1992a; Kobayashi et al., 1993; Inada et al., 1994;
Hayashi et al., 1997b; Kusumoto et al., 2011; Ohshima et al., 2012;
Toba et al., 2012; Nakamura et al., 2013; Matsumoto et al., 2014;
Müller-Fielitz et al., 2015) and i.v. administration (Wong et al., 1990d,
1990e; MacFadyen et al., 1992; Edwards et al., 1992a; Criscione et al.,
1993; Shibouta et al., 1993; Wienen & Entzeroth, 1994; Li & Widdop,
1996; Hayashi et al., 1997b; Cervenka et al., 1998; Bivalacqua et al.,
1999; Demeilliers et al., 1999; Siragy et al., 2000; Harada et al., 2009)
as well as other forms of parenteral administration (Soltis et al., 1993).
Whilemost of these studieswere performed in conscious animals, anes-
thetized animals have also been investigated (Zhuo et al., 1992; Macari
et al., 1993; Wienen & Entzeroth, 1994; Li & Widdop, 1996; Hayashi
et al., 1997b; Cervenka et al., 1998; Bivalacqua et al., 1999; Demeilliers
et al., 1999). In most of these studies with normotensive animals ARBs
have shown a small if any effect on BP unless high doses were adminis-
tered, i.e. doses exceeding those required to yield substantial inhibition
of responses to exogenously administered ANG (Yamamoto et al.,
1997b; Cervenka et al., 1998).
However, in some studies in normotensive rats some degree of
blood pressure lowering upon ARB administration has been observed
in nomotensive animals, with e.g. candesartan (Kobayashi et al., 1993;
Inada et al., 1994; Nishimura et al., 1998b), irbesartan (Soltis et al.,
1993), losartan (Soltis et al., 1993; Mazzolai et al., 2000), olmesartan
(Koike et al., 2001) or telmisartan (Yoshihara et al., 2013). Of note, a
lowered baseline BP was reported in AT1R knock-out mice, in which
telmisartan did not cause any additional change of BP (Rong et al.,
2010); amoderate BP lowering upon telmisartan treatmentwas report-
ed in ApoE/AT1R double knock-out mice (Fukuda et al., 2010). Moder-
ate BP lowering by losartan has been reported in normotensive
anesthetized rabbits (Hajj-Ali & Wong, 1993) or guinea pigs (El
Amrani et al., 1993), but at least rabbits generally are more sensitive
to ARBs thanmost other species (Sato et al., 1997). Sodiumdepleted an-
imals have normal to low basal BP but exhibit an activated RAS and
hence ARBs have been shown to lower BP in sodium-depleted rats
(Jover et al., 1991; Macari et al., 1993; Siragy et al., 2000) and dogs
(MacFadyen et al., 1992). BP lowering in normotensive sodium-
depleted monkeys has consistently been reported (Criscione et al.,
1993; DeGraaf et al., 1993; Lacour et al., 1993; Roccon et al., 1994),
but these data aremore difﬁcult to interpret as sodium repletemonkeys
within the same studies had similar BP lowering upon administration of
irbesartan, losartan or valsartan, indicating that normotensive monkeys
irrespective of the state of their sodium balance may be more respon-
sive to ARB-induced BP lowering. Greater BP lowering in sodium-
depleted animals has a clinical correlate, as ARBs cause greater BP low-
ering in patients who have been pre-treated with diuretics.
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within the same study, ARB-induced BP reductions were always
greater in hypertensive than in normotensive animals. The latter ob-
servation includes studies in which the antagonist potency to inhibit
pressor responses to exogenously administered ANG was similar in
normotensive and hypertensive animals, demonstrating that any
difference between the two was not explained by pharmacokinetic
differences or differences in AT1R responsiveness (Li & Widdop,
1996). In addition to BP normalization, ARBs were also reported to
normalize the disturbed auto-regulation of cerebral blood ﬂow
(Nishimura et al., 1998b).
In summary, ARBs as a class cause little BP lowering in normotensive
animals unless they are sodium-depleted, except in monkeys or when
very high doses are administered. Even in conditions where ARBs pro-
duce some BP lowering in normotensive animals, the extent of this ef-
fect is consistently lower than in ARB-responsive hypertension
models. Moreover, it is noteworthy that basically all of the above studies
in normotensive animals reported a lack of effect of ARBs on heart rate,
regardless whether BP was altered or not (see Section 4.1.2). However,
when valsartanwas administered to normotensive rats on top of an iso-
prenaline infusion, which already lowered BP and activated the RAS, no
futher BP loweringwas observed but rather an increase in heart rate be-
came the primary valsartan response (Blanc et al., 2000).
2.2. Spontaneously hypertensive rat (SHR)
The SHR is the most widely used animal model of arterial hyperten-
sion. It is a model of genetically caused hypertension based on many
generations of inbreeding. However, genetic drift may have occurred
in the inbreeding procedures, resulting in genetic heterogeneity be-
tween SHR currently available from multiple suppliers and the emer-
gence of speciﬁc substrains of SHR (Nabika et al., 1991). Moreover, in
most cases Wistar Kyoto rats are used as the normotensive control for
SHR, but the systematic breeding of these started later and has led to
even more heterogeneity (Lindpaintner et al., 1992). Moreover, it
should be noted that some of the phenotypes displayed by SHR and
plausibly linked to the pathophysiology of hypertension do not co-
seggregate with hypertension in cross-breeding studies (Kunes et al.,
1990; Orlow et al., 1991; Katsuya et al., 1992; Michel et al., 1992;
Pravenec et al., 1992; Lodwick et al., 1993; Pravenec et al., 1995), indi-
cating that hypertension and other phenotypes of SHR are genetically
determined but not necessarily by the same set of genes. For instance,
the hyperactivity phenotype did not coseggregate with the hyperten-
sive phenotype in such cross-breeding studies. All of these factors
need to be considered when comparing results reported with SHR and
Wistar Kyoto rats obtained from different suppliers and when trying
to understand the pathophysiology of hypertension-related phenotypes
in SHR. Therefore, several investigators have used other normotensive
rat strains such as Sprague-Dawley rats as (additional) comparators
for their ﬁndings in SHR.
All clinically used ARBs effectively lower BP in SHR, irrespective of
source of substrain. This was consistently observed with acute (oral
and parenteral) and chronic dosing and in conscious and anesthe-
tized animals. Moreover, hypertension in SHR can be aggravated
genetically, i.e. in the stroke-prone sub-strain of the SHR, or by
various other measures, and ARBs also lower BP in these models
(see Section 2.2.4).
2.2.1. Blood pressure lowering in established hypertension
SHR typically remain normotensive up to an age of 4–6 weeks, and
then exhibit increasing BP with time, which typically reaches fairly sta-
ble levels at or beyond 12 weeks of age. However, structural conse-
quences of hypertension, which contribute to the maintenance of
elevated BP, can become increasingly important in SHR aged 6 months
or older. Thus, ARB-induced BP lowering in SHR aged 12 weeks or
older can be seen as a model of the clinical situation where a patientpresents with established hypertension. In such animals i.v. (Harada
et al., 2009; Lee et al., 2010) or intra-peritoneal administration
(Grundt et al., 2009) of telmisartan dose-dependently acutely lowers
BP. Similar BP effects of acute oral or parenteral ARB administration
were reported with azilsartan (Kusumoto et al., 2011; Takai et al.,
2013b), candesartan (Inada et al., 1994; Yamada et al., 1995; Li &
Widdop, 1996; Wada et al., 1996a; Nishimura et al., 1998b; Inada
et al., 1999; Takai et al., 2013b), eprosartan (Inada et al., 1999),
irbesartan (Lacour et al., 1994; Inada et al., 1999), losartan (Wong
et al., 1990d; Tofovic et al., 1991; Cachofeiro et al., 1992; Ohlstein
et al., 1992; Kumagai et al., 1993; Oddie et al., 1993; Soltis, 1993;
Inada et al., 1994; Li & Widdop, 1996; Hashimoto et al., 1997; Inada
et al., 1999; Harada et al., 2009), olmesartan (Koike et al., 2001;
Harada et al., 2009) or valsartan (Yamamoto et al., 1997b; Inada et al.,
1999; Harada et al., 2009). This was also observed in a stroke-resistant
substrain of SHR following ligation of the middle cerebral artery during
a 15 months follow-up (Kurata et al., 2014a, 2014b). Interestingly, the
BP lowering effect of a single dose of ARBwas correlated to plasma con-
centration whenmeasured after 2 h but not after 24 h; in contrast, after
24 h BP reductionwas correlated to vascular ARB concentration,where-
as plasma and vessel wall concentration were not associated (Takai
et al., 2013b), indicating that compartmentalization into target tissue
may contribute to effect duration beyond what would be expected
based on pharmacokinetics as measured in plasma.
Evenmore relevant for the clinical treatment situation is the chronic
administration of ARBs to SHR with established hypertension. This has
mostly been done by oral administration, but parenteral administration
schemes, e.g. based on osmotic minipumps chronically delivering an
ARB subcutaneously have also been used (Nishimura et al., 1998b).
Again, all ARBs having been tested effectively lowered BP under these
conditions, e.g. azilsartan (Sueta et al., 2013; Hye Khan et al., 2014a;
Isegawa et al., 2015), candesartan (Mizuno et al., 1992b; Inada et al.,
1994; Mizuno et al., 1994; Takeda et al., 1994; Mori et al., 1995;
Nishimura et al., 1998b; Tsuchihashi et al., 1999; Jones et al., 2004;
Chen et al., 2010; Ishimitsu et al., 2010; Jones et al., 2012; Isegawa
et al., 2015), irbesartan (Lacour et al., 1994), losartan (Inada et al.,
1994; Li & Widdop, 1996; Hashimoto et al., 1997; Dai et al., 2007),
olmesartan (Koike et al., 2001), telmisartan (Wienen et al., 2001;
Mandarim-de-Lacerda & Pereira, 2004; Li et al., 2006; Dai et al., 2007;
Kumai et al., 2008; Liu et al., 2009a; Chen et al., 2010; Ma et al., 2010;
Khan & Imig, 2011; Liu et al., 2011; Zhong et al., 2011; Müller-Fielitz
et al., 2012; Zhu et al., 2012; Xu & Liu, 2013) and valsartan (Chow
et al., 1995; Scheidegger et al., 1996; Tea et al., 2000). Such ﬁndings ap-
parently apply to various substrains of SHR (Li et al., 2006). In one study
with 10 week old SHR being treated for 4 weeks, both azilsartan and
candesartan similarly lowered BP during the daytime resting phase of
the animals and the nighttime active phase, but in the ﬁrst two hours
of the active phase, i.e. immediately after daily dosing, azilsartan caused
greater BP reduction than candesartan (Isegawa et al., 2015). However,
interpretation of these data is challenging as the chosen dose of
azilsartan was more effective on overall BP than that of candesartan.
While most of these chronic treatment studies have started at ages
of 10–14 weeks, some started at much later time points e.g. at
8 months (Koike et al., 2001; Li et al., 2006; Choisy et al., 2015),
12 months (Mandarim-de-Lacerda & Pereira, 2004) or even
20 months (Jones et al., 2004, 2012); although it can be assumed that
at such late time points structural alterations of the cardiovascular sys-
tem including hypertrophy and ﬁbrosis already contribute to the BP
maintenance, ARBs were nevertheless successful in lowering it. In con-
trast AT2R antagonists did not lower BP in SHR (Tea et al., 2000) and
also did not attenuate BP reduction by an ARB (Jones et al., 2004,
2012). Taken together these ﬁndings demonstrate that ARBs as a class
are effective in BP lowering in SHR with established hypertension. On
a pathophysiological level these studies demonstrate that ANG contrib-
utes to the maintenance of elevated BP in established hypertension, at
least in the SHR model.
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Conceptually different from the question of an ANG contribution to
the maintenance of elevated BP is whether ANG similarly contributes
to hypertension development. As development of hypertension in SHR
is a fairly predictable process, multiple studies have explored whether
chronic administration of an ARB, either before onset of hypertension
or in early phases thereof, can prevent BP elevation (Fig. 1). Indeed pre-
ventive effects have been demonstrated for candesartan (Rizzoni et al.,
1998; Pollock & Morsing, 1999; Müller-Fielitz et al., 2012), irbesartan
(Vacher et al., 1995; Intengan et al., 1999; Zalba et al., 2001), losartan
(Morton et al., 1992; Oddie et al., 1992; Kawano et al., 2000a),
telmisartan (Miesel et al., 2012; Müller-Fielitz et al., 2012; Yoo et al.,
2015; Zou et al., 2015) and valsartan (Scheidegger et al., 1996). In
some cases even a very late start of ARB administration, i.e. after one
year, still could attenuate further BP elevations (Mandarim-de-Lacerda
& Pereira, 2004). Valsartan and enalapril also prevented hypertension
development in New Zealand genetically hypertensive rats
(Ledingham et al., 2000). Of note, depending on when treatment was
started, such preventive ARB administration not only attenuated the ge-
netically determined increase in BP but, at least in some cases,
completely prevented it. While ARBs presently are only indicated for
the treatment of hypertension, these data in SHR raise the possibility
that this drug classmay also have preventive effects on hereditary BP el-
evation; however, this has not been tested clinically.
2.2.3. Persistence of blood pressure lowering after end of treatment
The chronic infusion of ANG can cause hypertension, and such hy-
pertension can persist for a considerable time (at least weeks to
months) after the ANG administration has stopped. This raises the pos-
sibility that ARB administration may also have BP lowering effects that
extend well beyond the presence of the drug in the organism. An early
observation in this regard comes from a study in which losartan was
given to 3-week old SHR for 4 or 10 weeks (Morton et al., 1992). Both
treatments prevented BP elevations and their effects at least partly
persisted up to an age of 30 weeks after treatment had been stopped;
in this regard the 10-week treatment was more effective than the
shorter one, which may be related to a stronger effect on vascular hy-
pertrophy. Similar ﬁndings were reported from an independent study
(Oddie et al., 1992), but those investigators found that the persistent ef-
fects of a 6-week treatmentwith losartan starting at the age of 14weeks
were only transient, and 3 months after the end of ARB administration
BP had reapproached untreated SHR levels (Oddie et al., 1993).
Similar ﬁndings were obtained with candesartan given for four weeks
to 20-week old SHR (Paull & Widdop, 2001; Paull et al., 2001); inFig. 1. Effect of irbesartan on the development of hypertension in SHR with treatment
from the age of 4–20 weeks, followed by observation without further treatment for
another 8 weeks, i.e. irbesartan treatment was stopped at week 20. Data are means of
115 rats per group and have been drawn based on data published by Vacher et al.
(1995). Values on irbesartan treatment reported to signiﬁcantly differ from those in
control for all time points except 4 weeks, i.e. prior to start of treatment.those studies the gradual return of BP towards values of vehicle treated
rats was not necessarily accompanied by similar changes for regional
vascular conductance (Paull et al., 2001). Irbesartan attenuated hyper-
tension development when given to 4-week old SHR for 16 weeks;
within 8 weeks after discontinuation of treatment, BP remained signiﬁ-
cantly reduced but thereafter gradually approached levels of untreated
SHR (Vacher et al., 1995) (Fig. 1). In another study, SHR weighing
300 g (age not speciﬁed) were treated with telmisartan for 5 days; BP
remained signiﬁcantly lowered for 4 days after the end of telmisartan
treatment and numerically below values from vehicle-treated rats dur-
ing the entire 14 day observation period (Wienen & Schierok, 2001).
Similarly, the reduction of diastolic (but not systolic) BP achieved by
treatment with valsartan was also largely retained for at least 4 weeks
after treatment discontinuation in transgenic mice harboring human
angiotensinogen and renin genes (Inaba et al., 2011).
The withdrawal response to different drug classes has been directly
compared. In one study 20 week old SHR were initially treated for 4
weeks with either candesartan, perindopril or hydralazine (Paull &
Widdop, 2001). While the chosen doses of the three drugs produced
comparable BP lowering during active treatment, mean arterial pres-
sure returned to levels observed in vehicle-treated rats within 4 and
15 days after withdrawal of hydralazine or candesartan, respectively,
but remained consistently reduced to some degree for the 8-week
follow-up after withdrawal of perindopril treatment.
2.2.4. Stroke-prone spontaneously hypertensive rat and
otherwise aggravated hypertension in spontaneously hypertensive rat
Hypertension in SHR can be aggravated either in a hereditary
form, such as in the substrain of stroke-prone SHR, or by a range of
other interventions including high-salt diet, partial nephrectomy or
superimposed diabetes. Such aggravatedmodels may be representative
for some types of patients. Moreover, they can be associated with a
more rapid development of the sequelae of hypertension, e.g. stroke,
and hence be models for the prevention of such complications.
Various ARBs were found to lower BP in stroke-prone SHR including
candesartan (Nakamura et al., 1994b; Xie et al., 1999; Takai et al., 2011;
Kishi et al., 2012), losartan (Wagner et al., 1998), olmesartan (Tomita
et al., 2009), telmisartan (Wagner et al., 1998; Takai et al., 2007;
Thoene-Reineke et al., 2011; Kishi et al., 2012) and valsartan (Webb
et al., 1998a; Takai et al., 2007; Pu et al., 2008). Of note the beneﬁcial ef-
fects of an ARB in stroke-prone SHR were shown not only in treatment
but also in preventive study designs (Thoene-Reineke et al., 2011).
A high-salt diet can also aggravate hypertension in SHR butwith few
exceptions (Yoshida et al., 2011) apparently ARBs have little effect
under those conditions. E.g. an 8-week treatment with telmisartan did
not lower BP in SHR on a high-salt diet (Susic et al., 2013). When a
high-salt diet was given to stroke-prone SHR, neither telmisartan nor
valsartan remained an effective antihypertensive drug, although they
had lowered BP in stroke-prone SHR in the absence of a high-salt diet
(Takai et al., 2007). Valsartan also failed to lower BP in stroke-prone
SHR on a high-salt diet and furthermore did not signiﬁcantly enhance
the BP lowering effect of amlodipine under these conditions (Dong
et al., 2011). Similarly, eprosartan only produced rather limited BP low-
ering when given to stroke-prone SHR on a high-salt diet (Abrahamsen
et al., 2002) or those on a mixed high-salt, high-fat diet (Barone et al.,
2001; Behr et al., 2004). Finally, candesartan or telmisartan did not
lower BP in salt-loaded stroke-prone SHR continuously infused with
ANG (Kishi et al., 2014). This lack of effect apparently is related to the
suppression of RAS activity upon chronic administration of a high-salt
diet. However, a major BP lowering to levels below those in SHR on a
normal diet was seen in rats which had been on a high-salt diet for
8 weeks and then switched to a normal diet + telmisartan (Susic &
Frohlich, 2014); under these conditions, 8/9 rats treated with
telmisartan survived the normal diet phase, whereas only 1/9 rats sur-
vived when only switched to a normal diet. In salt-loaded stroke-
prone SHR continuously infused with ANG candesartan and, to an
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lowering (Kishi et al., 2014).
Impaired renal function can also cause hypertension, and the 5/6
subtotal nephrectomy is a frequently used model of this condition
(see Section 2.3). When 5/6 nephrectomy was performed in SHR,
candesartan continued to lower BP (Kohara et al., 1993), even when
an additional high-salt diet was administered (Okada et al., 1995). The
immunosuppressant cyclosporin A can also cause renal impairment,
and hypertension is a frequent side effect of cyclosporin treatment;
valsartan was shown to attenuate hypertension development in
young SHR concomitantly treated with cyclosporin A and a high-salt
diet (Lassila et al., 2000a).
As hypertension and diabetes mellitus are frequent comorbidities
(Michel et al., 2004), several groups have studied ARB effects in SHR
with a superimposed STZ-induced diabetes; under such circumstances
e.g. irbesartan (Bonnet et al., 2001; Cao et al., 2001), telmisartan
(Wienen et al., 2001) and valsartan (Hulthen et al., 1996) remained
effective BP-lowering drugs. When SHR were fed a cafeteria-style diet,
a model for the association of hypertension and the metabolic syn-
drome, telmisartan also provided effective BP lowering (Müller-Fielitz
et al., 2012).
Taken together these data demonstrate that the antihypertensive ef-
fect of ARBs as a drug class in SHR is largelymaintained under aggravat-
ing circumstances. The concomitant presence of a high-salt diet in SHR
appears to be an exception to this rule; this is not surprising as a high-
salt intake provides strong suppression of the RAS and hence leaves
little room for a RAS inhibitor to work (but see Section 2.2.5 for BP low-
ering by combination treatment).
2.2.5. Combination treatments
Many hypertensive patients require treatment with more than one
anti-hypertensive drug to reach target BP values. Accordingly, several
studies have addressed potential combinations of ARBs with represen-
tatives of other drug classes. In this regard most studies have focused
on combinations with diuretics, with Ca2+ entry blockers, or more re-
cently with neutral endopeptidase inhibitors; some of these combina-
tions were expected to exhibit synergies, for instance due to direct
RAS activation by diuretics or indirect inactivation due to baroreﬂex ac-
tivation by Ca2+ entry blockers.
Studies on a combination with diuretics have largely involved hy-
drochlorothiazide. Importantly, it should be noted that the BP-
lowering effect of thiazide diuretics in patients typically develops
much more slowly than its diuretic effect and may take days to weeks.
While this is in contrast to the antihypertensive effect of ARBs (see
Section 2.2.1), it implies that testing of ARB/diuretic combinations
should be based on treatment of at least several days. A 5-day treatment
with telmisartan lowered BP in SHR; while hydrochlorothiazide alone
did not signiﬁcantly lower BP, it signiﬁcantly enhanced the effects of
telmisartan starting on the ﬁrst day and reaching maximum reductions
on the last day of treatment (Wienen& Schierok, 2001). Additive to syn-
ergistic BP loweringwere also observedwith a combination of valsartan
and hydrochlorothiazide during a 2-week treatment (Webb et al.,
1998b). In a 2-week study with candesartan the addition of hydrochlo-
rothiazide also exhibited synergistic BP reductions, which exceeded the
effects of combinations with prazosin, atenolol or manidipine (Wada
et al., 1996b). Enhanced BP lowering by a combination of candesartan
and hydrochlorothiazide were also reported in stroke-prone SHR
(Takai et al., 2011). While neither telmisartan nor hydrochlorothiazide
signiﬁcantly lowered BP during an 8-week treatment in SHR on a
high-salt diet, their combination was effective (Susic et al., 2013); this
is in line with the view that high-salt intake suppresses the RAS and
that the presence of a diuretic resensitizes the animal to an ARB.
Ca2+ entry blockers, particularly those of the dihydropyridine fami-
ly, have also been tested in combinationwithARBs in SHR.Most of these
studies have used amlodipine, but studieswithmanidipine (Wada et al.,
1996b), lercanidipine (Lee et al., 2010) or cilnidipine (Takai et al.,2013a) have also been reported. In acute interaction studies, in which
multiple doses of either agent were tested, telmisartan and amlodipine
showed synergistic BP loweringwith the strongest synergism being ob-
served when the two were given in a 6:1 ratio (Liu et al., 2011). Within
the same study a 4-months combination treatment had produced great-
er BP lowering than either monotherapy, and also reduced BP variabili-
ty. In SHR on a high-salt diet, amlodipine lowered BP during an 8-week
treatment, whereas telmisartan alonewas ineffective (see above); how-
ever, the combination of both agents lowered BP to an at least numeri-
cally greater degree than amlodipine alone (Susic et al., 2013). Greater
blood pressure lowering effects of combinations with amlodipine have
also been reported for candesartan (Takai et al., 2011), irbesartan
(Shang et al., 2011), losartan (Choi et al., 2009) or valsartan (Takai
et al., 2013a). However, a combination of low doses of candesartan
and amlodipine produced lesser BP reductions in stroke-prone SHR
than candesartan monotherapy (Kim et al., 2000). A combination of
low dose valsartanwith amlodipine also did not yield enhanced BP low-
ering in salt-loaded stroke-prone SHR (Dong et al., 2011).
A third interesting treatment option was explored for the combina-
tion of an ARB with a neutral aminopeptidase inhibitor. Using valsartan
and CGS 25354 in combination produced slightly greater BP lowering
than valsartan alone during a 10 week treatment of stroke-prone SHR
(Pu et al., 2008). Similar data were obtained when valsartan was com-
bined with the endopeptidase inhibitor candoxatril (Hegde et al.,
2011). Of note, these combination studies have evaluated not only BP
reductions but also endpoints such as endothelium-dependent vasodi-
latation or cardiac ﬁbrosis, and were found to be beneﬁcial on these
endpoints as well (see below).
2.2.6. Effects on mortality, particularly in
stroke-prone spontaneously hypertensive rat
Insufﬁciently treated hypertension can lead to premature death,
possibly the hardest of all possible study endpoints. On pragmatic
grounds animal studies on potential survival beneﬁts of ARBs have
largely focused on models with a clearly increased mortality such as
the salt-loaded stroke-prone SHR. Several ARBs have been shown to en-
hance survival in such animals when treatment was started at an age of
10–14 weeks, e.g. candesartan (Bennai et al., 1999), eprosartan (Barone
et al., 2001), olmesartan (Takai et al., 2009) or valsartan (Webb et al.,
1998a; Takai et al., 2009). Interestingly, valsartan also improved surviv-
al in stroke-prone SHRon a high-salt diet, despite not lowering BP under
these conditions; the reduction inmortalitywas similar to that achieved
by amlodipine, and the valsartan/amlodipine combination completely
prevented mortality in this model (Dong et al., 2011). A summary of
mortality studies with ARBs in stroke-prone SHR and various other dis-
ease models is provided in Table 2. Interestingly, AT1R knock-out has
been shown to increase longevity as compared to healthy wild-type
mice (Benigni et al., 2009); based on comparable effects of such
knock-out and of ARB treatment on presumed underlying physiological
mechanisms, it has been proposed that ARBs may share this effect
(Cassis et al., 2010).
2.3. Renal hypertensive animals
The kidney contributes to BP control in multiple ways. Firstly, it af-
fects circulating blood volume by regulating the excretion of salt and
ﬂuid. Second, in reaction to the amount of sodium reaching the distal tu-
bules, itmediates renin releasewhich increases formation and release of
ANG and aldosterone. Thirdly, pressure natriuresis is a powerful mech-
anism with inﬁnite gain in BP control, a mechanism which in itself in-
volves the RAS (Romero & Knox, 1988). Hence, reductions of renal
perfusion or of nephron mass or function can activate the RAS and
lead to renovascular and renal mass-associated hypertension, respec-
tively. Therefore, ARBs typically cause strong BP reductions in animals
with renovascular hypertension or advanced nephropathy.
Table 2
Animal models in which ARBs were reported to reduce mortality/increase survival.
Model ARB reference
Stroke-prone SHR, salt-loaded Candesartan (Bennai et al., 1999)
Eprosartan (Barone et al., 2001)
Olmesartan (Takai et al., 2009)
Telmisartan (Webb et al., 1998a)
Valsartan (Webb et al., 1998a;
Takai et al., 2009;
Dong et al., 2011)
Stroke-prone SHR, salt-loaded plus
ANG infusion
Candesartan (Kishi et al., 2014)
Telmisartan (Kishi et al., 2014)
Aneurysm in ApoE knock-out mice
with intra-aortic elastase followed
by ANG infusion
Irbesartan (Iida et al., 2012)
Telmisartan (Iida et al., 2012)
Aneurysm in RGS2 knock-out mouse
with ANG infusion
Telmisartan (Matsumoto et al., 2010)
Mice with myocardial infarction Olmesartan (Chen et al., 2014)
Rats with myocardial infarction Olmesartan (Koike et al., 2001)
SHR with myocardial infarction Irbesartan (Richer et al., 1999)
CHF in mice due to transgenic
calsequestrin expression
Losartan (Günther et al., 2010)
Myocarditis in mice with
encephalomyocarditis virus
Candesartan (Tanaka et al., 1994)
Autoimmune myocarditis in rats Telmisartan (Sukumaran et al., 2010)
CHF in Dahl S rats on high-salt diet Losartan (von Lutterotti et al.,
1992)
Telmisartan (Takenaka et al., 2006)
Rats with 5/6 nephrectomy Candesartan (Podjarny et al., 2007)
SHR with 5/6 nephrectomy Candesartan (Kohara et al., 1993)
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Renovascular hypertension can be induced experimental animals in
multiple ways. The classic Goldblatt model uses animals which retain
both kidneys and have a unilateral reduction of renal blood ﬂow (RBF)
due to a clip on the renal artery of one kidney. However, a one-
kidney-one-clip model or acute single-sided renal artery ligation
models have also been used. Most animal models of renovascular
hypertension involve rats, but mice (Salguero et al., 2008), hamsters
(Jin et al., 1998) and dogs (Brooks et al., 1992a; Ito et al., 1995; Koike
et al., 2001; Kusumoto et al., 2011) have also been used to study ARB ef-
fects in renovascular hypertension.
Renovascular hypertension models generally are characterized by
strong RAS activation, which on theoretical grounds makes them very
sensitive to RAS inhibition. Accordingly, each clinically used ARB has
been shown to be effective in at least one model of renovascular hyper-
tension. This includes studies with azilsartan (Kusumoto et al., 2011),
candesartan (Yu et al., 1993; Inada et al., 1994; Ito et al., 1995; Li &
Widdop, 1995; Wada et al., 1996a), eprosartan (Brooks et al., 1992b),
irbesartan (Lacour et al., 1994), losartan (Wong et al., 1990a, 1990c,
1990e; Brooks et al., 1992b; Sigmon & Beierwaltes, 1993b; Zhang
et al., 1993b; Hashimoto et al., 1997), olmesartan (Koike et al., 2001;
Mire et al., 2005), telmisartan (Ries et al., 1993; Wienen et al., 1993;
Salguero et al., 2008; Kawai et al., 2009; Ye et al., 2010; Chaykovska
et al., 2013) and valsartan (Yamamoto et al., 1997b).
These data indicate that ARBs as a class effectively lower BP in
renovascular hypertension across different models and species. This
may involve direct effects on the kidney and those on the extra-renal
vasculature. For example in 2-kidney-1-clip renal hypertensive rats
losartan lowered BP alongwith an increase of RBF of the clipped kidney
but no change in the unclipped kidney (Sigmon & Beierwaltes, 1993b).
On the other hand, similar to ﬁndings from the SHR, the BP lowering by
candesartan in that model involved vasodilatation in multiple vascular
beds (Li & Widdop, 1995). While most studies have administered an
ARB early after induction of renal artery stenosis, treatment has also
been started as late as 32 weeks after inducing renal artery stenosis
and still provided similar BP lowering aswith early treatment as report-
ed with candesartan (Jin et al., 1998). Moreover, similar to the SHR, acombination of telmisartan and amlodipine produced synergistic BP
lowering in two-kidney-one-clip rats (Liu et al., 2011).
2.3.2. Hypertension associated with reduced renal mass or parenchymal
renal disease
Hypertension can also be a consequence of renal parenchymal dis-
ease, which experimentally often is mimicked by surgically induced
renal mass reduction. Renal mass reduction, with few exceptions
(Toba et al., 2012), is accompanied by an increase in BP. This BP eleva-
tion was prevented by treatment with candesartan (Mackenzie et al.,
1994; Hamaguchi et al., 1996; Noda et al., 1997, 1999; Sugimoto et al.,
1999; Li et al., 1999b; Podjarny et al., 2007), eprosartan (Gandhi et al.,
1999; Wong et al., 2000), irbesartan (Ziai et al., 1996; Cao et al., 2012),
losartan (Lafayette et al., 1992; Kanagy & Fink, 1993; Mayer et al.,
1993; Pollock et al., 1993a; Toba et al., 2013), telmisartan (Tsunenari
et al., 2005; Toba et al., 2013; Zou et al., 2014; Kadhare et al., 2015) or
valsartan (Wu et al., 1997). In a rat reduced renal mass model, losartan
also prevented the additional BP increase caused by a high-salt diet
(Kanagy & Fink, 1993).
Injection of an anti-Thy-1monoclonal antibody is being used as a rat
model of glomerulonephritis; in this model of renal hypertension
candesartan also lowers BP (Nakamura et al., 1997). Such reductions
were even found when anti-Thy-1 injection and uninephrectomy
were combined (Nakamura et al., 1999). In PCK rats, an orthologous
model of human autosomal recessive polycystic kidney disease,
telmisartan lowered BP to a level lower than that in control rats
(Yoshihara et al., 2013). Losartan lowered BP in rats with immune-
mediated kidney disease (passive Heyman nephritis) (Hutchinson &
Webster, 1992).
2.4. Dahl salt-sensitive rats
The Dahl salt-sensitive rat represents an inbred strain which is
genetically susceptible to BP elevation in response to a high-salt diet,
typically applied as a 4–8% NaCl part of their overall chow, sometimes
with additional NaCl in the drinking water; in contrast, there is a Dahl
salt-resistant inbred strain which does not exhibit major BP elevation
upon exposure to a high-salt diet (Rapp, 1982). Whether and to which
degree ARBs lower BP in Dahl salt-sensitive rats on a high-salt diet has
remained controversial. For instance studies with lack of effect were re-
ported for e.g. candesartan (Otsuka et al., 1998), losartan (von Lutterotti
et al., 1992), olmesartan (Kiya et al., 2010) and telmisartan (Takenaka
et al., 2006). Studies with moderate effects, as compared to the results
in SHR or renal hypertensive rats, were reported for candesartan
(Ideishi et al., 1994; Sugimoto et al., 1996), irbesartan (Leenen & Yuan,
2001), losartan (von Lutterotti et al., 1992; Liang & Leenen, 2008),
telmisartan (Liang & Leenen, 2008) or valsartan (Aritomi et al., 2010;
Biala et al., 2011; Nagasawa et al., 2015). However, a small number of
studies reported considerable antihypertensive effects in this model
with BP being reduced almost to the level of Dahl rats not exposed to
a high-salt diet, e.g. with azilsartan (Jin et al., 2014), irbesartan (Takai
et al., 2010), losartan (Liang & Leenen, 2008) or telmisartan (Liang &
Leenen, 2008; Satoh et al., 2010a). It is difﬁcult to determine whether
these equivocal results represent differences between ARBs or between
speciﬁc aspects of the model or assessment techniques being used.
However, it appears that ARBs as a class are less effective BP lowering
agents in the Dahl S model on a high-salt diet than in SHR or renal hy-
pertensive rats. Given that a high salt intake suppresses the RAS activity,
this ﬁnding is not entirely surprising. However, several investigators
have turned this apparent disadvantage into an advantage by studying
ARB effects on end-organ damage in the Dahl S rat, based upon the im-
plication that such effects may argue in favor of BP-independent organ-
protective ARB effects.
An interesting aspect of studies in this model is a potentially en-
hanced role for a local RAS in the brain. Thus, it was reported that an
11–12 day intracerebroventricular (i.c.v.) candesartan infusion lowered
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Dahl salt-resistant rats (Teruya et al., 1995). A partial inhibition of
hypertension development was also reported with chronic intra-
cerebroventricular irbesartan in Dahl salt-sensitive rats; as the applied
dose did not affect pressor responses to peripherally administered
ANG, it can be considered to have acted only within the brain (Leenen
& Yuan, 2001).
2.5. Mineralocorticoid-induced hypertension
Another hypertension model with low RAS activity is based on the
chronic administration of the mineralocorticoid deoxycorticosterone
acetate (DOCA), mostly applied in combination with a high-salt diet.
Similar to most studies in Dahl salt-sensitive rats on a high-salt diet,
ARBs typically caused small if any BP lowering in DOCA-based rat
models as shown with candesartan (Inada et al., 1994; Kim et al.,
1994b; Wada et al., 1995; Fujita et al., 1997; Brown et al., 1999),
irbesartan (Lacour et al., 1994), losartan (Wong et al., 1990a; Inada
et al., 1994), olmesartan (Koike et al., 2001), telmisartan (Sharma &
Singh, 2012) or valsartan (Yamamoto et al., 1997b). These ﬁndings are
similar to those seen in Dahl salt-sensitive rats on a high-salt diet and
not surprising given that mineralocorticoid treatment also suppresses
the RAS. Also in analogy to the Dahl ﬁndings and in contrast to those
with systemic ARB administration, i.c.v. candesartan was found to
lower BP in DOCA rats (Nishimura et al., 1998a). Thus, DOCA rats have
also been used as a model to study potential BP-independent ARB ef-
fects on end-organ damage (see corresponding sections).
2.6. Dietary, obesity and diabetes models of hypertension
Human hypertension often is associatedwith high salt intake, obesi-
ty and/or diabetes mellitus, and all of these can be mimicked in animal
models. Thus, a high-salt (3% of chow) diet given for 5 weeks to other-
wise healthy rats elevated systolic BP by about 35 mmHg, and this ele-
vation was completely prevented by concomitant telmisartan
treatment (Kamari et al., 2010); however, given the typical lack of BP
lowering in SHR on a high-salt diet (see Section 2.2.4) this ﬁnding is
difﬁcult to understand. A high-fat diet given for 12 weeks moderately
increased BP in otherwise healthy rats, albeit to a lesser degree than
the above high-salt diet, and concomitant telmisartan treatment nor-
malized BP in such animals (Wang et al., 2012c). Even a moderately
high-fat diet can induce obesity in rats, which is accompanied by an el-
evated BP; treatment with losartan initiated after induction of obesity
also reduced BP in such rats (Boustany et al., 2005). Hypertension in-
duced by a high-fat diet was also improved by telmisartan in mice
(Penna-de-Carvalho et al., 2014).
Type 2 diabetesmellitus also is often associatedwith some degree of
hypertension, possibly secondary to an impaired renal function.
Fructose-fed rats are a frequently used model of type 2 diabetes. Such
rats often but not always (Kobayashi et al., 1993) exhibit moderate hy-
pertension, and in this model e.g. candesartan (Iimura et al., 1995; Chen
et al., 1996a, 1996b; Higashiura et al., 2000), and telmisartan (Kamari
et al., 2008; Rabie et al., 2015) have been shown to lower BP. In one of
these studies telmisartan and aliskiren yielded similar BP reduction
(Rabie et al., 2015).
Telmisartan lowered BP in SHRSP.Z-Leprfa/IzmDmcr rats in some
(Kagota et al., 2013, 2014) but not all studies (Sugiyama et al., 2013).
Another model of non-insulin-dependent diabetes is the Cohen-
Rosenthal diabetic hypertensive rat, in which telmisartan and valsartan
lowered BP (Younis et al., 2010); in this model telmisartan was also re-
ported to prevent hypertension development when given early (Younis
et al., 2012). Koletsky (fak/fak) rats carry amissensemutation in the lep-
tin receptor on an SHR background, and azilsartan lowered BP in such
rats (Zhao et al., 2011); similarly, SHRcp rats also are an SHR-derived
strain with metabolic syndrome due to a spontaneous nonsense muta-
tion in the leptin receptor gene, and telmisartan and valsartan loweredBP during a 5-week study, but telmisartan yielded a greater reduction in
BP variability and in 24-h urinary noradrenaline excretion (Sueta et al.,
2014). Olmesartan (Harada et al., 1999) and telmisartan (Zhao et al.,
2013) were found to lower BP in Otsuka Long–Evans Tokushima fatty
rats, and azilsartan (Hye Khan et al., 2014b) and irbesartan (O'Donnell
et al., 1997) in obese Zucker rats. In db/dbmiceBP reductionwas report-
ed with losartan (Toyama et al., 2011), olmesartan (Shigahara et al.,
2014), telmisartan (Toyama et al., 2011; Shiota et al., 2012b) and
valsartan (Dong et al., 2010), although the numerical reduction did
not reach statistical signiﬁcance in all studies (Shiota et al., 2012b); in-
terestingly, the ARB effect on BP was not mimicked by aliskiren in this
model (Dong et al., 2010). In KK-Ay mice BP lowering was reported
with azilsartan and candesartan (Matsumoto et al., 2014), but
candesartan did not lower BP in another study (Iwai et al., 2007);
losartan and telmisartan were both reported not to lower BP in this
model (Iwanami et al., 2010).
Administration of STZ is themost frequently usedmodel of type 1 di-
abetes mellitus, and this diabetes model typically is not associated with
hypertension. Nevertheless, and in contrast to most ﬁndings in normo-
tensive rats (see Section 2.1), ARBs have been reported to lower BP in
the rat STZ model, e.g. candesartan (Kato et al., 1999), telmisartan
(Schäfer et al., 2007; Salum et al., 2014; Tojo et al., 2015) or valsartan
(Cao et al., 1998). Why STZ-treated rats are more sensitive to ARBs
with regard to BP lowering than other nomotensive rats has not been
explored.
2.7. Transgenic and knock-out hypertension models
Rat strains such as the SHR and the Dahl salt-sensitive rat have been
generated by generations of phenotype-driven inbreeding for many
years. More recently, rodent hypertension models have become avail-
able which are based on molecular transgenic or knock-out technolo-
gies. While some of these models were generated to produce speciﬁc
cardiovascular phenotypes, others have exhibited such phenotypes as
a byproduct.While transgenic and knock-outmice are technically easier
to generate than e.g. transgenic rats, phenotypic studies typically are
technically easier in rats than in mice. Moreover, there is a greater
body of physiological background knowledge for rats, whereas there is
a greater set of molecular tools for studies in mice. Therefore, both ap-
proaches have been applied and should be seen as complementary.
The ﬁrst transgenic model in the ﬁeld was a rat harbouring the
mouse Ren-2 renin gene, commonly referred to as the (mRen-2)27 rat
(Mullins et al., 1990). These animals exhibit a hypertensive phenotype,
with reduced renal renin expression but increased plasma levels of ac-
tive renin, pro-renin and ANG; ANG tissue levels and plasma aldoste-
rone are also elevated in this model (Campbell et al., 1995). In this
model BP normalization was reported with eprosartan (Rothermund
et al., 2001), irbesartan (Andreis et al., 2000; Rossi et al., 2000),
olmesartan (DeMarco et al., 2011), telmisartan (Böhm et al., 1995;
DeMarco et al., 2011) and valsartan (Kelly et al., 2000). Interestingly,
ARBs also lowered BP in this model when STZ-induced diabetes was
concomitantly present (Kelly et al., 2000). Valsartan was also shown
to lower BP in a model derived from a back-cross of (mRen-2)27 and
Lewis rats (Moniwa et al., 2012) and in double transgenic rats harboring
a human renin and an angiotensin gene (Mervaala et al., 1999).
A model has been created by mating transgenic mice harboring a
human renin or angiotensinogen gene. While either single transgenic
remained normotensive, the double transgenic animals exhibited hy-
pertension; a direct renin inhibitor lowered BP only in the double trans-
genic rats,whereas both captopril and losartan loweredBP in thedouble
transgenic and in the normotensive single transgenic mice (Fukamizu
et al., 1993), reﬂecting that human renin interacts poorly with the mu-
rine substrate. In another study in such double transgenic mice, BP was
lowered by azilsartan or olmesartan, with the former being more effec-
tive at the chosen dose levels (Iwanami et al., 2014). Valsartan also
lowered BP in this double transgenic model (Inaba et al., 2011). In the
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increase of systolic BP to levels of untreated mice, whereas diastolic BP
increased to a much smaller extent.
Among other genetically engineered models, a mouse with
transgenic C-reactive protein expression exhibited an exaggerated BP
response to ANG but the BP lowering effect of telmisartan was
maintained (Vongpatanasin et al., 2007). Elevated BP can also occur in
various knockout mouse models, and some studies have reported
ARB effects in such mice. For instance telmisartan lowered BP in a
knock-out mouse for endothelial NO synthase with superimposed
STZ-induced diabetes (Alter et al., 2012), and valsartan abolished
hypertension in collecting duct endothelin-1 knock-out mice (Ge
et al., 2008). Knock-out mice lacking hypoxia-inducible factor-1α
exhibt an exaggerated BP response in response to ANG infusion and
an elevated resting BP which was lowered upon telmisartan treatment
(Huang et al., 2013).2.8. Other hypertension models
Awide range of other hypertension models exists. Most of them are
based on the administration of ANG, on physiological or surgical inter-
ventions or exhibit an elevated BP as a side effect of treatment with
other drugs. However, hereditary hypertension in inbred rat strains is
not limited to the SHR or Dahl salt-sensitive rats but has also been re-
ported in several other strains. While the speciﬁc pathophysiology of
other hypertensive rat strains has not been elucidated in asmuch detail
as in the SHR (see Section 2.10), it is noteworthy that ARBs typically
were effective anti-hypertensive drugs in these other strains as well.
This includes valsartan in New Zealand genetically hypertensive rats
(Ledingham et al., 2000) or irbesartan in the SHHF/Mcc-facp rat, a
model of spontaneous hypertension and heart failure (Carraway et al.,
1999). However, a follow-up study in the latter model found that
irbesartan reduced BP in lean SHHF/Mcc-facp rats of either gender and
in male obese but not in female obese animals (Sharkey et al., 2001);
the reason for this gender difference, which has not been observed in
most other hypertension models, remains to be elucidated.
Chronic infusion of ANG, i.e. for days to weeks, can cause hyperten-
sion which persists for a long time after discontinuation of ANG admin-
istration. Not surprisingly, this form of ANG-induced hypertension is
prevented or at least attenuated by treatment with ARBs such as
azilsartan (Lastra et al., 2013; Carroll et al., 2015), candesartan (Inscho
et al., 1999), temisartan (Ren et al., 2012) or valsartan (Cao et al., 1999;
Sakai et al., 2008). A physiologically more interesting model is based on
the observation that exposure of rats to cold temperature (5°C) for 1–
3 weeks raises BP, possibly by the cold-induced activation of the sympa-
thetic nervous system; this cold-induced BP elevation was prevented by
losartan (Fregly et al., 1993).
Hypertension can also be induced by surgical intervention, e.g. aortic
banding which causes cardiac pressure overload. In this model ARBs
such as azilsartan (Quinn Baumann et al., 2013), telmisartan (Liu et al.,
2010; Aswar et al., 2013; Zhang et al., 2014a) or valsartan (Obayashi
et al., 1999) lowered BP and reduced systemic vascular resistance. A dif-
ferent surgical model causing hypertension is sino-aortic denervation,
and e.g. telmisartan lowered BP in rats exposed to this intervention
(Wang et al., 2006). Telmisartan lowered BP in rats when administered
after induction of myocardial infarction, and such BP lowering was not
affected by concomitant administration of GW9662 (Nagashima et al.,
2012). Candesartan was reported to lower BP in a rat kidney allograft
transplantation model (Mackenzie et al., 1997).
Endothelium-derived NO is an important contributor to vascular
tone, and its release can be reduced by NO synthase inhibitors such as
L-nitro-argininemethyl ester (L-NAME). Accordingly, chronic treatment
with L-NAME causes hypertension, and ARBs such as candesartan
(Okamura et al., 1994; Liu et al., 1998; Casellas et al., 1999; Fortepiani
et al., 1999), irbesartan (Luvara et al., 1998), losartan (Ribeiro et al.,1992; Jover et al., 1993; Sigmon & Beierwaltes, 1993a; Pollock et al.,
1993b) or olmesartan (Takemoto et al., 1997; Moningka et al., 2012)
lower BP in this model. Interestingly, the BP lowering effect in the L-
NAME rat model was observed on a low and a high sodium diet (Jover
et al., 1993; Okamura et al., 1994). On the other hand, candesartan
lowered L-NAME-induced BP in rats upon i.v. but not i.c.v. administra-
tion (Liu et al., 1998), indicating a peripheral site of action.
Some clinically used drugs can have hypertension as a side effect
and/or can be used experimentally to increase BP. For example the im-
munosuppressant cyclosporin A elevates BP, possibly due to its renal ef-
fects, and e.g. telmisartan (Al-Amran et al., 2011) and valsartan (Lassila
et al., 2000b) lowered BP in a rat model thereof. The dual vascular epi-
dermal growth factor/platelet-derived growth factor inhibitor linifanib,
which is under clinical development for the treatment of certain types
of cancer, also can cause hypertension as a side effect in rats; telmisartan
prevented this BP elevation, but RAS inhibition did not impair its effect
on tumor growth inmice (Franklin et al., 2009). Telmisartanwas report-
ed to attenuate the hypertension developing after a doxorubicin injec-
tion (Rashikh et al., 2014). Experimentally, chronic infusion of
isoprenaline can also cause hypertension, probably via elevation of car-
diac output and stimulation of renin release, and that alsowas attenuat-
ed by telmisartan (Goyal & Mehta, 2012). The moderate BP elevation
induced by the monoamine uptake inhibitor tesofensine was not miti-
gated by concomitant treatmentwith telmisartan (Bentzen et al., 2013).
2.9. Hypotensive states
A limited number of studies has explored whether ARBs affect BP in
already hypotensive conditions. Such work was primarily done in ani-
malswith acutely loweredBP. Thus, followinghemorrhage the vasocon-
striction response to ANG was attenuated in rats, and under such
conditions the BP lowering response to telmisartan was also reduced
(Pieber et al., 1999). However, it remains unclear whether this in part
also reﬂects the lower baseline BP in such animals. While not affecting
resting BP, ARBs such as losartan and telmisartan, at least in high
doses, can affect the BP response to tilting in rats, an animalmodel of or-
thostatic hypotension (Bedette et al., 2008); a studywith eprosartan did
not observe orthostatic hypotension (Ohlstein et al., 1992). Microinjec-
tion of renin into the rat nucleus tractus solitarii causes a depressor re-
sponse, which can be attenuated by concomitant application of ARBs
such as losartan or valsartan (Cheng et al., 2012)
Another experimental conditionwhere basal blood pressure is low is
the pithed rat, which eliminates the central nervous contribution to BP
control. In such animals candesartan, eprosartan, irbesartan, losartan,
EXP3174 or valsartan had no effect on basal BP despite blocking pressor
effects of endogenously administered ANG (Criscione et al., 1993;
Christophe et al., 1995; Balt et al., 2001c) although some early studies
reported losartan-induced BP lowering in this model (Wong et al.,
1990b), speciﬁcally when given on top of propranolol (Zhang et al.,
1993a).
2.10. Mechanistic considerations
The above parts of Section 2 demonstrate that ARBs as a class consis-
tently lower BP in almost all hypertension models ever studied, with
models with a markedly suppressed RAS being the notable exception.
Many of the above studies have also included information which helps
to clarify the underlying mechanisms of the BP-lowering effects of
ARBs. As expected based on the known effects of ANG, the following
overall actions of ARBs have been identiﬁed (Fig. 2):
– Effects on vascular smooth muscle cells (VSMC; see Section 3.1)
– Effects on cardiovascular remodeling (see Sections 3 and 4) includ-
ing those on angiogenesis (Nelissen-Vrancken et al., 1993;
Carbajo-Lozoya et al., 2012; Chaudagar & Mehta, 2014; Nenicu
et al., 2014; Soliman et al., 2014; Verhoest et al., 2014)
Fig. 2.Mechanisms involved in ANG-induced BP elevation. See Section 2.10 for details.
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adrenals (Wong et al., 1990c; Criscione et al., 1993; Andreis et al.,
2000; Lymperopoulos et al., 2014; Miura et al., 2015)
– Effects on renovascular and tubular function (see Section 7)
– Alterations of baroreﬂex function
– Non-renal effects on circulating volume
– Modulation of release of vasoactive neurotransmitters from sympa-
thetic nerve endings
– Effects on the central nervous system (see Section 2.10.1.)
The main underlying tissue mechanism of acute BP reduction by
ARBs is vasodilatation by inhibiting the vasoconstrictive effect of endog-
enous ANGmostlymediated by the blockade of AT1R onVSMC. Howev-
er, there is a range of other effects which may also contribute to BP
lowering by ARBs, but their relative contribution remains to be clariﬁed
andmay differ between experimental models; moreover, some of them
are more relevant for chronic than acute BP lowering. The mechanistic
complexity of ARB-induced BP lowering is illustrated by pharmacody-
namic interaction studies. Thus, the anti-hypertensive ARB effects in
SHR may be attenuated by NO synthase inhibition (Cachofeiro et al.,
1992) or concomitant treatment with capsaicin (Harada et al., 2009)
but not by a kinin antagonist (Cachofeiro et al., 1992) or by concomitant
ibuprofen treatment (Pollock & Morsing, 1999); however, the speciﬁc
mechanisms in many of those interactions have not been explored in
detail and it remains unclear whether they indeed reﬂect pharmacody-
namic interactions or just interference with independent pressure-
relevant mechanisms. Therefore, we will focus on the above eight
mechanisms. Somewill be covered in the indicated subsequent sections
of the manuscript, whereas the others will be discussed in this section,
with a dedicated subsection for the central nervous effects. In mostcases these effects are assumed to primarily occur by inhibition of en-
dogenous ANG. However, a role for inverse agonism, i.e. inhibition of re-
ceptor function in the absence of endogenous agonist, cannot be
excluded. Inverse agonism has been demonstrated e.g. for azilsartan
(Ojima et al., 2011; Miura et al., 2013), the losartan metabolite
EXP3174 (Noda et al., 1996; Miura et al., 2003; Feng et al., 2005),
olmesartan (Miura et al., 2006; Kiya et al., 2010), telmisartan (Bhuiyan
et al., 2009) and valsartan (Miura et al., 2008; Bhuiyan et al., 2009);
whether the parent compound losartan (Miura et al., 2003; Feng et al.,
2005; Bhuiyan et al., 2009) or candesartan (Feng et al., 2005; Miura
et al., 2013) exhibit inverse agonism, has remained controversial.
While inverse agonism is a clearly deﬁned in vitro property of some
ARBs (Michel et al., 2013) and the structural basis of inverse agonism
at AT1R is emerging (Takezako et al., 2015), it remains to be determined
whether it contributes in a relevant manner to their in vivo effects.
The baroreﬂex is primarily important for moment-to-moment BP
control, but by changing its sensitivity it can also become important in
longer term regulation (Hainsworth, 1991). In an early study in con-
scious SHR, both losartan and lisinopril given i.v. signiﬁcantly increased
the maximum gain of the baroreceptor reﬂex control of nerve activity
whereas the AT2R antagonist CGP 42112A did not (Kumagai et al.,
1993). In another study, SHR with a myocardial infarction exhibited a
lowered baroreﬂex gain, but chronic treatment with candesartan not
only restored this but raised it to levels above those of non-infarcted
control rats (Nishizawa et al., 1997). An improved baroreﬂex sensitivity
was also shown in SHR upon treatment with azilsartan or candesartan
(Sueta et al., 2013; Isegawa et al., 2015). Losartan also improved barore-
ﬂex sensitivity in a rat heart failure model (DiBona et al., 1998). While
microinjection of candesartan into the nucleus tractus solitarius did
not change BP in normotensive rats or SHR, it increased the baroreﬂex
sensitivity in both strains (Matsumara et al., 1998). However, i.c.v.
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salt-resistant rats (Teruya et al., 1995). Losartan also increased the baro-
reﬂex sensitivity in conscious rabbits (Wonget al., 1993). The baroreﬂex
sensitization by systemically given ARBsmay be independent of BP low-
ering, as in one study in SHR chronic treatment with irbesartan pro-
duced less if any BP reduction as compared to atenolol, nifedipine or
hydrochlorothiazide but nevertheless yielded a quantitatively similar
baroreﬂex sensitization; based on these ﬁndings it was speculated
that baroreﬂex sensitization along with a reduction of BP variability
may contribute to end-organ protection by ARBs (Xie et al., 2006).
Thus, ARBs as a class appear to increase the sensitivity of the baroreﬂex
and thereby stabilize moment-to-moment BP control.
The circulating volume reﬂects a balance between the intake of ﬂuid
salt and renal excretion as well as the osmotically active substances in
plasma and tissues. It contributes to BP control, and changes thereof
may be part of the anti-hypertensive mechanism of diuretics. The
most important long-term effect of ARBs on circulating volumemay re-
sult from their direct effects on tubular sodiumreabsorption; thiswill be
discussed in Section 7.1. Additionally, it has been found that atrial natri-
uretic peptide can promote a ﬂuid shift from the intravascular to an in-
terstitial compartment; thiswas antagonized by acute administration of
losartan or enaprilat (Valentin et al., 1993), indicating a role for endog-
enous ANG in keeping intravascular volume stable. In isolated beating
rat atria losartan and, to a much greater extent, telmisartan promoted
release of atrial natriuretic peptide; addition of the PPAR-γ antagonist
GW9662 reduced the telmisartan response to that seen with losartan
(Gao et al., 2014b). Acute infusion of telmisartan increased plasma
levels of atrial natriuretic peptide by approximately 80% (Gao et al.,
2014b). Another important role in the control of circulating volume is
played by the hormone vasopressin. Central nervous administration of
ANG causes a pressor response, which is partly mediated by peripheral
V1 vasopressin receptors, indicating that it may involve modulation of
vasopressin release from the pituitary; this vasopressin-dependent
part of the pressor response was inhibited by central administration of
losartan (Toney & Porter, 1993). More direct evidence comes from stud-
ies in which centrally applied ANG stimulated vasopressin release into
the circulation, and ARBs including irbesartan, losartan and telmisartan
given i.v. or orally inhibited this response (Culman et al., 1999; Gohlke
et al., 2001). However, the RAS can also affect circulating volume from
the input side as centrally administered ANG will increase drinking be-
havior and appetite for salt; peripherally administed ARBs inhibit this
drinking behavior (Culman et al., 1999; Gohlke et al., 2001). Thus,
ARBs acting on multiple levels can prevent ANG-induced increases in
circulating volume, and this may contribute to their effects on BP.
Another important player in BP control is the sympathetic nervous
system, which affects vascular tone directly but also indirectly e.g. by
promoting renin release or by reducingdiuresis. Post-ganglionic sympa-
thetic neurons express AT1R which couple to facilitation of the release
of noradrenaline and its cotransmitters (Nap et al., 2003). Thus, various
ARBs were reported to reduce the release of sympathetic transmitters
including noradrenaline and ATP as evoked by electrical ﬁeld stimula-
tion in various in vitro preparations e.g. in rat mesenteric artery (Balt
et al., 2001a), atrium (Shetty & DelGrande, 2000) and ventricle
(Guimaraes et al., 2011), rabbit thoracic aorta (Nap et al., 2002) and
mesenteric artery (Balt et al., 2002), guinea pig mesenteric artery
(Onaka et al., 1997) or atrium (Brasch et al., 1993) or canine pulmonary
artery (Guimaraes et al., 2011). In vivo locally administered irbesartan
inhibited ANG-stimulated catecholamine secretion from canine adre-
nals (Martineau et al., 1995). Most in vivo studies on prejunctional
AT1R were performed in pithed rats, where ANG enhances electrical
stimulation-induced noradrenaline release. In such studies various
ARBs including candesartan, eprosartan, irbesartan, losartan,
telmisartan and valsartan inhibited the ANG effect (Criscione et al.,
1993; Balt et al., 2001b, 2001c; Dendorfer et al., 2002). One study has
suggested that eprosartan but not irbesartan, losartan or valsartan
inhibited the stimulating effect of ANG on sympathetic transmitterrelease (Ohlstein et al., 1997), but the reason for this ﬁnding inconsis-
tent with a range of other studies remain unclear. More limited data in-
dicates that ARBs can block an inhibitory effect of ANG on acetylcholine
release from parasympathetic nerve endings (Rechtman & Majewski,
1993), a ﬁnding which is conceptually difﬁcult to understand and in
need of conﬁrmation.
2.10.1. Central nervous contributions to blood pressure control
The brain expresses AT1R (Speth & Karamyan, 2008) and adminis-
tration of ANG directly into the brain bymicroinjection into deﬁned nu-
clei or i.c.v. administration can elevate systemic BP; i.c.v. administration
of losartan prevented such elevations (DePasquale et al., 1992; Toney &
Porter, 1993; Culman et al., 1999; Gohlke et al., 2001). This centrally
evoked BP elevation apparently has one component related to activa-
tion of the sympathetic nervous system and one related to pituitary va-
sopressin release (Toney & Porter, 1993). While this raises the
possibility that ARBsmay lower BP in hypertension via a central nervous
mechanism of action, the two emerging questions arewhether centrally
administered ARBswill lower BP in hypertensive animals in the absence
of exogenous ANGadministration andwhether peripherally givenARBs,
i.e. in a therapeutic setting, would mimic that.
It has been reported that i.c.v. injection of ARBs such as candesartan
and losartan can lower BP in SHR (Bunting &Widdop, 1995). However,
in that study BP lowering was observed only at high doses which also
inhibited responses to peripherally administered ANG, i.e. a spill-over
to the periphery cannot be excluded. In another study i.c.v. losartan
did not lower BP in SHR whereas oral losartan did (DePasquale et al.,
1992). Injection of losartan into the anterior hypothalmus of salt sensi-
tive SHRs reduced BP, but injection into the posterior hypothalmus had
no effect (Yang et al., 1992b). In a follow-up study from the same inves-
tigators both losartan and EXP3174 injected into the anterior
hypothalmic area reduced BP in SHR on a low or high-salt diet (Yang
et al., 1992a). Microinjection of candesartan into the nucleus tractus
solitarius did not reduce BP in SHR, but interestingly nevertheless sensi-
tized the baroreﬂex in the injected rats (Matsumara et al., 1998). I.c.v.
candesartan also did not lower BP in the L-NAMEmodel whereas i.v. ad-
ministration did (Liu et al., 1998). Taken together these data do not yield
a conclusive picture, and the possibility exists that ARBsmust reach very
speciﬁc nuclei within the brain in sufﬁcient concentrations to exhibit
antihypertensive effects.
Even if it is considered that ARB-induced BP lowering can involve a
central nervous system mechanism, this will only be relevant to the
clinical situation with peripheral drug administration if the ARB pene-
trates into the central nervous system; however, the evidence in favor
of this possibility remains controversial. Moreover, central effects of pe-
ripherally administered ARBs may at least partly result from mediators
released in response to their peripheral vasodilating effects. While pre-
scribing information for all clinically used ARBs states poor to absent
brain penetration (Michel et al., 2013), several experimental studies
have suggested otherwise. Such studiesmostly are based on assessment
of brain functions following peripheral ARB administration. Notably,
negative studies in this regard have largely used single administration
of relative low ARB doses and/or have been based on whole body auto-
radiography upon systemic administration of radioactive labeled ARBs
which has limited sensitivity to detect brain penetration (Song et al.,
1991;Wienen et al., 2000). More recent PET studies have demonstrated
that peripherally injected [11C]-telmisartan can reach therapeutically
relevant concentrations in the brain of monkeys and humans (Noda
et al., 2012; Shimizu et al., 2012). Of note telmisartan appears to be
the most lipophilic ARB (Michel et al., 2013), which means that brain
penetration by other ARBs may be less.
On the other hand, positive studies have typically used relatively
high ARB doses (Muders et al., 2001; Gohlke et al., 2002) and/or extend-
ed treatment durations (Leenen & Yuan, 2001; Muders et al., 2001;
Groth et al., 2003; Hosomi et al., 2005). The BP lowering effect of i.v.
candesartan in SHR was accompanied by an increased release of the
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medulla, and blockade of glycine or GABA receptors attenuates BP low-
ering effect of candesartan; this apparently did not occur secondary to
peripherally mediated BP lowering as administration of nitroglycerin
did not change glycine or GABA release (Yamada et al., 1995). Chronic
systemic treatment with candesartan was found to prevent the BP-
increasing effect of ANG microinjection into the rostro-ventro-lateral
medulla in SHR (Tsuchihashi et al., 1999). Upon chronic dosing
telmisartan also was directly detected in the cerebrospinal ﬂuid of rats
(Gohlke et al., 2001). Accordingly, chronic telmisartan treatment re-
duced oxidative stress in SHR brain (Huang et al., 2012).
While these data do not provide unequivocal evidence for central
AT1R-mediated antihypertensive effects of peripherally administered
ARBs, it needs to be considered that under some conditions the blood–
brain-barrier may become leaky, e.g. with ageing (Farrall & Wardlaw,
2009), in hypertension (Pelisch et al., 2011) or in diabetes (Min et al.,
2012) which may lead to CNS involvement in the effects of ARBs
which otherwise have only poor brain access.
2.11. Hypertension conclusions
In conclusion, ARBs as a class are effective antihypertensive drugs in
all animal models of hypertension except those with a markedly sup-
pressed RAS activity (Table 1). They lower BP in established hyperten-
sion and can prevent the development of hypertension, at least to
some degree, even after discontinuation of treatment. This BP lowering
contributes to beneﬁcial effects on end-organ damage (see Sections 3, 4
and 7) and, at least to some degree, translates into a reduced mortality.
All ARBs appear to have a similar potential for BP reduction. However,
based on their pharmacological properties the duration of BP lowering
of a given dose and the doses required to reach a certain degree of BP
lowering differ considerably between ARBs (Michel et al., 2013).
While acute BP lowering apparently is predominantly mediated by di-
rect effects on vascular smooth muscle, the clinically more relevant
chronic antihypertensive effects probably involve additional indirect ef-
fects including those on renal function and cardiovascular remodeling.
Even animal models which are unresponsive to ARBs due to a sup-
pressed RAS in most cases exhibit BP lowering when ARBs are adminis-
tered in conjunction with other classes of antihypertensive drugs such
as diuretics or Ca2+ entry blockers. ARB doses too low to reduce BP
and animal models of hypertension with a suppressed RAS have been
important to dissect BP-dependent and –independent components of
ARB effects in end-organ protection (see Section 3, 4 and 7).
Of note, ARB doses required for effective BP lowering in rats and
some other species are several fold higher than in humans. This may re-
ﬂect various factors: Firstly, there is limited evidence to suggest intrinsic
species differences in sensitivity for BP-lowering effects of ARBs (Sato
et al., 1997). Second, inter-species comparisons of dose-response curves
are complicated by differences in bioavailability; inter-species differ-
ence in bioavailability have been reported for several ARBs (Michel
et al., 2013). Third, animal studies typically have been performed with
pure compoundwhereas clinical studies have been performedwith for-
mulated drug product. In many cases drug product formulation has
been optimized to yield desired pharmacokinetic proﬁles and, accord-
ingly, often yields different drug exposure and exposure over time as
compared to administration of pure compound. Therefore, doses re-
quired for BP lowering in one species such as rat cannot be directly ex-
trapolated to another species such as human. However, the observation
that some ARB effects, particularly on end-organ damage, can be ob-
served at doses yielding little BP lowering within a model and species
demonstrates that some ARB effects occur largely independent of BP
lowering. As discussed based on speciﬁc examples in subsequent sec-
tions, this conclusion is further supported by the ﬁnding that anti-
hypertensive drugs not acting via modulation of the RAS do not mimic
ARB effects when given in doses causing comparable BP lowering.
Therefore, we consider it very likely that this concept also applies tohumans, although possibly with different speciﬁc doses as compared
to those in animal studies.
3. Vascular function and atherosclerosis
Most blood vessels acutely react to ANGwith vasoconstriction. How-
ever, ANG may also be involved in vascular remodeling with hypertro-
phy of the vessel wall as well as atherosclerosis. As all of these interact
to some degree, this section discusses ARB effects on blood vessel func-
tion in general, and the subdivision intomultiple sections serves to clar-
ify the data, not to imply that the various effects occur independently of
each other.
3.1. Normal vascular function
AT1R are abundantly expressed in the vasculature.Whilemost stud-
ies have focused on those in VSMCs, AT1R are also found in the endothe-
lium (Watanabe et al., 2005). The expression of VSMC AT1R at the
protein level has been demonstrated by radioligand binding studies
(Wilson et al., 1989; Leung et al., 1992; Lyall et al., 1992; Viswanathan
et al., 1992; Criscione et al., 1993; Jaiswal et al., 1993; Sachinidis et al.,
1993; Dickinson et al., 1994; Kubo et al., 1996; Virone-Oddos et al.,
1997; Liang & Leenen, 2008). Detection of AT1R at the protein level by
receptor antibodies appears less reliable because most available AT1R
antibodies have been found to lack target-speciﬁcity (Adams et al.,
2008; Benicky et al., 2012; Herrera et al., 2013) and resulting data can
not necessarily be interpreted at face value.
The primary pathway of AT1R signal transduction is the activation of
phospholipase C to generate inositol phosphates accompanied by an el-
evation of intracellular Ca2+ concentrations. ANG-induced inositol
phosphate formation in rat VSMC is blocked e.g. by losartan and
EXP3174 (Ko et al., 1992; Lyall et al., 1992; Sachinidis et al., 1993;
Dickinson et al., 1994) and Ca2+ elevations in rat, porcine or human
VSMC e.g. by candesartan (Jaiswal et al., 1993; Koh et al., 1994;
Iversen & Arendshorst, 1999), eprosartan (Edwards et al., 1992a),
irbesartan (Herbert et al., 1994; Fortuno et al., 1999) or losartan and
EXP3174 (Ko et al., 1992; Leung et al., 1992; Sachinidis et al., 1993;
Herbert et al., 1994). Interestingly, intracellular microinjection of ANG
can also increase free Ca2+ concentrations in VSMCs, and this can also
be blocked by candesartan (Haller et al., 1999); while the physiological
relevance of this observation remains unclear, recent evidence suggests
that G-protein-coupled receptorsmay exist in a functional state in intra-
cellular compartments after internalization (Irannejad et al., 2013).
Candesartan and telmisartan were also reported to inhibit Ca2+ eleva-
tions in human umbilical artery endothelial cells (Ko et al., 1997) and
murine endothelium-derived bEnd.3 cells (Mulders et al., 2006). In
those cells ANG promoted endothelin-1 release, blocked by
candesartan, whichmay enhance the overall vasoconstriction response;
however, in vivo ANG infusion did not raise plasma endothelin-1 levels
in hypertensive patients (Ferri et al., 1999).
Secondary signal transduction events in the vasculature sensitive to
ARBs include the release of prostaglandin I2 (prostacyclin), e.g. in pigs
(Leung et al., 1992; Jaiswal et al., 1993), the stimulation of a Na/H-
antiporter, e.g. in rat (Ko et al., 1992), the activation of the mitogen-
activated protein kinases, extracellular signal-regulated kinase (ERK)
and p38 in rat VSMCs (Touyz et al., 2001a) or the cellular acidiﬁcation
rate as assessed in a Cytosensor microphysiometer (Dickinson et al.,
1994). Secondary signal transduction in the endothelium, at least in
some vessels, includes stimulation of NO release, which apparently is
mediated by activation of sphingosine kinase (Mulders et al., 2006). In
human coronary artery endothelial cells in culture an ARBwas reported
to increase endothelial NO synthase expression (Kurokawa et al., 2015).
While such signal transduction primarily causes acute changes of vascu-
lar tone, it can also lead to ARB-sensitive enhanced proto-oncogene ex-
pression (Lyall et al., 1992; Sachinidis et al., 1993; Touyz et al., 2001a)
and DNA synthesis and cell proliferation in rat and human VSMC
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1994; Flesch et al., 1995), whichmay be involved in the development of
vascular hypertrophy and atherosclerosis (see Section 3.3.1). Itmay also
lead to increased expression of pro-angiogenic factors (Kurokawa et al.,
2015). However, it should be noted that at least in some preparations
such as rat portal vein it has been questioned whether ANG effects on
prostaglandin or NO release contribute to its overall losartan-sensitive
effect on vascular tone (Zhang et al., 1993c).
All ARBs have been tested for their quantitative ability to inhibit
acute ANG-induced vasoconstriction in vitro. This work has mostly
been performed in isolated rabbit aorta (Wong et al., 1990c, 1990e;
Buhlmayer et al., 1991; Lin et al., 1992; Wienen et al., 1992; Edwards
et al., 1992a; Liu et al., 1992b; Bernhart et al., 1993; Cazaubon et al.,
1993; Criscione et al., 1993; Liu, 1993; Noda et al., 1993; Shibouta
et al., 1993; Wienen et al., 1993; Dickinson et al., 1994; Schambye
et al., 1994; Keiser et al., 1995; Jin et al., 1997;Ojima et al., 1997; Tamura
et al., 1997a; Inada et al., 1999; Morsing et al., 1999; Ojima et al., 2011).
However, antagonism of ANG-induced contraction of isolated blood
vessels was also shown in many other preparations including rabbit
mesenteric artery (Balt et al., 2002), rabbit renal artery (Zhang et al.,
1994; Li et al., 2001), rat aorta (Inada et al., 1994; Fortuno et al.,
1999), rat coronaries (Tschudi & Lüscher, 1995), rat carotid artery
(Inoue et al., 1999), rat portal vein (Zhang et al., 1993c; Morsing et al.,
1999), guinea pig aorta (Leung et al., 1993; Mizuno et al., 1995;
Hashimoto et al., 1997), hamster aorta (Nakamura et al., 1994a; Inoue
et al., 1999), dog pulmonary artery (Guimaraes et al., 2011), pig and
human coronary artery (Maassen van den Brink et al., 1999) and
human gastroepiploic artery (Jin et al., 1997) and human subcutaneous
microvessels (Garcha et al., 1999). Similar inhibition was also observed
for vasoconstriction induced by angiotensin I (Brooks et al., 1992b;
Inoue et al., 1999) or angiotensin(1–7) (Osei et al., 1993a). Of note,
ANG effects on the endothelium may at least partly counteract those
on the VSMC (Li et al., 2001; Mulders et al., 2006).
Accordingly, ARBs consistently inhibited acute ANG-induced BP ele-
vations in vivo. In contrast to the above studies with isolated blood ves-
sels, in vivo assessment of AT1R antagonism in the vasculature has
largely been done in rats (see below), but some studies have also been
performed in mice (Bivalacqua et al., 1999), hamsters (Trippodo et al.,
1995; Jin et al., 1997), dogs (Brooks et al., 1992b; Cazaubon et al.,
1993; Kubo et al., 1993; Christ et al., 1994; Ito et al., 1995; Hashimoto
et al., 1997; Hayashi et al., 1997b), cats (Osei et al., 1993b; Champion
& Kadowitz, 1997; Lambert et al., 1998; Champion et al., 1999a), pigs
(New et al., 2000) or monkeys (Cazaubon et al., 1993; Criscione et al.,
1993; Roccon et al., 1994) (for human studies see below). This involved
studies under a variety of experimental conditions, including conscious,
anesthetized or pithed animals and with oral or i.v. ARB administration.
Such inhibition has been reported for azilsartan (Kohara et al., 1996;
Kusumoto et al., 2011), candesartan (Kubo et al., 1993; Shibouta et al.,
1993; Wada et al., 1994; Kohara et al., 1996; Wada et al., 1996a;
Nakano et al., 1997; Champion et al., 1998; Koike et al., 2001;
Dendorfer et al., 2002; Maillard et al., 2002), eprosartan (Wang &
Brooks, 1992; Edwards et al., 1992a; Brooks et al., 1992b; Dendorfer
et al., 2002), irbesartan (Cazaubon et al., 1993; Lacour et al., 1994;
Christophe et al., 1995; Culman et al., 1999; Schuijt et al., 1999;
Dendorfer et al., 2002; Maillard et al., 2002), losartan (Wong et al.,
1990b, 1990d, 1990e, 1992; Brooks et al., 1992b; Moreau et al., 1993;
Shibouta et al., 1993; Gorbea-Oppliger et al., 1994; Christophe et al.,
1995; Mizuno et al., 1995; Kohara et al., 1996; Almansa et al., 1997;
Tamura et al., 1997a; Culman et al., 1999; Koike et al., 2001; Dendorfer
et al., 2002), olmesartan (Mizuno et al., 1995; Yanagisawa et al., 1996;
Koike et al., 2001; Kusumoto et al., 2011), telmisartan (Wienen et al.,
1993; Maillard et al., 2002; Vincent et al., 2005) and valsartan
(Criscione et al., 1993; New et al., 2000). Such in vivo antagonism stud-
ies were performed not only in healthy normotensive rats, but e.g. also
with chronic oral eprosartan treatment in conscious 5/6 nephrectomy
rats (Gandhi et al., 1999), with losartan in SHR (Wong et al., 1990d) orwith eprosartan as inhibitor of vasoconstriction induced by a 60 min
treatment with lipopolysaccharide in an in situ hamster cheek pouch
preparation (Gao et al., 1995). In some cases they also were not limited
to the inhibition of the systemic BP response to ANG but e.g. with
valsartan have also explored antagonism for speciﬁc vascular beds
(see below).
A large number of studies have also explored direct vascular ARB ef-
fects based on their ability to inhibit ANG-induced BP elevations in
human subjects, in most cases healthy volunteers. For instance
telmisartan increased basal ﬂow and blocked ANG-induced vasocon-
striction in the human forearm in situ (Schinzari et al., 2011). However,
most studies in humans in vivo have looked at BP to represent overall
vasoconstriction. Such studies were reported with most ARBs for in-
stance with candesartan (Delacretaz et al., 1995; Ogihara et al., 1995;
Belz et al., 1997; Malerczyk et al., 1998; Belz et al., 2000; Fuchs et al.,
2000; Gleiter et al., 2004), irbesartan (Belz et al., 1999; Maillard et al.,
1999; Mazzolai et al., 1999; Belz et al., 2000), losartan (Christen et al.,
1991; Munafo et al., 1992; Belz et al., 1997, 1999; Maillard et al., 1999;
Mazzolai et al., 1999; Belz et al., 2000; Fuchs et al., 2000; Gleiter et al.,
2004), telmisartan (Belz et al., 2000; Stangier et al., 2001), and valsartan
(Müller et al., 1994; Morgan et al., 1997; Belz et al., 1999;Maillard et al.,
1999;Mazzolai et al., 1999; Belz et al., 2000).Most of these studieswere
based on single or repeated oral ARB administration and have assessed
the degree of antagonism atmultiple time points. Some of these studies
have assessed inhibition of vasoconstriction in parallel with AT1R occu-
pancy as assessed by ex vivo radioreceptor assays. This approach allows
determining whether potential quantitative differences between drugs
related to chosen drug doses being on different parts of the respective
dose-response curve or to other factors. Indeed evidence for the latter
possibilitywas found in a study inwhich candesartan yielded a stronger
inhibition of ANG-induced BP elevation than losartan for a given level of
receptor occupancy, indicating greater afﬁnity and/or slower off-rate
from receptor (Belz et al., 1997; Fuchs et al., 2000).
However, the vasoconstricting effects of ANG do not occur uniformly
in all vascular beds. Thus, reductions in blood ﬂow upon systemic ad-
ministration of ANG have been observed in mesenteric artery
(Heinemann et al., 1998), gastric mucosa (Heinemann et al., 1999),
hindquarters (Widdop et al., 1993; Osei et al., 1993b; Champion et al.,
1999b), kidney (Widdop et al., 1993; Ruan et al., 1999), lung
(McMahon et al., 1992), isolated eye preparation (Meyer et al., 1995)
or cerebral vessels in an open-skull in situ preparation (Vincent et al.,
2005) in rats, mice, cats and/or pigs. On the other hand, ANG only min-
imally affected perfusion in femoral artery where blood ﬂow even in-
creased with ANG administration (Heinemann et al., 1998). Earlier
studies with antisera, ACE inhibitors or peptidic AT1R antagonists had
conﬁrmed this concept of non-uniform ANG effects on the vasculature.
Correspondingly, ARBs including candesartan, losartan, telmisartan and
valsartan increased blood ﬂow when given alone and/or reversed the
effects of ANG in gastric mucosa (Heinemann et al., 1999), hindquarters
(Widdop et al., 1993; Osei et al., 1993b), kidney (Widdop et al., 1993;
Kanagawa et al., 1997; Ruan et al., 1999), pulmonary circulation
(McMahon et al., 1992) or isolated eye (Meyer et al., 1995) but had
less consistent effects on splanchnic blood ﬂow (Kanagawa et al.,
1997) and lacked effects on blood ﬂow to the brain, heart, adrenals,
skin or skeletalmuscle (Kanagawa et al., 1997). Of note biphasic pressor
responses to ANG have been observed with an early losartan-sensitive
increase followed by a later AT2R-mediated decrease (Scheuer &
Perrone, 1993). Losartan also enhanced adenosine receptor-mediated
vasodilatation in some vascular beds (Smits et al., 1993). All of these
studies, however, exhibit some bias as they only reported on the vascu-
lar beds on which probes had been placed. A less biased approach has
been applied in a study based on deposition of radioactivemicrospheres
(Schuijt et al., 1999). This found that the ANG-induced decrease in sys-
temic vascular conductance was caused by reduced regional conduc-
tances in the gastrointestinal tract (52%), kidney (63%), skeletal
muscle (39%), skin (63%), mesentery and pancreas (32%), adrenal
Fig. 3. Acetylcholine-induced vasodilatation of aortic rings from 30 week old WKY, SHR
and SHR treated with irbesartan in weeks 16–30. Data are means ± SD of 20 animals.
Drawn based on data published by Zalba et al. (2001)).
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tance in adrenal, brain and kidney, and reversed all ANG responses.
Some ARBs, notably irbesartan, telmisartan and, in high concentra-
tions, losartan can also inhibit vasoconstriction mediated by thrombox-
ane A2 receptors, an effect not shared by other ARBs such as candesartan
and apparently being mediated by a direct molecular interaction with
TXA2 receptors (Li et al., 2000; Monton et al., 2000; Fukuhara et al.,
2001; Asano et al., 2006). The degree to which this contributes to their
effects on BP remains to be assessed. Similarly, irbesartan and losartan
but not candesartan or valsartan also inhibited thromboxane A2-
induced aggregation of human platelets (Li et al., 2000).
Some ARBs are partial agonists at PPAR-γ (Michel et al., 2013), and
PPAR-γ full agonists such as pioglitazone and rosiglitazone can cause
vasodilatation in several vascular preparations (Salomone & Drago,
2012) including human pulmonary artery (Kozlowska et al., 2013).
These effects may at least partly occur at the level of the endothelium
(Balakumar & Kathuria, 2012). Therefore, it has been studied whether
PPAR-γ-activating ARBs may at least in part cause vasodilatation via
this mechanism. In mouse mesenteric vessels telmisartan inhibited va-
soconstriction by RAS-independent agonists, and this inhibitionwas ap-
parently NO-mediated; such inhibition was blocked by GW9662 and
absent in PPAR-γ knock-out mice (Yuen et al., 2011). In rat femoral ar-
teries telmisartan but not losartan reduced phenylephrine vasoconstric-
tion and enhanced acetylcholine induced vasodilatation, and the
telmisartan effects were blocked by GW9662 (Siarkos et al., 2011).
However, it remains unclearwhether these examples are representative
for the overall vasculature asGW9662did not attenuate the BP lowering
effect by telmisartan in rats (Nagashima et al., 2012). Moreover,
telmisartan affected mitochondrial function in a manner not shared by
eprosartan; however, pioglitazone had opposite effects and the effects
were maintained in VSMC of PPAR-γ knock-out mice (Takeuchi et al.,
2013).
The vascular effects of ANG in VSMCs and endothelium can be mod-
ulated by those on noradrenaline release from sympathetic nerve end-
ings mediated by AT1R, as shown e.g. in rat mesenteric artery (Balt
et al., 2001a), rabbit thoracic aorta (Nap et al., 2002) andmesenteric ar-
tery (Balt et al., 2002), guinea pig mesenteric artery (Onaka et al., 1997)
or canine pulmonary artery (Guimaraes et al., 2011). Depending on the
vascular bed this may result in α1-adrenoceptor-mediated vasocon-
striction or β-adrenoceptor-mediated vasodilatation.
Vasoconstriction can be inhibited by the presence of perivascular ad-
ipose tissue, and such inhibition diminishes under hypoxic conditions.
Co-incubation of isolated segments of rat mesenteric artery with either
telmisartan or captopril prevented the effects of hypoxia (Rosei et al.,
2015).
In conclusion, ANG can acutely affect vascular tone by acting on
AT1Rs in VSMCs, endothelium and sympathetic nerve endings and
AT2R in VSMCs. In most vascular beds under most conditions the
AT1R VSMCs effect dominates, yielding vasoconstriction as the net re-
sponse. However, stimulation of AT2R in VSMCs and AT1Rs in endothe-
lium can attenuate the vasoconstriction response to some degree but in
most cases contribute to the total vascular response in a minor way
only.While ARBs can inhibit the ANGeffects on VSMC and endothelium,
their net effect almost always is vasodilatation as demonstrated in a
large variety of isolated blood vessel preparations and vascular beds
in vivo. Such inhibition was demonstrated in many species including
humans and, in experimental animals, under a variety of experimental
conditions. ARBs also can prevent agonist-induced desensitization of
vascular responses (Robertson et al., 1994). While these data demon-
strate the ability of ARBs to inhibit acute ANG-induced vasoconstriction,
this does not necessarily mean that ARBs will cause vasodilatation in
every blood vessel under all circumstances.While ARBs as a class inhibit
ANG-induced vasoconstriction and cause vasodilatations, some ARBs
can additionally cause vasodilatation by inhibiting thromboxane A2
and/or stimulating PPAR-γ receptors. While it remains to be investigat-
ed whether and to which degree relative to AT1R antagonism thiscontributes to BP lowering, the overall similarity in BP lowering poten-
tial betweenARBsmakes amajor contribution of these additionalmech-
anisms to overall BP lowering unlikely. Functional or morphological
damage to the endothelium may shift the balance between
vasoconstricting AT1R on VSMCs and vasodilating AT1R on endotheli-
um and lead to a greater vasoconstriction in response to ANG (see
below).
3.2. Altered endothelial function
The endothelium is a physiological modulator of VSMC function. By
release of NO and other factors it can cause vasodilatation, but it can
also releasemediatorswhich causeVSMC contraction.While the release
of vasodilating factors dominates in healthy endothelium inmost cases,
endothelial dysfunction can develop in pathological settings leading to a
more pronounced vasoconstriction response. Moreover, endothelial
dysfunction can be a step towards development of atherosclerosis. En-
dothelial function is typically assessed in vitro by determining the sen-
sitivity to a muscarinic receptor agonist such as acetylcholine to
induce relaxation of vascular preparations in an organ bath. Endothelial
dysfunction can be observed in multiple models of hypertension and
various other pathophysiological states. For example, acetylcholine-
induced vasodilatation was markedly reduced in aortic rings from
30 week old SHR, but this was largely restored in SHR which had been
treated with irbesartan from weeks 14–30 (Fig. 3) (Zalba et al., 2001).
Similar restoration of endothelial function was observed e.g. in small
mesenteric arteries from SHR upon treatment with candesartan
(Rizzoni et al., 1998), from obese SHR with azilsartan (Hye Khan et al.,
2014a) or from obese SHRSP.Z-Leprfa/IzmDmcr rats with telmisartan
(Kagota et al., 2014). The endothelial dysfunction in SHR can be further
worsened by ovariectomy, and irbesartan treatment restored it to a sim-
ilar degree as estrogen replacement (Wassmann et al., 2001). The endo-
thelial dysfunction in obese Zucker rats was fully restored by treatment
with azilsartan (Hye Khan et al., 2014b) and at least partially restored
upon treatment with azilsartan or candesartan in KK-Ay mice
(Matsumoto et al., 2014). Endothelial dysfunction can also be induced
by chronic arsenite exposure in rats and was also improved by
telmisartan treatment (Nirwane et al., 2015).
Two lines of evidence support the idea that ARB-induced normaliza-
tion of endothelial function is not primarily mediated by BP reduction.
Firstly, when given at doses causing similar BP reduction in obese SHR,
telmisartan but not amlodipine or moxonidine restored acetylcholine-
induced vasodilatation (Kagota et al., 2007). In Dahl S rats on a high
salt diet a 2-week treatment with telmisartan or hydralazine lowered
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induced relaxation of aortic rings (Satoh et al., 2010a). In another
model with a suppressed RAS, DOCA-treated rats, telmisartan also im-
proved endothelial function in aortic rings (Sharma & Singh, 2012).
Thus, ARBs improved endothelial dysfunction in several hypertensive
settings where effects were not explained by those on BP. Secondly,
telmisartan and ramipril similarly improved endothelial function in
ApoE knock-out mice on a high cholesterol diet, which are not hyper-
tensive, (Schlimmer et al., 2011). Telmisartan also improved endothelial
function in a normotensive, STZ-based rat model of type 1 diabetes,
along with a reduction of reactive oxygen species (Wenzel et al.,
2008); this improvement occurred similarly upon treatment with a
telmisartan dose, which did not lower BP, and with a telmisartan–
amlodipine combination treatment, which lowered BP (Mollnau et al.,
2013). Improved endothelial function upon telmisartan but not losartan
treatment was also reported in ApoE knock-out mice (Nakagami et al.,
2008); however, another study reported that telmisartan and ramipril
were similarly effective in restoring endothelial function in this model
(Schlimmer et al., 2011). In Watanabe hyperlipidemic rabbits, another
hereditary atherosclerosis model, telmisartan increased acetylcholine-
induced NO release, a surrogate marker of endothelial function;
telmisartan plus GW9662 or candesartan were less effective than
telmisartan, suggesting a possible involvement of both AT1Rs and
PPAR-γ (Ikejima et al., 2008). Some improvement of this surrogate
marker was also observed with valsartan, and this was further
enhanced by combination with pitavastatin (Imanishi et al., 2008a) or
aliskiren (Imanishi et al., 2008b). In the same model irbesartan also
improved endothelial function (Oelze et al., 2000). Thus, ARBs also im-
proved endothelial dysfunction in non-hypertensive models. A beneﬁ-
cial effect of ARBs as a class on endothelial function is also supported
by various clinical studies, in which ARBs and ACE inhibitors improved
endothelial function to a greater extent not only as compared to placebo
but also as compared to calcium channel blockers orβ-adrenoceptor an-
tagonists (Benndorf et al., 2007; Shahin et al., 2011), highlighting the
role of ANG in endothelial pathophysiology and RAS inhibition in its
treatment.
Endothelial dysfunction can be induced experimentally by treat-
ment with nitroglycerin for several days; in this model telmisartan
treatment prevented endothelial dysfunction and partially improvedni-
trate tolerance (Knorr et al., 2011). In a normotensive rat model with
subtotal nephrectomy it has been found that telmisartan improves en-
dothelial function in aortic rings, an effect blunted by GW9662 and
only partly mimicked by losartan; this has led the investigators con-
clude that the improvement of endothelial function may be mediated
by PPAR-γ (Toba et al., 2012). On the other hand, telmisartan also im-
proved acetylcholine-induced dilatation of mesenteric vessels in
SHRSP.Z Leprfa/IzmDmcr rats, a model of metabolic syndrome, but this
was not mimicked by the PPAR-γ full agonist pioglitazone (Kagota
et al., 2009, 2011).Moreover, improved of endothelial function in sever-
al othermodels by e.g. candesartan or irbesartan (see above) also argues
against a major role of PPAR-γ in this effect.
3.3. Vascular remodeling and atherosclerosis
During aging and in the context of various pathologies, most impor-
tantly arterial hypertension, the vasculature undergoes functional and
morphological changes. These mainly involve vascular hypertrophy,
which represents a relative or even absolute increase in the thickness
of the arterial media leading to an increased media/lumen ratio, also
referred to as inward remodeling. Long-standing hypertension as well
asmetabolic diseasemay also induce atherosclerosis. This occursmainly
in large andmediumarteries; it leads tomultiple types of cardiovascular
disease and ultimately premature death. Following early phases of
endothelial dysfunction, fatty streaks with macrophage and T-
lymphocyte invasion develop, leading to intermediate to advanced le-
sions, narrowing of the vascular lumen and thrombosis (Ross, 1999).The development of atherosclerotic lesions, often accompanied by hy-
pertrophy of vascular smooth muscle, involves a range of cell types; ac-
cordingly, several cell types in culture have been used as in vitromodels
of atherosclerosis development. In vivo a large variety ofmodels, largely
related to hypertension andmetabolic disease, have been used to study
vascular remodelling and atherosclerosis and its possible treatment.
Interpretation of studies on vascular remodeling and atherosclerosis
is hampered by the fact that investigators have used different pharma-
cological probes. Differing effects are preferentially interpreted to re-
ﬂect different mechanisms induced by different mechanisms inherent
to the molecules used. This makes comparisons between studies risky
as they have used different experimental models, experimental condi-
tions and/or probeswith different pharmacokinetic proﬁles, particularly
in a very complex setting such as atherosclerosis. This limitation should
be kept in mind in the interpretation of the subsequent data.
3.3.1. In vitro models
Although the development atherosclerosis is a complex process in-
volving the interaction of many cell types in the circulation and the ves-
sel wall, various in vitro models, largely based on culturing of one
speciﬁc cell type, have been used to allow a better molecular under-
standing of effects in speciﬁc cell types. These include endothelial
cells, VSMCs and inﬂammatory cells such as macrophages, monocytes
and other white blood cells. ARB effects on adipocytes, which can also
contribute to atherosclerosis via inﬂammatory mediators, will be cov-
ered in Section 6.1.
3.3.1.1. Endothelial cells. The endothelium not only plays an important
role in the acute regulation of vascular tone (see Section 3.1) but also
is involved in the migration of inﬂammatory cells to the vascular wall
(Ross, 1999) and in vascular development (Coultas et al., 2005); endo-
thelial cell proliferation is a relevant step in the development of intima
hyperplasia. Alterations of endothelial function may affect the perme-
ability of large molecules from the lumen to the vascular wall. ANG
can play an important role in these processes, but the effects of some
ARBs on the endothelium may additionally involve PPAR-γ and are in
line with those of selective PPAR-γ agonists (Cheang et al., 2015).
Human umbilical vein endothelial cells (HUVECs) are a frequently
used model of human endothelium.
Atherosclerotic plaques primarily develop in arterial regions ex-
posed to non-uniform shear stress, and are initiated by leukocyte-
endothelial interactions (Ross, 1999). In isolated rabbit jugular vein seg-
ments, deformation induced expression of pre-pro-endothelin-1 and
endothelin B receptor, which was inhibited by candesartan and
irbesartan (Lauth et al., 2001). In the same study, such expression was
also inhibited by irbesartan or ramiprilat in cultured porcine aortic en-
dothelium. In HUVECs, exposure to non-uniform shear stress combined
with TNF-α induced monocyte adherence, which was concentration-
dependently inhibited by telmisartan (Cicha et al., 2011); this inhibition
involved a reduced expression of the adhesion molecule VCAM-1 and
was blocked by GW9662. Other studies in HUVECs, based on TNF-α
stimulation alone, conﬁrmed the inhibitory effect of telmisartan on vas-
cular cell adhesion molecule (VCAM) 1 and also NF-κB expression;
while this was not mimicked by losartan, EXP3174 or EXP3179, it also
was not blocked by GW9662 (Cianchetti et al., 2008; Nakano et al.,
2009). However, as part of these studies both losartan and telmisartan
inhibited ANG-induced cell death (Cianchetti et al., 2008). Telmisartan
also inhibited the tumor necrosis factor (TNF) α-induced expression
of a secretory phospholipase A2 in HUVECs (Sonoki et al., 2012); while
ANG did not induce this phospholipase, the PPAR-γ inhibitor GW3335
did not block it, indicating that the effect may be independent of both
AT1Rs and PPAR-γ. Attenuation of the homocysteine-induced increased
monocyte chemoattractant protein (MCP) 1 and VCAM-1 expression in
HUVECswas attenuated by telmisartan; a PPAR-δ antagonist attenuated
this and a PPAR-δ agonist mimicked the telmisartan response (Xu et al.,
2014). In bovine retinal capillary cells asymmetric dimethylarginine, an
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pression at the mRNA and protein level; at the mRNA level this was
inhibited by both telmisartan and benazepril, indicating mediation via
AT1Rs, whereas at the protein level only telmisartan yielded signiﬁcant
inhibition (Chen et al., 2011). While all of these studies agree that
telmisartan can inhibit intercellular adhesion molecule-1 expression,
they are equivocal with regard to the involvement of AT1Rs, PPAR-γ
and, yet to be deﬁned, other mechanisms. In cultured HUVECs
telmisartan was also reported to down-regulate zona occludens-1
mRNAand protein levels, disrupt its continuous pericellular distribution
and increase their permeability; this effect was not mimicked by
valsartan but blocked by GW9662 (Bian et al., 2009). Telmisartan also
concentration-dependently prevented HUVEC apoptosis induced by
the glucose metabolite methylglyoxal (Baden et al., 2008) and ANG-
stimulated expression of matrix metalloproteinase-2 in HUVECs (Sato
et al., 2014c). Telmisartan but not irbesartan or valsartan increased
phosphorylation of endothelial NO synthase in HUVECs (Myojo et al.,
2014). As part of the same study it was shown that in vivo treatment
ofmicewith telmisartan resulted in increased phosphorylation of endo-
thelial NO synthase in the aorta. Accordingly, endothelial dysfunction
induced by ANG in isolated rabbit aortic rings was prevented by
telmisartan (Hu et al., 2014).
While NOproductionwas stimulated by ANG in some types of endo-
thelial cells (Mulders et al., 2006), in cultured bovine aortic endothelial
cells valsartan stimulated NO formation (Su et al., 2009). The latter was
related to an increased phosphorylation but not expression of endothe-
lial NO synthase. Both telmisartan and benazepril attenuated endotheli-
al cell proliferation induced by asymmetric dimethylarginine (Chen
et al., 2011). In bovine aortic endothelial cells, both azilsartan and
valsartan concentration-dependently inhibited proliferation in the ab-
sence of exogenous ANG but did not activate PPAR-γ (Kajiya et al.,
2011). Losartan reduced intimal hypertrophy in an organ culture
model of human saphenous vein (Varty et al., 1994). Detailedmolecular
studies on the mechanisms involved in endothelial cell proliferation,
sprouting and neo-angiogenesiswere also performed in primary bovine
retinal and immortalized ratmicrovascular endothelial cells aswell as in
a mouse model of oxygen-induced proliferative retinopathy, where
telmisartan and the AT2R antagonist PD 123319 had opposite effects
which involved both Gi and G12/13 G-proteins and rho kinase (Carbajo-
Lozoya et al., 2012). On theother hand, telmisartan, but neither losartan,
valsartan nor the Ca2+-entry blocker amlodipine, also inhibited HUVEC
proliferation and prevented their entry into the S-phase of the cell cycle
(Siragusa& Sessa, 2013). Thiswas linked to a speciﬁc change in gene ex-
pression as detected by microarray analysis, reduced phosphorylation
of Akt and glycogen synthase-3β leading to p53 accumulation in the nu-
cleus and rapid turnover of cyclin D1; on the other hand, telmisartan
down-regulated pro-apoptotic genes and protected HUVECs from
serum starvation-induced apoptosis.
While not necessarily directly linked to atherosclerosis develop-
ment, advanced glycosylation end products (AGE) and their receptor
RAGE play a central role in the development of diabetic vascular compli-
cations. In human microvascular endothelial cells telmisartan inhibited
RAGE expression, and in a clinical study also reduced circulating RAGE
in human plasma (Nakamura et al., 2005). Inhibition of RAGE expres-
sion in human endothelial cells was conﬁrmed in a later study and
shown to be blocked by GW9662 (Yamagishi et al., 2008).
Endothelial progenitor cells are a circulating pool of cells,which con-
tribute to endothelial replenishment. They express both AT1R and AT2R
(Endtmann et al., 2011), and have been used as amodel system to study
ARB effects. Telmisartan stimulated human endothelial progenitor cells
proliferation in vitro, and inhibited TNF-α-induced apoptosis of such
cells in a GW9662-sensitive manner (Honda et al., 2009; Cao et al.,
2014). Thiswas conﬁrmed by other investigators, who also demonstrat-
ed that telmisartan also increased the number of such cells in bonemar-
row and peripheral blood in mice in vivo (Steinmetz et al., 2010). An
in vivo increase in endothelial progenitor cells in circulating blood hasalso been reported with telmisartan in SHR (Yoo et al., 2015). In
human endothelial progenitor cells ANG induced expression of
NADPH oxidase and promoted senescence, and telmisartan inhibited
such ANG effects (Li et al., 2011). In another study ANG induced apopto-
sis of human endothelial progenitor cells through a pathway involving
c-Jun N-terminal kinase and p38 mitogen-activated protein kinase, de-
creased Bcl-2 and increased Bax, and activation of caspase 3; irbesartan
inhibited those effects (Endtmann et al., 2011). Within the same study
ANG infusion reduced the number of endothelial progenitor cells in
wild-type but not AT1aR knock-out mice, whereas telmisartan treat-
ment of patients with stable coronary artery disease increased circulat-
ing progenitor cell number. However, using rat bone marrow-derived
endothelial progenitor cells, ANG was reported to inhibit apoptosis
and to enhance NO release and adhesion potential, an effect being
blocked by valsartan (Yin et al., 2008). Circulating endothelial progeni-
tor cell numbers have been reported to be markedly increased in mice
with renovascular hypertension, a phenomenon that could be mim-
icked by ANG administration; treatment with telmisartan, quinapril
and hydralazine similarly reduced these circulating progenitor cells
(Salguero et al., 2008), indicating an effect secondary to BP lowering.
Culturing for many passages can induce cellular senescence in
endothelial cells. This was concentration-dependently reversed by
telmisartan, an effect blocked by GW9662 or PPAR-γ siRNA, but not af-
fected by co-incubation with ANG and not mimicked by eprosartan
(Scalera et al., 2008). Taken together these data show a beneﬁcial effect
of AT1R inhibition on endothelium proliferation and endothelial pro-
genitor cell number; telmisartan may have additional, PPAR-γ-
mediated effects on these cells but the relative roles of AT1R-mediated
and AT1R-independent effects remain unclear. Accordingly, a recent
meta-analysis has indicated that ARBs as a class improve endothelial
function in patients as assessed by ﬂow-mediated vasodilatation (Li
et al., 2014b).
3.3.1.2. Vascular smooth muscle cell (VSMC).While isolated and cultured
VSMCs have frequently been used as in vitro models of vascular hyper-
trophy and atherosclerosis, it is important to realize that AT1R expres-
sion can decline to non-detectable levels after several passages in
culture (Ko et al., 1997), a phenomenon that also applies to receptors
for other pro-contractile mediators in other types of smooth muscle
(Arrighi et al., 2013) and apparently represents a re-differentiation of
smooth muscle cells in culture from a contractile to a synthetic pheno-
type (Hendriks-Balk et al., 2008). Such AT1R down-regulation after sev-
eral passages in culture implies that the relative roles of AT1R-
independent ARB effects may be overestimated in late passages. With
this caveat in mind inhibition of ANG-induced hypertrophy and/or pro-
liferation has been shown in cultured VSMCs from multiple species in-
cluding rats (Ko et al., 1992; Millet et al., 1992; Sachinidis et al., 1992,
1993; Koh et al., 1994; Sung et al., 1994; Flesch et al., 1995; Itazaki
et al., 1995; Kubo et al., 1996; Sachinidis et al., 1996a, 1996b; Graf
et al., 1997; Virone-Oddos et al., 1997; Fukuda et al., 1999; Muniz
et al., 2001; Touyz et al., 2001b) and humans (Herbert et al., 1994;
Mueck et al., 1999;Wang et al., 2012a). Its antagonismhas been demon-
strated with multiple ARBs including candesartan and its prodrug (Koh
et al., 1994; Flesch et al., 1995; Itazaki et al., 1995; Kubo et al., 1996;
Sachinidis et al., 1996a, 1996b; Fukuda et al., 1999), eprosartan (Sung
et al., 1994), irbesartan (Herbert et al., 1994; Graf et al., 1997; Xi et al.,
1999;Muniz et al., 2001; Touyz et al., 2001b), losartan and its activeme-
tabolite EXP3174 (Ko et al., 1992; Millet et al., 1992; Sachinidis et al.,
1992, 1993; Herbert et al., 1994; Sung et al., 1994; Itazaki et al., 1995;
Virone-Oddos et al., 1997), telmisartan (Wang et al., 2012a) and
valsartan (Mueck et al., 1999; Wang et al., 2012a). However, a study
in isolated rat aorta found that ANG stimulated protein but not DNA
synthesis in a losartan-sensitive manner (Holycross et al., 1993),
questioning whether the proliferation-enhancing effects observed
with cultured VSMC also occur in situ. Moreover, it should be noted
that the overall in vitro effects of ANG on vascular hypertrophy are
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in vivo (see next paragraph). However, direct peri-vascular ANG
application to normotensive rat carotid arteries for 14 days induced
dose-dependent adventitia thickening with increased DNA synthesis,
neovascularization and collagen deposition; proliferation and collagen
disposition was blocked by valsartan, whereas the observed neovascu-
larizationmay beAT2R-mediated (Scheidegger &Wood, 1997). Perhaps
independent of proliferation, ARBs may also affect the inﬂammatory
part of atherosclerosis. Thus, in rat aortic VSMCs, telmisartan
concentration-dependently reduced TNF-α-induced interleukin (IL) 6
expression; this was prevented by GW9662 and not mimicked by
valsartan (Tian et al., 2009), suggesting PPARγ involvement.
Of note, ANG can not only promote VSMC hypertrophy and prolifer-
ation when given alone, but may have synergistic effects when admin-
istered in concert with other mediators such as prostaglandins
(Sachinidis et al., 1996b) or platelet-derived growth actor or epidermal
growth factor (Sachinidis et al., 1996a); these synergistic effects were
also sensitive to ARB treatment. On the other hand, it has remained con-
troversial whether ARBs will affect serum-stimulated VSMC prolifera-
tion, as this was inhibited by telmisartan (apparently not PPAR-γ-
mediated) (Wang et al., 2012a), whereas inhibition by candesartan
was found in one study (Kubo et al., 1996) but not in two others
(Mueck et al., 1999; Wang et al., 2012a). The basal VSMC proliferation,
i.e. in the absence of serum, was reported to be sensitive to candesartan
in cells isolated from SHR but not those fromWKY (Fukuda et al., 1999;
Kubo et al., 1996). This may relate to the observation that SHR VSMCs
express more angiotensinogen and ACE than those from WKY and ex-
hibit a greater ANG release (Fukuda et al., 1999). In another study
with human VSMCs, basal proliferation was inhibited by telmisartan
but not by eprosartan, irbesartan or valsartan (Yamamoto et al.,
2009b). Within the same study telmisartan, but not valsartan, similarly
inhibited basal proliferation of VSMCs obtained from wild-type and
PPAR-γ knock-out mice. Similarly, telmisartan but not candesartan,
eprosartanor irbesartan concentration-dependently inhibited prolifera-
tion of rat VSMCs in the presence or absence of platelet-derived growth
factor/insulin, but nonetheless this apparently was not PPAR-γ-related
(Benson et al., 2008). Taken together these data indicate that ARBs can
inhibit VSMC proliferation involving both AT1R and, for some ARBs,
AT1R-unrelated but not PPAR-γ-mediated effects. ANG also stimulates
adhesion of VSMC to collagen ﬁbronectin in irbesartan-sensitive man-
ner; while this is β1-integrin dependent, ANG itself did not change
integrin expression (Kappert et al., 2000).
Mechanistically, the anti-proliferative effect of ARBs appears
to involve an inhibition of ANG-induced elevations of intracellular
Ca2+-concentrations (Herbert et al., 1994; Koh et al., 1994; Ko et al.,
1997; Sakurada et al., 2013), activation of ERK (Sung et al., 1994; Graf
et al., 1997; Xi et al., 1999; Touyz et al., 2001a, 2001b; Kajiya et al.,
2011; Zhong et al., 2011) and other members of the mitogen-activated
protein kinase family (Touyz et al., 2001a, 2001b; Zhong et al., 2011), ty-
rosine phosphorylation of focal adhesion molecules such as paxilin
(Okuda et al., 1995), increased expression of c-fos and c-myc (Lyall
et al., 1992; Millet et al., 1992; Hirata et al., 1994; Xi et al., 1999), reduc-
tion of NO synthase (Nakayama et al., 1994) and endothelin-1 expres-
sion (Sung et al., 1994). The ANG-stimulated migration of VSMCs was
also inhibited (Graf et al., 1997; Xi et al., 1999). Such ﬁndings have not
only been obtained in VSMC from the general circulation but also from
specialized vessels, e.g. from the porcine ciliary artery (Dubey et al.,
1998); in this preparation ANG had only a low potency in stimulating
proliferation; the potency of ANG to promote proliferation was in-
creased in the presence of insulin, whereas its potency in stimulating
VSMC migration was independent of insulin. Moreover, as reported
frommurine aortic VSMCs, telmisartanmay inhibit autophagy, possibly
via a PPAR-γ pathway (Li et al., 2015).
3.3.1.3. Macrophages, monocytes and other white blood cells. The invasion
of the vascular wall by inﬂammatory cells including macrophages andmonocytes is an important step in the development of atherosclerotic
lesions (Ross, 1999). Therefore, ARB effects have also been tested in iso-
lated white blood cells. Circulating human monocytes typically express
little AT1R mRNA or protein, and ARBs do not modify cytokine release
from such cells; this expression pattern is not affected by exposure to
ANG or lipopolysaccharide (Larrayoz et al., 2009; Pang et al., 2012).
Nevertheless, candesartan and telmisartan were reported to inhibit
the lipopolysaccharide-induced expression and secretion of cytokines
such as TNFα, IL-1β and IL-6, whereas losartan had a smaller effect
(Larrayoz et al., 2009; Pang et al., 2012). Inhibition of
lipopolysaccharide-induced expression of TNFα and MCP-1 by
telmisartan but not losartan, olmesartan or valsartanwere also reported
by others, and in that study the telmisartan effects were abrogated by
small interfering RNA (siRNA) against PPAR-γ (Matsumura et al.,
2011). Telmisartan also inhibited lipopolysaccharide-induced IL-6 and
MCP-1 expression in the monocyte-derived THP1 cell line (Konda
et al., 2014). Additionally, telmisartan was shown to concentration-
dependently inhibit lipopolysaccharide-induced ERK and p38 phos-
phorylation, expression of PPAR-γ target genes NF-κb, CD36 and
ABCG1, expression of cyclooxygenase-2 expression and prostaglandin
E2 release, release of reactive oxygen species, reduction of IκB expres-
sion, and monocyte migration (Pang et al., 2012). PPAR-γ silencing by
corresponding siRNA abolished the effects of telmisartan on CD36 and
ABCG1 expression aswell as the inhibitory effects on IκB and TNF-α ex-
pression. The effect of telmisartan, and to a lesser extent of irbesartan,
on CD36 expression in human monocytes has also been shown by
other investigators (Kappert et al., 2009). Given the lack of AT1R expres-
sion in human monocytes (Larrayoz et al., 2009; Pang et al., 2012), the
direct effects of candesartan, irbesartan and telmisartan on PPAR-γ
(Erbe et al., 2006; Storka et al., 2008), and the attenuation of telmisartan
effects by PPAR-γ gene silencing (Pang et al., 2012), it appears that the
anti-inﬂammatory effects of these ARBs in human monocytes are not
mediated by AT1R but rather by PPAR-γ. In line with these in vitro ef-
fects, treatment of hypertensive patients with telmisartanwas reported
to lower the enhanced adhesiveness of monocytes obtained from such
patients to human endothelial cells, which occurred largely indepen-
dent of chemokine receptor expression (Syrbe et al., 2007).
Monocytes and the humanmonocyte cell line THP1 can differentiate
intomacrophages ormacrophage-like cells, respectively, and in contrast
to monocytes, these cells may become responsive to ANG. Thus, ANG
stimulated peroxide formation in differentiated THP1 cells and this
was inhibited by candesartan (Yanagitani et al., 1999). Similarly, other
investigators reported that ANG caused down-regulation of ABCA1 but
not and ABCG1 (both considered as PPAR-γ target genes) in differenti-
ated THP1 cells; these ANG effects were abolished by by telmisartan
and valsartan, whereas an AT2R antagonist or GW9662 remained with-
out effect, indicating mediation by AT1R (Chen et al., 2012a). These
transporters are relevant to atherosclerosis because they mediate cho-
lesterol efﬂux from macrophages. Telmisartan also increased the ex-
pression of ABCA1, ABCG1 and SR-B1 in differentiated THP1 cells in
the absence of exogenous ANG, an effect that was suppressed by
PPAR-γ knock-down (Nakaya et al., 2007). On the other hand, inmurine
peritonealmacrophages telmisartan increased PPAR-γ activity,whereas
losartan, olmesartan or valsartan did not (Matsumura et al., 2011). In
that study telmisartan induced CD36 and ABCA1 and ABCG1 expression
and suppressed macrophage proliferation induced by oxidized LDL, ef-
fects which were abrogated by PPAR-γ gene silencing. Whether these
differences regarding a role of PPAR-γ in ARB effects on the regulation
of macrophage function represent those between species and/or those
between primary cells and cell lines remains to be explored. Raw264.7
cells are another macrophage-derived cell line; telmisartan reduced
the inﬂammatory response to lipopolysaccharide administration
(Balaji & Ramanathan, 2014).
In isolated human lymphocytes telmisartan concentration-
dependently inhibited expression of the β2-integrin MAC-1, irrespec-
tive of the presence of ANG, indicating an AT1R-independent effect; in
Fig. 4. Effects of a 2 week treatment of 20 week old SHR with single daily s.c. injections of
saline (control), losartan or hydralazine on vascular hypertrophy. Data are means± SD of
5–10 animals. Calculated and drawn based on data published by Soltis (1993)).
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coronary artery disease, telmisartan also lowered MAC-1 expression,
whereas that of C-reactive protein, soluble intercellular adhesion
molecule-1 and IL-6 were not affected (Link et al., 2006). Migration of
CD4+ lymphocytes into the vessel wall is also an early step in the devel-
opment of atherosclerosis. Migration of such lymphocytes is stimulated
by stromal-derived factor, and this was concentration-dependently
inhibited by telmisartan (Walcher et al., 2008). Such inhibition was
mimicked by several PPAR-γ activators but not by eprosartan and
blocked by small interfering RNA against PPAR-γ. The molecular basis
of the AT1R-independent inhibition by telmisartan was an inhibition
of phosphatidylinositol 3-kinase activity.
3.3.2. In vivo models
Vascular remodeling including arterial wall hypertrophy and in-
creased media/lumen ratio and atherosclerosis are related phenomena.
While remodeling is most prominent with chronically elevated BP, ath-
erosclerosis occurs largely under hyperlipidemic conditions, as a conse-
quence of diabetes and upon mechanical damage to the endothelium
such as in the balloon injury models. Endothelial dysfunction can be
an early step in the development of atherosclerosis (see Section 3.2.).
The importance of studying ARB effects on atherosclerosis not only in
cultured cells but also in vivo is illustrated by a report that in an isolated
artery ANG promoted protein synthesis but, in contrast to cultured
VSMCs, not DNA synthesis (Holycross et al., 1993). The potential of
ARBs in vascular remodeling is indicated by studies inwhich chronic ad-
ministration of ANG induces aortic thickening in mice (Sakurada et al.,
2013) or rats (Cao et al., 1999).
3.3.2.1. Hypertension models. Effects of hypertension on vascular remod-
eling have largely been studied in SHR and their stroke-prone substrain
(Bennai et al., 1999; Kim et al., 1995c), but some studies have also been
performed in New Zealand genetically hypertensive rats (Ledingham
et al., 2000), Dahl salt-sensitive rats (Liang & Leenen, 2008) or in
(mRen-2)27 transgenically hypertensive rats (Rossi et al., 2000); it
has also been observed in pharmacologically induced hypertension,
e.g. by NO synthase inhibitor treatment (Takemoto et al., 1997; Luvara
et al., 1998) or in the surgically induced hypertension model of aortic
banding (Obayashi et al., 1999).
Vascular remodeling with media hypertrophy and hence increased
media/lumen ratio is a consistent feature of hypertension. It can also
be induced by chronic ANG treatment in normotensive rats, and this
can be blocked by ARBs such as valsartan (Cao et al., 1999), reﬂecting
the VSMC growth-promoting properties of AT1R. Multiple studies
have addressed the more relevant question, i.e. whether endogenous
ANG and AT1R contribute to vascular remodeling in animal models of
hypertension. Accordingly, treatment of SHR starting at an early age
when BP is still normal or only modestly elevated prevents vascular hy-
pertrophy development as shown with candesartan (Rizzoni et al.,
1998), irbesartan (Vacher et al., 1995; Intengan et al., 1999), losartan
(Morton et al., 1992) and telmisartan (Yoo et al., 2015). Perhaps more
relevant for the clinical situation, treatment with an ARB starting
when hypertension has already developed can reverse the vascular hy-
pertrophy as shown with candesartan (Kim et al., 1995c), losartan
(Oddie et al., 1993; Soltis, 1993; Dai et al., 2007) (Fig. 4) and telmisartan
(Dupuis et al., 2005; Dai et al., 2007; Zhong et al., 2011; Foulquier et al.,
2014). Similar observations were made in New Zealand genetically hy-
pertensive rats treated with valsartan or enalapril but not with
felodipine (Ledingham et al., 2000). A prevention or reversal of vascular
hypertrophy by ARBs has been shown in multiple vascular beds includ-
ing aorta (Soltis, 1993; Vacher et al., 1995; Kim et al., 1995c; Zhong et al.,
2011), coronaries (Takemoto et al., 1997), mesenteric vessels (Morton
et al., 1992; Oddie et al., 1993; Kim et al., 1995c; Rizzoni et al., 1998;
Intengan et al., 1999; Ledingham et al., 2000), tail artery (Soltis, 1993),
renal vessels (Bennai et al., 1999) or the cerebral vasculature (Bennai
et al., 1999; Dupuis et al., 2005; Foulquier et al., 2014). It also has beenobserved in the stroke-prone substrain of SHR (Kim et al., 1995c;
Bennai et al., 1999) or in diabetic SHR (Hulthen et al., 1996). On the
other hand, it should be noted that such anti-hypertrophic effects of
ARBs may not materialize in studies with short duration (Morton
et al., 1992). Moreover, some vascular beds with strong auto-
regulationmay not exhibit beneﬁcial effects on remodelling as reported
e.g. with candesartan in intrarenal arcuate and interlobular arteries
(Anderson et al., 1997). Similarly, irbesartan was reported ineffective
in reducing mesenteric artery hypertrophy in (mRen-2) 27 rats despite
lowering BP (Rossi et al., 2000). In an aortic banding ratmodel of cardiac
pressure overload, only high doses of candesartan reduced vascular hy-
pertrophy and arterial wave reﬂection, whereas both high and low
doses reduced cardiac hypertrophy in the same study (Obayashi et al.,
1999). A high dose of valsartan also reduced thoracic aorta hypertrophy
in this model along with normalization of expression of RGS proteins 2,
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not normalized (Wang et al., 2008).
Of note, the increase in peripheral resistance in hypertensive animals
not only involves a narrowed lumen of speciﬁc arteries and aterioles but
also an overall reduction of the number of microvessels, a phenomenon
termed vessel rareﬁcation (Struyker-Boudier et al., 1990). While such
rareﬁcation has been reported to be even worsened by benazeprilat,
valsartan was neutral in SHR (Scheidegger et al., 1996). Neither valsartan
norbenazeprilat affect theneovascularization of skeletalmuscle following
partial ligation of the iliac artery in normotensive rats (Scheidegger et al.,
1997). On the other hand, candesartan even increased capillary density in
the subendocardium of stroke-prone SHR (Xie et al., 1999).
Several studies have compared the ability of ARBs andACE inhibitors
to prevent or reverse vascular hypertrophy in SHR. Except for one study
in which the chosen dose of irbesartan was more effective than that of
fosinopril (Intengan et al., 1999), the two approaches were generally
found to be similarly effective with regard to vascular remodeling, e.g.
with candesartan vs. enalapril (Rizzoni et al., 1998), candesartan vs.
perindopril (Paull & Widdop, 2001), losartan vs. captopril (Morton
et al., 1992), telmisartan vs. ramipril (Dupuis et al., 2005) or, in diabetic
SHR,with valsartan vs. ramipril (Hulthen et al., 1996) or, in NO synthase
inhibitor-treated rats, with olmesartan vs. temocapril (Takemoto et al.,
1997). In the candesartan vs. perindopril study, beneﬁcial effects on vas-
cular hypertrophy were no longer visible after 8 weeks of treatment
withdrawal (Paull &Widdop, 2001). In New Zealand genetically hyper-
tensive rats valsartan and enalapril had similar effects on the media/
lumen ratio, but the former caused hypertrophic and the latter eutro-
phic outward remodeling (Ledinghamet al., 2000). Conversely, the ben-
eﬁcial effects of the ACE inhibitor temocapril were reported to be
insensitive to concomitant administration of the bradykinin receptor
antagonist icatibant (Takemoto et al., 1997), further supporting the cen-
tral role of AT1R in vascular hypertrophy.
Direct comparative studies of e.g. losartan vs. hydralazine in SHR
(Soltis, 1993), valsartan vs. lacidipine in diabetic SHR (Hulthen et al.,
1996) or valsartan vs. felodipine in New Zealand genetically hyperten-
sive rats (Ledingham et al., 2000) indicate that despite similar levels of
BP reduction, ARBs perform more favorably than to be expected based
on their anti-hypertensive effect. Although supported by only fewdirect
comparative studies, this speciﬁc role of RAS inhibiting vs. other anti-
hypertensive agents is pathophysiologically plausible based on the di-
rect ANG-induced and AT1R-mediated effects on VSMC growth (see
Section 3.3.1.2). In a mouse model with transgenic overexpression of
human renin and human angiotensinogen, valsartan treatment
prevented vascular remodeling and produced prolonged BP reduction,
whereas a dose of hydralazine causing similar initial BP-lowering had
less if any effects (Inaba et al., 2011). In endothelial NO synthase
knock-out mice valsartan and the direct renin inhibitor aliskiren re-
duced coronary remodeling, an effect not shared by hydralazine;
valsartan and aliskiren also prevented cuff injury-induced arterial inti-
mal thickening (Yamamoto et al., 2009a).
To explore mechanistic links between the in vitro studies on VSMC
growth and the in vivo situation, various studies have determined ARB
treatment effects on the expression of factors potentially contributing
to vascular remodeling. Thus, beneﬁcial effects of e.g. candesartan
(Kim et al., 1995c; Jones et al., 2004, 2012), irbesartan (Vacher et al.,
1995; Luvara et al., 1998), losartan (Dai et al., 2007; Liang & Leenen,
2008) or telmisartan (Dai et al., 2007; Liang & Leenen, 2008; Zhong
et al., 2011; Jin et al., 2012) were reported on the mRNA and/or protein
expression of ACE-2, proﬁlin-1 and PPAR-γ (Zhong et al., 2011; Jin et al.,
2012), endothelial NO synthase (Jin et al., 2012), inducible NO synthase,
NADPH diaphorase, intercellular adhesion molecule and VCAM-1
(Luvara et al., 1998), MCP-1 and its its receptor CCR2 (Dai et al.,
2007), several integrins (Intengan et al., 1999), transforming growth
factor-β (TGF-β), and the extracellular matrix molecules ﬁbronectin,
laminin and collagen I, III and IV (Kim et al., 1995c) in the vascular
wall; the latter was mirrored by a beneﬁcial effect on aortic collagencontent and collagen/elastin ratio (Vacher et al., 1995; Intengan et al.,
1999) and on overall vascular ﬁbrosis (Takemoto et al., 1997; Jones
et al., 2004; Liang & Leenen, 2008; Jones et al., 2012), which should
structurally affect the ability for vasodilatation. Of note, such ARB effects
have been observed even if treatment started as late as 20months of age
(Jones et al., 2004, 2012). Mesenteric microvessels from SHR exhibit in-
creased expression of transient receptor potential canonical channels
TRPC1, TRPC3 and TRPC5 and enhanced vasomotion in response to
norepinephrine in vitro, and the latter was blocked by TRPC1 or TRPC3
antibodies; a 16-week treatment with candesartan or telmisartan nor-
malized the TRPC expression and vasomotion in response to noradren-
aline whereas amlodipine at a dose producing similar BP reduction did
not (Chen et al., 2010). The telmisartan-induced BP reduction in SHR
was accompanied by restoration of heightened TRPC3 expression in
aorta, and thiswas notmimicked by an amlodipinedose yielding similar
BP lowering (Liu et al., 2009a). SHR also exhibit monocyte inﬁltration of
the vascular wall; this was inhibited by treatment with losartan or
telmisartan, even in doses not affecting BP (Dai et al., 2007).
Although long-standing hypertension is a major risk factor for ath-
erosclerosis, only few studies have used hypertension models to study
atherosclerosis endpoints other than vascular hypertrophy (Bennai
et al., 1999). More direct approaches to ARB effects in atherosclerosis
were studied in other models as described in the subsequent sections.
3.3.2.2. Apolipoprotein E1 knock-out mice. Disturbed lipid metabolism is
an important risk factor for the development of atherosclerosis, and
apolipoprotein E1 (ApoE) plays an important part in such metabolism.
Accordingly, ApoE knock-out mice, which spontaneously develop hy-
perlipidemia and atherosclerosis, have become an important animal
model for studying the pathophysiology, prevention and treatment of
atherosclerosis. Interferon-γ (IFNγ), MCP-1, or the MCP-1 receptor
CCR-2 are considered to be important pathophysiological factors for
the development of atherosclerosis, speciﬁcally in the ApoE knock-out
mouse.
Multiple ARBs were effective in preventing the development of ath-
erosclerosis in ApoE knock-out mice including irbesartan (Dol et al.,
2001), losartan (Keidar et al., 1997; Nakagami et al., 2008), olmesartan
(Tsuda et al., 2005), telmisartan (Grothusen et al., 2005; Takaya et al.,
2006; Blessing et al., 2008; Iwai et al., 2008; Fukuda et al., 2010;
Matsumura et al., 2011; Schlimmer et al., 2011) and valsartan (Li
et al., 2004). ACE inhibitors such as captopril (Keidar, 1998), ramipril
(Blessing et al., 2008; Matsumura et al., 2011; Schlimmer et al., 2011)
or temocapril (Tsuda et al., 2005) were also effective in this model,
pointing to a general role of ANG acting on AT1R. This general role is
also supported by the ﬁnding that atherosclerotic lesion area and
MCP-1 expression were lower in ApoE/AT1R double knock-out mice
(Tomono et al., 2008). Moreover, transplantation of bone marrow
from AT1aR knock-out mice into ApoE knock-out mice also improved
atherosclerotic lesion development (Endtmann et al., 2011).
The beneﬁcial ARB effects in the ApoE knock-out model do not in-
volve a reduction in circulating lipoprotein levels (Dol et al., 2001;
Grothusen et al., 2005; Kikuchi et al., 2007; Nakagami et al., 2008;
Nagy et al., 2010) or in ApoE/AT1R double knock-out mice (Fukuda
et al., 2010). However, an increased HDL cholesterol was reported in
one study (Fukuda et al., 2010), telmisartan was reported to increase
total cholesterol, LDL, VLDL and triglycerides without altering HDL in
the absence or presence of concomitant atorvastatin treatment
(Grothusen et al., 2005), and irbesartan was reported to increase total
cholesterol and triglyceride levels in such knock-out mice (Dol et al.,
2001). Rather they may involve various levels of the pathway to
athersclerotic lesions including reduced inﬁltration by macrophages
(Dol et al., 2001), reduced oxidative stress (Tsuda et al., 2005; Takaya
et al., 2006; Schlimmer et al., 2011) and reduced deposition of biglycans
(Nagy et al., 2010) and lipids in the vascularwall and enhanced collagen
and ﬁbrous cap thickness (Grothusen et al., 2005; Fukuda et al., 2010;
French et al., 2011). At the molecular level a reduced expression of
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was observed whereas the cytokine receptor CXCR2 was up-regulated
(Dol et al., 2001; Matsumura et al., 2011). Moreover, ARBs and ACE in-
hibitors reducedMCP-1 concentration in monocytes, number of macro-
phages and metalloproteinase-9 content (Grothusen et al., 2005).
Importantly, the above effects are not necessarily mimicked by other
BP-lowering medications (Nagy et al., 2010), indicating that they are
at least to some degree speciﬁc for RAS inhibition.
While similarly inhibiting the development of lipid-rich plaques and
IL-6 expression, telmisartan but not losartan increased expression of he-
patocyte growth factor (Nakagami et al., 2008). An additional knock-out
of AT1aR in ApoE knock-out mice mimicked some of the effects of
telmisartan, but treatment of such double-knock-out with telmisartan
yielded further improvement (Fukuda et al., 2010). Another study con-
ﬁrmed beneﬁcial effects of a combined AT1aR and ApoE knock-out; in
the absence of AT1R telmisartan did not cause additional improvement,
and ramipril even worsened atherosclerotic lesion development, the
latter effect apparently due to withdrawal of a protective AT2R-
mediated effect (Tiyerili et al., 2012).
Moreover, ARBs may not only prevent the development of athero-
sclerotic plaques but may also stabilize or even reduce them as shown
e.g. with azilsartan (French et al., 2011), telmisartan (Blessing et al.,
2008; Fukuda et al., 2010) (Fig. 5) and valsartan (Aono et al., 2012).
This ﬁnding is corroborated by studies with ApoE/AT1R double knock-
out mice which exhibit less plaque rupture (Aono et al., 2012). Plaque
stabilization has also been reportedwith valsartan in amodel of athero-
sclerosis induced by a combination of acquired diabetes combined with
a high-fat diet in Yorkshire swines (Chatzizisis et al., 2009).Fig. 5. Effect of genetic ablation or pharmacological inhibition on atherosclerosis in the
murine aortic arch. Upper panel: ApoE knock-out mice were compared to ApoE knock-
out mice with additional AT1R knock-out were fed normal chow and killed at age of
24 weeks (n = 4 each). Lower panel: 6 week old ApoE knock-out mice were fed a
Western-type diet and received either hydralazine (30 mg/kg/day, n = 3) or
telmisartan (10 mg/kg/day, n = 4) for 18 weeks. In both experiments, extent of
atherosclerosis was assessed as en face Sudan IV staining. Data are mean ± SD; *: p b
0.05 vs. ApoE knock-out or vs. ApoE knock-out with hydralazine treatment. Drawn
based on data published by Fukuda et al. (2010)).3.3.2.3. Other hyperlipidemic animal models. The Watanabe heritable
hyperlipidemic rabbit is a frequently used model, in which telmisartan
reduced atherosclerotic plaques; the telmisartan plus GW9662 combi-
nation or candesartan were less effective, indicating that both AT1R
and PPAR-γ contributed to the protective effect (Ikejima et al., 2008).
Some reduction of atherosclerotic plaque area was also reported with
olmesartan (Koike et al., 2001) or valsartan in this model; the latter
was further enhanced by concomitant treatment with pitavastatin
(Imanishi et al., 2008a) or aliskiren (Imanishi et al., 2008b). In contrast,
irbesartan reduced atherosclerotic plaques in this model only when ad-
ministered in doses exceeding those required to blockmost of the pres-
sor effect of exogenously administered ANG (Hope et al., 1999).
Atherosclerosis can also be induced in rabbits not genetically prone
for this condition by feeding them a high-cholesterol diet. In this
model valsartan reduced triglycerides but not cholesterol and produced
some reduction in aortic atherosclerotic plaque size, intima/media ratio
and macrophage inﬁltration; however, these effects were less pro-
nounced than those of benazepril, which also lowered cholesterol (Li
et al., 1999a). In similar studies, valsartan did not lower BP or plasma
cholesterol but reduced atherosclerotic lesions and vascular hypertro-
phy (de las Heras et al., 1999). A later study extended these ﬁndings
with valsartan to the rabbit pulmonary artery (Li et al., 2010b). In mon-
keys fed a high cholesterol diet, olmesartan reduced atherosclerotic le-
sion size in the aorta (Koike et al., 2001). Taken together, ARBs as a
class have some beneﬁcial effect on heritable or diet-induced athero-
sclerosis in rabbits and probably other species; telmisartan may cause
a greater effect due to additional stimulation of PPAR-γ.
3.3.2.4. Diabetes mellitus models. Although frequently associated with
hypertension in clinical practice, diabetes mellitus per se does not in-
crease BP. However, it is an important risk factor in the development
of atherosclerosis. While most studies on atherosclerosis-related end-
points were based on the STZ-induced model of type 1 diabetes, some
have also explored models of obesity and type 2 diabetes (Toyama
et al., 2011; Abdelsaid et al., 2014).
In an early study in rats with STZ-induced diabetes, valsartan,
ramipril in two doses with and without concomitant icatibant,
lacidipine or mibefradil were administered for 24 weeks (Cao et al.,
1998).While none of the treatments affected themetabolic parameters,
all except icatibant monotherapy reduced the media/lumen ratio of the
mesenteric artery. Of note, this was true for BP-lowering treatments
(valsartan and ramipril high dose with and without icatibant) as well
as the BP-neutral treatments (valsartan and ramipril low dose,
lacidipine or mibefradil). Others reported that the rat STZ-model of dia-
betes was associated with a reduced internal diameter, a narrower
media, fewer elastic and more collagen ﬁbers in the thoracic aorta; all
of these changes were attenuated by telmisartan treatment (Salum
et al., 2014). These data suggested that AT1R blockade can improve
diabetes-induced vascular remodeling, probably independent of BP
lowering.
In Goto–Kakizaki rats, a model spontaneously developing type 2
diabetes in the absence of obesity, azilsartan inhibited thickening of the
wall of cerebral vessels and reversed the loss of myogenic tone (Abdelsaid
et al., 2014). However, these data data are difﬁcult to interpret mechanisti-
cally as azilsartan also markedly lowered blood glucose in this model.
A later study compared 8-week treatments with losartan,
telmisartan and telmisartan plus GW9662 in db/db mice, a genetic
model of diabetes (Toyama et al., 2011). Losartan and telmisartan, irre-
spective of concomitant GW9662 treatment, similarly lowered BP in
these mice. None of the treatments affected fasting glucose but
telmisartan lowered the insulin resistance index; the latter was blocked
by GW9662 and not mimicked by losartan. The impaired endothelium-
dependent aortic vasodilatation by acetylcholine was improved to a
greater extent by telmisartan than by losartan, with the effect of the
former being attenuated byGW9662; similar differences between treat-
ments were observed for phosphorylation of aortic Akt and endothelial
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PPAR-α expression was not affected by any treatment. Thus, in contrast
to the above rat study, these ﬁndings indicate a possible additional con-
tribution of PPAR-γ activation to beneﬁcial ARB effects in diabetes-
associated atherosclerosis.
Other studies shed important light on these apparently contradicto-
ry studies with regard to the roles of AT1R and PPAR-γ in diabetes-
associated vascular remodeling and atherosclerosis. They were based
on ApoE knock-out mice, in which diabetes was induced by STZ treat-
ment. One study has explored the effects of treatment with olmesartan
or telmisartan on aorta and has also involved ApoE knock-out mice
(Ihara et al., 2007). While this study found that only telmisartan
lowered LDL cholesterol, both ARBs prevented activation of the RAGE
pathway, which in turn preceded AT1R up-regulation. Both treatments
and and also an ApoE/AT1R double knock-out prevented aortic athero-
sclerosis development. Within that study the ANG-induced RAGE ex-
pression in cultured VSMCs was also AT1R-mediated. In another study
using the same model and also looking at aorta, treatment with the
PPAR-γ antagonist GW9662 resulted in the highest elevation of fasting
glucose levels in diabetic ApoE and ApoE/AT1R knock-out mice, where-
as telmisartan treatment and AT1R deﬁciency in ApoE knock-out mice
showed the lowest fasting glucose levels (Tiyerili et al., 2013). Diabetic
ApoE knock-out mice had severe impairment of endothelial function,
enhanced oxidative stress and increased atherosclerotic lesion forma-
tion; all of these effects were signiﬁcantly less pronounced in the
ApoE/AT1R double knock-out or in telmisartan-treated ApoE knock-
out mice. Cotreatment of ApoE or ApoE/AT1R knock-out mice with
GW9662 eliminated the atheroprotective effects of AT1R deﬁciency or
telmisartan. Taken together these data show a clear role for AT1Rs and
hence ARBs in atherosclerosis development in diabetic animals. An ad-
ditional role for PPAR-γmay exist, but the presently available data are
insufﬁcient to quantify the relative contributions of the AT1R and
PPAR-γ, particularly as this may depend not only on the ARB being
used but also on speciﬁc aspects of the experimental model being
used. Thus, ARBs consistently reduce atheroscleoris in multiple models
of type 1 and type 2 diabetes, but some ARBs may have additional
AT1R-independent effects including those related to PPAR-γ
stimulation.
3.3.2.5. Balloon injury model. The balloon injury model, induced by tem-
porarily inﬂating a balloon inside a blood vessel, is frequently used to
study atherosclerosis and its treatment in experimental animals as it
provides an intervention which is clearly identiﬁed with regard to
time and location. Balloon injury causes local destruction of the endo-
thelium followed by neointima formation andVSMCmigration and pro-
liferation. This model has mostly been used in rat carotid arteries, but
some studies have also been performed in rat aorta (Viswanathan
et al., 1992; Moroi et al., 1997), rabbit carotid artery (Azuma et al.,
1992; Janiak et al., 1994) and dog carotid and femoral artery
(Miyazaki et al., 1999a, 1999b; Tea et al., 2000). ARB effects were gener-
ally comparable across these models and species.
In such studies the ARB or comparator drug was administered prior
to, concomitantly with or shortly after the balloon injury and then con-
tinued for several days toweeks. In one study, a single application at the
site of injury was as effective as repeated systemic administration
(Taguchi et al., 1993). The primary phenotype being studied in this
model is the neointima formation at the site of injury, and that was re-
duced by a variety of ARBs including candesartan (Kawamura et al.,
1993; Kino et al., 1994; Taguchi et al., 1994; Kino et al., 1995;
Miyazaki et al., 1999b; Tea et al., 2000), losartan and EXP3174
(Osterrieder et al., 1991; Prescott et al., 1991; Farhy et al., 1992, 1993;
Taguchi et al., 1993; Janiak et al., 1994), valsartan (Miyazaki et al.,
1999a) or experimental ARBs (Virone-Oddos et al., 1997) but also by
ACE inhibitors such as benazeprilat (Prescott et al., 1991), captopril
(Virone-Oddos et al., 1997), cilazapril (Osterrieder et al., 1991), enala-
pril (Farhy et al., 1992; Miyazaki et al., 1999b), lisinopril (Kino et al.,1994, 1995) or ramipril (Farhy et al., 1992, 1993; Taguchi et al., 1993;
Janiak et al., 1994). In contrast, neither AT2R antagonists (Janiak et al.,
1994) nor RAS-independent antihypertensive drugs such as hydral-
azine reduced neointima formation (Tazawa et al., 1999), indicating
that this is a speciﬁc effect of AT1R inhibition rather than of BP lowering.
Moreover, such ARB effects have not only been shown in normotensive
rats but also in SHR;while the extent of neointima formationwas great-
er in SHR than in normotensive rats, the beneﬁcial effect of an ARB or
ACE inhibitor was maintained (Kino et al., 1995).
However, some controversy exists about the comparison of neointi-
ma formation upon ARB and ACE inhibitor treatment. Most investiga-
tors found that both drug classes have a quantitatively similar effect
(Osterrieder et al., 1991; Prescott et al., 1991; Janiak et al., 1994; Kino
et al., 1994, 1995; Virone-Oddos et al., 1997), but some have reported
ACE inhibitors to be more effective than ARBs (Farhy et al., 1992,
1993; Taguchi et al., 1993). In their studies the greater effect of ACE in-
hibitors was abolished by the bradykinin receptor antagonist icatibant
and/or an NO synthase inhibitor. Of note the studies reporting greater
ACE inhibitor than ARB efﬁcacy have all been based on the comparison
of losartan with ramipril and may be explained by speciﬁc properties of
one of these two drugs, but not even all losartan/ramipril comparisons
supported a difference between the two drug classes (Janiak et al.,
1994). On the other hand, a study in dog carotid and femoral artery
found candesartan and enalapril to be equally effective in the femoral
artery whereas, in contrast to candesartan, enalapril was ineffective in
carotid artery (Miyazaki et al., 1999b). Thus, in the balance of all studies
ARBs and ACE inhibitors apparently have comparable effects on neoin-
tima formation, but additional roles for kinins and NO cannot be
excluded.
The above studies have also explored themolecular, cellular and tis-
sue mechanisms underlying neointima formation in this model and
how they are affected by ARBs. Balloon injury affects the expression
and functional status of various signalingmolecules at the site of neoin-
tima formation. This includes a reduced expression of platelet-derived
growth factor receptor α and β, which is not easy to understand as
the phosphorylation status of both receptor subtypes was enhanced;
the increased phosphorylation was apparently speciﬁc as it did not
apply to epidermal growth factor receptors or insulin receptor
substrate-1 (Abe et al., 1997). On the other hand, the expression of
immediate-early genes including c-fos, c-jun, jun B, jun D, and Egr-1
as well as of ornithine decarboxylase, TGF-β1, ﬁbronectin and collagen
was found to be increased (Kim et al., 1995b; Kim & Iwao, 1997;
Tazawa et al., 1999). All of these changes in expression and phosphory-
lation were ameliorated by candesartan treatment.
It was also found that at the site of neointima formation the expres-
sion of ACE and the alternative ANG-generating enzyme chymase were
up-regulated (Miyazaki et al., 1999a, 1999b). Moreover, the expression
of AT1R was also up-regulated, and this was prevented by candesartan
but not hydralazine treatment (Viswanathan et al., 1992; Tazawa
et al., 1999), indicating that it was not linked to BP lowering but rather
speciﬁcally to AT1R blockade. On the other hand, it was reported that
ANG reduces levels of the vasodilatory second messenger cGMP in rat
aorta neointima after balloon injury by stimulating AT2R; in contrast,
AT1R was not involved based on lack of inhibition by candesartan, and
no reduction of cGMP levels by ANG was observed in normal aorta
(Moroi et al., 1997).
ARBs such as losartan (Prescott et al., 1991; Azuma et al., 1992;
Taguchi et al., 1994) or candesartan (Kawamura et al., 1993; Taguchi
et al., 1994) were also reported to inhibit migration of VSMCs to the
site of injury and their proliferation in the media; the ACE inhibitor
benzaprilat mimicked these effects but was quantitatively less effective
(Prescott et al., 1991).
A key feature of the balloon injury model is an imbalance in
contraction/relaxation responses of the affected vessel. In a rabbit
carotid artery model contractile responses of aortic strips in vitro to
noradrenaline or ANG were signiﬁcantly increased six weeks after the
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treatment, starting one week prior to the injury, did not affect the in-
creased response to noradrenaline but similarly reduced that to ANG
in both control and injured vessels (Azuma et al., 1992). In the same
study balloon injury markedly reduced the vasodilation response to
acetylcholine; while losartan treatment did not affect this response in
control animals, it almost completely restored the response in the in-
jured vessels. Both the impairment after balloon injury and the restora-
tion upon losartan treatment apparently did not happen at the VSMC
level, as vasodilatation responses to sodium nitroprusside were similar
in all four study groups. Interestingly, the number of endothelial cells
was greater in the injured than the control vessels sixweeks after the in-
jury, whereas losartan did not affect their number in either condition. In
a rat carotid artery model balloon injury similarly caused intima thick-
ening as detected 14days after the injury, and in this case the thickening
was attenuated either by candesartan or the ACE inhibitor cilazapril,
started 6 days prior to the injury (Kawamura et al., 1993). Similar to
the rabbit model, vasodilatation of isolated carotid artery in response
to acetylcholine was almost completely abolished upon injury despite
the intimal thickening but scanning electron microscopy revealed that
the endothelial cells at the site of injury were morphologically abnor-
mal; candesartan dose-dependently restored acetylcholine-induced va-
sodilatation and normalized the morphological abnormalities, whereas
the vasodilatation response to sodium nitroprusside was similar in all
four treatment groups. Taken together these ﬁndings indicated a
shift of vascular contractility away from endothelium-dependent
vasdodilatation at the site of neointima formation, which is most likely
explained by a functional and morphological impairment at the level of
the endothelium. ARBs, at least when treatment is started prior to or
concomitnant with the injury, can prevent such changes. These ARB ef-
fects apparently are not BP-related as they are not mimicked by other
anti-hypertensive drugs and are not necessarily accompanied by BP
lowering.
A related model is the placement of a cuff on the femoral artery of
mice. In this model, neointima area was greater in double transgenic
mice harboring the human angiotensinogen and renin genes as com-
pared to wild-type mice (Inaba et al., 2011). This neointima formation
was prevented by valsartan but not by hydralazine.3.3.2.6. Other in vivo models of atherosclerosis. A similar phenotype as in
the balloon model can be induced by placing a cuff on the femoral ar-
tery. When this was done in wild-type or mas knock-out mice,
azilsartan reduced neointimal area and cell proliferation in the intima
andmedia, which was accompanied by a reduced expression of inﬂam-
mation markers including MCP-1, TNF-α and IL-1β (Ohshima et al.,
2014).
In a normotensive rat model of subtotal nephrectomy, endothelial
dysfunction as assessed by carbachol-induced relaxation of aortic rings
was normalized by telmisartan treatment (Toba et al., 2012). This was
partly inhibited by GW9662 and only partly mimicked by losartan; the
telmisartan + GW9662 combination caused quantitatively very similar
improvement as losartan treatment. A similar pattern of telmisartan,
telmisartan plus GW9662 and losartan was observed for vascular mac-
rophage invasion, osteopontin-positive cells, and osteopontin, VCAM-1
and NADPH oxidase expression, indicating concomitant involvement of
AT1R and PPAR-γ in all of these responses. The same group of investiga-
tors largely conﬁrmed such ﬁndings in a study using 5/6 rather than
subtotal nephrectomy (Toba et al., 2013).
In a mouse model of heterotopic heart transplantation between
MHC-antigen compatible strains, intima growth develops in the graft
coronary arteries; in this model treatment with either candesartan or
captopril reduced intima growth (Furukawa et al., 1996). Candesartan
and enalapril also reduced intima proliferation of cardiac vessels in a
rat heterotopic heart transplantation model treated with cyclosporin
A, interestingly more so in small than in large ones (Richter et al.,1999). These ﬁndings indicate that RAS blockade may be beneﬁcial to
reduce coronary atherosclerosis in heart transplant recipients.
3.4. Other effects on vascular function
Isolated studies on ARB effects on vascular function unrelated to hy-
pertension or atherosclerosis have also been reported. For example, one
study has explored effects of candesartan in isolated hearts obtained
fromWKY, SHR and SHR chronically treatedwith an NO synthase inhib-
itor (Fujita et al., 1995). In that study coronary ﬂowwas reduced in SHR
and even more so in SHR with NO synthase inhibition. Candesartan re-
stored coronary ﬂow in SHR but not in those treated with the inhibitor.
In another study, uric acid induced senescence and apoptosis in cultured
HUVECs, and this was attenuated by telmisartan, enalaprilat or
probenicid, the latter probably acting independent of the RAS (Yu
et al., 2010); the relationship of this ﬁnding to gout remains to be ex-
plored. In a third approach, aneurysm was induced by perfusion of iso-
lated abdominal aortic segments with elastase followed by a 14 day
treatment with telmisartan or hydralazine (Kaschina et al., 2008).
Telmisartan, but not hydralazine treatment, reduced aortic diameter
and aortic expression of matrix metallopeptidase 3, cathepsin D, NF-
κB, TNF-α, TGF-1β as well as caspase 3, p53 and Fas ligand proteins;
serum MCP-1 was also reduced. Chronic infusion of ANG can induce
aortic aneurysm in mice; this was abolished by a low telmisartan
dose, not lowering BP, in regulator of G-protein signaling-2 knock-out
but not wild-type mice (Matsumoto et al., 2010). Concomitantly,
telmisartan increased survival in knock-out but not wild-type mice.
Using similar models, effects of irbesartan and telmisartan were ex-
plored in mouse models of abdominal aortic aneurysm induced by ei-
ther chronic ANG infusion in ApoE knock-out mice or by transient
intraaortic administration of porcine pancreatic elastase in C57BL/6
mice (Iida et al., 2012). In the ApoE knock-out model both telmisartan
and irbesartan limited aneurysm enlargement, medial elastolysis,
smooth muscle attenuation, macrophage inﬁltration, adventitial
neocapillary formation, and the expression of proteinases and proin-
ﬂammatory mediators, whereas doxycycline, ﬂuvastatin or bosentan
did not affect aneurysm progression. In this model, aortic aneurysms
developed in 67% of ANG-infused mice and 40% died of rupture; strik-
ingly no telmisartan-treated mouse developed an aneurysm, and mor-
tality with irbesartan also was below 10%. Irbesartan and telmisartan
also reduced the expression of many inﬂammatory genes, an effect
not shared by the other treatments. Telmisartan was similarly effective
in the elastase model (irbesartan not investigated).
4. Heart function
AT1R in the heart have been directly demonstrated at the mRNA
level in many studies, e.g. by in situ hybridization in rat heart (Gasc
et al., 1994) or by Northern blots in the human heart (Mauzy et al.,
1992). Due to the problems with AT1R antibodies (Adams et al., 2008;
Xue et al., 2011; Benicky et al., 2012; Premer et al., 2013), reliable detec-
tion at the protein level has largely been based on radioligand binding
studies (Sechi et al., 1992b; Feolde et al., 1993a; Nakamura et al.,
1994a; Booz & Baker, 1996; Liang & Leenen, 2008). Of note, cardiac ex-
pression of AT1R at the mRNA and protein level is not limited to
myocytes but also found in ﬁbroblasts (Villareal et al., 1993).
4.1. Normal heart function
4.1.1. Signal transduction and cellular function
ARB effects on cardiac function at the cellular level have primarily
been studied in isolated cardiomyocytes from rats, but ﬁndings from
rabbits (Habuchi et al., 1995) and hamsters (Nakamura et al., 1994a)
have also been reported. Thus, losartan-sensitive activation of cardiac
AT1R has directly been shown to involve G-protein activation (Sechi
et al., 1992b). Accordingly, ARBs inhibit prototypical signal transduction
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pase C activation by losartan (Ishihata & Endoh, 1993; Feolde et al.,
1993b) (Pönicke et al., 1997), and of Ca2+ elevations by candesartan
(Kinugawa et al., 1993), irbesartan (Delisee et al., 1993) and losartan
(Delisee et al., 1993; Feolde et al., 1993b). Alternatively, the latter signal
transduction pathway has been assessed as Ca2+ efﬂux from isolated
cardiomyocytes, which was stimulated by ANG and inhibited by
candesartan and losartan (Fukuta et al., 1996). Ca2+ elevations can in-
volve mobilization from various types of intracellular stores and from
inﬂux from the extracellular space, the latter mostly occurring via spe-
ciﬁc Ca2+ channels (Krebs et al., 2015). Candesartan blocked the ANG-
induced L-type Ca2+ current in isolated rabbit sino-atrial node cells
(Habuchi et al., 1995). A more down-stream signaling event activated
via AT1R is the Na+/H+-exchanger, which may be relevant for cardiac
responses to ischemia (Xiao & Allen, 2003). ARBs were also reported
to prevent ANG-induced down-regulation of adiponectin receptors in
the H9C2 cardiomyocyte cell line (Wu & Guo, 2015).
Of note, cardiac ANG effects do not necessarily occur at the cardio-
myocyte level but may also be mediated by AT1R on ﬁbroblasts
(Schorb et al., 1995). In this regard it has been proposed that AT1R on
cardiomyocytes and ﬁbroblasts, using distinct signal transduction path-
ways, drive hypertrophy and proliferation, respectively (Yamazaki &
Yazaki, 1999). Effects on ﬁbroblasts may underly the beneﬁcial ARB ef-
fects on cardiac ﬁbrosis (see Section 4.2.). Moreover, they may also
occur by AT1R located in sympathetic nerve endings promoting nor-
adrenaline release (Brasch et al., 1993; Shetty & DelGrande, 2000;
Guimaraes et al., 2011) and parasympathetic nerve endings promoting
acetylcholine release (Rechtman & Majewski, 1993), in the cardiac en-
dothelium (Chua et al., 1993), or in coronary arteries (see
Section 4.1.4.). Effects of ARBs on hypertrophy and proliferation of
cardiomyocytes and cardiac ﬁbroblasts derived from healthy animals
will be discussed in Section 4.2.1.
4.1.2. Heart rate and conduction system
Autoradiographic studies, e.g. in rats, have shown that the cardiac con-
duction system expresses angiotensin receptors at the protein level,
which based on their sensitivity to losartan appear to belong exclusively
to the AT1R subtype (Saavedra et al., 1993). AT1R may also be involved
in the direct communication between cardiomyocytes as ANG reduced
junctional conductance between pairs of rat ventricular cells in culture
in a losartan-sensitive manner; interestingly, enalapril had an opposite
effect in this study (De Mello & Altieri, 1992). There may also be chronic
effects of ANG on conductivity between cardiomyocytes. Thus, ANG re-
leased from ﬁbroblasts was reported to suppress connexin-43 expression
in rat cardiomyocytes in a losartan-sensitive manner (Salameh et al.,
2013); this ﬁbroblast-dependent effect at least partly buffered the direct
stimulation of connexin-43 expression by isoprenaline.
Nonetheless, ARBs had only small effects if any on heart rate in
in vivo studies in multiple animal species. Most of this work was done
in rats, mostly SHR and other hypertension models, but some studies
have reported similar ﬁndings in dogs (MacFadyen et al., 1992;
Yamamoto et al., 1997b) and monkeys (DeGraaf et al., 1993; Lacour
et al., 1993). Speciﬁcally, small if any effects on heart rate have been re-
ported for candesartan (Takishita et al., 1994; Kito et al., 1996; Fujii
et al., 1998), eprosartan (Behr et al., 2004; Mukaddam-Daher et al.,
2009), irbesartan (Lacour et al., 1993; Lacour et al., 1994), losartan
(Wong et al., 1990d; MacFadyen et al., 1992; DeGraaf et al., 1993;
Lacour et al., 1993; Lacour et al., 1994), olmesartan (Tomita et al.,
2009), telmisartan (Wang et al., 2006), and valsartan (Criscione et al.,
1993; Kometani et al., 1997; Yamamoto et al., 1997b).
This general lack of ARBs on heart ratewhen used in animalmodels of
hypertension or heart disease does not necessarily contradict opposite
ﬁndings in speciﬁc experimental conditions. For instance, candesartan
attenuated the reﬂex tachycardia in response to a high dose of the Ca-
channel blocker manidipine (Sato et al., 1996). Telmisartan was reported
to prevent the heart rate increase in ratswith unilateral nephrectomy andadditional ethylene glycol injection (Kadhare et al., 2015). Moreover,
ARBs including losartan may inhibit positive chronotropic effects of ANG
inpithed rats (Knape&van Zwieten, 1988; Zhang et al., 1993a),most like-
ly by acting at the prejunctional level.
4.1.3. Inotropy
In line with these ﬁndings on signal transduction, candesartan was
shown to inhibit the ANG-induced shortening (Kinugawa et al., 1993)
and the spontaneous beating frequency (Yonemochi et al., 1997) of rat
neonatal cardiomyocytes. Similarly, losartan blocked the ANG-induced
positive inotropic effect in rabbit (Ishihata & Endoh, 1993) or guinea
pig ventricular strips, whereas an AT2R inhibitor was ineffective
(Feolde et al., 1993a); inhibition of positive inotropic ANG effects by
losartan was also reported from isolated human atrium (Zerkowski
et al., 1993) whereas studies in failing human ventricle reported en-
hanced calcineurin activity but only weak and inconsistent inotropic ef-
fects (Li et al., 2005). In conscious, salt-depleted dogs infusion of ANG
caused a small reduction in cardiac output, which was blocked by
losartan (MacFadyen et al., 1993). In the same study, losartan alone in-
duced a small rise in cardiac output in sodium-depleted dogs, which
was attributed to a rise in heart rate and stroke volume. However, in
most studies in the absence of exogenous ANG, ARBs lacked major ef-
fects on cardiac function. For instance, candesartan even in high concen-
trations lacked effects on cardiac function in isolated perfused guinea
pig heart, the spontaneous beating rate of the right atria or the contrac-
tile force of electrically-paced left atria (Kito et al., 1996). Moreover,
candesartan did not affect the increase in left ventricular pressure induced
by elevating perfusion pressure in a Langendorff preparation of Syrian
hamster heart (Nakamura et al., 1994a). In isolated guinea pig perfused
heart, candesartan had no effect on cardiac function and in isolated
guinea-pig atria it had no effect on the spontaneous beating rate of the
right atria or the contractile force of electrically-paced left atria (Kito
et al., 1996). In vivo, candesartan had no effect on left ventricular systolic
pressure, its dp/dtmax, or cardiac output in anesthetized dogs; moreover,
even at high doses, candesartan had little effect on cardiac output, right
atrial pressure, pulmonary artery pressure, pulmonary capillary wedge
pressure or respiration in conscious dogs (Kito et al., 1996). Similarly,
EXP3174 or enalprilat had little effect on cardiac function in anesthetized
dogs unless the RAS had been activated by furosemide pre-treatment
(Richard et al., 1993). ACE inhibitors were reported to cause up-
regulation of cardiac β-adrenoceptors in neonatal rat cardiomyocytes but
this was notmimicked by candesartan (Yonemochi et al., 1997) and rather
mediated by bradykinin receptors (Yonemochi et al., 1998). In contrast to
the data in healthy rats, treatment with telmisartan attenuated the reduc-
tion of dP/dtmax in those with STZ-induced diabetes (Salum et al., 2014).
4.1.4. Coronary blood ﬂow
Immunohistochemical studies have demonstrated the presence of
AT1R in human coronary arteries obtained as autopsy specimens
(Gross et al., 2002). While the validity of the antibodies used in these
studies has been questioned (see above), staining in non-
atherosclerotic sectionswas conﬁned to smoothmuscle cells in the vas-
cularmedia. However,with the advent of atherosclerosis, AT1R receptor
expression was also present in atherosclerotic plaques and involved
other cell types including inﬂammatory cells and myoﬁbroblasts.
These data are in line with those from animal models demonstrating
an up-regulation of AT1R in atherosclerotic lesions in the general circu-
lation (see Section 3.3.2.).
Exogenously appliedANGcauses contraction of isolated coronary ar-
teries, and thatwas antagonized by valsartan in rats (Tschudi & Lüscher,
1995) and by irbesartan in pigs and humans (Maassen van den Brink
et al., 1999). In vivo, losartan did not change cardiac perfusion or coro-
nary resistance in anesthetized rats (Sigmon & Beierwaltes, 1993a)
but increased coronary blood ﬂow in anesthetized dogs (Sudhir et al.,
1993). In the latter study, this effect was not affected by indomethacin
or propranolol but partially inhibited by L-NAME, indicating that it
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EXP3174 or enalaprilat decreased coronary resistance but did not affect
myocardial perfusion (Richard et al., 1993). In vivo pre-treatment with
candesartan at least partly normalized the elevated minimal coronary
resistance of SHR as measured in a Langendorff preparation (Takeda
et al., 1994).
4.2. Heart hypertrophy and ﬁbrosis
The heart can develop hypertrophy and ﬁbrosis in the context of
many diseases. While hypertrophy initially can support maintaining
cardiac output, it eventually turns into a risk factor of its own.
4.2.1. In vitro models
Cardiac overexpression of AT1R causes heart hypertrophy (Hein
et al., 1997). This can be mimicked in vitro by prolonged exposure to
ANGwhich also promotes the development of cardiomyocyte hypertro-
phy (Lijnen & Petrov, 1999; Hunyady & Turu, 2004). At the cellular level
this has primarily been studied in cultured rat neonatal cardiomyocytes.
In thismodel ANG induces a hypertrophy response, often assessed as in-
creased protein synthesis, which involves intermediary formation and
release of endothelin (Pönicke et al., 1997; Xia & Karmazyn, 2004). It
also involves an increased expression of several proto-oncogenes, atrial
natriuretic peptide (Hirata et al., 1994;Wang et al., 2012b), endothelin-
1 (Hirata et al., 1994), brain natriuretic peptide and visfatin (Chang
et al., 2012). DNA synthesis is also enhanced (Saris et al., 2002). At
least some of these responses are intracellularly mediated by ERK acti-
vation (Nyui et al., 1997; Aoki et al., 2000) and/or microRNA-19b (Gao
et al., 2014a). They are inhibited by various ARBs including candesartan
(Hirata et al., 1994; Nyui et al., 1997; Aikawa et al., 1999), eprosartan
(Saris et al., 2002), losartan (Ito et al., 1993; Booz & Baker, 1996) and
telmisartan (Chang et al., 2012; Gao et al., 2014a). Moreover, ANG can
not only promote hypertrophy but also apoptosis in rat neonatal
cardiomyocytes, a process involving inhibition of STAT3 phosphoryla-
tion and promotion of DNA fragmentation; such apoptosis induction
was also blocked by candesartan (Tone et al., 1998). However, not all
ANG responses in rat cardiomyocytes may be AT1R-mediated. Thus,
ANG caused an early (30 min) and a late (120 min) phosphorylation
of members of the JAK and STAT family of transcription factors;
candesartan inhibited the early but not the late phase (Kodama et al.,
1998). ANG also increased expression of T-type Ca2+-channels in neo-
natal rat cardiomyocytes, and this was inhibited by telmisartan;
valsartan did not mimic this telmisartan effect but inhibited it
(Morishima et al., 2009). Thus, some ANG effects on cardiomyocytes
may occur via non-AT1R sites. Cardiac hypertrophy has also been ob-
served in mice with cardiomyocyte-speciﬁc transgenic expression of
angiotensinogen (Mazzolai et al., 2000); this hypertrophywas attenuat-
ed by treatment with losartan or ramipril and was not accompanied by
ﬁbrosis or systemic BP elevation.
The hypertrophy response in cultured cardiomyocytes can not only
be elicited by addition of exogenous ANG but also by stretch. Mechani-
cal stretch activates a range of protein kinase cascades in
cardiomyocytes including protein kinase C, raf-1, S6 protein kinase
and ERK; this in vitro response is often considered to be amodel system
for the development of heart hypertrophy and is associated with in-
creased c-fos expression and protein synthesis. While neither
candesartan nor irbesartan affected stretch-induced hypertrophy of
rabbit cardiomyocytes (Blaauw et al., 2010), candesartan inhibited
stretch responses in isolated mouse (Nyui et al., 1997) or rat
cardiomyocytes (Kojima et al., 1994; Komuro et al., 1995; Yamazaki
et al., 1995). In addition to the AT1R component, stretch-induced hyper-
trophy also has an endothelin A receptor component; ARBs inhibit only
the former, and a combination of ARB and endothelin receptor antago-
nist is required for full inhibition of stretch effects (Yamazaki et al.,
1996a, 1998), apparently reﬂecting the ﬁnding that AT1R activation
promotes endothelin-1 release from cardiomyocytes but is not theonly factor to do so (Ito et al., 1993; Hirata et al., 1994). Conditionedme-
dium from stretched myocytes also caused the hypertrophy response,
and candesartan may provide stronger inhibition against conditioned
medium than against stretch itself (Yamazaki et al., 1996b). Stretch
also induced angiotensinogen mRNA expression in neonatal rat
cardiomyocytes via a candesartan-sensitivemechanism, potentially cre-
ating a positive feed-back loop (Tamura et al., 1997b). The candesartan
inhibition of stretch-induced ERK activation was absent in
angiotensinogen knock-out mice (Nyui et al., 1997). Interestingly, the
stretch-induced hypertrophy was even greater in angiotensinogen
knock-out than wild-type mice, but candesartan inhibited the response
only in the latter (Nyui et al., 1997). These studies established that ANG
and AT1R are involved in the stretch-induced cardiomyocyte hypertro-
phy, but are not the sole mediators. Moreover, these ﬁndings indicate
that a non-AT1R component of the RAS may exhibit an anti-
hypertrophic response in the heart. The idea that this may be the AT2R
(Diez, 2004) is supported by the ﬁnding that L-NAME treatment-
induced cardiac hypertrophy is greater in AT2R knock-out than wild-
typemice (Gross et al., 2004). ANG stimulates endothelin-1 release in car-
diacmyocytes (Ito et al., 1993);while endothelinmay in partmediate the
ANG-induced cardiac hypertrophy, the opposite is untrue, i.e. candesartan
did not inhibit the hypertrophy response directly induced by exogenous
endothelin (Yamazaki et al., 1996a). These data demonstrate that AT1R
are involved in the development of cardiomyocyte hypertrophy in re-
sponse not only to exogenous ANG but also to stretch, an in vitro surro-
gate of cardiac volume overload. However, they are not the only
mediator of the stretch hypertrophy response and may not protect from
hypertrophy e.g. due to increased exposure to endothelin. If indeed
AT2Rmediate an opposite response, this could mean that ARBs may pro-
vide more effective protection from hypertrophy development than ACE
inhibitors. On the other hand, cardiomyocyte-speciﬁc transgenic expres-
sion of angiotensinogen increased cardiac wall thickness in the absence
of systemic BP elevation, indicating that ANG can induce cardiomyocyte
hypertrophy independent of stretch; this was blocked by losartan or
ramipril, establishing an AT1R-mediated effect (Mazzolai et al., 2000).
AT1R may not only play a role in cardiomyocytes but also in cardiac
ﬁbroblasts ofmultiple species including humans (Kawano et al., 2000b).
AT1R have been detected on cardiac ﬁbroblasts in radioligand binding
studies (Schorb et al., 1993). Actually, ﬁbroblasts may express a greater
density of AT1R thanmyocytes (Kim et al., 1995a). They couple to eleva-
tion of intracellular Ca2+ concentrations (Schorb et al., 1993; Brilla et al.,
1997) and ERK activation (Schorb et al., 1995). In the absence of exoge-
nously added ANG, candesartan, eprosartan or irbesartan did not alter
the spontaneous proliferation of rat cardiac ﬁbroblast in culture, where-
as telmisartan caused inhibition, apparently in an AT1R-independent
manner (Benson et al., 2008). However, the presence of ANG resulted
in increased collagen mRNA expression and protein synthesis (Schorb
et al., 1993; Brilla et al., 1997; Lijnen et al., 2000, 2001) as well as en-
hanced expression of integrins, osteopontin and actininin (Kawano
et al., 2000a). Telmisartan reduced ANG but not TGF-β1-induced colla-
gen synthesis in rat cardioﬁbroblasts (Zhang et al., 2014b). While ANG
alonedid not affect secretion ofmatrixmetalloproteinase 9 from rat car-
diac ﬁbroblasts, it enhanced IL-1-induced secretion thereof (Okada
et al., 2010b). In isolated rat cardiac ﬁbroblasts telmisartan and
pioglitazone prevented the TNF-induced activity increase of matrix
metalloproteinase-2; this was blocked by GW9662 and not mimicked
by amlodipine (Nagashima et al., 2012), raising the possibility that
some ARBs may have AT1R-independent effects on ﬁbrosis. The above
studies were performed with rat cells, but a study in human cardiac ﬁ-
broblasts conﬁrmed that ANG increased ERK activation, DNA synthesis,
and expression of TGF-β1, laminin and ﬁbronectin; moreover, it en-
hanced plasminogen activator inhibitor-1 expression, which inhibits
metalloproteinases that degrade the extracellular matrix (Kawano
et al., 2000b). Such effects were inhibited by candesartan (Brilla et al.,
1997), irbesartan (Kawano et al., 2000a, 2000b), losartan (Schorb
et al., 1993, 1995) or telmisartan (Brilla et al., 1997; Lijnen et al., 2000,
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myocytes and ﬁbroblasts, ANG stimulated expression of connective tis-
sue growth factor, an important stimulus for collagen synthesis; these
effects were blocked by losartan and telmisartan (Ko et al., 2011).
Upon culturing on hydrated collagen gels, rat cardiac ﬁbroblasts exhib-
ited spontaneous and ANG-induced contraction; stimulated, but not
basal contraction was inhibited by telmisartan and an AT2R antagonist,
P-186 (Lijnen et al., 2000, 2001).
These ANG and AT1R effects on cardiac ﬁbroblasts are of potential
importance for cardiac ﬁbrosis but may also be relevant for cardiac hy-
pertrophy as evidenced by studies using co-culturing of cardiac
myocytes and ﬁbroblasts. Thus, early studies demonstrated that ANG
had little effect on protein synthesis of cardiomyocytes, but conditioned
medium from ANG-treated ﬁbroblasts enhanced protein synthesis; this
was prevented by addition of losartan to the conditionedmedium (Kim
et al., 1995a). In a similar vein, other investigators reported that the
ANG-induced protein synthesis in cardiomyocytes largely disappeared
when a puriﬁed preparation was used but was restored when non-
myocytes were also present (Pönicke et al., 1997). Similarly, stretch-
induced cardiomyocyte expression of atrial and brain natriuretic
peptides was only evident upon co-culture with non-myocytes and
inhibited by candesartan or an endothelin A receptor antagonist (Hara
et al., 1997). Stretch-induced neonatal rat cardiomyocyte hypertrophy
was more pronounced in co-culture; based on the surrogate marker of
production of atrial natriuretic peptide and brain natriuretic peptide,
hypertrophy responses were greater in the presence of non-myocytes
and blocked by candesartan (Harada et al., 1998b). The interaction of
cardiac ﬁbroblasts and cardiomyocytes in promoting cardiac hypertro-
phy and ﬁbrosis is schematically depicted in Fig. 6.
4.2.2. In vivo models of hypertension- or
resistance-associated cardiovascular hypertrophy
Chronic arterial hypertension inevitably leads to cardiac hypertrophy
as the heart has to pump against an elevated peripheral resistance. As
cardiac hypertrophy is an independent risk factor formorbidity andmor-
tality in hypertensive patients, ARB effects on cardiac hypertrophy have
been studied in almost as many animal models of hypertension as their
antihypertensive effects. Of note, the hypertension-induced cardiac hy-
pertrophy often is associatedwith cardiac ﬁbrosis; as this may impair di-
astolic ﬁlling, it has an additional adverse effect on cardiac function.
In an early study, a 7 or 14dayANG infusion increased left ventricular/
body weight ratio by 18.6% and 17.3%, respectively; concomitantFig. 6. Schematic drawing of the roles of cardiomyocytes and cardiac ﬁbroblasts in stretch-in
natriuretic peptide (BNP) was used as indicator of hypertrophic phenotype. Note that co-cult
caused further increases production. An ARB (valsartan) or endothelin receptor antagonist (BQ
and speciﬁcally (Harada et al., 1998b).treatment with losartan prevented this hypertrophy development,
whereas hydralazine in doses yielding similar BP lowering or enalapril
did not (Dostal & Baker, 1992), providing initial evidence that AT1R
blockade may provide anti-hypertrophic effects beyond BP lowering. In
a similar study, ANG infusion for up to 10 days induced hypertrophy
and ﬁbrosis along with increased expression of ﬁbronectin, collagen
type I and IV and atrial natriuretic factor (Crawford et al., 1994). The hy-
pertrophy was abolished by concomitant losartan treatment, whereas
hydralazine or prazosin, causing similar or greater BP lowering, did not;
in this model of exogenous ANG administration, trandolapril neither
lowered BP nor reduced cardiac hypertrophy. Similar ﬁndings were also
reportedwith azilsartan (Carroll et al., 2015). Acute pressure overload in-
duced by a 2 h vasopressin infusion increased atrial and ventricular brain
natriuretic peptide expression in SHR; these were blocked by bosentan
but not by losartan (Magga et al., 1997).
4.2.2.1. Spontaneously hypertensive rat (SHR). As with the antihyperten-
sive effects, those on cardiac hypertrophy were most often studied in
SHR, a model in which ACE inhibitors are well established to reduced
cardiac hypertrophy (Huang et al., 2014). Most of these studies assessed
cardiac hypertrophy as total heart or left ventricular weight in absolute
terms (Mizuno et al., 1994; Takeda et al., 1994; Vacher et al., 1995; Inada
et al., 1997; Xie et al., 1999; Kawano et al., 2000a; Paull &Widdop, 2001;
Jones et al., 2004, 2012) or relative to body weight (Oddie et al., 1993;
Kagoshima et al., 1994; Inada et al., 1997; Zhang et al., 1997; Dai et al.,
2007; Ishimitsu et al., 2010; Choisy et al., 2015) but some more recent
studies have also used echocardiography, sometimes even in longitudi-
nal assessments (Kojima et al., 1994; Kawano et al., 2000a; Barone et al.,
2001; Behr et al., 2004; Mukaddam-Daher et al., 2009; Hye Khan et al.,
2014a; Zou et al., 2015). Studies were performed in a preventive ap-
proach with ARB administration starting prior to onset of hypertension
(Oddie et al., 1992; Mizuno et al., 1992c; Kojima et al., 1994; Vacher
et al., 1995; Kawano et al., 2000a) and also in a treatment design with
young adult but already hypertensive SHR (Oddie et al., 1993; Kohya
et al., 1995; Barone et al., 2001; Ishimitsu et al., 2010; Zou et al., 2015)
and older SHR with established hypertension (Kagoshima et al., 1994;
Mizuno et al., 1994; Takeda et al., 1994; Kim et al., 1995c; Inada et al.,
1997; Zhang et al., 1997; Xie et al., 1999; Koike et al., 2001;
Mandarim-de-Lacerda & Pereira, 2004; Dai et al., 2007;
Mukaddam-Daher et al., 2009; Hye Khan et al., 2014a; Choisy et al.,
2015). Notably, some of these studies reported regression of cardiac hy-
pertrophy even when treatment was started at an age of 20 monthsduced hypertrophy and ﬁbrosis. Production of atrial natriuretic peptide (ANP) and brain
ure alone already increased ANP/BNP production, and that concomitant stretch and ANG
123) inhibits the effects of stretch or ANG in co-culture. For references, see Section 4.2.1.
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duced cardiac hypertrophy in SHR when hypertension had been aggra-
vated by a high-salt diet (Susic & Frohlich, 2014). Moreover, studies
were also performed in spontaneously hypertensive obese rats (Hye
Khan et al., 2014a), the stroke-prone substrain of SHR exhibiting aggra-
vated hypertension (Kim et al., 1995c; Inada et al., 1997; Xie et al., 1999;
Barone et al., 2001; Behr et al., 2004; Mukaddam-Daher et al., 2009) or
in SHR inwhich hypertension and hypertrophy had been aggravated by
STZ-induced diabetes (Wienen et al., 2001) and in salt-loaded stroke-
prone SHR continuously infused with ANG (Kishi et al., 2014). Similar
to the BP lowering, the antihypertrophy effects lasted considerably lon-
ger than the presence of the ARB can be expected based on pharmaco-
kinetic properties (Oddie et al., 1992). With few exceptions in
candesartan studies (Mori et al., 1995), such studies have uniformly re-
ported reduction or prevention of cardiac hypertrophy. Such studies
were reported e.g. with azilsartan (Hye Khan et al., 2014a), candesartan
(Kagoshima et al., 1994; Kojima et al., 1994;Mizuno et al., 1994; Takeda
et al., 1994; Kohya et al., 1995; Kim et al., 1995c; Inada et al., 1997;
Zhang et al., 1997; Xie et al., 1999; Paull & Widdop, 2001; Jones et al.,
2004; Ishimitsu et al., 2010; Jones et al., 2012; Choisy et al., 2015),
eprosartan (Barone et al., 2001; Behr et al., 2004; Mukaddam-Daher
et al., 2009), irbesartan (Vacher et al., 1995), losartan (Oddie et al.,
1992; Mizuno et al., 1992c; Oddie et al., 1993; Kawano et al., 2000a;
Dai et al., 2007), olmesartan (Koike et al., 2001) and telmisartan
(Wagner et al., 1998; Wienen et al., 2001; Mandarim-de-Lacerda &
Pereira, 2004; Dai et al., 2007; Zou et al., 2015). However, some data in-
dicate that regression of cardiac hypertrophywith losartanmay be lim-
ited to BP-lowering doses (Dai et al., 2007). On the other hand, a
reduction of cardiac hypertrophy by candesartan in 20 months old
SHR was not mimicked by treatment with hydralazine (Jones et al.,
2012) or only partially mimicked (Paull &Widdop, 2001). Interestingly,
when treatment was withdrawn for 8 weeks, a reduction of left ventri-
cle/bodyweight ratio was no longer observed in SHR previously treated
with hydralazine but remained detectable in those previously treated
with candesartan or perindopril (Paull & Widdop, 2001)
Some of these studies also revealed an additional potential layer
of complexity: treatment with candesartan produced similar BP low-
ering in the absence and presence of concomitant administration of
the AT2R antagonist PD123319, but only candesartan monotherapy
reduced cardiac hypertrophy (Jones et al., 2004, 2012). On the
other hand, such apparent interaction between AT1R and AT2R
blockade was not observed in 20 week old SHR (Jones et al., 2012).
Treatment with valsartan or enalapril but not with felodipine also re-
duced cardiac hypertrophy in New Zealand genetically hypertensive
rats (Ledingham et al., 2000), supporting the view that anti-
hypertrophic effects are speciﬁc for RAS inhibition and not simply a
reﬂection of BP lowering.Table 3
Head-to-head comparisons of anti-hypertrophic effects of ARBs and ACE inhibitors in the hear






Renovascular hypertensive rat Candesartan Perindopril
Dahl S on high-sodium Candesartan Captopril
DOCA rat Candesartan Captopril
Pressure overload rat Candesartan Quinapril
Losartan Ramipril
Volume overload rat Eprosartan Enalapril
Olmesartan Temocapril
Minoxidil-treated rat Losartan Enalapril
Post-MI rat Candesartan Delapril
Candesartan Cilazapril
Post-MI pig Eprosartan Captopril
STZ diabetes rat Valsartan CaptoprilSimilar protectionwas also provided against cardiac ﬁbrosis inmany
studies in SHR (Kagoshima et al., 1994; Kojima et al., 1994;
Mandarim-de-Lacerda & Pereira, 2004; Ishimitsu et al., 2010), including
that aggravated by concomitant L-NAME treatment (Akashiba et al.,
2008). Moreover, biochemical indicators of ﬁbrosis such as expression
of collagen, ﬁbronectin, integrins, osteopontin or α-actinin, which are
elevated in SHR, were also normalized by ARBs (Kim et al., 1995c;
Kawano et al., 2000a; Zou et al., 2015), including a study in which a
dose of amlodipine providing similar BP reduction did not prevent car-
diac collagen deposition (Zou et al., 2015). However, one study with a
14-week treatment with candesartan starting at an age of 32 weeks
did not detect regression of ﬁbrosis in the atrium (Choisy et al., 2015).
Several studies were performed to explore the relative roles of RAS
inhibition vs. BP reduction or of AT1R antagonism vs. ACE inhibition
for reduction or prevention of cardiac hypertrophy and ﬁbrosis
(Table 3). In such studies ARBs performed consistently better than hy-
dralazine (Kagoshima et al., 1994; Kojima et al., 1994; Kohya et al.,
1995; Zhang et al., 1997; Kawano et al., 2000a) or hydrochlorothiazide
(Zhang et al., 1997) when studied at doses yielding comparable BP re-
duction, supporting the speciﬁc role of the RAS in cardiac hypertrophy
development; although in some of these studies hydralazine was not
only less effective for hypertrophy reversal but also for BP reduction
(Choisy et al., 2015). In one study the anti-hypertrophic effect of
telmisartan was not mimicked by an amlodipine dose yielding compa-
rable BP lowering (Zou et al., 2015). While in one study candesartan
was less effective than lisinopril (Mori et al., 1995) or telmisartan
more effective than captopril (Wagner et al., 1998), the overall picture
supports that ARBs and ACEIs have similar effects on cardiac hypertro-
phy, e.g. in studies comparing candesartan with captopril (Kohya
et al., 1995), derapril (Zhang et al., 1997) or enalapril (Kagoshima
et al., 1994; Inada et al., 1997) in SHRor telmisartanwith lisinopril in di-
abetic SHR (Wienen et al., 2001). One study reported greater anti-
hypertrophy effects of telmisartan as compared to losartan in SHR
(Wagner et al., 1998). As ARB treatment lowered cardiac but increased
plasma ANG levels it was proposed that part of their anti-hypertrophic
action may relate to the tissue rather than systemic RAS (Mizuno
et al., 1992c, 1994). Taken together these studies demonstrate that
ARBs as a class prevent and reduce cardiac hypertrophy more than an-
tihypertensive drugs not acting on the RAS and to a comparable degree
as ACE inhibitors. Findings consistentwith this conclusionwere also ob-
tained in other animal models of hereditary hypertension, e.g.
irbesartan in SHHF/Mcc-facp rats (Carraway et al., 1999) or valsartan
in New Zealand genetically hypertensive rats (Ledingham et al., 2000).
4.2.2.2. Renal hypertension. In Goldblatt renal hypertensive rats, treat-
ment with candesartan or perindopril similarly reversed cardiac hyper-
trophy and ﬁbrosis as well as atrial natriuretic peptide expressiont. MI: myocardial infarction. For details, see Section 4.2.
Outcome References
ARB≈ ACE (Kohya et al., 1995)
ARB≈ ACE (Zhang et al., 1997)
ARB≈ ACE (Kagoshima et al., 1994; Inada et al., 1997)
ARB b ACE (Mori et al., 1995)
ARB N ACE (Wagner et al., 1998)
ARB≈ ACE (Nagai et al., 2004)
ARB≈ ACE (Ideishi et al., 1994)
ARB≈ ACE (Brown et al., 1999)
ARB≈ ACE (Mukawa et al., 1997)
ARB b ACE (Linz et al., 1991)
ARB N ACE (Brodsky et al., 1998)
ARB N ACE (Kim et al., 1997)
ARB N ACE (Ruzicka & Leenen, 1993)
ARB≈ ACE (Yamagishi et al., 1993; Nishikimi et al., 1995b)
ARB≈ ACE (Yoshiyama et al., 1999)
ARB≈ ACE (van Kats et al., 2000)
ARB≈ ACE (Zhang et al., 2008b)
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hypertensive and a low BP-neutral telmisartan dose equally reduced
cardiac hypertrophy and ﬁbrosis (Kawai et al., 2009), as conﬁrmed by
other investigators in the same model (Ye et al., 2010; Chaykovska
et al., 2013). In a 2-kidney-2-clip rat model, valsartan improved cardiac
function and reduced cardiac hypertrophy and ﬁbrosis as well as mRNA
levels of several matrix metalloproteinases (Fang et al., 2010). In rats
with 5/6 nephrectomy, eprosartan attenuated cardiac hypertrophy de-
velopment but did not signiﬁcantly alter the modestly increased
mRNA levels of TGF-β or ﬁbronectin (Wong et al., 2000). Telmisartan
was also reported to prevent cardiac hypertrophy in rats with
uninephrectomy additionally receiving an ethylene glycol injection
(Kadhare et al., 2015). Taken together these data extend the ﬁndings
on beneﬁcial ARB effects on cardiac hypertrophy and ﬁbrosis from
SHR to models of renal hypertension.
4.2.2.3. Low reninmodels. Low reninmodels of hypertension are interest-
ing for studies on cardiac hypertrophy as they exhibit limited ARB ef-
fects on BP (see Sections 2.4 and 2.5) and accordingly offer another
possibility to study BP-independent effects of AT1R inhibition. In Dahl
salt-sensitive rats on a high sodium diet, candesartan had little effect
on cardiac hypertrophy in one study (Sugimoto et al., 1996), whereas
in another study using this model both candesartan and captopril re-
duced cardiac hypertrophy to a similar extent (Ideishi et al., 1994).
Azilsartan reduced cardiac hypertrophy in Dahl salt-sensitive rats on a
high-salt, high-fat diet (Jin et al., 2014). Others reported that both
losartan and telmisartan prevented cardiac hypertrophy and ﬁbrosis
in Dahl salt-sensitive rats on a high-salt diet (Liang & Leenen, 2008).
The antihypertrophic and antiﬁbrotic effects of telmisartan as well as
those on expression of endothelial NO synthase were reported to be at-
tenuated upon cotreatmentwithGW9662 (Kobayashi et al., 2008), indi-
cating an additional role for PPAR-γ activation. Valsartan also reduced
cardiac hypertrophy in Dahl salt-sensitive rats on a high-salt diet
(Nagasawa et al., 2015). While addition of the two Ca2+ entry blockers
had no major effects on overall cardiac hypertrophy, their addition
yielded greater reduction in cardiomyocyte cross-sectional area, inter-
stitial ﬁbrosis, collagen content and macrophage inﬁltration; in this re-
gard, addition of cilnidipine had greater effects on ﬁbrosis, collagen
content and macrophage inﬁltration than amlodipine. The more pro-
nounced effects of cilnidipine were attributed to a greater inhibition of
cardiac ACE, AT1R and mineralocorticoid receptor expression as well
as urinary dopamine and adrenaline excretion.
In rats with hypertension induced by treatment with DOCA,
candesartan did not affect BP but prevented the development of cardiac
hypertrophy (Fujita et al., 1997). Both candesartan and captopril reversed
cardiac ﬁbrosis, collagen and ﬁbronectin expression and diastolic stiffness
with treatment starting twoweeks after that ofmineralocorticoid admin-
istration (Brown et al., 1999). Taken together these ﬁndings further cor-
roborate the concept that antihypertrophic and antiﬁbrotic effects of
ARBs in the heart occur at least partly independent of those on BP.
4.2.2.4. Surgically induced models. Cardiac hypertrophy can be induced
surgically by procedures causing pressure or volume overload of the
heart. The most frequently used surgical model of pressure overload is
based on banding of the ascending (Weinberg et al., 1997), transverse
(Li et al., 2010a, 2012a; Quinn Baumann et al., 2013; Müller et al.,
2013), or abdominal aorta (Linz et al., 1991; Mukawa et al., 1997;
Obayashi et al., 1997; Wang et al., 2008; Liu et al., 2010; Guan et al.,
2011; Aswar et al., 2013; Zhang et al., 2014a). In most cases the start
of RAS inhibitor treatment was before or right after induction of pres-
sure overload (Linz et al., 1991; Mukawa et al., 1997; Obayashi et al.,
1997, 1999; Li et al., 2010a; Quinn Baumann et al., 2013; Müller et al.,
2013), but in some cases it has also been applied one to six weeks
after the surgical procedure (Linz et al., 1991; Weinberg et al., 1997;
Liu et al., 2010; Guan et al., 2011; Aswar et al., 2013; Zhang et al.,
2014a). Most ARB pressure overload studies have used rats, but insome cases similar models were also applied to mice (Li et al., 2010a,
2012a; Quinn Baumann et al., 2013; Müller et al., 2013).
In one study the chosen losartan dose caused greater BP reduction
than ramipril, but ramipril exhibited a greater beneﬁcial effect on cardi-
ac hypertrophy than losartan, both in a preventive and in a treatment
design (Linz et al., 1991). In a later study, however, candesartan and
quinapril had similar effects on left ventricular hypertrophy in a preven-
tive design but only when either was used in a BP lowering dose; across
all study groups, left ventricularweight and BP at end of treatmentwere
well correlated, indicating a major role for BP lowering in the anti-
hypertrophic effects in this model (Mukawa et al., 1997). Other studies
conﬁrmed that BP-lowering doses of candesartan reduced left ventricu-
lar hypertrophy and ﬁbrosis in a preventive design aortic banding
model (Obayashi et al., 1997, 1999). Using in vivo pressure measure-
ments as well as ex vivo cardiomyocyte morphometry, they found
that ARB treatment reduced not only the width but also the length of
myocytes, leading to a reduction of midwall radius and hence wall
stress, which in turnmay contribute to a preservation of cardiac output.
An antihypertensive dose of telmisartan, started one week after aortic
banding, reduced not only left ventricular hypertrophy but also re-
versed the changed cardiac expression patterns in a proteomics analysis
(Liu et al., 2010). In other studies in this model telmisartan also reduced
cardiac hypertrophy andﬁbrosis; additionally, a reduced cardiomyocyte
apoptosis and endoplasmic reticulum stress markers were observed
(Guan et al., 2011; Zhang et al., 2014a). Irbesartan or amlodipine started
six weeks after surgery and maintained for another 15 weeks at doses
not lowering BP did not reduce cardiac hypertrophy but improved left
ventricular end-diastolic pressure (Weinberg et al., 1997).
An interestingmouse study has used transverse aorta constriction in
wild-type and AT1R knock-out animals, and compared effects of ﬁve
ARBs (candesartan, losartan, olmesartan, telmisartan and valsartan) in
both strains (Li et al., 2010a). Aortic banding increased heart/body
weight and cross-sectional area of individual cardiomyocytes and altered
cardiac gene expression to a similar extent in wild-type and knock-out
mice, raising the possibility that endogenousANGmaynot be apathogen-
ic factor in this mouse model. All ﬁve ARBs reduced cardiac hypertrophy
to levels close to those in sham-operated mice, whereas cross-sectional
cardiomyocyte area was only partly normalized. While effects of
candesartan, losartan and olmesartan were fully maintained in the
knock-out mice, those of telmisartan and valsartan were attenuated.
These differential effects of ARBs, particularly in the knock-out mice, are
difﬁcult to understand when considering their pharmacological proﬁle
with regard to AT1R-independent effects (Michel et al., 2013) and may
more likely reﬂect speciﬁc experimental circumstances including relative
differences in doses than true biological differences. In similar mouse
models, but restricted towild-type animals, BP-lowering doses of azilsartan
(Quinn Baumann et al., 2013) and telmisartan (Li et al., 2012a) reduced
overall cardiac hypertrophy and ﬁbrosis; the abstract of the latter report
also claims a signiﬁcant reduction in mortality, but corresponding data
were missing in the manuscript. A third study in this model reported that
telmisartan and ramipril both prevented development of cardiac hypertro-
phy and ﬁbrosis; while telmisartan effects were slightly greater, it also
exhibited somewhat greater BP reductions (Müller et al., 2013).
Animal models of cardiac volume overload have largely been based
on aorto-caval shunts. In one study a BP-lowering olmesartan dose
prevented the development of cardiac hypertrophy and concomitantly
the up-regulation of atrial natriuretic peptide and collagen III and the
down-regulation of Ca2+-ATPase; the chosen dose of temocapril as
comparator had smaller effects on most of these parameters but also
produced less BP lowering, which makes it difﬁcult to exclude that the
differences were due to relative underdosing of the ACEI (Kim et al.,
1997). Antihypertrophic effects of olmesartan in this model were con-
ﬁrmed in a later study (Koike et al., 2001). In a similarmodel eprosartan
also reduced heart hypertrophy to a greater extent than enalapril, but
BP data were not provided to place this into perspective (Brodsky
et al., 1998). A BP-lowering dose of candesartan also partly prevented
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it also normalized expression of several genes, including several in-
volved in cellular Ca2+ handlng (Hashida et al., 1999).
In conclusion, ARBs similar to ACEIs prevent or reduce cardiac hyper-
trophy and ﬁbrosis induced by surgically induced pressure or volume
overload. As these effects were seen only with BP-lowering doses in
most studies, they may largely be due to their BP lowering effects; this
contrasts the ﬁndings in the SHR and renal hypertensive models. How-
ever, even in the absence of beneﬁcial effects on BP or hypertrophy, they
may improve cardiac function.
4.2.2.5. Transgenic and knock-out models. Several studies have explored
ARB effects in (mRen-2)27 transgenic rats. Of note, RAS activation is no
longer controlled by the physiological negative feed-back loops. Thus,
the degree of RAS activation in such animals by far exceeds what is ob-
served in normal animals or under any pathophysiological condition,
necessating caution in extrapolating ﬁndings from these transgenic rats
to other conditions. In a study with telmisartan, even a dose not affecting
BP reduced cardiac hypertrophy in this model (Böhm et al., 1995). Simi-
larly, eprosartan also reduced cardiac hypertrophy and normalized sarco-
plasmic Ca2+ handling in this model in doses not lowering BP; however,
reduction of ﬁbrosis was only observed at the higher, antihypertensive
eprosartan dose (Rothermund et al., 2001). In another study, olmesartan
and telmisartan, when given in equally BP-lowering doses had similar ef-
fects against heart hypertrophy and ﬁbrosis and improved diastolic func-
tion (DeMarco et al., 2011). In double transgenic mice harbouring the
human renin and angiotensinogen genes, azilsartan and olmesartan re-
duced cardiac hypertrophy (Iwanami et al., 2014). Inmicewith hyperten-
sion due to knock-out of the endothelial NO synthase, valsartan and the
direct renin inhibitor aliskirenmarkedly and similarly suppressed cardiac
hypertrophy, inﬂammation and ﬁbrosis, as well as coronary remodeling;
these effects were not shared by hydralazine, indicating that they are
not explained by the anti-hypertensive effects of the two RAS inhibitors
(Yamamoto et al., 2009a).
4.2.2.6. Other hypertension and hypotensionmodels.ARB effects on cardiac
hypertrophy and ﬁbrosis have also been explored in several other hyper-
tensive models. For instance, in hypertensive, obese and diabetic
SHRSP.Z-Leprfa/IzmDmcr rats telmisartan lowered BP and restored re-
duced cardiac expression of phospholamban (Kagota et al., 2013). A 1–
3 week cold exposure raised BP and caused cardiac hypertrophy in rats,
and losartan treatment blocked this (Fregly et al., 1993). Prolonged infu-
sion of the β-adrenoceptor agonist isoprenaline also caused hypertension
and cardiac hypertrophy and ﬁbrosis in rats, and this was attenuated by
candesartan (Omura et al., 1994) or telmisartan (Goyal & Mehta, 2012).
In a similar study but with a slightly different design, neither captopril
nor telmisartan prevented isoprenaline-induced ﬁbrosis in rat heart,
and captopril evenworsened it; the latter was linked to an augmentation
of increased expression of matrix metalloproteinase 9 by captopril
(Okada et al., 2010a). Injection of very high isoprenaline doses on two
consecutive days caused reductions of BP and maximal positive left ven-
tricular pressure; a 14 day pre-treatment with valsartan prevented
those (Goyal et al., 2011c). Chronic treatmentwith theNOsynthase inhib-
itor L-NAME also caused hypertension and cardiac hypertrophy and ﬁbro-
sis, and this was attenuated by treatment with irbesartan (Luvara et al.,
1998) or olmesartan (Takemoto et al., 1997). The former also attenuated
increased expression of inducible NO synthase or VCAM-1 and ICAM-1
expression. Studies on cardiac hypertrophy and ﬁbrosis occurring after a
myocardial infarction will be discussed in Section 4.2.3.
Interestingly, cardiac hypertrophy can not only result from high BP
but also as a response to chronic treatment with a strong vasodilator,
minoxidil (Ruzicka & Leenen, 1993), possibly due to volume overload.
In minoxidil-treated rats, losartan did not decrease left ventricular
end-diastolic pressure but prevented cardiac remodeling; in contrast,
enalapril improved left ventricular end-diastolic pressure but did not af-
fect cardiac hypertrophy.In linewith the above experimental data in various animalmodels of
hypertension, clinical data also support that the use of ARBs in manage-
ment of hypertensive patients offers target organ protection over
and above their antihypertensive activity (Thürmann et al., 1998;
Silverstein et al., 2004).
4.2.3. Post-infarction models
Cardiac hypertrophy and ﬁbrosis often develop after a survived
myocardial infarction in order to compensate for the loss of contractile
function from the infarcted area. Effects of ARBs on post-infarction hy-
pertrophy and ﬁbrosis have mostly been explored in rats, but some
studies were also done in mice (Bonda et al., 2012; Nakamura et al.,
2013), rabbits (Miki et al., 2000; Makino et al., 2003) and pigs (van
Kats et al., 2000). In most of these studies ARB administration started
within one week after the infarction but duration of treatment and
follow-up varied between one week and 7.5 months.
A prevention of post-infarction cardiac hypertrophy development
was observed in most studies, including with azilsartan (Nakamura
et al., 2013), candesartan (Yamagishi et al., 1993; Hanatani et al.,
1995; Nishizawa et al., 1997), eprosartan (van Kats et al., 2000),
irbesartan (Ambrose et al., 1999; Richer et al., 1999; Gervais et al.,
2000), losartan (Smits et al., 1992), telmisartan (Nagashima et al.,
2012), and valsartan (Miki et al., 2000; Makino et al., 2003; Song et al.,
2014) across all species that have been investigated (Fig. 7). However,
in a dog model based not on coronary artery ligation but on
microembolization, valsartan did not affect cardiac hypertrophy devel-
opment (Tanimura et al., 1999). SHR and other hypertensive animals
exhibit baseline cardiac hypertrophy which can be prevented or
reduced by ARBs (see Section 4.2.2.1), but ARBs also prevented the ad-
ditional hypertrophy induced by myocardial infarction in SHR
(Nishikimi et al., 1995b; Nishizawa et al., 1997). Importantly, during
follow-up for 7.5 months, irbesartan treatment also reduced mortality
(Richer et al., 1999). The anti-hypertrophic effects of telmisartan were
not attenuated by concomitant treatment with GW9662 (Nagashima
et al., 2012). Although prevention of hypertrophy has been reported in
several studies with only few weeks of treatment, one study with
irbesartan found that this was detectable after 6 months but not after
6 weeks of treatment (Gervais et al., 2000). Mechanistic studies indicat-
ed that the prevention of post-infarction cardiac hypertrophy by ARBs
involve normalized expression of atrial natriuretic peptide (Hanatani
et al., 1995; Ambrose et al., 1999), TGF-β1 (Hanatani et al., 1995;
Yoshiyama et al., 1999), β-myosin heavy chain and α-skeletal actin
(Yoshiyama et al., 1999).
However, ARBs may differentially affect post-infarction cardiac hy-
pertrophy and ﬁbrosis. Thus, valsartan treatment for 6 weeks did not
prevent ﬁbrosis despite reducing hypertrophy in rats (Gervais et al.,
1999) and neither did a 3-month treatment in a dogmicroembolization
model (Tanimura et al., 1999). Similarly, irbesartan treatment for
7.5 months had little effect on subendocardial ﬁbrosis despite reducing
hypertrophy (Richer et al., 1999). Correspondingly, candesartan or
cilazapril only inconsistently inhibited the increased expression of col-
lagen I and III after myocardial infarction (Hanatani et al., 1995;
Yoshiyama et al., 1999). On the other hand, losartan fully prevented ﬁ-
brosis induced bymyocardial infarction (Smits et al., 1992) and aminor
but dose-dependent reduction of ﬁbrosis was observed with azilsartan
treatment in a mouse infarction model (Nakamura et al., 2013). More-
over, a 14 day treatment with a BP-lowering dose of telmisartan re-
duced heart/body weight ratio, cardiomyocyte cross-sectional area,
number of matrix metalloproteinase-2 positive cells and ﬁbrosis;
while amlodipine or telmisartan in combination with GW9662 yielded
similar BP lowering and hypertrophy reduction, these two treatments
did not signiﬁcantly reduce matrix metalloproteinase-2 positive cells
or attenuate ﬁbrosis (Nagashima et al., 2012). To mechanistically ex-
plain the observed ﬁbrosis prevention with telmisartan, one study in
mice demonstrated that during a 12-week follow-up telmisartan
prevented the infarction-induced up-regulation of cysteine-rich
Fig. 7. Effect of a 3 week oral treatment, starting immediately after the coronary artery ligation, with an ARB (valsartan) and an ACE inhibitor (temocapril) in a rabbit model of myocardial
infarction. Data are means ± SD of 5 animals. *: P b 0.05 vs. sham. Calculated and drawn based on data published by Makino et al. (2003).
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tein level (Bonda et al., 2012), which both are implicated in ﬁbrosis de-
velopment. Additional experiments in isolated rat cardiac ﬁbroblasts
showed that telmisartan, similar to pioglitazone, suppressed TNF-α-
induced matrix metalloproteinase-2 activity (Nagashima et al., 2012);
this inhibition was abolished by GW9662, indicating that it may relate
to the PPAR-γ agonism by telmisartan. This could explain why post-
infarction cardiac ﬁbrosis was prevented by ARBswith PPAR-γ agonism
including losartan and telmisartan but not other ARBs.
Several studies have compared ARB and ACEI effects on post-
infarction hypertrophy development. A quantitatively similar effect on
hypertrophy was found with candesartan and delapril (Yamagishi
et al., 1993; Nishikimi et al., 1995b) or candesartan and cilazapril in
rats (Yoshiyama et al., 1999), with eprosartan and captopril in pigs
(van Kats et al., 2000) or with valsartan and temocapril in rabbits
(Makino et al., 2003; Fig. 7), indicating that thismay be a general feature
of RAS inhibition. To explore whether such effects are speciﬁc for RAS
inhibitors, one study compared telmisartan with amlodipine. In doses
yielding similar BP reduction, both also had similar effects on myocyte
cross-sectional area and heart/body weight ratio, although this did not
reach signiﬁcance for amlodipine effects on the former (Nagashima
et al., 2012). An alternative approach is the comparison of ARB doses
with and without BP-lowering effects. In one such study, post-
infarction hypertrophy was prevented by a BP lowering but not a BP
neutral valsartan dose (Gervais et al., 1999). In another study, a low
and a high dose of either candesartan or cilazepril both lowered BP, al-
though to a somewhat different extent, but had quantitatively similar
effects on left ventricular weight (Yoshiyama et al., 1999).
In conclusions RAS inhibitors as a class appear effective in
preventing post-infarction cardiac hypertrophy. While the evidence is
not fully conclusive, this can most likely be explained by BP lowering.
In contrast to other pro-hypertrophic models, prevention of ﬁbrosis
has not consistently been observed and, in the positive cases, may be
AT1R-independent. These alterations alongwith the lack of contractility
of the scar tissue affect cardiac function; such functional effects are
discussed in Section 4.3.4.2.4. Blood pressure-independent and other in vivo models
While cardiac hypertrophy in most cases is a result of increased he-
modynamic demand to the heart, ﬁbrosis is a uniform response of the
organism to a variety of causative stimuli. Invariably, this involves
chronic inﬂammation and a complex signaling network, in which TGF
aswell as some interleukins play crucial roles, leading to activation of ﬁ-
broblasts and their transition to myoﬁbroblasts and resulting in in-
creased extracellular matrix deposition (Denton et al., 2006; Wynn &
Ramalingam, 2012). Accordingly, ARB effects on cardiac ﬁbrosis have
been tested in different non-hypertensive models. In a rat STZ model
of type 1 diabetes, for instance, irbesartan (Tang et al., 2013) and
telmisartan (Goyal et al., 2008) attenuated cardiac hypertrophy and ﬁ-
brosis. In this model telmisartan also normalized elevated time to
peak tension and time to half-maximal relaxation in isolated hearts
(Emre et al., 2010). When administered for 8 weeks, starting 5 weeks
after STZ injection, valsartan and captopril treatment similarly im-
proved cardiac ultrastructure as well as circulating levels of marker en-
zymes creatine kinase MB and lactate dehydrogenase (Zhang et al.,
2008b). Valsartan treatment, starting directly after the STZ injection,
also improved cardiac ﬁbrosis (Wang et al., 2009).
In a rat type 2 diabetesmodel, induced by a low dose of STZ on top of
a high-fat, high-sugar diet, telmisartan prevented cardiac hypertrophy
and improved cardiac function; concomitantly the decreased cardiac
expression of adiponectin and its receptor was restored (Guo et al.,
2011). Administration of STZ to neonatal rats also can be used to
mimic type 2 diabetes; in this model, telmisartan reduced cardiac hy-
pertrophy and ﬁbrosis (Goyal et al., 2011b). In other type 2 diabetes
rat models, valsartan partly reversed cardiac hypertrophy, ﬁbrosis and
apoptotic index (Yang & Peng, 2010), irbesartan reduced hypertrophy
and ﬁbrosis (Tang et al., 2013). Telmisartan also reduced cardiac hyper-
trophy in a type 2 diabetes model; moreover, although it had no effect
on atrial weight, it at least partly prevented the enhancement of nega-
tive inotropic effects of adenosine in isolated atria while not improving
the depressed positive inotropic effect of phenylephrine (Hussein et al.,
2011). Telmisartan (Sukumaran et al., 2012) and valsartan (Liu et al.,
2009b) also improved cardiac hypertrophy, ﬁbrosis and inﬂammation
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against cardiac myosin. Similarly, candesartan improved cardiac hyper-
trophy and inﬂammation in mice which had been inoculated with en-
cephalomyocarditis virus without affecting viral replication;
importantly, in this model the ARB at least numerically improved sur-
vival (Tanaka et al., 1994). The cardiac hypertrophy and ﬁbrosis induced
by a high dose of L-thyroxin was alleviated by imidapril and valsartan
(Zhang et al., 2007). Candesartan and captopril similarly reduced ﬁbro-
sis in a mouse model of heterotopic heart transplantation between
MHC-antigen compatible strains (Furukawa et al., 1996). Losartan re-
duced cardiac hypertrophy and ﬁbrosis in transgenic mice overexpress-
ing calsequestrin (Günther et al., 2010).
Given the crucial role of TGF-β in the development of ﬁbrosis
(Denton et al., 2006; Wynn & Ramalingam, 2012), it is not surprising
that mice with transgenic overexpression of TGF-β develop cardiac hy-
pertrophy and ﬁbrosis. In suchmice telmisartan reduced both hypertro-
phy and ﬁbrosis by normalizing the ratio between matrix
metalloproteinases and their endogenous inhibitors, TIMP-1and TIMP-
4; in contrast, metoprolol or a TGF antibody had antihypertrophic but
little antiﬁbrotic effects in this model (Seeland et al., 2009). In a
follow-up study, however, metoprolol appeared more effective than
telmisartan (Huntgeburth et al., 2011). Moreover, effects by additional
β-adrenoceptor stimulation with isoprenaline were attenuated bymet-
oprolol but not by telmisartan. Caveolin-1 knock-out mice spontane-
ously develop cardiac hypertrophy and ﬁbrosis; telmisartan treatment
reduced the hypertrophy, collagen expression and associated
perivascular ﬁbrosis of intramyocardial vessels (Krieger et al., 2010).
While not directly related to cardiomyocyte function, myxomatous
degeneration of the mitral valve is a pathological hallmark of mitral
valve prolapse; in cultured human valvular interstitial cells, TGF-β pro-
duced extracellular matrix production, which was abolished by
candesartan, losartan and telmisartan (Geirsson et al., 2012). Similarly,
pericardial thickening and ﬁbrosis can be a problem in patients having
undergone cardiac surgery; the pericardial ﬁbrosis induced by
pericardiectomy was attenuated by valsartan in a pig model (Loging
et al., 1999).
Taken together these data demonstrate that ARBs can prevent and
reduce cardiac hypertrophy and ﬁbrosis in a broad range of experimen-
tal models. Inmany cases these effects can already be observed in doses
not lowering BP, and the effects of BP-lowering doses typically consid-
erably exceed those observed with other antihypertensive drugs. This
leads to improved cardiac function, particularly diastolic function. Pos-
sible exceptions are models of cardiac pressure or volume overload,
where the beneﬁcial ARB effects are largely BP-dependent.
4.3. Myocardial infarction
ARB effects on myocardial infarction have been studied in several
settings. One group of studies has tested whether pre-treatment with
an ARB affects damage and recovery after myocardial infarction; this
may relate to the clinical question whether patients on ARB treatment
will incur less damage if a heart attack occurs (see Section 4.3.1). A sec-
ond group of studies has applied ARBs immediately (within few hours
to one day) after myocardial infarction, mimicking a situation where a
patient receives acute treatment in an intensive care unit (see
Section 4.3.2). Findings of an up-regulation of both AT1R and AT2R in
the infarcted and the non-infarcted parts of the heart (Nio et al., 1995)
or of increased ANG in the scar (but not the overall heart) (Yamagishi
et al., 1993), provide additional rationale for such studies. A third
group of studies has explored how ARB treatment started several days
or later after an infarction may affect chronic consequences, which
could be interpreted as models of secondary prevention (see
Section 4.3.3). Someof the studies fromall three groups have investigat-
ed ARB effects on long-term consequences of myocardial infarction;
while the functional consequences are discussed in this section, those
on cardiac hypertrophy and ﬁbrosis were discussed in Section 4.2.3.Effects on the prevention of heart failure are discussed in Section 4.4. Fi-
nally, some studies have exploredwhether ARBs interferewith ischemic
preconditioning (see Section 4.3.4).
Most studies in this ﬁeld have used ratmodels, but somewere based
on mice (Xu et al., 2009; Ye et al., 2011; Higashikuni et al., 2012; Chen
et al., 2014; Zeng et al., 2013b), rabbits (Hartman et al., 1993; Zhao
et al., 2009), pigs (Schmermund et al., 2000) or dogs (Jalowy et al.,
1998; Dörge et al., 1999; Nakai et al., 1999; Preckel et al., 2000). Most
studies were based on coronary ligation, but some have also applied
other models such as microembolization (Tanimura et al., 1999;
Schmermund et al., 2000), exposure to hypoxia (Maejima et al., 2011;
Zeng et al., 2013b) or to a high dose of isoprenaline (Goyal et al.,
2011c; Bayir et al., 2012). While most studies were performed in
in vivo settings, including open-chest preparations (Preckel et al.,
2000), some have also used in vitro models including isolated
cardiomyocytes (Matoba et al., 1999; Maejima et al., 2011) or isolated
heart preparations (Hartman et al., 1993; Yoshiyama et al., 1994;
Shimizu et al., 1999; Kim et al., 2012a). Of note, such in vitro models
mostly have used hypoxia to mimic myocardial infarction, but hyp-
oxia mimics only the oxygen supply side of the event and not the
lack of removal of metabolic breakdown products. Moreover, some
studies have used only short periods of myocardial ischemia to in-
duce stunning rather than full-ﬂedged myocardial infarction
(Dörge et al., 1999; Nakai et al., 1999). Finally, some studies have ex-
plored ARB effects in models with underlying other disease such as
type 1 (Goyal et al., 2010, 2011d) or type 2 diabetes (Ye et al.,
2011; Rinaldi et al., 2012).
4.3.1. Preventive angiotensin receptor blocker administration
A study acutely exposed rat neonatal cardiomyocytes to
candesartan, cilazepril or bradykinin, followed by 5.5 h of hypoxia and
1 h of reoxygenation (Matoba et al., 1999). While cilazepril and brady-
kinin reduced hypoxia-induced release of creatine kinase, candesartan
did not; moreover, icatibant prevented the cilazepril effects, suggesting
that protective ACEI effects in this in vitromodel are due to an increased
bradykinin exposure and not to RAS inhibition. Other in vitro studies
have used rat isolated heart in a Langendorff preparation. In one
study, rats were treated for one week with candesartan or delapril;
thereafter, ischemia was induced in isolated hearts (Yoshiyama et al.,
1994). Both treatments similarly reduced release of creatine kinase
and improved post-ischemia cardiac function; injection of ANG prior
to ischemiaworsened cardiac damage, and suchworseningwas attenu-
ated only by the ARB. Other in vitro studies did not rely on in vivo pre-
treatment but rather directly exposed the isolated heart to ARBs. Under
such conditions, high concentrations of neither valsartan (100 μM) nor
enalapril (20 μM) given immediately prior to ischemia induction affect-
ed the impaired cardiac function during the reperfusion period in a rat
Langendorff preparation (Hayashi et al., 1997a). On the other hand,
100 nM candesartan improved the double-product in ischemia and re-
duced the no-ﬂow area; 1 nM candesartan, however, was ineffective
(Shimizu et al., 1999). Similarly, acute exposure to losartan reduced in-
farct size in an isolated rat heart preparation, and also attenuated the
infarct-increasing effect of icatibant (Sato et al., 2000).
In vivo treatment with candesartan for 2 weeks reduced infarct size
due to ischemia in isolatedmouseheart,whereas ramipril treatment did
not (Lange et al., 2007). Similarly, a 2-week pre-treatment with
valsartan reduced infarct size in an in vivo ischemia/reperfusion setting
(Yang et al., 2009). Pre-treatment with telmisartan reduced infarct size
in Zucker diabetic fatty rats and improved systolic function as assessed
2 h after the ischemia period (Di Filippo et al., 2014). However, one
study found that telmisartan (but not losartan) in concentrations of 30
μM and more actually induced infarction; this was apparently due to
calcium overload caused by inactivation of voltage-gated Na+ channel
(Kim et al., 2012a). Based on a telmisartan afﬁnity of 5 nM for the
AT1R (Michel et al., 2013), this ﬁnding based on 60,000 fold therapeutic
concentration may not be applicable to a therapeutic setting. The
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sidered a model of cardiac ischemia. When this was applied to rabbit
heart in the absence and presence of RAS inhibition, losartan exhibited
much smaller cardioprotective effects than captopril (Hoyer et al.,
2014). In another rabbit study, not reporting on infarct size, pre-
treatment with candesartan or telmisartan reduced myocardial neutro-
phil inﬁltration and increased cardiac microvessel cross-sectional area
as observed after a 60 minutes ischemia period (Zeng et al., 2013a).
Short periods of ischemia often do not cause myocardial infarction
but a reversible state of impaired heart function, stunning. In a dog
study, both telmisartan and enalapril enhanced fractional shortening
during the reperfusion period following a 10 min coronary artery liga-
tion; while icatibant prevented the protection by enalapril, it did not af-
fect that by telmisartan (Nakai et al., 1999). Whether this reﬂected
inconsistent effects of RAS inhibition or a non-AT1R effect of telmisartan
has not been explored. In another dog study, balloon pumps were used
to maintain stable systemic hemodynamics and regional myocardial
blood ﬂow during a short period of ischemia; under these conditions
candesartan improved left ventricular function (Dörge et al., 1999).
The key questions regarding preventive ARB administration and
myocardial infarction are whether it reduces the incidence of heart at-
tacks andwhether the severity (infarct size) of the remaining ones is re-
duced. While addressing the ﬁrst one is difﬁcult in animal models, the
second one has frequently been explored, mostly based on coronary ar-
tery occlusion models; however, the answer to this question has been
equivocal. Thus, in a mouse model neither AT1R knock-out nor pre-
treatment with candesartan affected infarct size (Harada et al., 1998a).
Similarly, treatment with irbesartan starting 24 h before ligation and
maintained for 6 weeks did not reduce the size of transmural infarction
in rats as determined histologically at study end (Ambrose et al., 1999).
In a dog study using occlusion of the left anterior descending artery in an
open-chest preparation, acute irbesartan pre-treatment increased col-
lateral blood ﬂow to ischemia area but the observed reduction in infarct
size did not reach signiﬁcance (Preckel et al., 2000). On the other hand, a
2-week pre-treatment with two doses of valsartan reduced infarct size
in rats by about half (Yang et al., 2009). This was accompanied by inhi-
bition of release of creatine kinase and lactate dehydrogenase, TNF-α
and IL-6 levels and of TLR4 and NF-κB expression. Similarly, in a pig
model, acute pre-treatment with candesartan also reduced infarct size
by about half (Jalowy et al., 1998). In that study, the AT2R antagonist
PD123319, the bradykinin B2 receptor antagonist icatibant or the cyclo-
oxygenase inhibitor indomethacin had no effects on infarct size when
given alone but abolished the reduction by candesartan. In diabetic
db/dbmice on aWestern diet, valsartan, aliskiren and their combination
reduced infarct size in a dose-dependent manner; however, this reduc-
tion did not reach statistical signiﬁcance for the lower valsartan dose,
and all treatments were less effective than in non-diabetic mice (Ye
et al., 2011). In Zucker diabetic fatty rats, pre-treatment with
telmisartan also dose-dependently reduced infarct size (Rinaldi et al.,
2012). This was accompanied by lowered levels of plasma and cardiac
adiponectin and a reduced expression of inﬂammation markers NF-κB,
TLR2, TLR4 and TNF-α; the increased expression of inducible NO syn-
thase was abolished by telmisartan. The inconclusive picture emerging
from these studies is not easily explained by difference in species, ische-
mia protocol or speciﬁc aspects of the ARB under investigation. There-
fore, it remains unresolved whether pre-treatment with an ARB
reduces infarct size. However, even in studies where infarct size was
not reduced by pre-treatment with an ARB, myocardial function was
improved. For instance, irbesartan normalized the increased expression
of atrial natriuretic peptide and reduced cardiac hypertrophy in a rat
model despite a lack of reduction of infarct size (Ambrose et al., 1999).
As an alternative to coronary artery ligation, myocardial ischemia
can also be induced bymicroembolization.When such a model was ap-
plied to pigs, irbesartan administered immediately before the micro-
spheres increased the ratio of regional intramyocardial blood volume
and perfusion (assessed by electron-beam computed tomography)(Schmermund et al., 2000). When irbesartan treatment was continued
for 4 weeks, this ratio was also moderately increased, along with an in-
crease in ejection fraction; of note, this is a model inwhich ischemia did
not lead to cardiac hypertrophy. While not involving ischemia, chronic
intermittent hypoxia caused oxidative stress in mouse heart, and this
was attenuated by telmisartan (Zeng et al., 2013b). Moreover,
telmisartan also reduced excessive NO formation, IL-6 release and apo-
ptosis in the heart of rats exposed to intermittent hypoxia (Yuan et al.,
2015).
An alternative to coronary artery occlusion or microembolization is
the induction of myocardial infarction by injection or infusion of a
high dose of theβ-adrenoceptor agonist isoprenaline. One group has re-
ported a number of studies using this model in rats. In an early study, a
13 day pre-treatment with telmisartan counteracted the isoprenaline-
induced alterations of inotropy, lusitropy and left ventricular end-
diastolic pressure, levels of damage markers creatine kinase and lactate
dehydrogenase and the oxidative stress markers superoxide dismutase
and malondialdehyde (Goyal et al., 2009). In another study of similar
design, valsartan pre-treatment for 15 days prior to isoprenaline admin-
istration improved myocardial function and levels of creatine kinase,
lactate dehydrogenase and antioxidant enzymes superoxide dismutase
and catalase (Goyal et al., 2011c). To determine whether such protec-
tionwas speciﬁc for ARBs, a general feature of RAS inhibition or a conse-
quence of BP lowering, effects of valsartan, ramipril and lacidipine were
compared with isoprenaline administration after 1–2 or after 29–30
days of treatment (Keles et al., 2009). Short and long treatment with
all three drugs prevented the isoprenaline-induced reduction of NO,
the increase in creatine kinase and lactate dehydrogenase and the
DNAdamagemeasured in circulating leukocytes. A later study of similar
design but only using a 30 day pre-treatment period supported this con-
clusion: all three drugs similarly attenuated the isoprenaline-induced
increase in superoxide dismutase, catalase and malondialdehyde
(Bayir et al., 2012). While these studies indicated the possibility that
the protective effects on an ARB may occur secondary to BP lowering,
somewhat different conclusions can be derived from using the same
model in rats with STZ-induced diabetes. In such studies, telmisartan
improved redox status and functional recovery, inhibited Bax expres-
sion, and reduced TUNEL-positive cells, necrosis and edema; all of
these telmisartan effects were attenuated by GW9662 (Goyal et al.,
2010). In a follow-up study, telmisartan normalized BP, left ventricular
contractility (assessed as dP/dt) and end-diastolic pressure and reduced
infarct size; telmisartan also reduced endogenous antioxidants, cre-
atine kinase and lactate dehydrogenase release, prevented the in-
crease in TNF-α and malondialdehyde, and also reduced Bax
expression and TUNEL-positive cells, inﬂammation and myocardiac
necrosis; GW9662 when given alone had opposite effects on most
of these parameters, and when administered in combination attenu-
ated the effects of telmisartan (Goyal et al., 2011d). These studies do
not support the concept that ARB effects in the isoprenaline model of
myocardial infarction occur secondary to BP lowering and rather
raise the possibility that at least those of telmisartanmay occur inde-
pendent of BP and involve PPAR-γ agonism. Whether the conﬂicting
ﬁndings of the valsartan/ramipril/lacidipine and the telmisartan/
GW9662 studies can be explained by the presence of diabetes re-
mains to be determined.
4.3.2. Early post-infarction angiotensin receptor blocker administration
While it remains controversial whether animals receiving ARB treat-
ment exhibit a reduced infarct size (see Section 4.3.1), with exception of
one azilsartan study (Nakamura et al., 2013) it has consistently been re-
ported that early post-infarction treatmentwith anARB (up to 24 h after
the occlusion) does not affect infarct size. For instance, such ﬁndings
were reported for candesartan (Yamagishi et al., 1993; Hanatani et al.,
1995; Nio et al., 1995), telmisartan (Maejima et al., 2011) and valsartan
in rats (Hayashi et al., 1997a) and for losartan (Hartmanet al., 1993) and
valsartan in rabbits (Miki et al., 2000;Makino et al., 2003). Interestingly,
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ramipril plus ANG combination (Hartman et al., 1993), raising the pos-
sibility of an AT1R-independent effect of the ACE inhibitor.
Based on a somewhat unusual study design, it has been reported
that valsartan or enalapril when given immediately after coronary liga-
tion in anesthetized dogs lowered BP and heart rate and prevented the
rise in left ventricular end-diastolic pressure and the decrease in cardiac
output (Yamamoto et al., 1997a). However, most studies have started
ARB treatment one day after the infarction. One early study reported
that losartan did not restore cardiac output in a ratmodel, inwhich cap-
topril had done so in previous experiments by these investigators
(Smits et al., 1992). Cardiac output was also unaffected in rats upon ei-
ther valsartan or enalapril treatment (Hayashi et al., 1997a) or in rabbits
upon valsartan or temocapril treatment (Makino et al., 2003),
questioning whether this indeed reﬂects a difference between the two
drug classes. However, when other parameters of cardiac function
were explored, administration of an ARB early after myocardial infarc-
tion typically had beneﬁcial functional effects despite a lack of effect
on infarct size (for effects on hypertrophy and ﬁbrosis see
Section 4.2.3). Thus, candesartan (Yamagishi et al., 1993; Nishikimi
et al., 1995b) and valsartan (Hayashi et al., 1997a; Gervais et al., 1999)
reduced left ventricular end-diastolic pressure; candesartan
(Yoshiyama et al., 1999), telmisartan (Maejima et al., 2011) and
valsartan (Makino et al., 2003) improved left ventricular dilatation, sys-
tolic and diastolic function and ejection fraction; candesartan improved
fractional shortening (Hanatani et al., 1998); candesartan lowered car-
diac expression of atrial natriuretic peptide (Hanatani et al., 1998),
and telmisartan lowered plasma levels of brain natriuretic peptide
(Maejima et al., 2011). Valsartan treatment reduced elevated plasma
noradrenaline and expression of β-adrenoceptor kinase and Giα G-
proteins and restored lowered β-adrenoceptor density, depressed
adenylyl cyclase activity (Makino et al., 2003). Improvement of heart
function uponARB treatment after amyocardial infarctionwas similarly
seen in both normotensive rats and SHR (Nishikimi et al., 1995b). How-
ever, one study in a mouse model of myocardial infarction did not ob-
serve major telmisartan effects on systolic or diastolic function nor on
cardiac expression of atrial natriuretic peptide, but prevented up-
regulation of CCN gene expression (Bonda et al., 2015).
One study explored ARB effects on atrial ﬁbrillation by treating rab-
bits with valsartan starting immediately after the infarction for a period
of 12 weeks (Zhao et al., 2009). In this study, atrial ﬁbrillation was ob-
served in 4 rabbits of the infarction group as compared to 2 each in
the control and the valsartan-treated infarction group. Moreover, the
mean duration of atrial ﬁbrillation episodes was 39 s in the infarction
vs. 9 s in the other two groups. A numerical reduction in the density of
IKACh current density in left atrium upon valsartan treatment did not
reach statistical signiﬁcance. Given the overall small numbers, however,
these ﬁndings are difﬁcult to interpret. In another study, ventricular ﬁ-
brillation was induced, followed by closed chest resuscitation and deﬁ-
brillation; telmisartan, administered 10 min after the resuscitation,
increased myocardial contractility without affecting cardiac index, sys-
temic or pulmonary vascular resistance, or myocardial perfusion
(Strohmenger et al., 1997). In a rat study on coronary artery function
aftermyocardial infarction, a low valsartan dose not affecting BP slightly
improved basal left and right ventricular coronary ﬂow and resistance
values, but decreased left and right coronary vascular reserve (Gervais
et al., 1999). A high valsartan dose decreased BP and slightly improved
basal left ventricular ﬂow and resistance values but only the right ven-
tricular coronary vascular reserve was increased.
Several studies have explored factors which may explain the ob-
served functional improvements upon ARB administration in the ab-
sence of infarct size reduction. For instance, candesartan prevented
the up-regulation of cardiac AT1R (Nio et al., 1995) and mitigated the
increased expression of β-myosin heavy chain and α-skeletal actin
(Yoshiyama et al., 1999). Telmisartan in doses not lowering BP reduced
macrophage inﬁltration, TUNEL staining, activation of matrixmetalloproteinase-2 and -9 and expression of TGF-β1, connective tissue
growth factor and osteopontin expression and increased expression of
the endogenous matrix metalloproteinase inhibitor TIMP-1 as com-
pared to rats treated with vehicle, losartan or telmisartan plus
GW9662 (Maejima et al., 2011). In additional experiments with 24 h
in vitro hypoxia, telmisartan increased expression of TIMP-1 and re-
duced expression of TGF-β1 in neonatal rat cardiomyocytes, whereas
it reduced activity of metalloproteinase-2 and -9 and expression of con-
nective tissue growth factor and osteopontin in cardiac ﬁbroblasts. As
these telmisartan effects were abolished by concomitant GW9662 and
notmimicked by losartan, theymay not represent class effects but rath-
er speciﬁc properties of telmisartan. However, this remains to be con-
ﬁrmed in additional studies.
Finally, some studies have compared the functional effects of early
administration of ARBs with those of other RAS inhibitors or RAS-
independent anti-hypertensive drugs. In such studies ARBs and ACEIs
had similar effects, for instance candesartan and cilazapril on systolic
and diastolic function, left ventricular dilatation and expression of β-
myosin heavy chain, α-skeletal actin and atrial natriuretic peptides in
rats (Yoshiyama et al., 1999). Candesartan and delapril also had similar
effects on left ventricular end-diastolic pressure in both normotensive
rats and in SHR (Yamagishi et al., 1993; Nishikimi et al., 1995b). In
C57BL/6 mice, valsartan and aliskiren had similar beneﬁcial effects on
hemodynamics as assessed by echocardiography, and their combination
was even more effective; however, hydralazine did not mimic these ef-
fects (Higashikuni et al., 2012), indicating that they may be speciﬁc for
RAS inhibitors. In other studies valsartan and enalapril in rats (Hayashi
et al., 1997a) and valsartan and temocapril in rabbits (Makino et al.,
2003) also yielded similar improvement of cardiac function after myo-
cardial infarction. Taken together these data show that early post-
infarction administration of ARBs improves functional outcomes in ex-
perimental animals despite not affecting infarct size. The relevance of
this is demonstrated by a study in which olmesartan increased
rupture-free survival in amousemodel, apparently at least in part by re-
ducing post-infarction inﬂammation and cardiomyocyte apoptosis
(Chen et al., 2014).
4.3.3. Late post-infarction angiotensin receptor blocker administration
It has also been explored howARBs affect outcomes if treatmentwas
started 1 week or later after the heart attack; however, start of treat-
ment was very heterogeneous in such studies, ranging from 7 to 21
days after the infarction, which makes comparison of the results difﬁ-
cult. Similar to treatment starting early after myocardial infarction
(see Section 4.3.2), ARB administration starting 1 week or later after
the event also did not affect infarct size (Nishizawa et al., 1997; Richer
et al., 1999; Xu et al., 2009). Nonetheless it typically improved cardiac
function and morphology in most studies. One of the few exceptions
was use of losartan in rats during days 21–35 after infarction, which
did not restore cardiac output, while captopril had done so in a previous
study using the same protocol (Smits et al., 1992). For instance, in both
normotensive rats and SHR candesartan starting 1 week after ligation
and maintained for 3 weeks almost normalized left ventricular end-
diastolic pressure as well as right and left ventricular hypertrophy
(Nishizawa et al., 1997). Irbesartan treatment in rats starting 1 week
after the infarction and maintained for 7.5 months dose-dependently
decreased left ventricular end-diastolic pressure whereas cardiac hy-
pertrophy was improved but not normalized with a BP-lowering and a
lower, BP neutral dose; moreover, the elevated urinary cGMP excretion
was dose-dependently reduced (Richer et al., 1999). In another study
irbesartan starting after 8 days was maintained for 6 weeks or
6 months (Gervais et al., 2000); long-, but not short-term treatment
prevented endothelial function decline, opposed right ventricular coro-
nary dilatation reserves (dipyridamole testing) impairment, prevented
pericoronary ﬁbrosis development, and improved systemic hemody-
namics. In another study, valsartan or ramipril were administered
starting 3 weeks after myocardial infarction and maintained for
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et al., 2009); both drugs reduced left ventricular hypertrophy and
myocyte cross-sectional area, collagen deposition and left ventricular
diastolic dimension and improved ejection fraction, but all to a smaller
extent in the B1 receptor knock-out mice. In dog model where myocar-
dial ischemia had been induced bymicroembolization, a 3-month treat-
ment with valsartan restored ejection fraction and left ventricular end-
systolic and end-diastolic volume (Tanimura et al., 1999).
Secondary hyperaldosteronism is a frequent consequence of myocar-
dial infarction and may contribute to cardiovascular remodeling. The
ANG-induced adrenal aldosterone release can be blocked by various
ARBs including azilsartan, irbesartan, losartan, olmesartan or telmisartan
whereas AT2R antagonists are ineffective (Miura et al., 2015); however,
ANG-stimulated aldosterone release is not mediated by canonical AT1R
signaling but rather by β-arrestin 1 (Lymperopoulos et al., 2009). Based
on adrenal-targeted, adenovirus-mediated gene transfer, β-arrestin 1
also appears to mediate hyperaldosteronism in a post-infarction setting
(Lymperopoulos et al., 2011). In light of biased agonism exhibited by
ARBs (Tilley, 2011;Wilson et al., 2013) and the role of β-arrestin 1 in al-
dosterone release, it is interesting that in a post-infarction setting inmice
candesartan and valsartan but not by irbesartan or losartan reduced
hyperaldosteronism (Lymperopoulos et al., 2011, 2014); similarly,
candesartan and valsartan had stronger beneﬁcial effects on ejection
fraction and isoprenaline-induced inotropy (increase in dP/dtmax).
Other than differential tissue penetration and PPAR-γ activation
(Michel et al., 2013), this represents an additional mechanism how
ARBs can have differential effects.
Taken together these data demonstrate that ARBs as a class improve
cardiac morphology and function in experimental animals even when
treatments start a week or later after the event. These beneﬁcial effects
are similar to those of other RAS inhibitors. Most importantly, ARBs in-
cluding irbesartan (Richer et al., 1999) and olmesartan (Koike et al.,
2001) improved long-term survival after myocardial infarction; this
may require a BP-lowering dose but apparently is unrelated to infarct
size.
4.3.4. Ischemic preconditioning
Ischemic preconditioning is an endogenous protective mechanism
in which short periods of ischemia protect against tissue damage in-
duced by later,more pronounced ischemia (Ferdinandy et al., 2014). Ex-
perimental conditioning studies typically use infarct size due to the later
ischemia episode as the primary outcome parameter. Ischemic precon-
ditioning can be mimicked by activation of various receptors, including
those for adenosine or bradykinin, coupling to protein kinase C activa-
tion with subsequent opening of the mitochondrial ATP-sensitive K+
channels (Miki et al., 2000). Members of the mitogen-activated protein
kinase family also appear to be important mediators of such precondi-
tioning (Michel et al., 2001). As AT1R stimulation can activate protein
kinase C and mitogen-activated protein kinases (Michel et al., 2013),
ANG-induced preconditioning has been explored. Indeed, exogenously
administered ANG induced some degree of preconditioning in isolated
rabbit heart (Liu et al., 1995; Sharma & Singh, 1999; Miki et al., 2000);
this was prevented by ARBs including candesartan and losartan, but
not by an AT2R antagonist, indicating mediation via AT1R. Moreover,
the ANG-induced preconditioning was no longer detected in rabbit
hearts with hypertrophy due to a coronary artery ligation two weeks
earlier (Miki et al., 2000). Endogenous ANG apparently is also capable
of cardiac preconditioning, as the degree of preconditioning observed
in transgenic (mREN-2)-27 rats was greater than in normotensive
Sprague-Dawley rats (Randall et al., 1997). Accordingly, candesartan at-
tenuated ANG-induced preconditioning in isolated rat heart; this was
similarly observed whether infarct size or ischemia-induced release of
lactate dehydrogenase or creatine kinase was assessed (Sharma &
Singh, 1999). However, if ANG is given on top of ischemic precondition-
ing, itmay abolish the protective effect of preconditioning, an effect sen-
sitive to losartan (Xiao & Allen, 2003).Based on reports of ANG-induced preconditioning, it may be as-
sumed that ARBs could have the opposite effect. Indeed it was reported
from a rabbit in vivo model that candesartan, given 20 min prior to the
initial ischemia period, attenuated preconditioning by a 3 or 30 min is-
chemia episode (Nakano et al., 1997). However, in isolated rat heart,
acute exposure to candesartan (Sharma & Singh, 1999) or losartan
(Xiao & Allen, 2003) had no effect on ischemic preconditioning. Similar-
ly, a 2-week pretreatment with candesartan in an in vivo mouse model
did not enhance the protection offered by ischemic preconditioning;
however, these data are not easy to interpret as candesartan alone re-
duced infarct size to a similar degree as ischemic preconditioning
alone (Lange et al., 2007). On the other hand, a 1-week in vivo pre-
treatment with losartan enhanced the effect of cardioprotective effects
of ischemic preconditioning as assessed in isolated heart (Butler et al.,
1999). This study had included an additional group of rats with high-
salt diet-induced cardiac hypertrophy; in these animals the effect of
preconditioningwas greater than in control rats, but similarly enhanced
by losartan (Butler et al., 1999). Finally, a study in rabbits has used a
rather complex design (Miki et al., 2000). The animals underwent a
sham procedure, coronary artery ligation or ligation with subsequent
valsartan treatment. Two weeks later, hearts were isolated, mounted
in a Langendorff set-up and exposed to ischemic preconditioning; at
this time, ligated but not ligated rats with valsartan treatment had de-
veloped cardiac hypertrophy. In vitro ischemic preconditioning reduced
infarct size in control rabbits but not in thosewith cardiac hypertrophy;
in valsartan-treated rats, effects of preconditioning were observed but
to a smaller extent than in control animals. Taken together, ischemic
preconditioning can be mimicked by exogenous ANG acting via AT1R.
However, inmost studies ARBsdid not attenuate effects of ischemic pre-
conditioning; in some cases with chronic pre-treatment ARBs even en-
hanced cardiac protection by preconditioning.
4.4. Heart failure
CHF often has a poor prognosis, which is worse than that of many
malignancies. It is a condition with many possible causes including
chronic arterial hypertension, acutely survived myocardial infarction
and viral infections; moreover, in many cases a speciﬁc cause cannot
be identiﬁed, which are referred to as idiopathic. Based on previous
knowledge of beneﬁcial effects of ACE inhibitors in patients with CHF
and animal models thereof, numerous studies have been performed to
explore ARB effects in animalmodels of CHF;many of themwere specif-
ically designed to compare ARB and ACE inhibitor effects. In line with
the many causes of CHF, a wide range of models were used in such re-
search (Hongo et al., 1997); while most of them were done in rats,
mice (Tarikuz Zaman et al., 2013; Chen et al., 2014) including genetical-
ly modiﬁed ones (Günther et al., 2010), hamsters (Nakamura et al.,
1994a; Trippodo et al., 1995; Taniyama et al., 2000), rabbits (Makino
et al., 2003), dogs (Yamamoto et al., 1997a; Spinale et al., 1997b;
Tanimura et al., 1999; Suzuki et al., 2001), pigs (Spinale et al., 1997c;
Krombach et al., 1998; Clair et al., 2000) and sheep (Fitzpatrick et al.,
1992) were also used. ARB effects on cardiac hypertrophy and ﬁbrosis
as well as long-term functional outcomes after a myocardial infarction
have been discussed in Sections 4.2 and 4.3; this section will focus on
in vivo studies in animal models of CHF.
The Syrian hamster is a species genetically prone to develop CHF;
speciﬁcally several inbred strains including BIO14.6, BIO53.58, BIO TO2
or UM-X 7.1 are often used as an animal model of CHF and its treatment.
They are also suitable for ARB studies as they exhibit elevated plasma
ANG (Nakamura et al., 1994a). Conﬁrming earlier ﬁndings with an ACE
inhibitor and a neutral endopeptidase inhibitor, acute administration of
irbesartan or an endopeptidase inhibitor did not improve left ventricular
end-diastolic pressure, whereas their combination did (Trippodo et al.,
1995). An 8-week treatment with candesartan did not affect heart func-
tion in control hamsters as assessed in a Langendorff preparation but im-
proved inotropic function in those with CHF (Nakamura et al., 1994a).
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diac hypertrophy in this study. In another study, cardiomyopathic ham-
sters were treated for 8 weeks with olmesartan, temocapril, hydralazine
or vehicle (Taniyama et al., 2000). While both RAS inhibitors restored
lowered cardiac expression of hepatocyte growth factor and reduced el-
evated collagen expression and ﬁbrotic area, hydralazine did not share
these effects at a dose producing at least as much BP lowering as
olmesartan or temocapril, indicating that these beneﬁcial effects were
not a consequence of hemodynamic alterations. Valsartan and the
renin inhibitor aliskiren similarly improved cardiac function but their
combination did not yield additional improvement (Crespo et al.,
2012), indicating that this BP-independent effect may be shared by
RAS inhibitors in general. Transgenic mice with overexpression of
calsequestrin also spontaneously develop CHF; in such mice losartan
treatment reduced cardiac hypertrophy and ﬁbrosis, improved cardiac
function and,most importantly, reducedmortality resulting in an almost
doubling of lifespan (Günther et al., 2010).
Continued (mostly 3–5 weeks) and substantial elevation of heart
rate (more than 200 beats per minute) based on electrical pacing also
is a frequently applied CHF model, most often used in large animals
such as dogs and pigs. The model is characterized by an increased left
ventricular pre- and after-load, low cardiac output and left ventricular
dilatation (Suzuki et al., 2001). It has been used in preventive designs,
i.e. with ARB administration concomitant with pacing, or in a treatment
design, i.e. with acute or chronic ARB treatment starting after CHF had
developed. In a preventive setting, concomitant irbesartan treatment
for 3 weeks reduced left ventricular end-diastolic dimension and peak
wall stress (Clair et al., 2000).Within that study a vasopressin V1a recep-
tor antagonist had similar effects; however, only combination treatment
increased left ventricular fractional shortening. In a dog pacing model
valsartan dose-dependently prevented the increase in left ventricular
end-diastolic pressure and, at least in the higher dose, the decline of
inotropy (assessed as dp/dt) (Yamamoto et al., 1997a). Spinale and col-
leagues reported effects of valsartan in a pig pacing model in ﬁve arti-
cles, two of which apparently reporting at least partly the same data.
In the ﬁrst study, they compared effects of valsartan, benazepril and
their combination with vehicle; the doses of the two RAS inhibitors
had been chosen to yield a 50% reduction in pressor responses to angio-
tensin I and ANG without lowering of mean arterial pressure (Spinale
et al., 1997c; Spinale et al., 1998). While the ACE inhibitor and the ARB
similarly normalizedmyocyte action potential duration, only benazepril
or the combination treatment prevented the reduction in left ventricu-
lar fractional shortening and myocyte shortening velocity; however,
combination treatment was superior to each monotherapy for all pa-
rameters. In a follow-up study using a similar design but considerably
higher doses of both RAS inhibitors, valsartan and benazepril alone at-
tenuated the fall in cardiac output, but only the combination fully
prevented it, both at rest and during exercise (Krombach et al., 1998).
Both monotherapies reduced systemic and pulmonary resistance, but
only combination treatment normalized it. All three treatments attenu-
ated the elevation of plasma noradrenaline and endothelin levels, but
only combination treatment restored left ventricular myocardial blood
ﬂow. In a third study, the high valsartan dose normalized left ventricular
fractional shortening and end-diastolic dimension (Clair et al., 1998a).
However, valsartan did not appear to favorably affect the degree of
left ventricular dilation and myocardial collagen structure in this
study. A fourth study compared the effects of the low valsartan dose,
bosentan or their combination (New et al., 2000). Neithermonotherapy
improved left ventricular stroke volume or plasma noradrenaline, but
the combination did. Only bosentan and the combination reduced left
ventricular wall stress and restored left ventricular myocyte shortening
velocity. Taken together these studies indicate that ARBs can prevent or
at least attenuate some but not all parameters of pacing-induced CHF;
however, greater effects are observed when either a high dose is used
or the ARB is combined with a vasopressin or an endothelin receptor
antagonist.Other studies using pacingmodels have explored whether ARBs can
improve cardiac function when given in a treatment setting, i.e. when
CHF has already developed. In an early study in an ovine pacing
model, acute administration of losartan lowered plasma aldosterone
and atrial natriuretic peptide and mean arterial and left atrial pressure;
glomerular ﬁltration rate (GFR) and urinary sodium excretion were
maintained despite a fall in renal perfusion pressure; all of these re-
sponses were similar to those seen with captopril (Fitzpatrick et al.,
1992). Other investigators, using a similar design, reported that single
doses of losartan, its active metabolite EXP3174 (dogs do not generate
this metabolite) and enalapril similarly reduced pulmonary artery pres-
sure, pulmonary capillary wedge pressure, peripheral resistance and
mean arterial pressure and increased stroke volume; left ventricular
pressure (assessed as dp/dt) was not affected (Suzuki et al., 2001). In
similar studies, except for using a pig pacingmodel, valsartan acutely in-
creased cardiac output and reduced systemic vascular resistance (Clair
et al., 1998b). While such acute dosing provides pathophysiological in-
sight, it reﬂects the clinical situation in a limited way only. More rele-
vant in this regard are chronic treatment studies. In one such study
CHF was induced by pacing in dogs, and irbesartan was administered
for 4 weeks thereafter (Spinale et al., 1997b). This improved cardiac hy-
pertrophy, ejection fraction and myocyte shortening velocity to control
levels but did not restore left-ventricular dilatation (Spinale et al.,
1997b). In a parallel report on apparently the samedogs butwith an ad-
ditional fosinopril group, fosinopril improved myocyte geometry and
function; both treatments increasd β-adrenoceptor density, but only
fosinopril also normalized cAMP response (Spinale et al., 1997a), indi-
cating that the ARB only partly mimicked the ACE inhibitor effects.
Other investigators have applied a hybrid between a preventive and a
treatment design by starting two doses of candesartan treatment after
8 days of pacing in dogs and then continued pacing and candesartan
treatment for another 14 days (Maeda et al., 1997). This resulted in a
partial recovery of right atrial pressure and cardiac output and an en-
hanced renal plasma ﬂow, GFR, urinary ﬂow rate and sodium excretion;
elevations of plasma aldosterone were abolished, those of noradrena-
line attenuated, but those of atrial natriuretic peptide not altered as
compared to vehicle-treated dogs.
Aorta-caval shunts are used to generate models of cardiac volume
overload. An aorta-caval shunt increased left ventricular end-diastolic
pressure, right atrial pressure, right ventricular systolic pressure, left
and right ventricular weight, and left ventricular end-diastolic volume
index as compared to sham-operated rats (Nishikimi et al., 1995a). In
contrast, in rats treated with candesartan or delapril none of these pa-
rameters differed signiﬁcantly from sham controls. Losartan and capto-
pril treatment started 3 weeks after shunt surgery in rats similarly
decreased mean arterial pressure and normalized left ventricular end-
diastolic pressure and regressed cardiac hypertrophy; right atrial pres-
sure and cardiac contractility (assessed as dp/dt) were not affected by
either treatment (Qing & Garcia, 1992). Others reported that 30 days
after shunt surgery, CHF rats exhibited a blunted atrial natriuretic pep-
tide response to acute volume expansion; acute treatment with
valsartan or ramipril normalized this (Willenbrock et al., 1999). In a
rat aorta-caval shunt model, in which treatment started 3 days prior
to surgery, losartan and enalapril had similar effects on cardiac and sys-
temic hemodynamics, including a major reduction in left ventricular
end-diastolic pressure (Ruzicka et al., 1993). However, losartan reduced
left ventricular dilation and left and right ventricular hypertrophy,
whereas enalapril caused only modest dilation and did not affect
hypertrophy.
One group of investigators has explored telmisartan effects in a rat
model of autoimmune myocarditis based on immunization of Lewis
rats with cardiac myosin. In their initial study telmisartan treatment
was started 4 weeks after immunization and maintained for another
4 weeks (Sukumaran et al., 2010). Telmisartan at least partly restored
cardiac function as measured by echocardiography, most importantly
ejection fraction. It also reduced cardiac ﬁbrosis and reversed cardiac
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of the inﬂammatory cytokines interleukin-1β and -6 and MCP-1. Most
importantly, telmisartan treatment markedly improved survival (60%
vs. 90% vs. 100% in vehicle vs. telmisartan vs. healthy control rats, re-
spectively). In follow-up studies, telmisartan treatment started immedi-
ately after immunization and was maintained for 3 weeks (Sukumaran
et al., 2011a, 2011b). In both studies, and similar to the initial study,
telmisartan at least partly restored left ventricular end-diastolic pres-
sure and cardiac contractility (assessed as dp/dt) and prevented cardiac
hypertrophy and ﬁbrosis development. Telmisartan treatment also at
least partly normalized increased expression of cytokines interleukins
1β and 6, tumor necrosis factor-α and interferon-γ, NADPH oxidase
subunits p47phox, Nox-4, and gp91phox, tumor necrosis factor
receptor-associated factor-2, C/EBP homologous protein and glucose-
regulated protein 78. Moreover, telmisartan treatment decreased the
protein expression levels of total and phosphorylated mitogen-
activated protein kinases ERK, JNK and p38, and ofmyocardial apoptotic
markers. In contrast myocardial protein levels of ACE-2 and the ANG 1–
7 mas receptor were upregulated.
Aortic banding induces pressure overload leading to cardiac hyper-
trophy; 4 weeks after the banding procedure, mice were put on a
high-salt diet for another 4 weeks, causing additional hypertrophy, car-
diac dysfunction and sympathetic hyperactivity (Ito et al., 2009). In such
mice a 28-day i.c.v. administration of telmisartan reduced sympathetic
activation and cardiac hypertrophy and increased fractional shortening.
When aortic banding was performed in mice on a high-fat diet, treat-
ment with azilsartan reduced cardiac hypertrophy and ﬁbrosis and im-
proved cardiac output (Tarikuz Zaman et al., 2013). CHF can also be
induced in Dahl S rats by feeding a high-salt diet; in this model, a 5-
week telmisartan treatment of rats with CHF moderately reduced
heart weight, normalized fractional shortening and lung weight and,
most importantly, reduced mortality (Takenaka et al., 2006). It can
also be induced in rats by chronic alcohol intake; in thismodel valsartan
treatment improved left ventricular end-diastolic pressure, ejection
fraction and fractional shortening (Sang et al., 2011).
Others have explored ARB effects in rat models of CHF caused by
cancer chemotherapeutics including 5-ﬂuorouracil, adriamycin or
doxorubicin. Pre-treatment with telmisartan was reported to prevent
the 5-ﬂuorouracil-induced increase of serum levels of cardiac troponin
T, aspartate aminotransferase and alanine aminotransferase (Khudhair
& Numan, 2014). Losartan and telmisartan attenuated the adriamycin-
induced growth retardation and at least partly reversed the reduced
left ventricular ejection fraction; expression of angiotensin(1–7) and
AT1R but not AT2R or mas was also restored (Zong et al., 2011). Treat-
mentwith telmisartan for 1week at least partly restored left ventricular
end-diastolic pressure and ejection fraction in doxorubicin-induced
cardiotoxicity (Hadi et al., 2012). Based on expression levels of various
cytokines, the authors primarily attributed this to reduced inﬂamma-
tion. In a preventive design, others treated rats for 12 days with
telmisartan or vehicle and injected doxorubicin on day 7 (Abd El
Samad & Raafat, 2012). In this setting telmisartan prevented
doxorubicin-induced ﬁbrosis development, assessed as collagen area
percentage, and reduction of cardiomyocyte diameter.
Injection of monocrotaline produces a model of pulmonary hyper-
tension but can also be used as a (right ventricular) heart failure
model (Campian et al., 2006). The cardiac hypertrophy and ﬁbrosis ob-
served in this model was attenuated by telmisartan (Okada et al., 2009;
Guo et al., 2014; Li et al., 2014a) or valsartan (Campian et al., 2009).
Telmisartan also reduced the pulmonary hypertension and pulmonary
vascular inﬂammation in monocrotaline-treated rats (Guo et al., 2014)
and improved endothelial function in the pulmonary artery (Li et al.,
2014a). Similar to other CHF models, monocrotaline injection can lead
to skeletalmusclemyopathy. To address this, twoweeks aftermonocro-
taline injection rats were assigned to irbesartan or nifedipine treatment
for another 2 weeks (dalla Libera et al., 2001). Irbesartan did not im-
prove the lowered left/right ventricular mass ratio or the rightventricular cavity dilatation but decreased skeletal muscle apoptosis
and atrophy as well as circulating tumor necrosis factor-α levels; nifed-
ipine behaved similarly for the lack of cardiac improvement but did not
mimic the beneﬁcial effects on skeletal muscle.
In conclusion, ARBs improve cardiac function in a wide range of CHF
models. A limited number of studies indicate that they do so beyond
what can be expected based on their BP effects. Whether ARBs or ACE
inhibitors do better has remained controversial, as evidence in both di-
rections has been reported. This equivocal evidencemay represent scat-
ter around overall similar effects or differences between speciﬁc
models.5. Embolism and stroke
Arterial hypertension is a major cause of stroke; accordingly, some
degree of stroke prevention can be expected from ARBs based on their
anti-hypertensive effects. This sectionwill look at ARB effects on platelet
function and coagulation, cerebral blood ﬂow, stroke incidence and
stroke outcomes.
High concentrations (N1 μM) of some ARBs, speciﬁcally irbesartan
(Li et al., 2000; Monton et al., 2000; Fukuhara et al., 2001), losartan
(Liu et al., 1992a; Li et al., 2000; Monton et al., 2000), telmisartan
(Monton et al., 2000; Asano et al., 2006) and valsartan (Monton et al.,
2000) also have AT1R-independent, direct antagonistic effects on
thromboxaneA2 receptors. Direct thromboxaneA2 receptor antagonism
by some ARBs results in platelet inhibition (Liu et al., 1992a; Lambert
et al., 1998; Champion et al., 1999a; Li et al., 2000; Monton et al.,
2000). Based on these studies, the ratio between concentrations re-
quired for inhibition of AT1R and of thromboxane A2 receptors appears
lowest for losartan, as it has relatively low AT1R and relatively high
thromboxane A2 receptor afﬁnity. In vivo, telmisartan treatment of
type 1 diabetic rats normalized the elevated activation state of platelets
as assessed by ﬁbrinogen binding (Schäfer et al., 2007). In patients with
concomitant hypertension and chronic-stage ischemic stroke, a 4-week
treatment with losartan (but not telmisartan) reduced platelet activa-
tion as assessed by CD62P expression; however, neither losartan nor
telmisartan altered spontaneous platelet aggregation in such patients
(Yamada et al., 2007). Losartan also failed to affect pulmonary vascular
resistance in a lamb model of acute pulmonary embolism induced by
silicon microsphere injections (Dias-Junior et al., 2012). In contrast to
the above-mentioned ARBs, candesartan consistently failed to inhibit
thromboxane A2 receptors (Li et al., 2000; Monton et al., 2000;
Fukuhara et al., 2001). Accordingly, candesartan did not inhibit throm-
bus formation or aortic expression of plasminogen activator inhibitor-
1 protein in an SHR model of thrombosis; improvement by imidapril
in this model were attributed to AT2R activation (Mitsui et al., 1999).
Thus, the overall importance of direct thromboxane A2 receptor antag-
onism by some ARBs remains unclear.
Auto-regulation of cerebral blood ﬂow is an important mechanism
to maintain constant perfusion of the brain in the presence of ﬂuctuat-
ing BP. To achieve this, cerebral resistance vessels dilate if perfusion
pressure drops and constrict if it increases. The auto-regulation of cere-
bral blood ﬂow can be altered in SHR, where cerebral blood ﬂow stays
constant up to higher levels of BP as compared to WKY (Nishimura
et al., 1998b). Candesartan did not affect baseline cerebral blood ﬂow
but lowered the threshold for autoregulation in WKY and SHR, i.e. the
BP range over which cerebral blood ﬂow stayed constant was shifted
to lower levels (Vraamark et al., 1995). It also at least partially normal-
ized cerebral blood ﬂow auto-regulation in SHR in other studies
(Nishimura et al., 1998b). Improvement of cerebral blood ﬂow auto-
regulation was also reported in SHR e.g. with telmisartan even in low
doses not lowering BP (Kumai et al., 2008). However, other investiga-
tors found that low telmisartan or ramipril doses that were insufﬁcient
to improve cerebral blood ﬂow as monotherapy did so in when admin-
istered in combination (Dupuis et al., 2010).
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models, e.g. losartan in Dahl S rats on a high-salt diet (von Lutterotti
et al., 1992) or candesartan (Inada et al., 1997) or telmisartan in
stroke-prone SHR (Thoene-Reineke et al., 2011). These effects were
shared by enalapril and ramipril, respectively, pointing to a general
role of RAS inhibition rather than a speciﬁc role of AT1R antagonism;
moreover, they may be BP-independent as a low candesartan dose,
not lowering BP, similarly reduced stroke incidence.
Many more studies have explored whether ARBs, given in a preven-
tive or early treatment settingwill improve outcomes, particularly of is-
chemic stroke. Such research was stimulated by reports on effects of
ANG, ARBs and ACE inhibitors on brain plasticity, which have recently
been reviewed elsewhere (Horiuchi & Mogi, 2011). Most studies were
based on pre-treatmentwith anARB for 1 to 4weeks, followed by occlu-
sion of the middle cerebral artery in rats or mice. For instance, a 7-day
pre-treatment of normotensive rats with telmisartan reduced infarct
volume, prevented histopathological neuronal changes in the peri-
infarct corticle regions, and improved sensomotoric function in forelimb
and hindlimb placing tests (Kobayashi et al., 2009). A reduction in in-
farct size was also demonstrated in normal mice upon pre-treatment
with telmisartan (Haraguchi et al., 2009) or valsartan (Li et al., 2008a),
by losartan and telmisartan in KK-Ay diabetic mice (Iwanami et al.,
2010), by telmisartan in ApoE knock-out mice (Iwai et al., 2008), or by
valsartan in chimeric mice harboring transgenes for both human renin
and human angiotensinogen (Inaba et al., 2009); where investigated,
this was accompanied by improved neurological function. Reductions
in neurological damage were also reported in prevention settings in
models of transient cerebral ischemia, including with valsartan in rats
with transient forebrain ischemia induced by bilateral common carotid
artery ligation (Wakai et al., 2011) or with irbesartan (Dai et al., 1999),
telmisartan (Thoene-Reineke et al., 2011) or valsartan in rats (Groth
et al., 2003) or mice (Miyamoto et al., 2008) with transient occlusion
of the middle cerebral artery. The neuroprotection associated with
ARB pre-treatment appears to involve reduced inﬂammation
(Haraguchi et al., 2009; Thoene-Reineke et al., 2011) and superoxide
anion formation (Inaba et al., 2009), increased capillary density (Li
et al., 2008a), and up-regulation of NO synthase and NO production
(Li et al., 2008a; Thoene-Reineke et al., 2011); whether alterations of
MCP-1 or TNF-α are involved has remained controversial (Li et al.,
2008a; Thoene-Reineke et al., 2011). Interestingly, the protective effects
of valsartan inmicewere at least partly retained if preventive treatment
was discontinued 2 weeks prior to ischemia; this was attributed to an
increased capillary density upon valsartan treatment (Li et al., 2008a).
On the other hand, a preventive effect of telmisartan in ApoE knock-
out mice was partly attributed to a reduced atherosclerosis (Iwai et al.,
2008). These data suggest that ARBs as a class can have preventive ef-
fects on the size of the ischemic region in rodent models of stroke. Ac-
cording to some studies (Haraguchi et al., 2009), even a 2-hour pre-
treatment may already exert preventive effects. As telmisartan and
ramipril were similarly effective in a transient brain ischemia rat
model (Thoene-Reineke et al., 2011), it appears that these effects may
extend to RAS inhibitors in general. On the other hand, data with per-
manent ischemia in KK-Ay diabetic mice indicate that losartan only
partly mimicked the telmisartan effects, whereas GW9662 partly
blocked them (Iwanami et al., 2010). Partial inhibition of telmisartan
pre-treatment-associated infarct size reduction byGW9662was also re-
ported in non-diabeticmice (Haraguchi et al., 2009), indicating the pos-
sibility that a PPAR-γ-mediated component may exist on top of that of
RAS inhibition. In one of the few studies in which an ARB was adminis-
tered after the ischemia period, candesartan was reported to promote
angiogenesis in a ratmodel of transientmiddle cerebral artery occlusion
(Soliman et al., 2014). However, in the interpretation of all ARB data in
stroke prevention and treatment, it needs to be considered that animal
models of prevention of stroke incidence or stroke size reduction have
not shown consistent predictive value with regard to reduction of
stroke incidence in patients (Tymiianski, 2015).In a large series of manuscripts one group has extensively evaluated
the effect of a low BP-neutral and a higher BP-lowering dose of
telmisartan administered for up to 15months after a 90minute ligation
of the middle cerebral artery; it appears that all of these reports are
based on the same or at least strongly overlapping set of animals but
most of the articles do not explicitly say so. This model apparently was
used not only to study ARB effects on post-cerebral ischemia recovery
but also used as a model of dementia development. In this model
telmisartan treatment increased the number of PPAR-γ-positive neu-
rons (Deguchi et al., 2014; Omote et al., 2015) and reduced that of
AT1R- or insulin receptor-positive neurons (Deguchi et al., 2014;
Omote et al., 2015), oxidative brain damage as assessed as presence of
AGE, 4-hydroxynonenal and phosphorylated α-synuclein (Fukui et al.,
2014; Sato et al., 2014b), brain inﬂammation as assessed by presence
of MCP-1 and TNF-α (Sato et al., 2014a), damage to the neurovascular
unit (Kono et al., 2015; Liu et al., 2015b), ApoE and LDL receptor expres-
sion (Yamashita et al., 2014) and amyloid-β-, phosphorylated τ- and
TNF-α-positive neurons and senile plaques (Kurata et al., 2014a,
2014b). All of these effects were already seen with the low telmisartan
dose but became more prominent with the higher dose.
While the above data largely relate to ischemic stroke, hemorrhagic
stroke and subarachnoidal hemorrhage can also occur. When given at
doses with similar BP effects, telmisartan but not candesartan improved
internal diameter of pial blood vessels at baseline and during
hemorrhage-induced hypotension; this difference was attributed to
PPARγ activation, as the effects of candesartan in combination with pio-
glitazone were similar to those of telmisartan (Foulquier et al., 2012). A
single dose of telmisartan, administerd 2 hours after intracerebrovascular
hemorrhage, reduced hemorrhage volume, brain edema, and inﬂamma-
tory or apoptotic cells in the perihematomal area and, most importantly,
neurological deﬁcits (Jung et al., 2007). In a rat model of subarachnoidal
hemorrhage, acute pre-treatment with peripherally or intracisternally
administered irbesartan aggravated the hemorrhage-induced decrease
in cerebral perfusion pressure; central, but not peripheral, irbesartan ad-
ministration increased intra-cranial pressure in this model (Fassot et al.,
2001).
6. Metabolic effects
AT1R are found at the mRNA and protein level in multiple cell types
and tissues relevant for carbohydrate and lipid metabolism. In rat gut
enterocytes, AT1Rwere found in the brush bordermembrane; exposure
of such cells to ANG inhibited SGLT1-mediated glucose transport in a
losartan-sensitive manner (Wong et al., 2007). The pancreas expresses
multiple components of the RAS including angiotensinogen, ACE and
AT1R (Hasegawa et al., 2009). Accordingly, telmisartan decreased the
accumulation of palmitate-induced reactive oxygen species in isolated
mouse pancreatic β cells and in the β cell-derived cell line MIN6
(Saitoh et al., 2009). In in vivo studies ARBs such as telmisartan or
valsartan or ACE inhibitors such as perindopril were reported to im-
prove pancreatic islet function in models of hereditary and induced di-
abetes including STZ-treated rats (Li et al., 2009; Yuan et al., 2010; Li
et al., 2012b), db/db mice (Cheng et al., 2008) and diabetic Torii rats
(Hasegawa et al., 2009). The production of RAS components by adipo-
cytes is exacerbated during obesity; among those, angiotensinogen
has been detected more consistently than renin or ACE (Frigolet et al.,
2013). As reviewed elsewhere, at least part of the beneﬁcial effects of
RAS inhibitionmay bemediated by an interactionwith the sympathetic
nervous regulation ofmetabolic function (Ernsberger & Koletsky, 2006).
ARB effects on glucose and lipid metabolism have been explored in
numerous animal models. While realizing the relatedness of glucose
and lipid metabolism, we have separated our discussion of correspond-
ing in vivo data into ﬁve main sections, one each on body weight and
food intake, on glucosemetabolism, on lipidmetabolism, on adipose tis-
sue mass and function and on liver morphology and function. As the
data may differ between species and animal models under
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on lean euglycemic animals, lean animals with diabetes, and obese ani-
mals with and without diabetes. The latter two groups include models
in which diabetes and/or obesity were induced, for instance by speciﬁc
toxins or diets, and those with hereditary causes including those in-
duced by molecular genetic techniques. In Sections 6.2–6.6 data are an-
alyzed ﬁrst for mouse and then for rat studies, and within each group
studies on induced models are discussed prior to those on hereditary
models.
6.1. In vitro studies
Many in vitro studies on ARB effects in adipocytes were performed
using the mouse pre-adipocyte cell line 3T3-L1. In undifferentiated
3T3-L1 cells a high concentration of telmisartan (10 μM) was reported
to reduce lipid accumulation (Konda et al., 2014). However, 3T3-L1
cells can be differentiated into mature adipocytes using a cocktail of in-
sulin, a glucocorticoid and a phosphodiesterase inhibitor. Therefore, it
has repeatedly been explored how ARBs affect this differentiation pro-
cess of 3T3-L1 cells. The typically used differentiation protocols led to
an up-regulation of renin, angiotensinogen and ACE, leading to an in-
creased ANG formation; concomitantly, AT1R mRNA was reduced,
whereas AT2R mRNA was increased (Hung et al., 2011). In the same
study, differentiation increased mRNA expression of apelin,
adiponectin, RBP4, resistin and visfatin; losartan, PD123,319, captopril
or perindopril further enhanced apelin mRNA and protein expression,
but inhibited mRNA expression of the other four typical adipocyte mol-
ecules.Moreover, differentiationmarkedly increased lipid accumulation
and reactive oxygen species generation, which bothwere also inhibited
by all four RAS inhibitors. The up-regulation of adiponectin mRNA and
protein during 3T3-L1 cell differentiation was conﬁrmed by others,
who additionally showed an increased expression and release of IL-6
(Hasan et al., 2014). During 3T3-L1 differentiation an increased expres-
sion of lipoprotein lipase mRNA and protein level expression as well as
functional activity was also observed, which was further enhanced by
valsartan (Saiki et al., 2008). In a somewhat different approach, 3T3-
L1 cells were exposed to the differentiation cocktail for 24 hours only,
followed by azilsartan or valsartan treatment for 7 days (Kajiya et al.,
2011). At the single tested concentration of 10 μM each, the two ARBs
differentially affected the expression proﬁle of 3T3-L1 cells: both stimu-
lated lipid accumulation, although azilsartan more than valsartan;
azilsartan induced mRNA expression for PPAR-α, PPAR-δ, adipsin and
adiponectin, whereas valsartan reduced mRNA for PPAR-γ. Telmisartan
but not valsartan promoted differentiation of 3T3-L1 cells as assessed by
lipid accumulation (Fujimoto et al., 2004).When humanpre-adipocytes
were isolated and differentiated in vitro presence of irbesartan, losartan
or telmisartan increased lipid content as marker of adipogenesis,
whereas eprosartan did not; however, the bell-shaped concentration-
response curve for telmisartan (minor stimulation at 0.1 μM, strong at
1 μM and none at 10 μM) is difﬁcult to interpret mechanistically
(Janke et al., 2006). Within that study irbesartan, losartan, telmisartan
and the PPAR-γ agonist pioglitazone but not eprosartan enhanced
gene expression of PPAR-γ target genes adiponectin and lipoprotein li-
pase; GW9662 abolished the effects of irbesartan and pioglitazone, inhi-
bition of effects of other ARBswas not reported. However, a therapeutic
dose of irbesartan had no effect on the expression of either PPAR-γ tar-
get gene in abdominal subcutaneous adipose tissue of patients. Taken
together these ﬁndings demonstrate that 3T3-L1 cells express a local
RAS, which is regulated during their differentiation into mature adipo-
cytes. ARBs and ACE inhibitors can interferewith this differentiation, in-
dicating autocrine feedback loops in this model.
Other studies exposed 3T3-L1 cells to ARBs after differentiation into
adipocytes had been completed. Valsartan was reported to reduce the
elevated expression and the enhanced release of IL-6 (Hasan et al.,
2014) but had limited effect on the expression of several metabolically
relevant proteins and their phosphorylation status such as insulinreceptor β, insulin receptor substrate 1 and the glucose transporter
GLUT4; moreover, it had no effect on the regulation of these proteins
by TNF-α (Iwashita et al., 2012). Exposure to uric acid for 2 days up-
regulated the local RAS in 3T3-L1 cells and increased generation of reac-
tive oxygen species; apparently, the up-regulation of the local RAS had
stronger effects on reactive oxygen species than the direct anti-
oxidant effect of uric acid (Zhang et al., 2015). Losartan or captopril
inhibited the increase in reactive oxygen species. A reduction of reactive
oxygen species in the absence of uric acidwas reportedwith telmisartan
(Rios et al., 2012). In that studymRNA expression of endothelial and in-
ducible NO synthase was reduced, but the phosphorylation pattern of
endothelial NO synthase suggested an increased enzymatic activity; un-
fortunately, no functional data were included in that report. Various
studies have reported that some ARBs can stimulate adiponectin ex-
pression in 3T3-L1 cells; thiswas consistently reportedwith telmisartan
(Fujimoto et al., 2004; Yamada et al., 2008; Brody et al., 2009;
Inomata-Kurashiki et al., 2010), an effect mimicked by losartan (Brody
et al., 2009) but not by candesartan (Yamada et al., 2008). As this pat-
ternmatches that for PPAR-γ activation, AT1R-dependent and indepen-
dent ARB effects may exist in these cells. Thus, telmisartan and
pioglitazone but neither candesartan nor ANG stimulated expression
of a reporter gene under control of the adiponectin promotor
(Moriuchi et al., 2007). Similarly, the telmisartan-induced up-
regulation of adiponectin mRNA was mimicked by pioglitazone but
not by candesartan; however, the relevance of these mRNA changes
did not become fully clear, as the corresponding protein data were
equivocal (Yamada et al., 2008). However, in the same study
telmisartan caused greater increases in plasma adiponectin than
candesartan in hypertensive diabetic patients during a 3 month treat-
ment. A telmisartan-induced increase in adiponectin mRNA and pro-
tein, along with increased Sirt1 expression, was also reported by
others; the role of PPAR-γ in this regulation is difﬁcult to determine as
GW9662 had differential effects at the mRNA and protein level (Shiota
et al., 2012a). On the other hand, ANG was also reported to enhance
adiponectin expression in 3T3-L1 cells (Clasen et al., 2005). The appar-
ent puzzle that ARBs can have the same effect was resolved by the ob-
servation that the ANG effect was inhibited by an AT2R antagonist,
whereas irbesartan enhanced the ANG effect on adiponectin expression
(Clasen et al., 2005). Finally, telmisartan but not valsartan was reported
to increase protein expression of fatty acid binding protein-4, insulin re-
ceptor β, and glucose transporters GLUT1 and GLUT4 and to enhance
glucose uptake; these ﬁndings were mimicked by troglitazone but not
by candesartan and were reduced by the PPAR-γ antagonist T0070907
(Fujimoto et al., 2004; Furukawa et al., 2011). In human subcutaneous
adipocytes, telmisartan induced a pattern of gene expression changes
compatible with a differentiation towards brown fat (Konda et al.,
2014). Taken together these studies suggest that ARBs can regulate
the expression of many genes important for adipocyte function at the
mRNA and protein level. Most of the ARB effects on adipocytes are ana-
bolic, i.e. favor glucose uptake and, thereby, are likely to improve glu-
cose metabolism in metabolic syndrome and diabetes. Telmisartan
may have additional effects on some parameters via PPAR-γ.
Hepatocytes express several members of the RAS including renin,
angiotensinogen, ACE and AT1R; some of these are up-regulated
upon TGF-β treatment (Sakamoto et al., 2009). In guinea pig
hepatocytes irbesartan and losartan inhibited ANG-induced inositol
phosphate formation and, as a down-stream consequence, phos-
phorylase stimulation (Garcia-Sainz et al., 1997). Inhibition of inositol
phosphate formationwas also demonstrated for irbesartan and losartan
in a rat hepatic epithelium-derived cell line (Hines et al., 1999). In the
human hepatic stellate cell line, LX2, losartan and telmisartan sup-
pressed TGF-β-induced expression of ﬁbrosis markers procollagen,
metallomatrixproteinase 13 and α-smooth muscle actin and also that
of AT1R but the effects of telmisartanweremore pronounced and/or oc-
curred at earlier time points than those of losartan; as telmisartan but
not losartan prevented TGF-β-induced down-regulation of PPAR-γ, it
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sibly PPAR-γ-mediated effect may be involved (Sakamoto et al., 2009).
Telmisartan in the absence of exogenous ANG stimulated expression of
PPAR-α target genes in the human hepatoma cell line, HepG2, and in
murine hepatic AML12 cells, and such expression was blocked by
PPAR-α siRNA (Clemenz et al., 2008; Yin et al., 2014). Telmisartan also
increased the expression of lipoprotein lipase inHepG2 cells, apparently
via a pathway involving PPAR-α (Yin et al., 2014). In another human
hepatoma cell line, Hep3b, AGE induced generation of reactive oxygen
species and subsequent expression of C-reactive mRNA and protein
(Yoshida et al., 2006). Telmisartan inhibited this AGE effect; such inhibi-
tion was prevented by GW9662 and was not mimicked by candesartan,
indicating that they occur via PPAR-γ stimulation. Telmisartan also
concentration-dependently down-regulated RAGE mRNA and basal
and AGE-induced RAGE protein expression (Yoshida et al., 2006). In a
follow-up study in Hep3b cells, AGE markedly increased phosphoryla-
tion of serine-307 of the insulin receptor substrate-1 and reduced its as-
sociation with phosphatidylinositol-3-kinase as well as insulin-
stimulated glycogen synthesis (Yoshida et al., 2008). Telmisartan
inhibited these AGE effects; this was again blocked by GW9662 and
was not mimicked by candesartan, conﬁrming a role for PPAR-γ in the
telmisartan effects in Hep3b cells. Thus, at the cellular level ANG in-
duces pro-ﬁbrotic gene expression, ARBs as a class can inhibit hepato-
cyte AT1R signal transduction, and some ARBs may have additional
AT1R-independent, PPAR-γ-mediated effects.
A smaller number of studies have explored ARB effects on skeletal
muscle cells and cell lines derived from them. In cultured murine
myotubes telmisartan up-regulated levels of PPAR-δ and phosphorylat-
ed adenosine monophosphate-activated protein kinase α (Feng et al.,
2011). As these effects were absent in myotubes derived from PPAR-δ
knock-out mice, PPAR-δ appears to be involved, although not necessar-
ily as a direct molecular target of the ARB. Follow-up work from the
same group explored telmisartan effects in palmitate-induced insulin-
resistant C2C12 myotubes (Li et al., 2013). In this model the ARB en-
hanced insulin-stimulated Akt and Akt substrate of 160 kDa phosphor-
ylation as well as translocation of the glucose transporter GLUT4 to the
plasmamembrane. Consistentwith the previous knock-outmouse data,
these effects were inhibited by antagonists of PPAR-δ and
phosphatidylinositol-3 kinase, but not by those of PPAR-α and PPAR-γ.
6.2. In vivo studies on body weight and food intake
6.2.1. Studies in lean euglycemic animals
In contrast to humans, rodents exhibit a physiological body weight
gain duringmost of their adult life span without necessarily developing
obesity. Several studies have explored whether ARBs can interfere with
this physiological body weight gain but have yielded equivocal results.
In wild-type mice a lack of effect has been shown with telmisartan
(Araki et al., 2006; Iwanami et al., 2010; Zidek et al., 2013) and valsartan
(Cole et al., 2010). However, others reported inhibition of physiological
weight gain with ageing in mice with telmisartan (He et al., 2010; Feng
et al., 2011; Penna-de-Carvalho et al., 2014); interestingly, this inhibi-
tion was absent in concomitantly studied PPAR-δ KO mice (He et al.,
2010; Feng et al., 2011). However, addition of telmisartan did not in-
duce weight loss (He et al., 2010).
Similarly equivocal data on ARB effects on physiological bodyweight
gain have been reported in rats. Thus, a lack of effect has been found
with azilsartan in normal rats (Sueta et al., 2013; Abdelsaid et al.,
2014) and during chronic ANG infusion (Lastra et al., 2013) and with
candesartan (Kobayashi et al., 1993) and valsartan in normal rats
(Komers & Cooper, 1995). Some studies with telmisartan conﬁrmed
such a lack of effect (Goyal et al., 2008; Emre et al., 2010; Xu et al.,
2011; Bentzen et al., 2013; Kushwaha & Jena, 2013; Yoshihara et al.,
2013),whereas others (partly from the same investigators) reported in-
hibition of physiological weight gain with ageing in healthy rats (Goyal
et al., 2011a, 2011b; Liang et al., 2011b). In normotensive rabbits neithercandesartan nor telmisartan (alone or in combination with GW9662)
affected body weight during a 2-week treatment (Zeng et al., 2013a).
In SHR azilsartan (Sueta et al., 2013), candesartan (Anderson et al.,
1997) or valsartan did not affect physiological body weight gain
(Chow et al., 1995; Chow et al., 1997) or mitigated the slowing of
body weight gain (Ishimitsu et al., 2010); candesartan failed to inhibit
body weight gain in (mRen-2)27 rats (Kelly et al., 2000). The same
was observed with a low and medium dose of candesartan, whereas a
high dose caused some inhibition (16 vs. 2 or 6 mg/kg/d) (Müller-
Fielitz et al., 2011); similarly, in lean Zucker rats low doses of
candesartan had no effect (Ecelbarger et al., 2010) while a high dose
caused inhibition (Müller-Fielitz et al., 2011). In contrast, inhibition of
body weight gain in SHR was repeatedly reported with telmisartan at
low doses (He et al., 2010; Younis et al., 2010). Some of the rat studies
also included a group treated with an ACE inhibitor. Except for one
studywith benazepril (Chow et al., 1995), the ACE inhibitors benazepril
(Chow et al., 1997) and ramipril (Komers & Cooper, 1995) also failed to
affect physiological body weight gain. The body weight reduction in
salt-loaded stroke-prone SHR was attenuated by valsartan (Yoshida
et al., 2011). Feeding SHR a high-salt diet resulted in a loss of body
weight, and that was ameliorated by telmisartan treatment (Susic &
Frohlich, 2014).
Food intakewas reportednot be altered by telmisartan in normoten-
sive mice (Penna-de-Carvalho et al., 2014) or rats (Goyal et al., 2011a;
Bentzen et al., 2013) or in Dahl salt-sensitive rats on a high-fat, high-
salt diet (Jin et al., 2014) or by candesartan in SHR unless the latter
was given in very high doses (Müller-Fielitz et al., 2011); a very high
dose of candesartan also lowered food intake in lean Zucker rats
(Müller-Fielitz et al., 2011). Telmisartan also did not affect the reduction
in food intake in rats induced by treatmentwith themonoamine uptake
inhibitor tesofensine (Bentzen et al., 2013). As body weight effects of
telmisartan were proposed to occur via an effect on the central nervous
system (Müller-Fielitz et al., 2011), differences between ARBs in this re-
gard may be explained by their different quantitative ability to pass the
blood–brain-barrier (Michel et al., 2013).
Rats with 5/6 nephrectomy loose weight; this was prevented by
telmisartan or troglitazone treatment but not by telmisartan +
GW9662 treatment, indicating a role of PPAR-γ in the protection from
weight loss in thismodel (Zou et al., 2014). Telmisartanwas also report-
ed to prevent the weight loss in rats with uninephrectomy additionally
receiving an ethylene glycol injection (Kadhare et al., 2015). Thus, ARBs
and other RAS inhibitors did not exhibit consistent effects on physiolog-
ical body weight gain in lean euglycemic animals.
6.2.2. Studies in lean diabetic animals
STZ treatment destroys pancreatic β-cells and is themost frequently
usedmeans to generate animal models of type 1 diabetes. Similar to the
situation inmost patients with type 1 diabetes, the STZmodel is typical-
ly associated with weight loss. Neither telmisartan nor valsartan
prevented the weight loss upon STZ treatment in wild-type mice
(Kurihara et al., 2008), neither olmesartan nor telmisartan prevented
body weight loss in STZ-treated ApoE knock-out mice (Ihara et al.,
2007), and telmisartan did not prevent it in STZ-treated endothelial
NO synthase knock-out mice (Komala et al., 2014). Similarly, in other-
wise healthy rats neither olmesartan (Gandhi et al., 2012), nor
telmisartan (whether given alone or in combination with amlodipine)
(Goyal et al., 2008; Emre et al., 2010; Kushwaha & Jena, 2013; Mollnau
et al., 2013; Salum et al., 2014; Tojo et al., 2015) or valsartan (Komers
& Cooper, 1995; Allen et al., 1997; Cao et al., 1998; Remuzzi et al.,
1998; Siragy & Huang, 2008) prevented the reduced body loss in STZ-
treated animals. Some of these studies have also included other RAS in-
hibitors including aliskiren (Gandhi et al., 2012), benazepril (Remuzzi
et al., 1998) or ramipril (Allen et al., 1997; Cao et al., 1998), which also
did not prevent reduced body weight gain. Similarly, neither irbesartan
nor captopril or their combination (Cao et al., 2001), neither telmisartan
nor lisinopril (Wienen et al., 2001) and neither valsartan nor ramipril
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Valsartan also failed to do so in STZ-treated diabetic (mRen-2)27 rats
(Kelly et al., 2000). The body weight reduction upon STZ treatment
holds up even when animals are fed a high-fat diet; under such condi-
tions neither valsartan nor perindopril prevented body weight loss in
otherwise healthy rats (Li et al., 2009; Yuan et al., 2010) and irbesartan
yielded similar results in STZ-treated SHR on a high-sucrose, high-
cholesterol diet (Tang et al., 2013). Taken together, RAS inhibition
does not prevent the body weight loss observed in STZ-inducedmodels
of type 1 diabetes in normotensive and hypertensive animals, even in
the presence a high-fat diet, which in the absence of STZ treatment in-
duces obesity. In Goto–Kakizaki rats, a lean model of type 2 diabetes,
azilsartan did not affect body weight (Abdelsaid et al., 2014).
6.2.3. Studies in obese animals with and without diabetes
Obesity is a medical problem of globally growing prevalence (Scully,
2014). It can lead to type 2 diabetes and is a risk factor for many other
conditions including various types of cardiovascular disease. Therefore,
using awide range of mouse and ratmodels including thosewith type 2
diabetes, it was explored whether ARBs can prevent or reverse obesity.
Some of these models have applied a preventive design, i.e. started
treatment with an ARB prior to or concomitant with the obesity-
inducing intervention.
In otherwise healthy mice the body weight gain induced by a high-
fat diet was inhibited by telmisartan (Foryst-Ludwig et al., 2010; Rong
et al., 2010; Noma et al., 2011). Interestingly, such inhibition wasmain-
tained with telmisartan in AT1R knock-out mice (Rong et al., 2010;
Noma et al., 2011).
Similar preventive study designs have also been applied to rats with
high-fat diet-induced obesity. In such animals losartan did not affect
body weight gain (Boustany et al., 2005), and neither did azilsartan in
Dahl salt-sensitive rats on a high-fat, high-salt diet (Jin et al., 2014). In
contrast, inhibition was observed in normal rats on a high-fat diet,
with candesartan (Müller-Fielitz et al., 2012; Schuchard et al., 2015;
Wang et al., 2012d) and telmisartan (Zanchi et al., 2007; Liang et al.,
2011b; Miesel et al., 2012; Müller-Fielitz et al., 2012; Wang et al.,
2012c; Müller-Fielitz et al., 2015). Telmisartan also reduced body
weight gain in SHR on a high-fat diet (He et al., 2010) and in normal
rats and Zucker rats on a high-fat dietwith additional pioglitazone treat-
ment (Zanchi et al., 2007). Of note, the attenuation of body weight gain
in direct comparative studies was larger with telmisartan than ramipril
(Miesel et al., 2012). Amlodipine in a dose providing similar BP lowering
as telmisartan did not reduce body weight gain (Müller-Fielitz et al.,
2014). Thus, such prevention if it is observed apparently does not
occur secondary to BP lowering and may only partly be explained by
RAS inhibition.
Preventive designs have also been applied to other models of in-
duced obesity. Thus, telmisartan inhibited body weight gain in mice in-
duced by pioglitazone, regardless whether pioglitazonewas given alone
or on top of a high-fat diet (Aubert et al., 2010). Obesity induced by fruc-
tose feeding was not prevented by candesartan in a study in which the
ACE inhibitor alacepril caused inhibition (Chen et al., 1996a, 1996b). It
also was not prevented by telmisartan or aliskiren (Rabie et al., 2015).
In contrast, telmisartan inhibited body weight gain in fructose-fed
rats, in those with olanzapine treatment-induced obesity and in those
with on a high-fructose diet combined with olanzapine treatment
(Ramesh Petchi et al., 2012).
While prevention of obesity or attenuation of obesity development
by ARBs is an interesting concept, it probably is clinically more relevant
whether ARBs will lower body weight when given to already obese an-
imals, i.e. whether they are effective in a treatment design. In a treat-
ment setting of high-fat diet-induced obesity in mice, irbesartan was
without effect (Aubert et al., 2010), whereas candesartan (Fujisaka
et al., 2011) and telmisartan lowered body weight (Araki et al., 2006;
Aubert et al., 2010; He et al., 2010; Souza-Mello et al., 2010; Fujisaka
et al., 2011; Li et al., 2013; Penna-de-Carvalho et al., 2014), althoughone of these telmisartan studies did not conﬁrm this; moreover, one
of the ‘positive’ studies found the effect of telmisartan to be maintained
in AT1R knock-out mice. Telmisartan also lowered body weight under
such conditions in rats (Goyal et al., 2011a; Müller-Fielitz et al., 2014)
or guinea pigs (Xu et al., 2015) on a high-fat diet. In one of these studies,
this effect was not observed with amlodipine or an amlodipine +
telmisartan combination (Müller-Fielitz et al., 2014). Such body weight
reduction was also observed for a telmisartan + metformin combina-
tion or, with even greater effects, a telmisartan + sitagliptin combina-
tion (Souza-Mello et al., 2010; Souza-Mello et al., 2011).
Some studies in a treatment designwere performed in hereditary rat
models of obesity. In Zucker diabetic fatty rats neither candesartan
(Ecelbarger et al., 2010) nor irbesartan lowered body weight (Munoz
et al., 2009). Similarly, olmesartan (Harada et al., 1999; Kikuchi et al.,
2007) and telmisartan (Zhao et al., 2013) were ineffective in
Otsuka Long–Evans Tokushima Fatty rats. Azilsartan treatment
caused a minor reduction in body weight gain in spontaneously hyper-
tensive obese rats (Hye Khan et al., 2014a) and a somewhat greater at-
tenuation of body weight gain in Koletsky rats (Zhao et al., 2011). In
SHRSP.Z-Leprfa/IzmDmcr rats telmisartan did not affect body weight
gain (Kagota et al., 2013, 2014; Sugiyama et al., 2013). Thus, ARBs
have yielded inconsistent effects on body weight in mouse and rat
models of obesity, regardlesswhether given in a preventive or in a treat-
ment setting. In the absence of studies to the contrary, this drug class
may have amodest effect on bodyweight in obesitywhichmay be of in-
sufﬁcient magnitude to allow consistent detection. Effects with
telmisartan may be more consistent, which may relate to better pene-
tration into the brain (Michel et al., 2013) and/or AT1R-independent ef-
fects (Aubert et al., 2010; Rong et al., 2010).
Type 2 diabetes is most often found in association with obesity, both
in animal models and patients. However, some animal models exist in
which type 2 diabetes is observed in the absence of obesity such as
non-obese Cohen diabetic or Cohen-Rosenthal non-obese diabetic hy-
pertensive rats on a high-sugar, copper-free diet (Younis et al., 2010).
Among the hereditary mouse models of obesity, neither losartan nor
telmisartan affected body weight gain in KK-Ay mice (Iwanami et al.,
2010), whereas azilsartan (Iwai et al., 2007) and telmisartan (Noma
et al., 2011) attenuated it in such mice on a high-fat diet; interestingly,
telmisartan even reduced body weight gain when pair-feeding was
used to eliminate differences in food intake as a possible cause. In con-
trast, lack of prevention of body weight gain by ARBs was reported in
KK-Ay mice with azilsartan (Matsumoto et al., 2014), candesartan
(Iwai et al., 2007; Matsumoto et al., 2014), telmisartan or valsartan
(Takasu et al., 2006; Tomono et al., 2008; Ushijima et al., 2013). Lack
of inhibition of body weight gain was also reported in in KK/Ta mice
with candesartan (Fan et al., 2004), in db/db mice with losartan
(Nagata et al., 2013), telmisartan (Shiota et al., 2012b; Shigahara et al.,
2014) or valsartan (Dong et al., 2010; Gao et al., 2010; Ye et al., 2011),
and in ob/ob mice with valsartan (Imran et al., 2010). However, one
study reported a minor reduction of body weight gain in db/db mice
upon olmesartan treatment (Shigahara et al., 2014).
Among rat models of type 2 diabetes, a lack of inhibition of body
weight gain was reported with telmisartan in rats that had received
STZ in the neonatal phase (Goyal et al., 2011b). On the other hand,
body weight gain during development was attenuated by telmisartan
as compared to vehicle or, in a second series of experiments, by
telmisartan as compared to valsartan or rosiglitazone in non-obese
Cohen diabetic rats on a high-sugar, copper-free diet (Younis et al.,
2010). As part of the same study, telmisartan did not affect bodyweight
gain relative to vehicle in Cohen-Rosenthal non-obese diabetic hyper-
tensive rats on a high-sugar, copper-free diet, but in a second series of
experiments yielded smaller body weight increases than valsartan
(Younis et al., 2010).
Treatment designs have also been applied to other type 2 diabetes
models. Under such conditions, telmisartan reduced body weight in
rats that had been treated with a combination of nicotinamide and
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pioglitazone + glimepiride did not have this effect (Sharma et al.,
2014). In the type 2 diabetes model of a high-fat diet combined with
an STZ injection, a reduction of bodyweight upon telmisartan treatment
was reported by one group (Hussein et al., 2011) whereas another even
reported an increase in body weight relative to vehicle treatment (Guo
et al., 2011); in a similarmodel, neither valsartan nor perindopril affect-
ed bodyweight (Li et al., 2009). Thus, conﬂicting data have been report-
ed in animal models of type 2 diabetes; in the absence of reports on
enhanced body weight gain, ARBs may exert an effect which is too
small for robust detection.
Prevention of body weight gain or body weight reductions can the-
oretically result from increased energy expenditure and/or reduced eat-
ing. The latter has been assessed bymeasurement of food intake (grams
of food pellets being consumed) or of energy intake (multiplying food
intake times energy content of food). While the latter is more precise,
for the present analysis results from both approaches are combined. In
healthy wild-type mice and PPAR-δ knock-out mice telmisartan did
not affect food intake (Feng et al., 2011). In db/db mice neither
olmesartan nor telmisartan affected food intake (Shigahara et al.,
2014). In wild-type mice on high-fat diet neither candesartan
(Fujisaka et al., 2011) nor irbesartan (Aubert et al., 2010) affected food
intake whereas mixed data were reported for telmisartan; thus,
telmisartan was reported not to affect food intake (Araki et al., 2006;
Foryst-Ludwig et al., 2010; Rong et al., 2010; Fujisaka et al., 2011; Shiota
et al., 2012a; Li et al., 2013) or to reduce it (Aubert et al., 2010;
Souza-Mello et al., 2010; Noma et al., 2011).Within one of these studies,
the telmisartan-induced reduction of food intake was conﬁrmed in a
second group ofmice inwhich itwas notmimicked by irbesartan;with-
in that study telmisartan also reduced food intake in wild-type mice
with concomitant high-fat diet + pioglitazone treatment (Aubert
et al., 2010). Within a studywhere telmisartan did not alter food intake,
it also failed to do so in AT1R knock-out mice on a high-fat diet (Rong
et al., 2010). On the other hand, within studies where telmisartan did
lower food intake, this effect was maintained in AT1R knock-out mice
(Aubert et al., 2010; Noma et al., 2011). Where a reduced food intake
had been observed in wild-type mice on a high-fat diet, it was not due
to taste aversion (Noma et al., 2011). In conclusion, data on food intake
in mice are inconsistent; if anything, telmisartan may have an effect in
this regard. However, a study in which prevention of body weight
gain upon telmisartan treatment was maintained in mice with forced
pair-feeding (Noma et al., 2011) would argue that an effect on food in-
takemay not be necessary to prevent bodyweight gain. However, what
else may explain it is unclear as in the same study telmisartan did not
alter energy expenditure (Noma et al., 2011).
In rats on a high-fat diet, candesartan did not affect food intake
(Sugimoto et al., 2006), whereas losartan lowered food intake in
obesity-prone and –resistant rats on a high-fat diet (Boustany et al.,
2005). Similar to mice, equivocal food intake data were reported with
telmisartan in rats on a high-fat diet. Thus, reduced food intake with
telmisartan treatment was reported in some studies including one
where candesartan was ineffective (Sugimoto et al., 2006; Goyal et al.,
2011a; Müller-Fielitz et al., 2015); in SHR on a cafeteria diet both
candesartan and telmisartan lowered food intake (Müller-Fielitz et al.,
2012). On the other hand, in some studies telmisartan even increased
food intake in SHRon a cafeteria diet relative to control or ramipril treat-
ment (Miesel et al., 2012;Müller-Fielitz et al., 2014). Even a high dose of
candesartan failed to reduce food intake in obese Zucker rats (Müller-
Fielitz et al., 2011), whereas the candesartan analog azilsartan reduced
food intake in obese Koletsky rats (Zhao et al., 2011). One study has re-
ported that telmisartan but not valsartan improved caloric expenditure
in rats on a high-fat diet (Sugimoto et al., 2006). However, comparison
of the food intake data from various studies is complicated by the fact
that investigators assessed this for different time points and/or inter-
vals. Telmisartan did not alter food intake in guinea pigs on a high-fat
diet (Xu et al., 2015).Similarly controversial data were reported in animal models of type
2 diabets. In such models telmisartan was reported to reduce food in-
take in neonatally STZ-treated rats (Goyal et al., 2011b) or in KK-Ay
mice on a high-fat diet (Noma et al., 2011), whereas others did not
ﬁnd such effects with azilsartan or candesartan (Iwai et al., 2007),
telmisartan or valsartan in KK-Ay mice (Takasu et al., 2006; Ushijima
et al., 2013) or with losartan or telmisartan in db/db mice (Toyama
et al., 2011; Nagata et al., 2013) or valsartan in such mice on a high-
fat diet (Dong et al., 2010; Shiota et al., 2012b). Whether these
divergent ﬁndings represent differences between animal models,
study designs or ARBs or simply reﬂect data variability remains to be
determined. However, with very few studies reporting increased food
intake upon ARB treatment, the overall data if anything argue in favor
of a possible reduction as a contributor to often reported attenuation
of body weight gain or body weight reduction. As ARBs apparently
have only small and inconsistent effects on food intake, more consis-
tently observed reductions in body weight or body weight gain seem
to be related to glucose and fat metabolism in general as discussed in
the next sections.6.3. In vivo studies on glucose homeostasis
The most frequently studied parameters of glucose homeostasis are
blood or plasma concentrations of glucose,measured under steady state
conditions or after a fasting period, insulin andHbA1c. Insulin sensitivity
has often been studied as changes of glucose and/or insulin after a glu-
cose or insulin tolerance test, or based on the HOMA insulin-resistance
index.6.3.1. Studies in lean euglycemic animals
Most data on ARB effects on glucose homeostasis in euglycemic an-
imals come from the control groups of studies in obese and/or diabetic
rodents. In such studies, neither telmisartan (Araki et al., 2006; Emre
et al., 2010; Iwanami et al., 2010; Feng et al., 2011; Zidek et al., 2013)
nor valsartan (Cole et al., 2010) affected plasma glucose or insulin in
normal mice nor did telmisartan in ApoE knock-out mice (Feng et al.,
2011) or losartan or telmisartan in such knock-out mice on a high-fat
diet (Nakagami et al., 2008). In lean euglycemic rats ARBs typically did
not affect plasma glucose or insulin for example with azilsartan in nor-
motensive rats (Abdelsaid et al., 2014), in chronically ANG-infused rats
(Lastra et al., 2013) or in SHR (Kusumoto et al., 2011), candesartan in
normotensive rats (Kobayashi et al., 1993) or SHR (Müller-Fielitz
et al., 2011), olmesartan in SHR (Kusumoto et al., 2011), telmisartan in
normotensive rats (Goyal et al., 2008; Emre et al., 2010; Xu et al.,
2011; Goyal et al., 2011a; Kushwaha & Jena, 2013; Ola et al., 2013),
losartan or telmisartan in rats with 5/6 nephrectomy (Toba et al.,
2013; Zou et al., 2014), or valsartan in normotensive rats (Komers &
Cooper, 1995) or in hypertensive (mRen-2)27 rats (Kelly et al., 2000).
Telmisartan also did not affect HbA1c in normotensive rats (Emre
et al., 2010). However, telmisartan was reported to lower glucose and
insulin in SHR but not in the SHR/NIH substrain which harbors a dele-
tion mutation in the fatty acid translocase CD36, which is a known tar-
get gene of PPAR-γ (Li et al., 2006).
Nevertheless, ARBs may improve insulin sensitivity in lean
euglycemic animals, but the data are equivocal. Thus, increased insulin
sensitivity as assessed by glucose infusion rate in a hyperinsulinemic,
euglycemic clamp experiment was reported with azilsartan and
olmesartan in SHR (Kusumoto et al., 2011). Moreover, telmisartan re-
duced glucose excursions during an oral glucose tolerance test in mice
(Penna-de-Carvalho et al., 2014). On the other hand, valsartan treat-
ment did not change insulin sensitivity in one study in SHR, whereas
benazepril did so (Chow et al., 1995); in a follow-up study from the
same group the lack of effect of valsartan was conﬁrmed, whereas
benazepril now also was ineffective (Chow et al., 1997).
Fig. 8. Effect of an ARB (valsartan) and an ACE inhibitor (perindopril) on basal plasma
glucose and i.v. glucose tolerance and insulin release tests in a rat model of type 2
diabetes. Diabetes had been induced by a high-fat diet plus a single low-dose injection
of streptozotocin. One week after start of the diet, pharmacological treatment started
and was continued for another 8 weeks. Data are means ± SD of 8–10 animals.
Calculated and drawn based on data published by Yuan et al. (2010).
42 M.C. Michel et al. / Pharmacology & Therapeutics 164 (2016) 1–816.3.2. Studies in lean diabetic animals
Only few studies have explored glucose homeostasis in lean diabetic
mice. For instance, neither telmisartan nor valsartan affected the mark-
edly elevated blood glucose upon STZ treatment in C57BL/6 mice
(Kurihara et al., 2008). A similar ﬁnding was reportd with olmesartan
and telmisartan in STZ-treated ApoE knock-out mice (Ihara et al.,
2007) and for telmisartan in STZ-treated endothelial NO synthase
knock-out mice (Komala et al., 2014). Within the former study AT1R
knock-out on top of the ApoE knock-out also did not attenuate the glu-
cose elevation upon STZ treatment. In Akita (Ins2+/C96Y) mice, a non-
obese insulin-dependent model of spontaneous type 1 diabetes,
telmisartan had little effect on blood glucose or HbA1c levels (Fujita
et al., 2012; Koshizaka et al., 2012). Similar to STZ, injection of alloxan
destroys pancreatic β cells and, accordingly, can also be used as a
model of type 1 diabetes. Patients with a genetic defect in catalase
have a high incidence of diabetes, and alloxan-induced diabetes is ag-
gravated in catalase deﬁcient mice. Treatment with a low telmisartan
dose (0.1 mg/kg per day) starting one day before alloxan injection and
continued for another 7 days markedly reduced occurrence of diabetes
upon alloxan injection from 36.4% to 0% in wild-type mice and from
65.2% to 20% in catalase-deﬁcientmice (Kikumoto et al., 2010). Unfortu-
nately, other ARBs have not been tested in this model to the best of our
knowledge.
In rat models with STZ-induced diabetes, glucose levels typically
were not affected by ARBs including candesartan (Kato et al., 1999),
irbesartan (Tang et al., 2013), losartan (Senapathy et al., 2014),
telmisartan (Wienen et al., 2001; Singh et al., 2006; Yao et al., 2007;
Onozato et al., 2008; Kosugi et al., 2010; Mulay et al., 2010; Satoh
et al., 2010b; Lakshmanan et al., 2011; Mudagal et al., 2011; Alter
et al., 2012; Bishnoi et al., 2012; Zhang et al., 2012; Kushwaha & Jena,
2013; Mollnau et al., 2013; Ola et al., 2013; Senapathy et al., 2014)
and valsartan (Komers & Cooper, 1995; Hulthen et al., 1996; Cao et al.,
1998; Remuzzi et al., 1998; Kelly et al., 2000; Siragy & Huang, 2008;
Zhang et al., 2008b; Li et al., 2009; Yuan et al., 2010; Senapathy et al.,
2014; Tang et al., 2012) (Fig. 8). Similarly, HbA1c was not improved by
irbesartan (Bonnet et al., 2001; Cao et al., 2001; Tang et al., 2013),
telmisartan (Tojo et al., 2015) or valsartan (Allen et al., 1997; Cao
et al., 1998; Remuzzi et al., 1998)). Moreover, irbesartan also failed to
improve the HOMA insulin-resistance index (Tang et al., 2013). Several
of these studies also included an ACE inhibitor treatment group, in
which plasma glucose (Komers & Cooper, 1995; Cao et al., 1998; Kato
et al., 1999; Zhang et al., 2008b; Li et al., 2009; Yuan et al., 2010) or
HbA1c (Allen et al., 1997; Cao et al., 1998) alsowas not altered.However,
a few exceptions from this pattern exist. Thus, in contrast to several
other studies, olmesartan or aliskiren lowered glucose and increased in-
sulin in one study (Gandhi et al., 2012) and telmisartan or trandolapril
lowered plasma glucose (Hamed & Malek, 2007; Goyal et al., 2008;
Rao et al., 2011) or HbA1c in others (Hamed & Malek, 2007; Emre
et al., 2010). Moreover, in a study where neither valsartan nor
perindopril had major effects on plasma glucose, both increased fasting
blood insulin concentration and pancreatic islet function as assessed by
insulin concentration over time (Li et al., 2009). In a follow-up study, the
same group also reported that both drugsmoderately improved glucose
excursions during an i.v. glucose tolerance test (Yuan et al., 2010)
(Fig. 8).
ARB effects on glucose homeostasis have also been studied in
STZ-treated hypertensive rat strains. Thus, in STZ-treated SHR nei-
ther telmisartan nor lisinopril (Wienen et al., 2001) and neither
valsartan nor ramipril affected glucose levels (Hulthen et al., 1996).
Similarly, in other studies neither irbesartan nor captopril nor their
combination affected HbA1c levels in SHR (Bonnet et al., 2001; Cao
et al., 2001). STZ-induced diabetes has also been studied in MWF
rats, which also spontaneously develop hypertension but to a lesser
degree than SHR; in this model, neither valsartan nor benazepril af-
fected glucose levels which had been increased by STZ-treatment
(Remuzzi et al., 1998). Finally, valsartan treatment also did not affectplasma glucose in transgenic (mRen-2)27 rats pre-treated with STZ
(Kelly et al., 2000). Thus, RAS inhibitors as a class have little effect
on glucose homeostasis in lean animal models of diabetes.
In Goto–Kakizaki rats, azilsartan treatment starting an age of 12 or
18 weeks and continued until week 18 or 22, respectively, markedly
lowered but did not normalize blood glucose levels (Abdelsaid et al.,
2014). Of note, study designs starting ARB administration prior to or
concomitant with the β cell toxin may affect the onset of pancreatic
damage as they may mitigate oxidative damage to the β cells induced
by the toxin.
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Dedicated studies on ARB effects on glucose homeostasis were per-
formed in mouse and rat models of obesity with and without concomi-
tant type 2 diabetes. When given to mice on a high-fat diet, valsartan
improved glucose tolerance and reduced fasting blood glucose levels
and serum insulin levels (Cole et al., 2010). Using a similarmodel, others
reported that telmisartan, sitagliptin, metformin or dual combinations
thereof reduced hyperinsulinemia and improved responses to an oral
glucose tolerance or an intra-peritoneal insulin tolerance test (Souza-
Mello et al., 2010). In a follow-up paper based on the same set of mice
(Souza-Mello et al., 2011), a lowering of fasting plasma glucose, the in-
sulin/glucose and the insulin/glucagon ratio were also reported upon
telmisartan, sitagliptin or combination treatment. Using a similar
model, other investigators reported that telmisartan normalized insulin
levels and glucose excursions during intraperitoneal glucose and insulin
tolerance testing (Li et al., 2013). Improved glucose excursions with
telmisartan upon an intraperioneal or oral glucose tolerance test or an
insulin tolerance test in mice on a high-fat diet were conﬁrmed by
others (Foryst-Ludwig et al., 2010; Penna-de-Carvalho et al., 2014).
However, telmisartan did not alter glucose and insulin levels in mice
on a high-fat diet in other studies (Aubert et al., 2010). While these
data indicate an ARB class effect, telmisartan also normalized fasting
plasma glucose and insulin aswell as glucose concentrations after an in-
sulin challenge in AT1R knock-out mice on a high-fat diet (Rong et al.,
2010), indicating possible AT1R-independent effects. This idea is sup-
ported by the observation that a partial PPAR-γ agonist without AT1R
antagonist properties also improved fasting glucose levels and glucose
excursions during an oral glucose tolerance test in a model of type 2 di-
abetes, rats on a high-fat diet with additional STZ injection (Liu et al.,
2015a).
STZ injections in ApoE knock-out mice are a model of non-obese
type 2 diabetes; in this model, olmesartan actually increased plasma
glucose, whereas it was not affected by telmisartan or by olmesartan
in ApoE/AT1R double-knock-out mice (Ihara et al., 2007). The db/db
mouse is an animal model of obesity, diabetes and dyslipidemia that is
caused by a point mutation in the gene encoding the leptin receptor.
In db/db mice valsartan did not alter blood glucose with treatment du-
ration of 4–8weeks (Dong et al., 2010; Gao et al., 2010), but one of these
studies reported a minor reduction after 12 weeks of treatment (Gao
et al., 2010); moreover, another study in db/db mice found a reduced
glucose excursion in an oral glucose tolerance test (Cheng et al.,
2008). Similarly, inconclusive results were reported with losartan
which did not reduce plasma glucose or HbA1c after 8 weeks of treat-
ment (Toyama et al., 2011; Nagata et al., 2013), but in one of these stud-
ies a reduction was observed after 4 weeks (Nagata et al., 2013).
Similarly, both olmesartan and telmisartan did not affect glucose levels
in db/dbmice after 2 or 6weeks of treatment but caused aminor reduc-
tion after 4 weeks (Shigahara et al., 2014). In another study, telmisartan
also failed to affect fasting glucose levels after 8 weeks, but nevertheless
reduced the HOMA insulin-resistance index; the latter effect was
abolished by concomitant treatment with GW9662 and not mimicked
by losartan (Toyama et al., 2011). In another study in db/db mice on a
high-fat diet telmisartan also did not alter basal glucose or insulin levels
but slightly improved glucose excursions in an insulin tolerance test
(Shiota et al., 2012b). KK-Ay are a different inbred mouse strain sponta-
neously developing obesity and diabetes; in these mice azilsartan and
candesartan (Iwai et al., 2007; Matsumoto et al., 2014), losartan
(Iwanami et al., 2010) or telmisartan (Takasu et al., 2006; Iwanami
et al., 2010) did not lower glucose levels, although telmisartan lowered
basal insulin in one of these studies. However, azilsartan and
candesartan lowered glucose during an oral glucose tolerance test
(Iwai et al., 2007); similarly, azilsartan and candesartan (Iwai et al.,
2007) or telmisartan and valsartan enhanced glucose lowering during
an insulin-tolerance test in KK-Ay mice (Ushijima et al., 2013) with
the latter two additionally reducing the HOMA insulin-resistance
index. However, one study did not ﬁnd improvements in glucose orinsulin tolerance tests in KK-Ay mice upon treatment with azilsartan
or candesartan (Matsumoto et al., 2014). Using the opposite approach,
a 2-week infusion of ANG enhanced glucose excursions in an oral glu-
cose tolerance test or an insulin tolerance test, providing a mechanistic
basis why ARBs can improve glucose tolerance (Ohshima et al., 2012).
This argument was further strengthened within the study, as these en-
hanced glucose excursions were attenuated by concomitant treatment
with telmisartan but not with hydralazine, indicating that they did not
occur secondary to BP lowering. KK/Ta mice spontaneously develop
type 2 diabetes associatedwith fasting hyperglyacemia, glucose intoler-
ance, hyperinsulinaemia, mild obesity and dyslipidaemia; in such mice
candesartan treatment for up to 22 weeks did not affect fasting glucose
or peak glucose levels during a glucose tolerance test (Fan et al., 2004).
A-ZIP/F1 mice are a transgenic mouse model lacking adipose tissue but
having increased food intake and body weight with insulin-resistance.
In this model telmisartan treatment did not affect body weight, food in-
take, or plasma glucose but lowered plasma insulin and theHOMA insu-
lin-resistance index; it also increased insulin sensitivity in an orgal
glucose tolerance test and an insulin tolerance test, whereas liver hyper-
trophy was not affected (Rong et al., 2009), indicating that at least for
telmisartan beneﬁcial effects on glucose homeostasis may occur inde-
pendent of adipose tissue.
Other investigators have used otherwise healthy rats or SHR on a
high-fat or cafeteria diet to explore ARB effects on glucose homeostasis
but these experiments yielded conﬂicting results. Candesartan did not
change HbA1c or plasma insulin levels or HOMA insulin-resistence
index in normotensive rats or SHR on a high-fat diet in one study
(Chung et al., 2010). In another study, candesartan did not alter fasting
plasma glucose but lowered fasting plasma insulin in rats on a high-fat
diet (Wang et al., 2012d). It also improved glucose excursions in an
oral glucose tolerance test and glucose infusion rate during
euglycemic-hyperinsulinemic clamp analysis. Irbesartan improved in-
sulin sensitivity in rats when chronically administered concomitantly
with a high-fat diet (de las Heras et al., 2009). In rats on a high-fat
diet both valsartan and perindopril improved insulin sensitivity, an ef-
fect attributed to an increase in pancreatic microvessel density (Li
et al., 2009). Studies with telmisartan have yielded conﬂicting ﬁndings.
One group reported that telmisartan treatment attenuated the increase
in fasting plasma glucose in rats on a high-fat diet and improved the
HOMA insulin-resistance index (Wang et al., 2012c). Another group
found that telmisartan did not alter plasma glucose in rats on a normal
diet but attenuated the glucose elevation in rats on a high-fat diet to a
similar degree as low dose metformin (Goyal et al., 2011a). Others re-
ported a lowering of glucose in rats on a high-fat diet; while losartan
also lowered blood glucose, its effect was weaker at the chosen doses
(Rosseli et al., 2009); in that study only telmisartan but not losartan
lowered plasma insulin and the HOMA insulin-resistance index. Yet an-
other group observed that telmisartan did not alter fasting plasma glu-
cose or insulin or the HOMA insulin-resistance index in rats on a normal
diet but attenuated the elevation of both in rats on a high-fat diet (Xu
et al., 2011). The ﬁndings of a fourth group point in the opposite direc-
tion. In their hands, telmisartan and telmisartan + ramipril but not
ramipril alone increased fasting plasma glucose without alterations of
fasting insulin in SHR on a cafeteria diet (Miesel et al., 2012); glucagon
levels were increased by all three treatments, but more so with
telmisartan than with ramipril. In an oral glucose tolerance test, glucose
excursions were not affected while insulin excursions were attenuated
by telmisartan and telmisartan + ramipril. In another study from the
same group, telmisartan but not candesartan increased fasting plasma
glucose but both ARBs similarly prevented the high-fat diet-induced
lowering of plasma glucagon and actually increased it to levels above
those observed in SHR on a normal diet (Müller-Fielitz et al., 2012). In
an additional follow-up study from that group telmisartan and
telmisartan + amlodipine treatment but not amlodipine alone also in-
creased fasting plasma glucose and insulin and the HOMA insulin-
resistance index (Müller-Fielitz et al., 2014). Glucose or insulin
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telmisartan. In their most recent study they reported that telmisartan
did not alter basal glucose or insulin levels; during an oral glucose toler-
ance test, however, glucose excursions remained unaffected whereas
insulin excursions were reduced by about half (Schuchard et al.,
2015). In rats on a high-fat, high-calorie diet neither valsartan nor
perindopril affected plasma glucose or insulin concentrations (Li et al.,
2009). In Dahl salt-sensitive rats on a high-fat, high-salt diet treatment
witz azilsartandid not alter plasma glucose (Jin et al., 2014). Glucose ex-
cursions during an intra-peritoneal glucose tolerance test in
telmisartan-treated rats on a high-fat diet were somewhat greater in
unilaterally nephrectomized than in intact rats (Chin et al., 2015), but
these ﬁndings are difﬁcult to interpret as no direct comparison with
values in the absence of telmisartan treatment was reported.
Potential ARB effects on glucose homeostasis have also been ex-
plored in rat models of acquired and hereditary type 2 diabetes. One
model of acquired type 2 diabetes is the fructose-fed rat, characterized
by hyperinsulinemia, increased plasma ANG and mild hypertension. In
early studies, candesartan was reported not to affect plasma glucose
or insulin concentrations (Kobayashi et al., 1993). This was conﬁrmed
by other investigators who also reported a lack of alteration of elevated
plasma glucose and insulin levels upon candesartan or alacepril treat-
ment; they also reported a lack of effect on glucose or insulin excursions
upon intra-peritoneal glucose loading (Chen et al., 1996a). However, in
a later study the same group reported a reduced glucose and insulin ex-
cursion upon both candesartan and alacepril treatment in this model
without providing an explanation for these apparently contradictory re-
sults (Chen et al., 1996b). Reduced steady-state plasma glucose and in-
sulin upon candesartan treatment of fructose-fed rats was reported by
others (Shimamoto et al., 1994). A minor lowering of plasma glucose
upon candesartan or delapril treatment was also reported by others in
fructose-fed rats (Iimura et al., 1995). In later studies, the latter group
did not detect changes of fasting plasma glucose with either olmesartan
or temocapril in fructose-fed rats; however, they noticed an improved
insulin sensitivity as assessed during glucose infusion upon both treat-
ments (Higashiura et al., 2000). A reduced plasma glucose was also re-
ported with telmisartan treatment of fructose-fed rats, olanzapine-
treated rats or fructose-fed/onlanzepine-treated rats (Ramesh Petchi
et al., 2012); reduced insulin levels were also reported in this model
with telmisartan (Kamari et al., 2008). Others also reported reduced
glucose and insulin levels in fructose-fed rats with telmisartan and
aliskiren (Rabie et al., 2015). Thus, ARB effects on glucose homeostasis
in the fructose-fed rat model of type 2 diabetes remain equivocal, with
apparently inconsistent results even reported within research groups;
when ARBs were reported to improve glucose homeostasis in this
model, this effect typically was shared by an ACE inhibitor, indicating
that it may be a general effect of RAS inhibition, albeit perhaps too
small to allow robust detection.
While injection of STZ is primarily used as amodel of type 1 diabetes,
lower doses of STZ, particularly when applied on top of other interven-
tions, can also be used as amodel of type 2 diabetes. Thus,multiple ARBs
have been tested in rats, including SHR (Tang et al., 2013),whichhad re-
ceived an STZ injection on top of a high-fat diet. In this model, valsartan
started 4 weeks after diabetes induction did not improve insulin sensi-
tivity (Yang & Peng, 2010). Others reported that both valsartan and
perindopril did not alter fasting blood glucose concentration in this
model but increased fasting blood insulin and insulin excursions during
acute glucose loading (Li et al., 2009). These investigators conﬁrmed
their ﬁndings in a follow-up study which also showed reduced plasma
glucose excursions after an acute glucose load in rats treated with
valsartan or perindopril (Yuan et al., 2010). They also reported that
telmisartan reduced glucose and increased insulin excursions after an
acute glucose load in this model (Li et al., 2012b). Reduced plasma glu-
cose and insulin concentrations in this type 2 diabetes model upon
telmisartan treatment were also reported by other groups (Guo et al.,
2011; Hussein et al., 2011). One of these studies found the effects oftelmisartan on both parameters and also on the HOMA insulin resis-
tance index to be weaker than those of rosiglitazone, but the combina-
tion of rosiglitazone + telmisartan was more effective than
rosiglitazone alone (Hussein et al., 2011). In contrast, irbesartan was
found not to alter HbA1c or the HOMA insulin-resistance index in this
model (Tang et al., 2013). In a direct comparative study in rats on a
high-fat diet combined with a STZ injection, telmisartan, lisinopril and
aliskiren caused a similar reduction in serum glucose, indicating that
this is a general feature of RAS inhibition in this model (Hassanin &
Malek, 2014). STZ injection can also create a type 2 diabetes model
when administered directly after injection of nicotinamide. In this
model telmisartan reduced fasting blood glucose to a similar extent as
metformin + pioglitazone + glimepiride combination but in contrast
to that combination also markedly lowered body weight (Sharma
et al., 2014). A type 2 diabetes model can also be generated by injecting
STZ into neonatal rats; in this model telmisartan also lowered serum
glucose and insulin concentrations (Goyal et al., 2011b). Taken together,
ARBs and ACE inhibitors improved glucose homeostasis in most studies
with type 2 diabetes rat models involving STZ injections.
ARB effects have also been studied in inbred rat models spontane-
ously developing obesity and/or type 2 diabetes. In spontaneously
hypertensive/NIH-corpulent rat (SHR/NDmcr-cp) valsartan up to very
high doses failed to improve elevated glucose levels (Tominaga et al.,
2009), and a similar lack of glucose alteration was reported with
azilsartan in Koletsky obese hypertensive rats (Zhao et al., 2011);
however, in the latter model plasma insulin and the HOMA
insulin-resistance index were lowered by azilsartan treatment. In
SHRSP.Z-Leprfa/IzmDmcr rats telmisartan did not affect basal glucose
or insulin levels or their excursion during an oral glucose tolerance
test (Kagota et al., 2013, 2014). In Otsuka Long–Evans Tokushima
Fatty rats, olmesartan did not affect basal glucose or insulin levels or
glucose infusion rate under euglycemic hyperinsulinemic clamp condi-
tions (Harada et al., 1999); a later study conﬁrmed the lack of effect of
olmesartan on glucose levels in this model but reported for a high
(but not low) dose of olmesartan a reduction in HbA1c (Kikuchi et al.,
2007). Telmisartan and valsartan also did not affect basal glucose levels
in these rats; however, telmisartan but not valsartan or amlodipine
lowered insulin levels (Mori et al., 2007). Despite a lack of effect of
telmisartan on fasting plasma glucose, telmisartan attenuated glucose
and insulin excusions in an orgal glucose tolerance test (Zhao et al.,
2013). Zucker diabetic fatty rats spontaneously develop obesity and di-
abetes due to a mutation in the leptin receptor, i.e. can be considered a
rat homolog of the db/db mouse. In obese Zucker rats candesartan did
not affect basal glucose or insulin levels (Müller-Fielitz et al., 2011)
and actually increased glucose excursions during a glucose tolerance
test (Ecelbarger et al., 2010); in contrast, azilsartan was reported to
lower glucose AUC during an i.p. glucose tolerance test in this model
(Hye Khan et al., 2014b). In this model olmesartan was reported not
to affect serum glucose but to lower serum insulin levels (Munoz
et al., 2009), whereas irbesartan was found to improve the HOMA insu-
lin sensitivity index (Clasen et al., 2005). In Cohen-Rosenthal non-obese
diabetic hypertensive rats, neither rosiglitazone, nor telmisartan nor
valsartan altered insulin levels (Younis et al., 2010). However,
telmisartan but not valsartan lowered basal glucose levels and im-
proved the HOMA insulin-resistance index. Spontaneously Diabetic
Torii rats are a model of non-obese type 2 diabetes; in this model,
treatmentwith telmisartan starting at 8weeks of age suppressed subse-
quent diabetes development, apparently by protecting pancreatic β-
cells (Hasegawa et al., 2009). Similarly, an increased pancreatic β-cell
mass has been reported after 6 weeks of treatment with olmesartan
or telmisartan in db/db mice (Shigahara et al., 2014). In spontaneously
hypertensive obese rats azilsartan treatment did not alter fasting blood
glucose but increased the AUC during a glucose tolerance test (Hye
Khan et al., 2014a).
Taken together, ARBs as a class can improve glucose homeostasis in
many rodent models of obesity and type 2 diabetes but the results are
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consistencies may relate to differences between the experimental
models. Beneﬁcial ARB effects weremore often detected by dynamic as-
sessment of glucose homeostasis, i.e. glucose or insulin tolerance tests,
than by static assessments, i.e. basal glucose or insulin concentrations.
Thus, ﬁndings of improved insulin sensitivity as assessed by glucose or
insulin tolerance tests or by the HOMA insulin-resistance index were
often observed in the absence of improvements in basal glucose or insu-
lin levels, indicating possible effects on glucose disposition. Studies
reporting positive metabolic ARB effects in obesity and/or type 2 diabe-
tesmodels typically found that this was a shared effect of ARBs and ACE
inhibitors, indicating a general feature of RAS inhibition. In line with
these non-clinical observations, ARBs andACE inhibitors have improved
glucose tolerance and insulin sensitivity in patients in controlled clinical
trials (vander Zijl et al., 2011) and in large observational studies (Michel
et al., 2004). Moreover, ARBs reduced the incidence of diabetes in large
clinical outcome studies (Andraws & Brown, 2007; Mathur et al., 2007).
In additional to such class effects, telmisartan exerted apparently AT1R-
independent beneﬁcial effects in some rodent studies. Accordingly, a
systematic meta-analysis of clinical studies comparing telmisartan
with other ARBs in patients with insulin resistance or diabetes con-
ﬁrmed that the former had greater beneﬁcial effects on fasting glucose,
fasting insulin and insulin sensitivity than other ARBs (Suksomboon
et al., 2012).
6.4. In vivo studies on lipid metabolism
Studies of potential ARB effects on lipid metabolism have largely
been performed in the same animalmodels as those on glucose homeo-
stasis, often within the same studies. Themost frequently explored out-
come parameters were serum and plasma cholesterol including its
subfractions and triglycerides.
6.4.1. Studies in lean euglycemic animals
Telmisartan did not affect triglyceride levels in PPAR-δ knock-out
mice (Feng et al., 2011), in ApoE knock-out mice (Blessing et al.,
2008), in mice on a high-fat diet (Nakagami et al., 2008; Nagy et al.,
2010) or in ApoE/AT1R double knock-out mice (Fukuda et al., 2010)
but increased HDL in the latter. On the other hand, one study in ApoE
knock-out mice reported telmisartan (in the absence or presence of
concomitant atorvastatin treatment) to increase total cholesterol, LDL,
VLDL and triglycerides without altering HDL (Grothusen et al., 2005);
similarly, irbesartan was reported to increase blood cholesterol and tri-
glyceride levels in such knock-out mice (Dol et al., 2001).
In stroke-resistant SHR, a 15 month treatment with telmisartan did
not affect triglycerides or total or LDL cholesterol (Kurata et al., 2014a,
2014b). The Imai rat is a hereditary model of hypertension and hyper-
lipidemia. In such rats olmesartan almost normalized plasma levels of
total, LDL and VLDL cholesterol as well as triglycerides (Rodriguez-
Iturbe et al., 2004). Chronic exposure of rats to arsenite can increase
plasma cholesterol and triglycerides, and this was preventd by
telmisartan (Nirwane et al., 2015). Thus, ARBs as a class apparently
have little effect on plasma lipids in lean euglycemic animals.
6.4.2. Studies in lean diabetic animals
In ApoE knock-out mice with additional STZ treatment, olmesartan
treatment or additional AT1R knock-out did not alter elevated total cho-
lesterol or LDL and also did not affect triglycerides; telmisartan treat-
ment reduced LDL within the same study (Ihara et al., 2007). In a rat
model of non-obese type 2 diabetes, induced byneonatal STZ treatment,
telmisartan treatment lowered total, LDL and VLDL cholesterol and tri-
glycerides and increased HDL cholesterol (Goyal et al., 2011b). In rats
ﬁrst treated with a high-sucrose, high-cholesterol diet and then with
STZ, subsequent irbesartan treatment did not alter total or LDL choles-
terol or triglycerides (Tang et al., 2013).6.4.3. Studies in obese animals with and without diabetes
In otherwise healthy mice on a high-fat diet telmisartan treatment
was reported to lower triglyceride levels in serum, liver and skeletal
muscle (Araki et al., 2006; Clemenz et al., 2008). Other investigators
treated mice on a high-fat diet with either telmisartan, sitagliptin or
their combination (Souza-Mello et al., 2011). In that study triglycerides
were not affected by eithermonotherapy but reduced by approximately
50% by combination treatment. Total cholesterol was reduced by
telmisartan and combination treatment but not by sitagliptin mono-
therapy, whereas LDL cholesterol was lowered by all three treatments
with theweakest effect for sitagliptin and the strongest for combination
treatment. Neither treatment affected HDL cholesterol. Telmisartanwas
also reported to lower triglyceride levels in KK-Ay mice (Takasu et al.,
2006) andA-ZIP/F-1 transgenicmice (Ronget al., 2009); in the latter an-
imals triglyceride levels were also reduced in the liver. In diabetic db/db
mice treatment with valsartan for 4, 8 and 12 weeks lowered total, LDL
and HDL cholesterol and triglycerides (Gao et al., 2010).
In rats on a high-fructose diet cholesterol and triglyceride levels
were reduced by alecapril but not candesartan (Chen et al., 1996b);
using a similar model, others reported a reduction of triglycerides
(Kamari et al., 2008) or of total and LDL cholesterol and of triglycerides
accompanied by increased HDL cholesterol upon telmisartan treatment
(Ramesh Petchi et al., 2012). In rats on a high-fat diet candesartan
lowered triglyceride levels by about 40%without reaching statistical sig-
niﬁcance (Guo et al., 2008), and irbesartan treatment reduced total cho-
lesterol (de las Heras et al., 2009). Using a similar model, others
reported that telmisartan lowered total, LDL and VLDL cholesterol as
well as triglycerides and concomitantly increased HDL cholesterol
(Goyal et al., 2011a; Rabie et al., 2015); in the latter studies both
drugs also reduced glucose excursions during an oral glucose tolerance
test. Another group conﬁrmed these ﬁndings except for those on HDL
cholesterol (Xu et al., 2011). Others conﬁrmed the telmisartan effect
on LDL cholesterol and triglycerides but did not observe alterations of
total or HDL cholesterol (Wang et al., 2012c). Yet other investigators re-
ported in a rat high-fat diet model that telmisartan decreased triglycer-
ides and increased HDL cholesterol without alterations of total or LDL
cholesterol (Müller-Fielitz et al., 2014, 2015). In Dahl salt-sensitive
rats on a high-fat, high-salt diet azilsartan treatment reduced total cho-
lesterol with minor if any effects of triglycerides (Jin et al., 2014). In rats
on a high-fat diet with additional STZ treatment, monotherapy with ei-
ther telmisartan or rosiglitazone lowered total and LDL cholesterol and
triglycerides and increased HDL cholesterol; combination treatment
had even stronger effects on all four parameters (Hussein et al., 2011).
Lowering of total cholesterol and triglycerides upon telmisartan treat-
ment in a similar model was conﬁrmed by others (Guo et al., 2011). In
a direct comparative study in rats on a high-fat diet combined with a
STZ injection, telmisartan, lisinopril and aliskiren caused a similar re-
duction in triglycerides and total and LDL cholesterol, indicating that
this is a general feature of RAS inhibition in this model (Hassanin &
Malek, 2014) (Fig. 9). A reduction of total and LDL cholesterol and of tri-
glycerides along with an increase in HDL cholesterol upon telmisartan
treatment was also reported in a rat model of olanzapine-induced obe-
sity (RameshPetchi et al., 2012). Among ratmodels of hereditary obesity,
azilsartan did not alter triglycerides in Koletsky rats (Zhao et al., 2011) or
cholesterol or triglycrides in obese Zucker rats (Hye Khan et al., 2014b)
and telmisartan caused only minor reductions of total cholesterol or tri-
glycerides in SHRSP.Z-Leprfa/IzmDmcr rats (Kagota et al., 2013, 2014).
However, azilsartan lowered serum cholesterol and triglycerides in spon-
taneously hypertensive obese rats (Hye Khan et al., 2014a), candesartan
lowered triglycerides in obese Zucker rats (Ecelbarger et al., 2010),
irbesartan lowered total cholesterol and triglycerides in obese Zucker
rats (Munoz et al., 2009), and valsartan lowered total cholesterol and tri-
glycerides in SHR/NDmcr-cp rats (Tominaga et al., 2009). In Otsuka Long–
Evans Tokushima Fatty rats olmesartan lowered total cholesterol (but
only in a high dose) but not triglycerides (Kikuchi et al., 2007). In the lat-
ter strain, a 16-week treatment with telmisartan (but not equally anti-
Fig. 9. Effects of an ARB (telmisartan), an ACE inhibitor (enalapril) and a direct renin
inhibitor (aliskiren) on triglycerides, total cholesterol and LDL cholesterol in a rat model
of type 2 diabetes. Rats were put on a high-fat diet, followed by a single low-dose
injection of STZ to induce diabetes (except for the control group that stayed on a normal
diet). Thereafter some of the diabetic rats were treated for 12 weeks with the respective
RAS inhibitor. Data are means ± SD of 10 rats in the control and diabetic and 15 rats in
the treated groups. Drawn based on published data (Hassanin & Malek, 2014).
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cursions in an acute oral fat tolerance test (Mori et al., 2007). Telmisartan
treatment also lowered LDL cholesterol in such rats, which at least for the
higher of two doses was accompanied by an increase in HDL cholesterol
(Zhao et al., 2013).
In guinea pigs on a high-fat diet, treatment with telmisartan slightly
lowered plasma triglycerides whereas total, LDL or HDL cholesterol
were not affected (Xu et al., 2015). Moreover, it did not enhance the
cholesterol-lowering effect of pitavastatin in this model.
In conclusion, in contrast tomost studies in lean euglycemic animals,
ARBs lowered total and LDL cholesterol as well as triglycerides and in-
creased HDL cholesterol in many studies. While this was not observed
consistently, in the absence of studies reporting opposite effects ARBs
as a class appear to exert a beneﬁcial effect on serum and plasma lipid
proﬁles in obese animals with andwithout concomitant diabetes, albeit
perhaps not robust enough to allow consistent detection.
6.5. In vivo studies on adipose mass and function
AT1R, AT2R along with angiotensinogen, renin and ACE are also
expressed in adipocytes, both in native tissue (Putnam et al., 2012)
and in the 3T3-L1 mouse adipocyte cell line (Hung et al., 2011; Zhang
et al., 2015), which has frequently been used in functional studies. Obe-
sity is characterized by an increase in total body fat, most often accom-
panied by an increase of individual adipocte size. Experimental studies
with ARBs typically have not assessed total body fat mass but rather
that of one ormore anatomically deﬁned regions such as visceral or sub-
cutaneous fat depots.
Our search did not identify any study reporting increased fat depots
upon treatmentwith an ARB. In only a few studies a lack of effect of ARB
treatment on the size of fat depots was reported; these included studies
in healthy mice with telmisartan (Penna-de-Carvalho et al., 2014) or
valsartan (Tomono et al., 2008), otherwise healthy PPAR-δ knock-out
mice with telmisartan (He et al., 2010; Feng et al., 2011), mice on a
high-fat diet with candesartan (Fujisaka et al., 2011), in KK-Ay mice
with azilsartan or candesartan (Iwai et al., 2007; Matsumoto et al.,
2014), in ob/ob mice with valsartan (Imran et al., 2010), in healthy
rats with telmisartan (Goyal et al., 2011a), in rats on a high-fat diet
with telmisartan (Zanchi et al., 2007) and in obese Koletsky rats with
azilsartan (Zhao et al., 2011). However, most studies have reported
that treatmentwith an ARB, particularly in rodentmodels of obesity, re-
duces fatmass and/or adipocyte size (Table 4). These included studies in
normal healthymicewith telmisartan (Kudo et al., 2009; He et al., 2010;
Feng et al., 2011; Zidek et al., 2013), in mice on a high fat diet with
irbesartan (Aubert et al., 2010) and telmisartan (Aubert et al., 2010;
Souza-Mello et al., 2010; Fujisaka et al., 2011; Penna-de-Carvalho
et al., 2014), mice on a high-fat diet with additional pioglitazone treat-
ment with telmisartan (Aubert et al., 2010), ApoE knock-out mice on a
high-fat diet with losartan or telmisartan (Nakagami et al., 2008),AT1R knock-out mice on a high-fat diet with telmisartan (Rong et al.,
2010), mice on a methionine- and choline-deﬁcient high-fat diet with
telmisartan (Kudo et al., 2009), and in KK-Ay mice with azilsartan
(Iwai et al., 2007) or valsartan (Tomono et al., 2008). It also included
several rat studies including those in otherwise healthy SHR with
telmisartan (He et al., 2010), in rats on a high-fat diet with candesartan
(Müller-Fielitz et al., 2012), irbesartan (de las Heras et al., 2009),
losartan (Rosseli et al., 2009), telmisartan (Sugimoto et al., 2006;
Rosseli et al., 2009; Goyal et al., 2011a; Miesel et al., 2012;
Müller-Fielitz et al., 2012; Wang et al., 2012c; Müller-Fielitz et al.,
2014) or valsartan (Sugimoto et al., 2006; Guo et al., 2008) including
those in SHR with candesartan (Chung et al., 2010) or telmisartan (He
et al., 2010), in rats on a high-fat diet and additional pioglitazone treat-
ment with telmisartan (Zanchi et al., 2007), in fructose-fed rats with
telmisartan (Ramesh Petchi et al., 2012; Rabie et al., 2015), in rats
with olanzapine-induced obesity with telmisartan (Ramesh Petchi
et al., 2012), or in Otsuka Long–Evans Tokushima Fatty rats with
olmesartan (Harada et al., 1999), telmisartan (Mori et al., 2007; Zhao
et al., 2013) or valsartan (Mori et al., 2007). Telmisartan also reduced
the size of epididymal and retroperitoneal fat pads in guinea pigs on
a high-fat diet; when those guinea pigs were treated with a
telmisartan + pitavastatin combination, reductions in fat pad size
were greater than to be expected based on the two monotherapies
(Xu et al., 2015).
Although the effects were not fully consistent across all time points
(Fujisaka et al., 2011) or all anatomical locations (Müller-Fielitz et al.,
2014) within some experimental series, the vast majority of studies
suggest that ARBs as a class can reduce body fat mass in rodent models
of obesity and probably even lean mice and rats. In rats on a high-
fructose diet the reduction in adipocyte mass was similar with
telmisartan and aliskiren (Rabie et al., 2015), arguing for a shared effect
of all RAS inhibitors. On the other hand, experiments with ramipril
mimicked the effects of telmisartan for a reduction of visceral but not
that of subcutaneous fat depots (Miesel et al., 2012) and provided evi-
dence that such reductions may not be a general feature of RAS inhibi-
tion. While losartan and telmisartan had similar effects in ApoE
knock-out mice on a high-fat diet in direct comparative studies
(Nakagami et al., 2008), irbesartan was less effective than telmisartan
in wild-type mice on a high-fat diet (Aubert et al., 2010), valsartan
less than telmisartan in rats on a high-fat diet (Sugimoto et al., 2006)
or valsartan less than telmisartan in Otsuka Long–Evans Tokushima
Fatty rats (Mori et al., 2007); epididymal and perirenal fat mass was
lower in telmisartan- than losartan-treated polydactylus/Cub rats on a
high-sucrose, high-fat diet (Sugimoto et al., 2008). Together with the
observation that telmisartan also reduced body fat in AT1R knock-out
mice on a high-fat diet (Rong et al., 2010), these data suggest that on
top of the fat mass reducing effects of ARBs as a class, telmisartan may
exert additional AT1R-independent effects. Whether the PPAR-δ-
dependent component of adipose tissue reduction of telmisartan
(Feng et al., 2011) represents the ARB class or the telmisartan-speciﬁc
AT1R-independent part remains to be determined. From a physiological
point of view, it remains to be understood why ARBs had only inconsis-
tent effects on body weight and much more consistent ones on adipose
tissue mass. We do not propose that ARBs increase the mass of other
body compartments. Rather we feel that it is most likely that effects of
adipocyte mass are of insufﬁcient magnitude to have consistent effects
on overall body weight.
Adiponectin is a polypeptide secreted from adipose tissue which
regulates glucose homeostasis and fatty acid oxidation. Adiponectin ex-
pression is stimulated by at least some ARBs in cultured adipocytes
(Yamada et al., 2008; Brody et al., 2009; Inomata-Kurashiki et al.,
2010). This is reﬂected by various in vivo studies. While some studies
with telmisartan in ob/ob mice (Araki et al., 2006), rats on a high-fat
diet (Müller-Fielitz et al., 2014) or fructose-red rats (Kamari et al.,
2008) have reported no change of adiponectin levels, and some found
a lack of effect for both candesartan and telmisartan in SHR on a high-
Table 4







Healthy mouse Telmisartan (Kudo et al., 2009; He et al., 2010; Feng et al., 2011; Zidek et al., 2013)
Telmisartan (Penna-de-Carvalho et al., 2014)
ApoE knock-out mice Valsartan (Tomono et al., 2008)
PPAR-γ knock-out mice on high-sucrose diet Telmisartan (Zidek et al., 2013)
PPAR-δ knock-out mice Telmisartan (He et al., 2010; Feng et al., 2011)
Mice on high-fat diet Candesartan (Fujisaka et al., 2011)
Irbesartan (Aubert et al., 2010)
Telmisartan (Aubert et al., 2010; Souza-Mello et al., 2010; Fujisaka et al., 2011;
Penna-de-Carvalho et al., 2014)
Mice on high-fat diet + pioglitazone Telmisartan (Aubert et al., 2010)
ApoE knock-out mice on high-fat diet Losartan (Nakagami et al., 2008)
Telmisartan (Nakagami et al., 2008)
AT1R knock-out mice on high-fat diet Telmisartan (Rong et al., 2010)
Mice on methione- and choline-deﬁcient high-fat diet Telmisartan (Kudo et al., 2009)
KK-Ay mice Azilsartan (Iwai et al., 2007)
Candesartan (Iwai et al., 2007)
Valsartan (Tomono et al., 2008)
Rat models
Healthy rats Telmisartan (Goyal et al., 2011a)
Telmisartan (Rabie et al., 2015)
SHR Candesartan (Chung et al., 2010)
Telmisartan (He et al., 2010)
Rats on high-fat diet Candesartan (Müller-Fielitz et al., 2012)
Irbesartan (de las Heras et al., 2009)
Losartan (Rosseli et al., 2009)
Telmisartan (Sugimoto et al., 2006; Rosseli et al., 2009; Goyal et al., 2011a;
Miesel et al., 2012; Müller-Fielitz et al., 2012; Wang et al. 2012c;
Müller-Fielitz et al., 2014)
Telmisartan (Zanchi et al., 2007)
Valsartan (Sugimoto et al., 2006; Guo et al., 2008)
SHR on high-fat diet Candesartan (Chung et al., 2010)
Telmisartan (He et al., 2010)
Rats on high-fat diet with pioglitazone Telmisartan (Zanchi et al., 2007)
Rats on high-fructose diet Telmisartan Ramesh Petchi et al., 2012; Rabie et al., 2015)
Rats treated with olanzapine Telmisartan Ramesh Petchi et al., 2012)
Koletsky rat Azilsartan (Zhao et al., 2011)
Otsuka Long–Evans Tokushima Fatty rat Olmesartan (Harada et al., 1999)
Telmisartan (Zhao et al., 2013)
Guinea pig models
Guinea pigs on high-fat diet Telmisartan (Xu et al., 2015)
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that ARBs increase plasma adiponectin. These include studies with
irbesartan in Zucker diabetic fatty rats (Clasen et al., 2005; Munoz
et al., 2009), with olmesartan or aliskiren in the STZmodel of type 1 di-
abetes (Gandhi et al., 2012) with high but not low dose olmesartan
(Kikuchi et al., 2007) and with two doses of telmisartan (Zhao et al.,
2013) in Otsuka Long–Evans Tokushima Fatty rats, andwith telmisartan
in SHR (Younis et al., 2010), mice (Araki et al., 2006; Souza-Mello et al.,
2010; Zidek et al., 2013) or rats on a high-fat diet (Wang et al., 2012c),
rats on such a diet with additional STZ injection (Hussein et al., 2011),
mice on a methionine- and choline-deﬁcient high-fat diet (Kudo et al.,
2009), Cohen diabetic rats and Cohen-Rosenthal non-obese diabetic hy-
pertensive rats (Younis et al., 2010). In a direct comparative study in rats
on a high-fat diet combined with a STZ injection, telmisartan, lisinopril
and aliskiren caused a similar normalization of adiponectin levels, indi-
cating that this is a general feature of RAS inhibition in this model
(Hassanin & Malek, 2014). Of note, the telmisartan-induced increase
in serum adiponectin in mice on a high-fructose diet was absent in
adipocyte-speciﬁc but not skeletal muscle-speciﬁc PPAR-γ knock-out
mice (Zidek et al., 2013). Thus, ARBs as a class seem to increase
adiponectin levels in most studies, thus reversing the reduced
adiponectin levels typically observed in obese animal models and
humans. Interestingly, increased plasma adiponectin levels upon ARBtreatment have been observed not only in models of obesity and diabe-
tes but also in rats on a high-salt diet; in such animals plasma
adiponectin was reduced by telmisartan but not by clonidine or hydral-
azine (Kamari et al., 2010). The lack of hydralazine effect indicates that
elevation of adiponectin levels does not occur secondary to improved
blood supply to adipose tissue as a result of vasodilatation.
6.6. Liver morphology and function
The liver is an important organ in glucose and fat metabolism and
may at least in part mediate ARB effects on plasma levels of glucose,
cholesterol and triglycerides. On the other hand, obesity and diabetes
may alter morphology and function of the liver, i.e. induce hypertrophy,
steatosis and ﬁbrosis. Such alterations of liver morphology may at least
partly result from activation of the RAS. Thus, AT1R are expressed in the
liver of various mammalian species (de Gasparo & Whitebread, 1995;
Garcia-Sainz et al., 1997; Hines et al., 1999). In primary human hepatic
stellate cells, ANG incubation for 3 days induced protein expression of
Arhgef1, rho kinase and α-smooth muscle actin, probably secondary
to activation of Jak2, which are believed to play a role in induction of
liver ﬁbrosis; losartan inhibited these responses to a similar degree as
the JAK inhibitor AG490 (Granzow et al., 2014); within the same
study it was found that chronic infusion of ANG can lead to activation
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not AT1R knock-out mice (Granzow et al., 2014).
Against this background several in vivo studies, mostly primarily de-
signed to explore ARB effects on glucose and lipid metabolism, have re-
ported on liver mass as an outcome parameter. None of them reported
an increase in liver mass upon treatment with an ARB, and in few
cases a lack of effect was reported; the latter included a study in normal
micewith telmisartan (Kudo et al., 2009), one in mice on a high-fat diet
with losartan (Nakagami et al., 2008), one in SHR (Li et al., 2006), two in
rats on a high-fat diet with telmisartan (Müller-Fielitz et al., 2014;
Schuchard et al., 2015). However, in many studies a reduced liver
mass was found upon treatment with an ARB. These included studies
in wild-type mice on a high-fat diet with telmisartan (Nakagami et al.,
2008; Souza-Mello et al., 2010), in AT1R knock-out mice on a high-fat
diet with telmisartan (Rong et al., 2010), mice on a methionine- and
choline-deﬁcient high-fat diet with telmisartan (Kudo et al., 2009),
rats on a high-fat diet with candesartan (Müller-Fielitz et al., 2012),
losartan (Rosseli et al., 2009) or telmisartan (Sugimoto et al., 2006;
Rosseli et al., 2009; Miesel et al., 2012; Müller-Fielitz et al., 2012), rats
with neonatal STZ treatment with telmisartan (Klein et al., 2014),
fructose-fed rats with telmisartan (Ramesh Petchi et al., 2012), and
olanzapine-treated rats with telmisartan (Ramesh Petchi et al., 2012).
Taken together these data demonstrate a reduction of liver mass by
about 15% in both mice and rats likely to develop non-alcoholic liver
steatohepatitis upon treatment with ARBs as a class (Fig. 10).
Telmisartan may have additional effects partly because it concentrates
in liver (Clemenz et al., 2008) and partly AT1R-independently; in
favor of the latter it was reported that its effects in rats on a high-fat
diet was not mimicked by ramipril (Miesel et al., 2012) and that it re-
duced liver mass in AT1R knock-out mice on a high-fat diet (Rong
et al., 2010).
Indeed morphological evidence for amelioration of non-alcoholic
steatohepatitis with ARBs was found in several studies. In mice on a
high-fat diet telmisartan was reported to promote expression of PPAR-
α-dependent gene expression (Clemenz et al., 2008). In mice on a
high-fat diet which had received a low dose of STZ 2 days after birth,
treatment with telmisartan reduced hepatic inﬂammation and ﬁbrosis
(Cynis et al., 2013). In mice on a methionine- and choline-deﬁcient
high-fat diet telmisartan treatment attenuated liver steatosis with
decreased hepatic triglycerides and ﬁbrogenesis with decreased type I
collagen and TGF-β1 mRNA expressions (Kudo et al., 2009); it also sup-
pressed the inﬁltration of macrophages into the liver and decreased he-
patic MCP-1 and its receptor mRNA expressions. In other studies, the
fatty liver induced by a high-fat diet in rats was reverted by treatment
with losartan or telmisartan (Rosseli et al., 2009). Similarly, telmisartan
reduced liver ﬁbrosis that had been induced in rats by a short- or long-
term methionine- and choline-deﬁcient diet (Nakagami et al., 2010).
Telmisartan also prevented liver ﬁbrosis in a rat bile duct ligation
model (Yi et al., 2012), in high-fat diet-induced progression from simpleFig. 10. Effect of ARB treatment on liver mass in mice and rats. Studies involved different
ARBs and healthy animals as well as those from various models of metabolic disease; for
details, see Section 6.6. Each data point represents the mean data from one study,
expressed as % of the value observed in the control group not receiving an ARB. Mean ±
SD of all studies within a species are indicated.steatosis to non-alcoholic steatohepatitis in a ﬁsh (Oryzias latipes)
model (Kuwashiro et al., 2011), in PCK rats (Yoshihara et al., 2013)
and in a rat model of Schistozoma mansoni infection (Attia et al.,
2013). In rats on a choline- and L-amino acid-deﬁcient diet, telmisartan
not only prevented development of ﬁbrosis but also the occurrence of
hepatocellular carcinoma (0/10 vs. 6/11 animals) (Tamaki et al.,
2013). In rats on a high-fructose diet, telmisartan and aliskiren ﬁbrosis
in the portal vein along with a reduction of congestion in the portal
vein and of inﬂammatory cell inﬁltration in the portal area and between
hepatocytes (Rabie et al., 2015). In a murine genetic model of liver
ﬁbrosis, Abcb4 knock-out mice), telmisartan as monotherapy did not
preventﬁbrosis development but exhibited a strong effectwhen admin-
istered in combination with propranolol (Mende et al., 2013). Losartan
attenuated ischemia/reperfusion-induced liver damage in mice in the
absence but not in the presence of GW9662, indicating a PPAR-γ-
mediated effect (Koh et al., 2013).
7. Renal effects and nephroprotection
RAS inhibition is a clinically well established principle of
nephroprotection, particularly in the context of diabetic nephropathy
(Hughes & Britton, 2005; Strippoli et al., 2006; Bernstein et al., 2013).
While BP lowering per se can have nephroprotective effects, the beneﬁ-
cial effects of RAS inhibitors appear to exceed those of other antihyper-
tensive drug classes in patients (Grifﬁn & Standridge, 2012). Moreover,
PPARs, which can be activated by some ARBs (Michel et al., 2013), can
also contribute to the regulation of renal function (Röszer & Ricote,
2010). Against this background, numerous studies have explored ARB
effects on renal function and its alterations in disease.
7.1. Normal renal function
The presence of renal AT1R at the protein level has e.g. been demon-
strated as binding sites for radiolabeledANGanalogs or for [3H]-losartan
in whole rat kidney (Wienen & Entzeroth, 1994), rat glomeruli (Wilson
et al., 1989; Gauquelin & Garcia, 1992; Chansel et al., 1993b), rat
mesangial cells (Ernsberger et al., 1992; Zhou et al., 1993), rat tubule
fragments (Poggioli et al., 1992), rat renal epithelial cells (Hines et al.,
1999) or rabbit whole kidney (Edwards et al., 1992b; Liang & Leenen,
2008). Autoradiographic studies have demonstrated that most ANG re-
ceptors in rat and human kidney are AT1R andmainly found in glomer-
uli and medullary vascular bundles (Sechi et al., 1992a; Correa et al.,
1995).
7.1.1. Signal transduction and in vitro studies
The canonical signaling pathway of AT1R is coupling to PLC via a per-
tussis toxin-insensitive G-protein, Gq, but additional pathways exist
which in concert lead to engagement of various down-stream signaling
pathways (de Gasparo et al., 2000). Thus, ANG elicits a variety of signal
transduction responses in the kidney and isolated renal cells, which are
blocked by ARBs. Stimulation of inositol phosphate accumulation and
inhibition by ARBs was observed in rat mesangial cells (Madhun et al.,
1993) and in freshly isolated fragments from rat proximal tubules
(Poggioli et al., 1992). The latter effect was conﬁrmed in cultured rat
proximal tubule cells, where it was observed only with administration
from the basolateral but not from the apical side (Schelling et al.,
1992). In line with the role of inositol phosphates in releasing Ca2+
from intracellular stores, ANG also caused an elevation of intracellular
Ca2+ in rat mesangial cells (Madhun et al., 1993), isolated
preglomerular arterioles (Iversen & Arendshorst, 1999) and proximal
tubules (Poggioli et al., 1992; Zhang & Mayeux, 2012), which was
blocked by candesartan, eprosartan or losartan. An AT1R-mediated ele-
vation of intracellular Ca2+ has also been observed in a canine tubular
cell line, Madin-Darby canine kidney cells (Touyz et al., 2001c). In
highmicromolar concentrations, losartanwas reported to elevate intra-
cellular Ca2+ in mesangial cells, but this was not accompanied by
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tributable non-speciﬁc effects at very high concentrations (Chansel
et al., 1993a). ARB-sensitive inhibition of forskolin-stimulated cAMP
formation was reported in rat isolated glomeruli (Edwards & Stack,
1993), mesangial cells (Madhun et al., 1993; Zhou et al., 1993) and
proximal tubules (Poggioli et al., 1992). Thus, renal AT1R couple to the
well-known primary signaling pathways of PLC activation, intracellular
Ca2+ elevation and inhibition of adenylyl cyclase.
Several lines of evidence indicate that ANG canmodulate the forma-
tion and release of NO in the kidney via AT1R, but such modulation ap-
pears to be complex. Direct evidence for ANG-stimulated NO release has
been obtained in perfused microdissected rat renal resistance arteries;
these were inhibited by candesartan and losartan, which did not alter
basal NO release in the absence of exogeneous ANG (Thorup et al.,
1999). Indirect evidence comes from the observation that ANG-
stimulated, eprosartan-sensitive cGMP formation in rat proximal tu-
bules was blocked by an NO synthase inhibitor (Zhang & Mayeux,
2012). On the other hand, infusion of valsartan increased renal intersti-
tial ﬂuid levels of NO metabolites, cGMP and bradykinin in conscious
rats on a low-sodium diet, whereas the AT2R or icatibant had opposite
effects; a combination of valsartan with either PD 123319 or with
icatibant abolished the elevations seen with valsartan (Siragy et al.,
2000). The latter data support a concept where ANG does not but an
ARB promotes NO release, apparently secondary to release of bradyki-
nin. In line with the latter observations, acute pre-treatment with an
NO synthase inhibitor did not affect the BP response to candesartan in
anesthetized normotensive rats but blocked the candesartan-induced
reduction of renal vascular resistance; concomitant administration of
L-arginine restored the renovasodilatory effect of candesartan
(Demeilliers et al., 1999). Finally, a study in cultured rat mesangial
cells reported that ANG (via a candesartan-sensitive pathway) and
TGF-β inhibited IL-1β-induced NO release; in this regard a reduced
NO synthase mRNA expression appeared to play a role in TGF-β but
not ANG effects (Ihara et al., 1999). Thus, both stimulatory and inhibito-
ry effects of ANG and AT1R inhibition of NO release have been reported,
apparently reﬂecting amixture of direct and indirect effects that at least
partly mitigate each other.
Other AT1R-activated signaling pathways in the kidney which have
been lesswell characterized include activation of themitogen-activated
protein kinase JNK via pertussis toxin-sensitive and –insensitive
pathways independent of protein kinase C in rat mesangial cells
(Huwiler et al., 1998), activation of a Na+/H+-antiporter in an isolated
rat macula densa preparation (Bell & Peti-Peterdi, 1999), activation of
a Na+/HCO3-cotransporter in rabbit renal tubules (Eiam-Ong et al.,
2015), and a reduction of free intracellular Mg2+ concentrations,
which depended on the concentration of extracellular Na+ but not in-
tracellular free Ca2+ (Touyz et al., 2001c). A net effect of all of the
above signaling events, at least in mesangial cells, is an ANG-stimulated,
ARB-sensitive increase in protein synthesis; whether this also results in
proliferation remains controversial (Anderson et al., 1993; Bakris & Re,
1993; Madhun et al., 1993).
The kidney also has important endocrine functions by releasing
renin and erythropoietin. Renin release is an important step in the ho-
meostatic system regulating ANG formation, and as part of the physio-
logical feed-back loop ANG itself suppresses renin release (Hackenthal
et al., 1990). This partly reﬂects a direct effect on the macula densa
but may also partly occur indirectly due to alterations of BP lowering
and sodium and ﬂuid homeostasis. Moreover, the sympathetic nervous
systems via β-adrenoceptor stimulation, in humans β1-adrenoceptor
stimulation (Motomura et al., 1990), is an important stimulus of renin
release, and activity of the RAS and the sympathetic nervous system
can cross-regulate each other. Accordingly, all drugs inhibiting forma-
tion or action of ANG increase renin secretion, as reported in numerous
studies across a wide range of models and species including humans.
More recent evidence demonstrates that at the macula densa level
thismay involve the convergent activation of cAMP formation, probablythrough indirect augmentation via the activity of prostaglandins E2 and
I2,β-adrenoceptors andNO (Kimet al., 2012b). Formation and release of
the hematopoietic hormone erythropoietin is another important endo-
crine function of the kidney. While anemia and lowered oxygen satura-
tion are key stimulants for erythropoietin release, ANG has consistently
been found to stimulate erythropoietin expression in experimental
models and in humans; experimentally this can be inhibited by ARBs
(Kim et al., 2014) but this appears to reﬂect a minor modulatory role
only as lowering of hemoglobin or hematocrit typically is not observed
upon treatment with RAS inhibitors.
7.1.2. Renal blood ﬂow and glomerular ﬁltration
Radioligand binding studies with isolated rat renal microvessels
demonstrated that vascular ANG receptors belong predominantly if
not exclusively to the AT1R subtype (De Leon & Garcia, 1992). Studies
in several in vitro preparations have demonstrated that ANG causes va-
soconstriction of renal vessels via an AT1R. This includes experiments
with losartan in isolated rat (Hayashi et al., 1993) and rabbit renal artery
(Zhang et al., 1994) andwith telmisartan in isolated rat kidney (Wienen
& Entzeroth, 1994). In rabbits ANG can cause vasoconstriction of affer-
ent and efferent glomerular arterioles via AT1R; this effect was en-
hanced when AT2R were blocked by PD 123319, and in the presence
of candesartan the vasoconstrictor response to ANG was turned into a
vasodilator response of the efferent arteriole (Endo et al., 1997).
Several studies have explored ARB effects on RBF in the presence or
absence of exogenous ANG; of note some of these studies did not report
RBF but rather renovascular resistance or renal plasma ﬂow. Thus, the
ANG-induced reduction of RBF was attenuated for instance by
candesartan (Li & Widdop, 1996; Ruan et al., 1999). However, the situ-
ationmay bemore complex, as ANGwas reported to reduce cortical but
to increase papillary RBF in rats; while both effects were blocked by
losartan, the increased papillary ﬂow apparently was caused by locally
released mediators including prostaglandins and the kallikrein system
(Nobes et al., 1991). An ANG-induced reduction in cortical blood ﬂow
was conﬁrmed by others and shown to be candesartan-sensitive
(Cervenka et al., 1998). ANG also caused a reduction of RBF in mice,
which was markedly attenuated in AT1R knock-out mice and by
candesartan in wild type mice (Ruan et al., 1999).
ARB effects on RBF in the absence of exogenous ANG administration
may be species-dependent. Thus, in the absence of exogenous ANG,
candesartan increased RBF and decreased renovascular resistance in
wild type mice (Traynor & Schnermann, 1999). Within that study a
lowered renovascular resistance was also found with untreated AT1R
knock-out mice, conﬁrming a role of endogenous ANG in the regulation
of renal perfusion. Moreover, similar to studies in rats, candesartan im-
paired autoregulation of RBF in wild type mice in that study. In guinea
pigs, a losartan-induced RBF increase in the absence of exogenous
ANG has also been shown and was shared by an ACE inhibitor and a
human renin inhibitor also inhibiting guinea pig renin (El Amrani
et al., 1993), suggesting that this RBF effect of losartan is a general fea-
ture of RAS inhibition. In healthy normotensive dogs ARBs consistently
increased RBF and/or renal plasma ﬂow in doses typically not affecting
BP. This was shown for instance with candesartan (He et al., 1994; Ito
et al., 1995; Kito et al., 1996), losartan (Chan et al., 1992; Keiser et al.,
1992; Nishiyama et al., 1992) or valsartan (Hayashi et al., 1997b).
While most of the dog studies had been performed in anesthetized an-
imals, some were also reported from conscious dogs (Ito et al., 1995). A
different situation may exist in rats. In isolated perfused rat kidney,
telmisartan increased perfusate ﬂow (Wienen & Entzeroth, 1994).
Candesartan increased RBF in rats and attenuated the reduction caused
by the NO synthase inhibitor L-NAME (Kawata et al., 1996). While one
study reported an eprosartan-induced increase in RBF in rats in the ab-
sence of exogenous ANG (mostly due to an increase in cortical with
smaller effects onmedullary bloodﬂow) (Brodsky et al., 1998), other in-
vestigators did not observe thiswith eprosartan in healthy rats (Wang&
Brooks, 1992). Losartan and enalapril also lacked effect on basal RBF/
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Beierwaltes, 1993a). In another study, three different candesartan
doses were compared in the absence of exogenous ANG (Cervenka
et al., 1998); the low dose slightly increased RBF, the medium dose
had no effect and the high dose, which also considerably reduced BP, ac-
tually reduced it. Taken together these studies suggest that ARBs as a
class as well other other types of RAS inhibitors increase RBF in healthy
mice, guinea pigs and dogs but have smaller and inconsistent effects in
rats. This suggests that the RAS appears to exert less tonic control over
renovascular resistance in healthy rats than in other species and/or
that major BP reductions more easily overrule direct RBF effects in this
species. Endogenously released ANGmay also play a role in the autoreg-
ulation of RBF, as thiswas inhibited by losartan (Cupples, 1993). Of note,
the above studies are based on acute ARB administration and do not
necessarily allow conclusions on chronic administration.
The GFR is an important indicator of overall renal function; other
than colloid osmotic pressure, the GFR is affected by the pressure and
resistance of the afferent and efferent arteriole. Reported ARB effects
onGFR in healthy animals have been inconsistent. In isolated rat kidney,
telmisartan increased GFR (Wienen & Entzeroth, 1994). In vivo one
study found an increased GFR upon acute losartan administration in
rats (Zhuo et al., 1992), but a lack of effect on GFR was reported with
eprosartan (Wang & Brooks, 1992; Brodsky et al., 1998), losartan or
enalapril (Baylis et al., 1993). In one study comparing three different
candesartan doses, the low dose not affecting BP increased GFR, the
middle one with minor BP lowering was neutral on GFR, and the high
dose lowering BP also reduced GFR (Cervenka et al., 1998). In guinea
pigs, losartan and lisinopril increased GFR to a minor extent whereas a
renin inhibitor did so to a greater extent (El Amrani et al., 1993). Dog
studies have also yielded inconsistent results. While an increase in
GFR was reported with losartan (Chan et al., 1992; Nishiyama et al.,
1992), a lack of effect was found in another losartan study (Keiser
et al., 1992) and with valsartan (Hayashi et al., 1997b); for candesartan
both lack of effect (Ito et al., 1995) and aGFR increasewere reported (He
et al., 1994). In a rat study in which eprosartan alone did alter RBF or
GFR, it attenuated the increase caused by glycine infusion-induced
hyperﬁltation (Wang & Brooks, 1992). Therefore, the above studies do
not allow clear conclusions on ARB effects on GFR in healthy, normoten-
sive animals. However, in each study ACE inhibitors or renin inhibitors
exhibited similar effects (or lack thereof) as ARBs, suggesting class ef-
fects of RAS inhibition. Studies comparing multiple doses of a given
ARB suggest that the absence or presence of BP lowering importantly
contributes to observed GFR changes.
7.1.3. Tubular function and diuresis
Some studies have explored ARB effects on tubular function using
isolated proximal tubule preparations. In isolated perfused rabbit prox-
imal tubules eprosartan, irbesartan, losartan and valsartan inhibited
para-amino-hippurate secretion (Edwards et al., 1999). Losartan was
also a substrate of that transporter. In transfected cells all tested ARBs
inhibited uptake of uric acid or estrone-3-sulfate by OAT1, OAT3 and
OAT4 with olmesartan and valsartan exhibiting IC50 values comparable
to their clinically observed unbound peak plasma concentrations;
candesartan, losartan and telmisartan inhibited uric acid uptake by
MRP4, but only losartan had an IC50 comparable to its estimated kidney
concentration (Sato et al., 2008). In similar studies in transfected
Xenopus laevis oocytes others reported inhibition of uric acid uptake
by irbesartan, losartan, telmisartan and valsartan but not by
candesartan (Nakamura et al., 2010). Such in vitro ﬁndings translated
into alterations of uric acid excretion in rats (Li et al., 2008b). While
they may be relevant for the use of some ARBs in patients with hyper-
uricemia/gout (Dang et al., 2006) or for some drug-drug-interactions,
they have limited implications for overall kidney function.
Several studies have explored ARB effects on diuresis, natriuresis
and kaliuresis in healthy experimental animals, mostly in rats and
dogs. In an early study in rats, candesartan was reported not to affectdiuresis, natriuresis or kaliuresis in oral doses up to 300 mg/kg (Kito
et al., 1996). In a later study, study an i.v. low candesartan dose (0.01
mg/kg) increased sodium excretion, while higher doses (0.1–1 mg/kg)
along with the lowering of BP, RBF and GFR also reduced natriuresis
(Cervenka et al., 1998). Azilsartan also did not change diuresis but
inhibited the increase in urine production upon a 10-day ANG infusion
(Carroll et al., 2015). Losartan, in a dose not affecting BP, was reported
to increase diuresis and natriuresis whereas enalapril did not affect ei-
ther parameter (Baylis et al., 1993). Losartan also increased diuresis
and natriuresis (but not kaliuresis) in another rat study, in which frac-
tional proximal ﬂuid reabsorption decreased from 73% to 64% and frac-
tional distal sodium reabsorption from 98% to 94% (Zhuo et al., 1992).
Telmisartan increased urine ﬂow in isolated perfused rat kidney, and
in vivo increased diuresis and natriuresis (but not kaliuresis) in at
least some doses in rats (Wienen & Entzeroth, 1994). In dogs acute
treatment with ARBs consistently increased diuresis and natriuresis as
reported with candesartan (He et al., 1994), losartan (Chan et al.,
1992; Nishiyama et al., 1992) or telmisartan (Schierok et al., 2001).
Taken together ARBs as a class, similar to ACE inhibitors, appear to in-
crease diuresis and natriuresis but not kaliuresis in rats and dogs, but
the effect was less consistently reported in rats. Part of the lack of con-
sistency in ﬁndings may relate to the observation that high ARB doses
may cause a degree of BP lowering which may overrule direct effects
on tubular function.
Themicropuncture technique has been used to obtain amoremech-
anistic understanding of the observed diurectic ARB effects. Earlymicro-
puncture studies established that losartan and the AT2R antagonist
PD123177 similarly inhibit bicarbonate, chloride, sodium andwater ab-
sorption in the S1 proximal tubule segment, but their combination was
not more effective than either alone (Cogan et al., 1991). Inhibition of
proximal tubule ﬂuid absorption by losartan was conﬁrmed by others,
and the extent of this effect was similar to that of enalapril (Zhuo
et al., 1992). Similar ﬁndings were also obtained by investigators
using candesartan, EXP3154 or losartan (Smart et al., 1999).
Tubuloglomerular feedback is an important mechanism in the auto-
regulation of renal function and markedly inhibited in rats by
candesartan; moreover, candesartan inhibited the enhancements
caused by the NO-synthase inhibitor L-NAME (Kawata et al., 1996). In
mice tubuloglomerular feedback was abolished by treatment with
candesartan or in those with AT1R or ACE knock-out (Traynor &
Schnermann, 1999).
In addition to their direct effects on renal function, ARBsmightmod-
ify the response to pathophysiological interventions or to other drugs in
healthy animals. In sodium-restricted rats losartan lowered BP but had
only minor effects on cumulative urine volume, sodium excretion and
water intake (Jover et al., 1991). Similarly, neither losartan nor captopril
inhibited the anti-natriuretic response to acute volume depletion in
uninephrectomized conscious dogs (Nelson & Osborn, 1993). On the
other hand, candesartan, losartan and ACE inhibitor derapil similarly
inhibited furosemide-induced increase in renal prostaglandin E2 excre-
tion in rats (Fujimura et al., 1994). Moreover, losartan and captopril
blocked the inhibition of sodium excretion by erythropoietin in isolated
rat kidney (Brier et al., 1993).7.2. Development and progression of nephropathy
Nephropathy can develop from kidney-speciﬁc conditions such as
chronic glomerulonephritis but can also be the result of primarily
non-renal conditions such as arterial hypertension, ureteral obstruction
or diabetes. A range of animal models exist for these conditions;
while some of them mimic extra-renal causes, e.g. the SHR or the
STZ-induced diabetes, others are based on direct renal damage, e.g.
the 5/6 nephrectomy model. The most frequently used functional and
morphological outcome parameters from in vivo studies are albuminuria
and ﬁbrosis, respectively.
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Based on the large number of cell types contributing to renal func-
tion, multiple models have been used to study renal pathology and its
therapeutic modulation at the cellular level. The most frequently used
ones are mesangial and tubular cells. Cultured mesangial cells are fre-
quently used to model glomerulonephritis and glomerulosclerosis.
ANG stimulated protein synthesis in mesangial cells from rats
(Madhun et al., 1993), mice (Anderson et al., 1993) and humans
(Bakris & Re, 1993; Orth et al., 1995) in a losartan-sensitive manner.
In microarray experiments with human mesangial cells, ANG induced
expression of 27 and inhibited that of 7 genes, and this was inhibited
by valsartan in all cases (Naito et al., 2009). The up-regulated genes in-
cluded those encoding pro-inﬂammatory mediators such as MCP-1, LIF
and cyclooxagenase-2; interestingly, this was observed similarly in the
presence of normal and elevated glucose concentrations and also in
the absence and presence of simvastatin. In rat mesangial cells ANG
also affected the intracellular localization of proteins which shufﬂe
cyclooxygenase-2 and plasminogen activator inhibitor-1 in a
valsartan-sensitive manner; similar observations were made in acutely
ANG-infused rats in vivo (Doller et al., 2009). In mouse mesangial cells
ANG induced mRNA expression and release of IL-6, which was blocked
by candesartan (Moriyama et al., 1995). Moreover, both ANG and IL-6
stimulated proliferation as assessed by [3H]-thymidine incorporation,
and the stimulatory ANG effect was blocked by an IL-6 antibody. How-
ever, the overall role of ANG in mesangial cell proliferation has
remained controversial as this has been observed by some (Orth et al.,
1995) but not other investigators (Madhun et al., 1993). These experi-
ments establish ANG, acting on AT1R, as a local inducer of inﬂammatory
and perhaps proliferative responses in the glomerulum. In cultured
mouse podocytes ANG or AGE induced DNA damage and cell detach-
ment, both of which were prevented by telmisartan (Fukami et al.,
2013).
In the absence of exogenous ANG, the AGE-induced increase in su-
peroxide generation, expression of RAGE and VCAM-1 and reduced ex-
pression of ACE2 were inhibited in mesangial cells by olmesartan but
not azilsartan (Ishibashi et al., 2014). Exposure of rat mesangial cells
and glomerular epithelial cells to a high glucose concentration caused
oxidative stress and increased mRNA and protein expression of MCP-
1, TGF-β and CTGF; all of these effects were prevented by valsartan
(Huang et al., 2011; Jiao et al., 2011). In cultured human mesangial
cells telmisartan reduced RAGE expression and AGE-induced superox-
ide generation andMCP-1 expression; these reductions were prevented
by GW9662 and not mimicked by candesartan (Matsui et al., 2007).
Glomerulosclerosis, similar to other ﬁbrotic conditions, is character-
ized by deposition of extracellular matrix, and TGF-β is an important
mediator in this process. In rat mesangial cells in the absence of
exogenous ANG, telmisartan but not valsartan up-regulated PPAR-γ ex-
pression and inhibited the TGF-β-induced extracellularmatrix accumu-
lation; such inhibition was sensitive to GW9662 indicating PPAR-γ
involvement (Yao et al., 2008). In rat mesangial cells TGF-β in the ab-
sence of exogenous ANG also activated protein kinase A and and stimu-
lated CREB expression; both telmisartan and troglitazone inhibited the
TGF-β effects and the expression of collagen and smooth muscle actin
(Zou et al., 2010). In human mesangial cells telmisartan prevented
TGF-β-induced collagen expression, apparently involving a PPAR-δ
pathway (Mikami et al., 2014). Therefore, the overall evidence from cel-
lularmodels supports a role of ARBs as a class in the prevention or treat-
ment of glomerulonephritis and glomerulosclerosis, for instance in the
context of diabetic nephropathy; this may partly occur by antagonizing
locally formed ANG. Telmisartan may have an additional PPAR-γ-
mediated effect on glomerular pathology.
In proximal tubule cells, TNF-α caused release of lactate dehydroge-
nase and N-acetyl-β-glucosaminidase, and this was inhibited by
olmesartan and valsartan (Kagawa et al., 2008). Release of N-acetyl-β-
glucosaminidase was also stimulated by exposure to albumin, and that
was also inhibited by olmesartan and valsartan; such inhibition in theabsence of exogenous ANG can be explained by the observation that al-
bumin caused ANG release from tubule epithelial cells (Takao et al.,
2009). In a human proximal tubule cell line, HK-2, ANG reduced the ex-
pression of bone morphogenetic protein-7, a renoprotective peptide,
and such reduction was abolished by telmisartan (Bramlage et al.,
2010). In the absence of exogenous ANG, TNF-α induced epithelial-to-
mesenchymal transition in HK-2 cells; this was blocked by telmisartan
in the absence but not presence of GW9662 (Chen et al., 2012b). In pri-
mary human proximal tubule cells, TNF-α induced the production of
vascular endothelial growth factor at the mRNA and protein level, and
this was inhibited by telmisartan; the TNF-α effect apparently involved
phosphorylation of mitogen-activated protein kinase p38 and of heat-
shock protein 27, which also was inhibited by telmisartan (Kimura
et al., 2014). The latter telmisartan effects apparently occurred indepen-
dent of PPAR-γ and rather involved PPAR-δ. In Madin-Darby Canine
Kidney cells, a distal tubule-derived cell line, ANG stimulated expression
of the NF-κB-dependent transcription factor Ets-1 in a losartan-
sensitivemanner (Kumar et al., 2010). Thus, these data support the con-
cept that ARBs as a class can protect tubule epithelial cells from patho-
logical stimuli including TNF-α, and this may at least partly be due to
blocking effects of ANG released by such stimuli; however, these protec-
tive ARB effects may also involve AT1R-independent mechanisms, sug-
gesting that their extent may vary between ARBs.
7.2.2. Models of primary renal disease
The most frequently used in vivo model of primary renal disease is
based on a surgical reduction of renal mass. This is most often per-
formed as 5/6 nephrectomy in rats, butmore severemodels such as sub-
total (17/18) nephrectomy (Toba et al., 2012) and less severe models
such as unilateral nephrectomy (Matsuo et al., 2013; Ziai et al., 1996)
have also been used. Nephrectomy in already hypertensive rats (Ziai
et al., 1996) or in those receiving an additional ethylene glycol injection
(Kadhare et al., 2015) has also been studied. Other than by surgical renal
mass reduction, nephropathy can also be induced immunologically, for
instance by injection of a monoclonal antibody against Thy-1
(Nakamura et al., 1997), which has also been applied in conjunction
with unilateral nephrectomy (Song et al., 2012).
In rat reduced renal mass models, ARBs as a class reduced albumin-
uria, the most frequently used functional parameter (Fig. 11). This was
shown for instance with candesartan (Mackenzie et al., 1994;
Hamaguchi et al., 1996; Shibouta et al., 1996; Noda et al., 1997; Hamar
et al., 1999; Noda et al., 1999; Sugimoto et al., 1999; Li et al., 1999b;
Podjarny et al., 2007), eprosartan (Gandhi et al., 1999; Wong et al.,
2000; Sasser et al., 2012), irbesartan (Ziai et al., 1996; Tu et al., 2008;
Cao et al., 2012), losartan (Lafayette et al., 1992; Pollock et al., 1993a;
Toba et al., 2012, 2013), telmisartan (Tsunenari et al., 2005; Toba
et al., 2012, 2013; Zou et al., 2014), or valsartan (Wu et al., 1997;
Zhang et al., 2008a). Interestingly, losartan and enalapril even lowered
proteinuria in doses where they did not reverse the BP elevation caused
by renal mass reduction (Pollock et al., 1993a). While most studies
started ARB treatment immediately after renal mass reduction, studies
with candesartan (Shibouta et al., 1996), losartan (Mayer et al., 1993)
or telmisartan (Zou et al., 2014) reported improved proteinuria even
when treatment started 4–11 weeks after the 5/6 ablation, suggesting
that ARBs may not only be beneﬁcial in a prevention but also in a treat-
ment setting. Importantly, candesartan treatment has been reported to
reducemortality in ratswith reduced renalmass (Podjarny et al., 2007).
Some of these studies have directly compared improvement of albu-
minuria upon treatment with an ARBwith that caused by an ACE inhib-
itor or a RAS-independent antihypertensive drug. In such studies ARBs
andACE inhibitors exhibited comparable improvements of albuminuria,
for instance with candesartan vs. enalapril (Shibouta et al., 1996; Noda
et al., 1997; Hamar et al., 1999; Noda et al., 1999; Sugimoto et al.,
1999), candesartan vs. ramipril (Li et al., 1999b), irbesartan vs. enalapril
(Ziai et al., 1996), irbesartan vs. perindopril (Cao et al., 2012), losartan
vs. enalapril (Lafayette et al., 1992; Pollock et al., 1993a), telmisartan
Fig. 11. Effects of ARBs on proteinuria in rat models of renal disease based on renal mass
reduction. Each pair of data points connected by a line represents one study with the
control/vehicle data shown as the left and ARB treatment data as the right symbol. Note
that in one study data were reported for albumin (Tsunenari et al., 2005), in all other
studies for total protein excretion. In a one study protein data were reported normalized
for urinary creatinine (Sugimoto et al., 1999) and in another per 100 g body weight
(Pollock et al., 1993a); in both cases data were back-calculated to total protein by the
present authors; in all other studies absolute values were given. Based on data reported
in (Lafayette et al., 1992; Pollock et al., 1993a; Mackenzie et al., 1994; Hamaguchi et al.,
1996; Ziai et al., 1996; Wu et al., 1997; Gandhi et al., 1999; Hamar et al., 1999; Noda
et al., 1999; Sugimoto et al., 1999; Wong et al., 2000; Tsunenari et al., 2005; Tu et al.,
2008; Cao et al., 2012; Sasser et al., 2012; Toba et al., 2012). In some cases, values were
estimated from printed ﬁgures, and some studies reported data for more than one ARB.
Despite major differences in baseline proteinuria, start and duration of treatment, all 16
studies analyzed here have consistently reported major reductions of proteinuria upon
ARB treatment.
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1997; Zhang et al., 2008a). The two classes of RAS inhibitor typically
improved proteinuria to a similar extent, demonstrating that
renoprotection in this model is a general feature of RAS inhibition.
This conclusion is further supported by direct comparative studies
with losartan and telmisartan, which also showed that the PPAR-γ an-
tagonist GW9662 did not affect the telmisartan-induced reduction in
proteinuria (Toba et al., 2012, 2013). In some studies, the effect of an
ARB and ACE inhibitor combination was larger than that of either drug
alone (Cao et al., 2012), but in others it was reported to be smaller
thanwith eachmonotherapy (Lafayette et al., 1992); the former ﬁnding
may be explained by submaximally effective doses of either agent,
whereas the latter is somewhat difﬁcult to explain based on the
known pharmacology of both agents.
Moreover, it was reported that losartan and enalapril lowered pro-
teinuria also in doses where they did not reverse the BP elevation
(Pollock et al., 1993a), pointing to a BP-independent effect. To explore
this in more detail, some investigators compared effects of ARBs with
those of RAS-unrelated BP-lowering medications. In one such study,
the reduction of proteinuria was comparable but numerically greater
with candesartan thanwithmanidipine (Hamaguchi et al., 1996). In an-
other study, three active treatments were compared which all caused
similar BP lowering, losartan, enalapril and a reserpine/hydralazine/hy-
drochlorothiazide combination (Lafayette et al., 1992). While losartan
and enalapril caused a similar improvement of albuminuria, the RAS-
independent drug combination did not. Moreover, the β-adrenoceptor
biased ligand nebivolol (Frazier et al., 2011), when given in a dose not
lowering BP, did not improve proteinuria in a study where an ARB did
(Sasser et al., 2012). On the other hand, clopidogrel improved protein-
uria in 5/6 nephrectomy rats, and the clopidogrel + irbesartan combi-
nation was more effective in this regard than either drug alone (Tu
et al., 2008)
While proteinuria is themost frequently used indicator of damage in
studies with renal mass reduction, other functional and also morpho-
logical parameters have also been used. Thus, renal mass reduction
leads to glomerulosclerosis, and this has been reported to be reduced
by treatment with candesartan (Mackenzie et al., 1994; Shibouta et al.,
1996; Noda et al., 1997, 1999), eprosartan (Gandhi et al., 1999),
irbesartan (Ziai et al., 1996; Cao et al., 2012), losartan (Lafayette et al.,
1992), telmisartan (Tsunenari et al., 2005; Zou et al., 2014) or valsartan(Wu et al., 1997). In all cases where an ACE inhibitor was studied in
comparison, it had similar effects as the ARB, for instance in the compar-
ison of candesartan with enalapril (Noda et al., 1997; Sugimoto et al.,
1999), losartan with enalapril (Lafayette et al., 1992), telmisartan with
enalapril (Tsunenari et al., 2005) or valsartan with ramipril (Wu et al.,
1997). However, when given in a later stage of the condition,
candesartan had a greater effect than enalapril (Noda et al., 1997). On
the other hand, the ARB effect on histologically detected
glomerulosclerosis was also shared by RAS-independent agents such
as manidipine (Hamaguchi et al., 1996), indicating that it may at least
partly be a consequence of BP lowering. Interestingly, the inhibition of
glomerulosclerosis upon ARB treatment was observed not only when
the drug was given early, i.e. mimicking a preventive approach, but
also when treatment started severalmonths after the renal mass reduc-
tion, i.e. an treatment approach (Noda et al., 1999).
ARBs including candesartan (Shibouta et al., 1996; Noda et al., 1997,
1999), eprosartan (Wong et al., 2000), telmisartan (Tsunenari et al.,
2005; Matsuo et al., 2013; Zou et al., 2014) and valsartan (Wu et al.,
1997) also reduced interstitial ﬁbrosis and/or collagen expression in
the remaining renal tissue, an effect being shared by ACE inhibitors
such as enalapril (Noda et al., 1997; Wu et al., 1997; Tsunenari et al.,
2005).
ARBs also prevented renal inﬁltration by inﬂammatory cells, as
shown for instance with candesartan (Noda et al., 1997; Hamar et al.,
1999), telmisartan (Tsunenari et al., 2005) or valsartan (Wu et al.,
1997). In one study the candesartan effect on macrophage inﬁltration
was mimicked by the IL-2 synthesis inhibitor tacrolimus, and the com-
bined administration of both drugs caused even greater reduction
(Hamar et al., 1999). Reduced renal massmodels typically exhibit an in-
creased level of TGF-β1 expression in the remnant tissue. This increase
was inhibited by various ARBS, including candesartan (Noda et al.,
1997; Noda et al., 1999), eprosartan (Wong et al., 2000), irbesartan
(Tu et al., 2008), telmisartan (Tsunenari et al., 2005) and valsartan
(Wuet al., 1997). At the functional levels ARBs reduced the elevated glo-
merular capillary pressure typically observed after renal mass reduc-
tion, as reported e.g. with candesartan (Mackenzie et al., 1994),
irbesartan (Ziai et al., 1996) and losartan (Lafayette et al., 1992; Mayer
et al., 1993). Taken together these data demonstrate that ARBs as a
class, similar to ACE inhibitors, are effective in the prevention and treat-
ment of renal damage induced by renal mass reduction. This can be ob-
served by morphological parameters including glomerulosclerosis and
ﬁbrosis but also functionally as shown by a reduced proteinuria. BP re-
duction may partly explain this effect, but parts of it apparently are in-
dependent of BP reduction.
Themost frequently used alternative to renal mass reduction for the
generation of animal models of primary kidney disease is the immuno-
logical induction of renal damage. Early work on the latter was based on
injection of an antibody directed against glomerular basement mem-
brane in rats. This induced transient elevation of both plasma renin
and angiotensinogen, followed by acute nephritis as indicated by pro-
teinuria, hypoalbuminemia, hypercholesterolemia and an increase in
serum creatinine; candesarten administed 2 h before an injection with
the antibody prevented the nephritis, whereas successive administra-
tion of this drug for 1 week from 3 d after the injection of antibody
did not (Yayama et al., 1995b), indicating that AT1R play a pathophysi-
ological role in the development of this nephritis model but not in its
maintenance. In this model glomerulonephritis is accompanied by an
early increase in TGF-β1 mRNA in the renal cortex, which can be sup-
pressed by repeated candesartan administration, apparently inhibiting
locally generated ANG (Yayama et al., 1995a).
For studies in a treatment design, more informative data come from
injection of a monoclonal antibody against Thy-1, a 25 kDa protein
expressed on the endothelium-facing surface ofmesangial cells; this an-
tibody is sometimes used in combination with unilateral nephrectomy
as an animal model of mesangioproliferative glomerulonephritis
(Cheng et al., 1995). In the anti-Thy-1 rat model, administration of
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the early up-regulation of MCP-1 at the mRNA and protein level (Wolf
et al., 1998). A 10-week treatment with candesartan starting shortly
after injection of the antibody prevented the increase in proteinuria
and in renal expression of TGF-β1 and type I and III collagen; hydral-
azine administerd in equally BP-lowering doses dit not mimic the
candesartan effect (Nakamura et al., 1997). A follow-up study from
the samegroup compared effects of candesartanwith those of cilazapril,
cilazapril + icatibant, and hydralazine (Nakamura et al., 1999). This
study conﬁrmed the beneﬁcial effects of candesartan and the lack of ef-
fect of hydralazine. Cilazapril mimicked the candesartan effect, and this
was not attenuated by concomitant icatibant.
From a treatment perspective possibly even more interesting are
studies in which an ARB was administered several days or weeks after
the anti-Thy-1 injection. In one study a low telmisartan dose, a high
telmisartan dose and a hydrochlorothiazide+hydralazine combination
were started 4 days after disease induction; while the low telmisartan
dose did not lower BP, the high dose and the diuretic + hydralazine
dose lowered BP to a similar extent (Villa et al., 2011). All three treat-
ments reduced glomerular endothelial cell proliferation and glomerular
and interstitial matrix deposition on day 14; however, only the high
telmisartan dose reduced podocyte damage and tubular cell dedifferen-
tiation on day 9 and mesangial cell activation on day 14. In a follow-up
study from the samegroup, treatmentwith a low and a high telmisartan
dose, atenolol or a hydrochlorothiazide+hydralazine combinationwas
started 28 days after disease induction and maintained until day 131
(Villa et al., 2013). At study end, the high telmisartan dose but neither
atenolol nor the hydrochlorothiazide + hydralazine combination
prevented loss of renal function and reduced proteinuria compared to
control rats; moreover, only the high telmisartan dose ameliorated
glomerulosclerosis, tubulointerstitial damage, cortical matrix
deposition, podocyte damage and macrophage inﬁltration and reduced
cortical expression of platelet derived growth factor receptor-α and -β
as well as TGF-β1. The low telmisartan dose exhibited minor but
signiﬁcant efﬁcacy in the absence of antihypertensive effects. In another
study, valsartan given from weeks 2 to 8 after anti-Thy-1 injection
prevented glomerulosclerosis progression (Song et al., 2012). Taken
together these data demonstrate that both ARBs and ACE inhibitors
are renoprotective in the Thy-1 model of glomerulonephritis. Such pro-
tection is observed in preventive and treatment designs, even if treat-
ment started several weeks after disease induction. BP lowering does
not play a major role in renoprotection in this model as several classes
of anti-hypertensive drugs had only little beneﬁcial effect on renal
function.
In a rat model of IgA nephropathy induced by a combination of bo-
vine serum albumin, lipopolysaccharide and CCl4, a 10 week treatment
with losartan, telmisartan or rosiglitazone markedly improved protein-
uria, mesangial cell proliferation and inﬂammatory cell inﬁltration with
telmisartan having the quantitatively greatest effect (Xing et al., 2010).
In a mouse model anti-glomerular basement membrane nephritis, in-
duced by injection of a rabbit anti-serum against mouse glomerular
basement membrane, treatment with telmisartan but not with hydral-
azine suppressed glomerular damage (Hamano et al., 2011). Co-
administration of GW9662 attenuated the renoprotective effect of
telmisartan, and losartan only partly mimicked the telmisartan effect.
In ratswith passiveHeyman nephritis, a high losartan dose and enal-
april reduced proteinuria numerically to the same level, but thiswas dif-
ﬁcult to interpret as control group for the losartan treated rats exhibited
a very low proteinuria prior to treatment (Hutchinson & Webster,
1992). Within that study a lower losartan dose had the expected basal
proteinuria, and against this baseline level a reduction with losartan
was observed. In contrast to enalapril, both losartan doses increased
GFR in that study. Taken together these data show a renoprotective
ARB effect in animal models of primary renal disease which is indepen-
dent of BP lowering; some ARBs may have an additional PPAR-γ-
mediated component of renoprotection.7.2.3. Spontaneously hypertensive rat (SHR)
Some vascular beds exhibit a greater sensitivity to ANG-induced va-
soconstriction in SHR as compared to normotensive rats. Therefore, sev-
eral investigators have explored ARB effects on RBF. Isolated pre-
glomerularmicrovessels from SHR andWKY exhibited a similar density
of ANG binding sites, which largely consisted of AT1R in both strains
(Chatziantoniou & Arendshorst, 1993). Basal intracellular Ca2+ concen-
trations and candesartan-sensitive ANG-induced elevations thereof
were similar in smoothmuscle cells isolated frompreglomerular vessels
of WKY and SHR (Iversen & Arendshorst, 1999). In isolated afferent ar-
terioles ANG induced a stronger concentration-dependent vasoconstric-
tion in vessels from young, pre-hypertensive SHR as compared to age-
matched WKY; however, this strain difference was attributed to a loss
of AT2R-mediated vasodilatation in SHR and not to an increased
sensitivity of AT1R (Endo et al., 1998). In line with these observations,
ANG similarly reduced RBF in SHR and WKY in some studies
(Chatziantoniou & Arendshorst, 1993). However, in other studies an ex-
aggerated ANG-induced RBF reduction in SHR as compared to WKY
have been reported (Li &Widdop, 1996; Ruan et al., 1999); this was ob-
served either as a greater RBF reduction for a given ANG dose or as a
greater ANGpotency to cause a certain degree of RBF lowering. Irrespec-
tive ofwhether RBF reductionwas enhanced, inhibition of ANG-induced
reduction by ARBs was similar in both strains as shown for instance
with candesartan (Li & Widdop, 1996; Ruan et al., 1999) or losartan
(Chatziantoniou & Arendshorst, 1993). In the absence of exogenous
ANG, candesartan (Takishita et al., 1994; Li & Widdop, 1996; Inishi
et al., 1997), losartan (Kline& Liu, 1994; Li &Widdop, 1996), olmesartan
(Koike et al., 2001) and valsartan (Hayashi et al., 1997b) increased RBF
in SHR, which is in contrast to the equivocal RBF data in normotensive
rats (see Section 7.1.2). In direct comparative studies, the ARB-
induced RBF elevation was only seen in the hypertensive rats but not
normotensive rats (Li & Widdop, 1996). Within SHR, the ARB-induced
increase in perfusion was speciﬁc for the kidney as it was not observed
in several other tissues (Koike et al., 2001). Moreover, it occurred at BP-
lowering ARB doses, whereas a similarly BP lowering dose of
nicardipine reduced RBF (Takishita et al., 1994). In the absence of exog-
enous ANG, GFR was increased in SHR by candesartan (Inishi et al.,
1997) but not by losartan (Kline & Liu, 1994). These data demonstrate
that ARBs as a class increase RBF in SHR, and this does not occur as a con-
sequence of but rather despite BP lowering.
Other studies have explored ARB effects on tubular function in the
SHR. The activity of the tubuloglomerular feedback mechanisms, as
assessed by micropuncture and stop-ﬂow studies, was increased in 7-
week old SHR as compared to two different normotensive rat strains,
and this exaggerated response was normalized by treatment with
candesartan (Brännström & Arendshorst, 1999). Reports on ARB effects
on diuresis and natriuresis are inconsistent. Thus, acute exposure to a
BP-lowering dose of losartan did not affect urine ﬂow in SHR (Wong
et al., 1990d). At renal artery pressures between 130 and 175 mm Hg
losartan also failed to alter urine ﬂow or total or fractional sodium ex-
cretion, but sensitized the pressure-natriuresis mechanism (Kline &
Liu, 1994). Treatment with candesartan for up to two weeks caused
only minor and inconsistent enhancements of diuresis and natriureses
in SHR (Wada et al., 1996b). Treatment with a BP-lowering dose of
telmisartan for up to two weeks had only minor effects on diuresis
and natriuresis in SHR, but tended to enhance the diuretic effect of hy-
drochlorothiazide (Wienen & Schierok, 2001). Azilsartan did not alter
natriuresis relative to vehicle in normotensive rats or SHR but increased
it in the hypertensive/NIH-corpulent SHR/NDmcr-cp strain (Sueta et al.,
2013). Thus, ARBs as a class appear to have only minor effects on diure-
sis and natriuresis in SHR but may sensitize the pressure-natriuresis
mechanism; moreover, they may enhance the effects of concomitantly
administered diuretics.
Based on nephroprotective ﬁndings in animal models of primary
renal disease (see Section 7.2.2), it has been explored whether ARBs
also provide nephroprotection in SHR. Of note indicators of renal
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and older and typically are less pronounced than in the renal mass re-
duction models. In young SHR candesartan treatment starting before
the development of over hypertension did not affect the number or vol-
ume of glomerula (Kett et al., 1996). In 15 week old SHR, a 12 month
treatment with candesartan almost normalized urinary protein excre-
tion and histologically assessed glomerulosclerosis (Ishimitsu et al.,
2010). In 32 week old SHR, a 6 week treatment with olmesartan dose-
dependently attenuated proteinuria, interestingly to a considerably
greater extent than in DOCA-salt-treated rats (Koike et al., 2001). In 1
year old SHR, a 15-week treatment with telmisartan reduced glomeru-
lar volume whereas proteinuria and plasma and urine creatinine
concentrations were not affected to a major extent (Mandarim-de-
Lacerda & Pereira, 2004). A considerably larger reduction of renal albu-
min excretion was reported in another study in which 20 week old SHR
were treated with telmisartan for 16 weeks; glomerular extracellular
matrix was also reduced in that study (Zhu et al., 2012). Azilsartan
was reported to fully prevent development of proteinuria in spontane-
ously hypertensive obese rats alongwith a reduction in a glomerular in-
jury score (Hye Khan et al., 2014a). Of note the negative study reported
a much smaller urinary protein excretion in the control group than the
positive studies.
As nephropathy develops more slowly in SHR than in the reduced
renal mass models, several investigators have used SHR with aggravat-
ed hypertension; this includes the stroke-prone strain of SHR and SHR
with additional reduction of renal mass, treatment with cyclosporine
A or salt-loading (data on diabetes in SHR will be discussed in
Section 7.2.6). In one study stroke-prone SHR were treated with one
of three candesartan doses or with enalapril from weeks 22 to 32 and
at that point were compared to age-matched WKY rats (Kim et al.,
1994a, 1994c). The low candesartan dose did not reduce BP, the middle
dose reduced it to a similar extent as enalapril, and the high dose nor-
malized BP. Vehicle-treated stroke-prone SHR had a greater kidney
weight thanWKY rats, and all four treatments reduced renal weight, al-
though not reaching WKY levels. Candesartan dose-dependently re-
duced renal protein excretion; the lowest dose not lowering BP
already by about half, the middle dose similarly to enalapril, but even
the highest dose did not reduce it to WKY levels. All four treatments
prevented the rise in blood urea nitrogen and markedly reduced the
serum creatinine elevation. Moreover, all four treatments markedly re-
duced the strongly increased mRNA expression of TGF-β1, ﬁbronectin
and collagens I, III and IV. In a quantitative analysis of histological exam-
ination, the low candesartan dose was without effect on all parameters,
whereas the high dose reduced ﬁbrinoid necrosis of the glomerulus, tu-
bular atrophy, hypertrophy of the tubular basementmembrane, and hy-
pertrophy and ﬁbrinoid necrosis of the afferent arteriole; however,
none of the treatments affected interstitial ﬁbrosis. A follow-up study
from the same group using a similar design conﬁrmed that even a low
candesartan dose without BP effects markedly reduced proteinuria
after 10 weeks of treatment; however, when assessed 4 weeks after
start of treatment, a reduction of proteinuria was not longer detectable
for the low candesartan dosewhereas the two other doses and enalapril
exhibited a similar degree of proteinuria improvement as after
10 weeks of treatment (Inada et al., 1997). Other investigators
compared nephroprotection by candesartan with that by hydralazine,
applied at dose yielding similar BP lowering; under these conditions
candesartan exhibited a greater reduction of proteinuria and
glomerulosclerosis index (Nakamura et al., 1994b). A reduction in
urinary albumin excretion and TGF-β1 and ﬁbronectin mRNA
expression by candesartan but not by hydralazine was also reported in
another study in stroke-prone SHR (Obata et al., 1997). Other investiga-
tors treated 4 months old stroke-prone SHRwith losartan, two doses of
telmisartan or captopril for 38 days (Wagner et al., 1998). All four
treatments lowered BP, although observed to a much smaller exent
with the lower telmisartan dose; nevertheless, all four treatments
yielded a similar reduction in renal albumin excretion andglomerulosclerosis index. Taken together these ﬁndings consistently
demonstrate that ARBs and ACE inhibitors as a class provide
nephroprotection in stroke-prone SHR. These effects were also seen at
ARB doses providing limited or no BP lowering and theywere notmim-
icked by hydralazine, demonstrating that the nephroprotection in this
animal model occurs largely independent of BP lowering. However,
low ARB doses not lowering BP may require a longer treatment time
to achieve nephroprotection.
To achieve an even greater aggravation of hypertension, ARB effects
have also been tested in stroke-prone SHR which had additionally re-
ceived a high-salt diet or a high-salt, high-fat diet. In salt-loaded
stroke-prone SHR, treatment with valsartan or benazepril starting at
10.5 weeks of age lowered BP, prevented proteinuria, decreased the se-
verity of histopathological changes in the kidney and,most importantly,
prolonged survival (Webb et al., 1998a). In another study 10 week old
stroke-prone SHR received 2 weeks of a high-salt diet accompanied by
valsartan, hydralazine or no drug (Yoshida et al., 2011). Compared to
untreated WKY rats, stroke-prone SHR on a high-salt diet exhibited a
markedly increased tubuloinsterstitial injury score, which was strongly
reduced by valsartan but not by hydralazine. Other investigators put
stroke-prone SHR on a high-salt/high-fat diet for 2 weeks and then
added control or eprosartan treatment for up to 12 weeks (Barone
et al., 2001). While hypertensive rats on a normal diet exhibited only
a minor degree of proteinuria in this study, those on the high-salt/
high-fat diet had a higher BP and a much greater renal protein
excretion; eprosartan normalized this to levels observed in WKY. Im-
portantly, rats receiving control treatment started dying as early as
4 weeks after initiation of treatment and almost all died after 9–
12 weeks; in contrast, not a single rat died in the eprosartan group.
The reduction of proteinuria by eprosartan in stroke-prone rats on a
high-salt/high-fat diet was conﬁrmed in a study of similar design
(Abrahamsen et al., 2002). Additionally, this study reported that
eprosartan reduced body weight loss by the diet and the development
of renal hypertrophy, largely restored histologically observed renal
damage, and themarkedly elevated mRNA expression of TGF-β1, ﬁbro-
nectin and collagen I and III.
Candesartan has also been tested in SHR in which renal damage had
been aggravated by renal mass reduction surgery. In one such study,
12 week old SHR underwent a 5/6 nephrectomy and 1 week later
were randomized to receive candesartan, delapril, hydralazine or vehi-
cle for 4 weeks (Kohara et al., 1993). The three active treatments simi-
larly lowered BP but only the RAS inhibitors reduced proteinuria,
serum creatinine and histologically assessed glomerulosclerosis. How-
ever, all three treatments improved blood urea nitrogen and reduced
mortality. In another study, SHR underwent a 5/6 nephrectomy follow-
ed by a high-salt diet and treatmentwith candesartan or enalapril or no
treatment for 8 weeks (Kanno et al., 1994; Okada et al., 1995). Both RAS
inhibitors lowered BP, reduced proteinuria and improved histopatho-
logical changes. The immunosuppressant cyclosporine A elevates BP
and causes renal damage (Marcen, 2009). SHR aged 8–9 weeks were
placed on a combination of high-salt diet and cyclosporine A treatment
and additionally received treatment with enalapril or two doses of
valsartan or no treatment (Lassila et al., 2000b). All active treatments
prevented the cyclosporine A-induced BP increase and similarly
lowered urine volume, serum creatinine, proteinuria and histologically
determined glomerular damage index. A separate set of animals re-
ceived enalapril or an enalapril + icatibant combination, but addition
of the bradykinin receptor antagonist affected neither BP lowering nor
nephroprotection. In conclusion, RAS inhibition whether by ARBs or
ACE inhibitors provides nephroprotection in SHR, including those in
which hypertension and/or renal damage had been aggravated by vari-
ous approaches. Such nephroprotection occurs apparently largely inde-
pendent of BP lowering. Similar improvement of proteinuria has also
been reported in another genetic model of hypertension with renal dis-
ease, the Imai rat, upon treatment with olmesartan (Rodriguez-Iturbe
et al., 2004).
55M.C. Michel et al. / Pharmacology & Therapeutics 164 (2016) 1–817.2.4. Other hypertension models
Against the background of nephroprotective effects of RAS inhibition
in SHR, several other animal models of hypertension have also been
used to explore renal effects of ARBs. Acute infusion of ANG in healthy
rats had only minor effects on renal plasma ﬂow, GFR or ﬁltration frac-
tion but dose-dependently increased renal protein excretion in an
irbesartan-sensitive manner (Lapinski et al., 1996). Chronic ANG infu-
sion was reported to deteriorate renal autoregulatory capability in a
candesartan-sensitivemanner (Inscho et al., 1999). Moreover, a chronic
ANG infusion caused podocyte injury and markedly increased urinary
albumin excretion in rats which were mitigated by concomitant
telmisartan treatment (Ren et al., 2012). Chronic ANG infusion in mice
induced expression of various pro-inﬂammatory molecules in the tu-
bules in a telmisartan-sensitive manner (Kumar et al., 2010). Moreover,
a 5-day ANG infusion also caused renal ﬁbrosis, and this was attenuated
by valsartan in a dose where it only weakly mitigated the ANG-induced
BP elevation (Sakai et al., 2008). However, not only ANGbut also chronic
aldosterone administration caused nephropathy in rats, which was
characterized by enhanced urinary albumin excretion, that was attenu-
ated by telmisartan and eplerenone but not by amlodipine, despite the
latter causing the greatest BP reduction (Liang et al., 2011a). Aldoste-
rone administration also caused glomerulosclerosis and podocyte apo-
ptosis which were inhibited by telmisartan and amlodipine, although
to a smaller extent than by eplerenone.
Studies in animal models of renovascular hypertension have largely
focused on vascular, glomerular and tubular function in the 2-kidney-1-
clip Goldblatt model in rats and dogs. Acute treatment with losartan re-
duced renal vascular resistance in such rats with renovascular hyper-
tension; this effect was shared by enalapril but not by furosemide
(Wang et al., 1992). Others have acutely administered candesartan di-
rectly into the renal artery of the non-clipped kidney in a dose not af-
fecting systemic BP but sufﬁcient to suppress renal vasoconstricting
responses to ANG (Cervenka et al., 1999). At this dose, in the absence
of exogenous ANG, candesartan increased RBF, GFR and absolute and
fractional sodium excretion to a similar extent as in sham-operated nor-
motensive rats. A third study applied micropuncture to assess effects of
a 5 day treatment with losartan or captopril on glycine-induced
hyperﬁltration (De Nicola et al., 1992). In comparison to normotensive
control rats, renal hypertensionwas associatedwith a loss of renal func-
tional reserve and a decrease in absolute proximal reabsorption during
glycine administration. Losartan and captopril normalized systemic and
glomerular capillary pressure and prevented the glycine-induced de-
crease in proximal reabsorption, but only captoptil increased single
nephron GFR, suggesting involvement of AT1R-mediated and AT1R-
independent effects contributing to the captopril effect. Looking at
chronic effects, investigator have treated 2-kidney-1-clip rats with
telmisartan, the dipeptidylpeptidase IV inhibitor linagliptin or their
combination for 16 weeks (Chaykovska et al., 2013). Telmisartan
alone or in combination normalized BP and prevented development of
proteinuria in such animals, whereas linagliptin alone did not. Neither
treatment affected histologically determined glomerulosclerosis in the
clipped or the non-clipped kidney; telmisartan but not linagliptin or
the combination increased ﬁbrosis in the clipped kidney but none of
the treatments did so in the non-clipped kidney. In 2-kidney-1-clip
dogs an acute administration of candesartan or enalapril markedly
lowered BP but did not alter effective renal plasma ﬂow or GFR (Ito
et al., 1995). A 14 day treatment of 2-kidney-1-clip renal hypertensive
dogs with olmesartan also lowered BP andmoderately increased diure-
sis and natriuresis (Koike et al., 2001).
Dahl salt-sensitive rats on a high-salt diet are an interestingmodel to
study renal effects of ARBs as RAS activity is suppressed in these ani-
mals. Treatment of Dahl salt-sensitive rats on a high-salt, high-fat diet
with azilsartan, chlorthalidone or their combination for 26 days
(starting concomitantly with the diet) did not alter GFR, diuresis, natri-
uresis or kaliuresis but reduced proteinuria, renovascular and tubular
injury, glomerulosclerosis and renal ﬁbrosis (Jin et al., 2014). In mostcases, however, ARB treatment was started several weeks after initia-
tion of the high-salt diet. Under these conditions, a 4 week treatment
with candesartan or captopril similarly reduced glomerulosclerosis
score and urinary protein excretion in salt-loaded Dahl salt-sensitive
rats (Ideishi et al., 1994). In another study, candesartan and cilazapril
similarly reduced proteinuria and improved histologically determined
glomerulosclerosis despite little BP lowering (Otsuka et al., 1998). A
4 week treatment with irbesartan reduced glomerulosclerosis score,
proteinuria and renal mRNA expression of TGF-β, MCP-1 and collagen
I; none of these effects was mimicked by amlodipine, despite both
drugs yielding similar BP lowering (Takai et al., 2010). A 10 week treat-
ment with losartan had only little effect on BP but delayed the histolog-
ically determined occurrence of renal damage and concomitantly
increased survival (von Lutterotti et al., 1992). A 5-week treatment
with losartan or telmisartan similarly reduced tubular ﬁbrosis (Liang &
Leenen, 2008). In another study, telmisartan and hydralazine lowered
BP to a similar extent, but telmisartan reduced glomerular damage
and renal protein excretion considerably more than hydralazine
(Satoh et al., 2010a). Olmesartan treatment also reduced renal protein
excretion (Kiya et al., 2010). In a dose causing moderate BP lowering,
valsartan but not amlodipine reduced renal protein excretion but the
glomerulosclerosis score was not altered by either treatment (Aritomi
et al., 2010). Taken together, ARBs as a class and ACE inhibitors similarly
improved renalmorphology and function in Dahl salt-sensitive rats on a
high-salt diet. These effects were observed regardless of whether BP
lowering was observed and, in cases where BP lowering was seen,
were not shared by RAS-independent anti-hypertensive drugs.
A limited number of studies have also explored ARB effects in the rat
DOCA-salt model of hypertension. Treatment with candesartan or enal-
april did not affect BP but similarly reduced renal protein excretion and
mRNA expression of TGF-β, ﬁbronectin and several collagen isoforms;
upon histological examination this was accompanied by decreased epi-
thelial atrophy, basementmembrane hypertrophy and glomerularﬁbri-
noid necrosis (Kim et al., 1994b). A reduction of urinary protein
excretion and an improvement of renal histology in the absence of BP
changes were conﬁrmed in another study with candesartan treatment,
in which these effects were mimicked by enalapril (Wada et al., 1995).
An attenuated proteinuria in the absence of BP lowering in DOCA-salt
hypertensive rats was also reported with olmesartan (Koike et al.,
2001). Taken together these data further support the concept of
nephroprotection by ARBs as a class, which is shared with ACE inhibi-
tors and occurs independent of BP lowering.
In transgenic (mRen-2)27 rats acute treatment with candesartan or
captopril reversed the rightward-shift of the pressure natriuresis curve
typically observed in these animals (Gross et al., 1995). In this model a
9 week treatment with telmisartan dose-dependently reduced
glomerulosclerosis and albuminuria (Fig. 12); of note, the lowest
telmisartan already reduced albumin excretion by more than half de-
spite not lowering BP, whereas the highest dose had an even greater ef-
fect on albuminuria (Böhmet al., 1995). Other investigators conﬁrmed a
reduction of proteinuria with a BP-lowering dose of telmisartan and ex-
tended these ﬁndings to an amelioration of loss of adhesion, proximal
tubule basolateral remodeling and tubulo-interstitial ﬁbrosis (Whaley-
Connell et al., 2011). A third groupusedheterozygote rats transgenically
expressing the mouse Ren-2 gene, which resulted in a milder pheno-
type without major proteinuria; these were treated with valsartan,
bosentan or vehicle (Kelly et al., 2000). Despite having a markedly ele-
vated BP (reduced by both active treatments), these rats did not exhibit
major albuminuria; valsartan did not change this but bosentanmarked-
ly increased urinary albumin excretion. However, vehicle-treated rats
had an increased glomerulosclerosis index, which was reduced by
both active treatments – albeit to a greater extent by valsartan. In
congenic mRen-2.Lewis hypertensive rats monotherapy with valsartan
or aliskiren for 2 weeks lowered BP to a similar extent; neither mono-
therapy hadmajor effects on urinary protein excretion but combination
treatment lowered it by half (Moniwa et al., 2013). However, the
Fig. 12. Effects of telmisartan on BP, albuminuria and glomerulosclerosis in m(Ren-2)27
transgenic rats. Note that a dose not lowering BP already is effective, but a BP lowering
dose even more so. Data are means ± SD of 9–10 animals, except for BP; *: p b 0.05 vs.
control. Drawn based on data published by Böhm et al. (1995). Note that relative size of
error bar suggest that the underlying data on albuminuria and glomerulosclerosis index
are likely not to exhibit Gaussian distribution; hence, medians with conﬁdence intervals
may have been more appropriate for description but means have been reported in the
underlying paper.
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periglomerular ﬁbrosis, disorganized tubular proliferation, and tubular
dilatation/atrophy; many congestive, enlarged glomeruli with
aneurysmatic capillary dilatations aswell as somenonperfused (sclerot-
ic) glomeruli were also observed in this group. The authors interpreted
this as a renal homeostatic stress response attributable to loss of
tubuloglomerular feedback upon combined AT1R blockade and renin
inhibition. In double-transgenic rats harboring both the human reninand angiotensinogen genes, valsartan, cilazapril or the human renin in-
hibitor, RO 65-7219, prevented the development of albuminuria
(Mervaala et al., 1999). While only the ARB and the ACE inhibitor
lowered BP, all three treatments similarly prevented monocyte/
macrophage inﬁltration and the renal overexpression of adhesion
molecules, plasminogen activator inhibitor-1, and ﬁbronectin.
Taken together these data conﬁrm the role of ARBs and ACE inhib-
itors as nephroprotective agents and extend them to additional
animal models; however, they also raise the possibility that dual
RAS inhibition may have adverse effects, but it remains unclear
whether this a speciﬁc feature of mRen-2.Lewis rats or also applies
to other models.
ARB effects on renal function have also been explored upon absence
or inhibition of one or more isoforms of NO synthase. Endothelial NO
synthase knock-out mice with additional cuff injury of the femoral ar-
tery developed prominent glomerulosclerosis and glomerular macro-
phage inﬁltration along with increased urinary albumin excretion as
compared to wild-type mice (Yamamoto et al., 2009a). These parame-
ters were not affected by treatment with hydralazine but similarly im-
proved by treatment with valsartan or aliskiren and even more so by
combination of the two RAS inhibitors. A more frequently applied
model is the inhibition of all NO synthases by treatment with L-NAME,
typically applied to rats. Acute administration of L-NAME markedly re-
duced RBF in anesthetized and conscious rats; concomitant losartan
treatment abolished this RBF reduction in anesthetized but not in con-
scious animals (Sigmon & Beierwaltes, 1993a). Chronic administration
of L-NAME leads to damage of pre-glomerular vessels, a reduced RBF
andGFR, a right-shifted pressure-natriuresis curve and an increased uri-
nary albumin excretion. Treatment with ARBs including candesartan,
losartan and olmesartan reduced vascular damage (Casellas et al.,
1999), RBF and GFR reduction (Ribeiro et al., 1992; Fortepiani et al.,
1999; Moningka et al., 2012), a right-shifted pressure-natriuresis
curve (Fortepiani et al., 1999), glomerular damage (Ribeiro et al.,
1992; Okamura et al., 1994; Moningka et al., 2012), and attenuated
albumin excretion (Okamura et al., 1994; Casellas et al., 1999;
Moningka et al., 2012). In direct comparative studies, candesartan was
more effective than hydralazine for protection of pre-glomerular vessels
while both similarly lowered BP and albumin excretion (Casellas et al.,
1999).While candesartan, captopril and the Ca2+ entry blocker verapa-
mil similarly lowered BP and improved renal hemodynamics, neither
normalized pressure-natriuresis (Fortepiani et al., 1999). Olmersartan,
the atypical β-blocker nebivolol and their combination similarly im-
proved GFR and normalized BP and urinary protein excretion
(Moningka et al., 2012). These data demonstrate that in NO synthase in-
hibition models ARBs and other RAS inhibitors similarly improve renal
function and morphology; these effects are partly but not fully shared
by other BP lowering treatments. The beneﬁcial renal effects of an
ARB were maintained when a high-salt diet was given in addition to L-
NAME treatment (Okamura et al., 1994). Taken together, the studies
in this section consistently support a role of the RAS in hypertensive
nephropathy.
7.2.5. Ureteral obstruction
Obstruction of the ureter imposes retrograde pressure in kidney
which may lead to renal damage, speciﬁcally ﬁbrosis. As renal dysfunc-
tion secondary to ureteral obstruction is likely to have a very different
pathophysiology than other models of renal disease, it is an interesting
extension to studies of potential renoprotective effects of ARBs. Studies
in this area are typically based on unilateral obstruction, which allows
using the contra-lateral kidney as internal control. The damage imposed
by such obstruction can be detected by proxy parameters as early as 12
hours after obstruction (Moriyama et al., 1997), but most studies have
applied treatment phases of several days or weeks.
Some studies have focused on the effects of ureteral obstruction on
the intrarenal vasculature. To better observe vascular effects of RAS in-
hibition, an early study has pre-treated rats with either losartan or
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for 1 day and thenmeasured renovascular function 3 hours after release
of the obstruction (Pimentel et al., 1993). The obstructed as compared to
the contra-lateral kidney exhibitedmarked reductions in GFR and renal
plasmaﬂowwhichwere attenuated but not restored to control levels by
either RAS inhibitor in a dose lowering systemic BP. Based on increased
mRNA expression of renin and ACE in the vasculature of the obstructed
kidney, these changes in renal hemodynamics were interpreted as
reﬂecting at least partly inhibition of the local RAS. Both drugs also in-
creased diuresis, natriuresis and kaliuresis from the obstructed kidney.
An increase in renal levels of ACE and ANG was also reported in a
study following obstructed animals for up to 5 weeks; in that model
losartan also lowered the elevated BP (El-Dahr et al., 1993). Another
study explored acute effects of candesartan in comparison to
manidipine two months after surgically induced hydronephrosis in
stroke-prone SHR (Kimura et al., 1994). In this model both drugs re-
duced BP and dilated the afferent and efferent arterioles, thereby in-
creasing glomerular blood ﬂow.
Other investigations focused on the renal ﬁbrosis occurring second-
ary to ureteral obstruction. In mice, a 7-day treatment with telmisartan
(Sugiyama et al., 2005) or a 28-day treatment with valsartan markedly
reduced renal ﬁbrosis in the obstructed kidney (Sakai et al., 2008). In
rats, candesartan and lisinopril similarly ameliorated the ﬁbrotic chang-
es observed in the renal interstitium 7 days after the obstruction; this
accompanied by reduced mRNA expression of type I collagen and the
collagen-speciﬁc molecular chaperone HSP47 (Moriyama et al., 1997).
In another study the effects of valsartan, aliskiren and their combination
were tested 7 and 14 days after induction of the obstruction, using drug
doses which yielded similar small reductions of BP (Wu et al., 2010).
Both drugs similarly attenuated the increase in tubular dilatation, inter-
stitial volume, α-smooth muscle actin expression and interstitial colla-
gen deposition. For all of these parameters the combination was more
effective than either drug alone, but still failed to inhibit more than
half of the obstruction-induced increase. Of note, the renal damage
caused by ureteral obstruction did not induce proteinuria. In contrast,
proteinuria was observed in a mouse model of ureteral obstruction,
and this was ameliorated by telmisartan treatment starting 5 days
prior to ureteral ligation; renal ﬁbrosis was also reduced in this model
(Wong et al., 2014).
Taken together, ureteral obstruction leads to activation of the renal
tissue RAS. BP-lowering doses of RAS inhibitors as a class and perhaps
also RAS-independent BP lowering drugs can attenuate the renovascu-
lar changes and ﬁbrosis in the obstructed kidney but fail to restore
normal renal function and morphology, even when applied prior to
obstruction. In AT1R knock-out mice with hydronephrosis induced by
unilateral ureteral obstruction telmisartan reduced renal ﬁbrosis, glo-
merular and tubulointerstitial injury, and area staining positive formac-
rophages,myoﬁbroblasts or TGF-β1 as observed 14 days after induction
of the obstruction (Kusunoki et al., 2012). For all of these parameters
losartan exhibited smaller effects or even a lack of effect; moreover,
the effects of telmisartan were blocked by GW 9662. Presence of hepa-
tocyte growth factor in the obstructed kidney and in serum was in-
creased by telmisartan but not by losartan or by obstruction alone, an
effect also prevented by GW 9662; this appears of interest as an anti-
body against hepatocyte growth factor similarly to GW 9662 prevented
all beneﬁcial effects of telmisartan in the obstructed kidney. These data
support the idea that some ARBs may improve renal morphology and
function in the ureteral obstruction model beyond the beneﬁt derived
from RAS inhibition.
7.2.6. Diabetes mellitus and obesity
7.2.6.1. Studies in lean diabetic animals. RAS inhibitors are established
agents to prevent or ameliorate renal damage caused by long-standing
diabetes mellitus. Correspondingly, many studies have assessed
nephroprotective effects of ARBs, alone or in combination with otherdrugs, in variety of animal models of type 1 and type 2 diabetes.
Among models of type 1 diabetes, rats and mice treated with STZ have
been used most often to explore nephroprotective effects of ARBs. Of
note, this is amodel inwhichARBs typically have little effect on blood glu-
cose (see Section 6.3.2), indicating that observed nephroprotective effects
are not related to an anti-diabetic action per se. Thus, ARBs as a class con-
sistently reduced proteinuria in the STZ model of type 1 diabetes as ob-
served for instance with candesartan (Kato et al., 1999), irbesartan
(Bonnet et al., 2001; Cao et al., 2001), telmisartan (Singh et al., 2006;
Satoh et al., 2010b; Mudagal et al., 2011; Rao et al., 2011; Bishnoi et al.,
2012; Zhang et al., 2012; Tojo et al., 2015), or valsartan (Allen et al.,
1997; Remuzzi et al., 1998; Kelly et al., 2000; Chen et al., 2008; Tang
et al., 2012). Of note, several of these studies have been performed
under condition of aggravated renal damage, for instance with STZ appli-
cation to hypertensive rat strains such as SHR (Bonnet et al., 2001; Cao
et al., 2001; Wienen et al., 2001), MWF rats (Remuzzi et al., 1998) or
transgenic (mRen-2)27 rats (Kelly et al., 2000) or following 5/6 nephrec-
tomy (Chen et al., 2008). One study provided evidence that an ARB may
also suppress renal gluconeogenesis in a rat STZmodel (Tojo et al., 2015).
In line with the clinical data, several studies have demonstrated a
similar extent of nephroprotection by an ARB and an ACE inhibitor, for
example candesartan vs. enalapril (Kato et al., 1999), telmisartan vs.
benazepril (Singh et al., 2006), telmisartan vs. Lisinopril, valsartan vs.
benazepril (Remuzzi et al., 1998) or valsartan vs. ramipril (Allen et al.,
1997). However, in few studies the ARB has been reported to more ef-
fectively reduce proteinuria than the ACE inhibitor, for instance with
irbesartan vs. captopril (Cao et al., 2001). Some studies have also ex-
plored the effect of combination treatments on proteinuria. In a study
in which both telmisartan and trandolapril rduced proteinuria, their
combination was even more effective (Rao et al., 2011). In contrast, in
a study where captopril monotherapy lacked effect, the combination
of irbesartan and captopril did not reduce albuminuria to a greater ex-
tent than irbesartan alone (Cao et al., 2001). Other studies in which
combination treatment provided greater nephroprotection than ARB
monotherapy included studies with telmisartan combined with
fenoﬁbrate (Bishnoi et al., 2012), with aspirin (Mulay et al., 2010), or
with atorvastatin (Mudagal et al., 2011).
While the above studies show a class effect of ARBs for reduction of
proteinuria in rat models of STZ-induced diabetes, studies on other pa-
rameters of renal damage have yielded less consistent results. Thus, a
reduction of serum concentrations of urea was reported in some
(Singh et al., 2006; Bishnoi et al., 2012; Zhang et al., 2012) but not
other studies (Mulay et al., 2010; Satoh et al., 2010b). Similarly, a re-
duced serum creatinine was found in some (Mudagal et al., 2011;
Bishnoi et al., 2012; Zhang et al., 2012; Tang et al., 2012) but not other
studies (Wienen et al., 2001; Mulay et al., 2010; Satoh et al., 2010b;
Mudagal et al., 2011). Effects on GFRwere also inconsistent across stud-
ies (Remuzzi et al., 1998; Kelly et al., 2000;Wienen et al., 2001; Onozato
et al., 2008; Satoh et al., 2010b; Zhang et al., 2012; Tojo et al., 2015).
While a lack of alteration in the diabetic as compared to the control
group may explain a lack of ARB treatment in some instances, we
have not identiﬁed a general reason for the lack of consistency in this re-
gard. Differences in glucose levels in the STZ model between labs and
between animals may have contributed to these inconsistent ﬁndings.
ARBs were also reported to reduce histologically observed glomeru-
lar and tubular damage in the rat STZ model of type 1 diabetes, for in-
stance with irbesartan (Cao et al., 2001), telmisartan (Singh et al.,
2006; Satoh et al., 2010b; Mudagal et al., 2011) or valsartan (Allen
et al., 1997; Remuzzi et al., 1998; Kelly et al., 2000; Tang et al., 2012).
Other reported ARB effects in this model include a reduction of elevated
renal lipid peroxides and increase of lowered superoxide dismutase and
reduced glutathione (Hamed & Malek, 2007; Bishnoi et al., 2012) and a
reduction of the endogenous inhibitor of NO synthase, asymmetric
dimethyl-arginine, and concomitant increase in renal NOmetabolite ex-
cretion (Onozato et al., 2008). In an array study 1541 genes were found
to be differentially expressed upon telmisartan treatment, including
Fig. 13. Effects of an ARB (olmesartan), a Ca2+-entry blocker (nifedipine) and a β-
adrenoceptor antagonist (atenolol) on blood pressure and proteinuria in a model of
spontaneously developing obesity and type 2 diabetes. Spontaneously hypertensive/
NIH-corpulent (SHR/NDmcr-cp) rats aged 13 weeks were treated with olmesartan,
nifedipine or atenolol for 20 weeks. Data are means ± SD of 10 animals. Calculated and
drawn based on published data (Izuhara et al., 2005).
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2012). While the latter set of genes may be speciﬁcally regulated by
ARBswith knownPPAR-γ agonism, in linewith the array studies several
ARBs were found to normalize the expression of mRNA expression of
HIF-1α, tissue inhibitor of metalloproteinase-1 and endothelin-1
(Tang et al., 2012) or the inﬂammation markers NFκB, TNF-α, TGF-β
and cyclooxygenase-2 (Kato et al., 1999; Kelly et al., 2000; Cao et al.,
2001; Chen et al., 2008; Mulay et al., 2010; Huang et al., 2011; Rao
et al., 2011) or the ﬁbrosis marker ﬁbronectin (Rao et al., 2011).
The STZmodel of type diabetes has also been applied to mice. In line
with the ﬁndings in rats, telmisartan reduced proteinuria along with a
normalization of the renal expression of protein kinase C-α, TGF-β1
and vascular endothelial growth factor (Yao et al., 2007). Others report-
ed that telmisartan inhibited renal ﬁbrosis along with normalization of
the expression of TGF-β1 and collagen III (Lakshmanan et al., 2011). A
reduction in proteinuria by telmisartan was conﬁrmed by others in
STZ-treated mice alongwith a reduction in serum creatinine, mesangial
expansion and ﬁbronectin and collagen III and IV deposition; all of these
effectswere similarly observedwith enalapril treatment, indicating that
they represent class effects of RAS inhibition (Kosugi et al., 2010). Com-
parable ﬁndings have been obtained within that study when the exper-
imentswere performed in endothelial NO synthase knock-outmice, and
a reduction in proteinuria in such knock-out mice was conﬁrmed in
later studies alongwith a reduced glomerulosclerosis, tubular apoptosis
and collagen disposition and parenchymal macrophage inﬁltration
(Komala et al., 2014). Others reported in STZ-treated knock-out mice
that the proteinuria was numerically reduced by about 40% by a low
telmisartan dose not affecting BP; however, the reduction of proteinuria
only reached statistical signiﬁcance when a combination of telmisartan
and the dipeptidylpeptidase inhibitor linagliptin was administed which
attenuated proteinuria by about 60% (Alter et al., 2012; Ott et al., 2012).
In the Akita mouse model of spontaneously occurring non-obese
insulin-dependent diabetes, telmisartan lowered proteinuria and TGF-
β and VEGF expression but did not affect glomerulosclerosis
(Koshizaka et al., 2012). The reduction in proteinuria was conﬁrmed
by other investigators, but this was not mimicked by amlodipine treat-
ment (Fujita et al., 2012). In thatmodel telmisartan, but not amlodipine,
reduced the elevated GFR but not a mesangial expansion score. Thus,
ARB effects on proteinuria in rat and mouse models of type 1 diabetes
may be shared features of RAS inhibitors but apparently do not occur
secondary to BP lowering.
7.2.6.2. Studies in obese animals with and without diabetes. Effective low-
ering of blood glucose can at least partly prevent diabetic nephropathy,
for instance with sulfonylureas or thiazolidinediones in db/db mice
(Tong et al., 2015). In contrast, ARBs have only small and inconsistent
effects on blood glucose or insulin levels in animal models of obesity
and type 2 diabetes (see Section 6.3.3). Potential nephroprotective ef-
fects of ARBs have also been explored in rodent models of obesity
with and without concomitant type 2 diabetes. In rats receiving a
high-fat, high-carbohydrate diet in combination with an STZ injection,
telmisartan reduced albuminuria and blood urea nitrogen and creati-
nine (Wu et al., 2013). In spontaneously hypertensive/NIH-corpulent
(SHR/NDmcr-cp) rats olmesartan, nifedipine and atenolol similarly nor-
malized BP but only olmesartan reduced proteinuria (from139.1 to 63.4
mg/d as compared to 8.6 mg/d in Wistar Kyoto rats) and a histology-
based glomerular damage score (Izuhara et al., 2005) (Fig. 13). In a
later study from the same group seven doses of valsartan have been
tested during an 8-week treatment (Tominaga et al., 2009). While a re-
duction in proteinuria was already detectable at the lowest dose of 4
mg/kg/d, the reductions became dose-dependently greater reaching a
maximum at 160 mg/kg/d. The same was true for BP reductions, and
there was tight correlation between systolic BP and urinary protein
level across the eight treatment groups, except that low valsartan
doses had proportionally greater effects on proteinuria than on systolic
BP (Fig. 14). A reduction of proteinuria was also shown for telmisartanbut not hydralazine in SHRSP.Z-Leprfa/IzmDmcr rats, whichwas accom-
panied by reduced glomerulosclerosis and interstitial ﬁbrosis
(Sugiyama et al., 2013). Otsuka-Long–Evans-Tokushima-Fatty rats are
anothermodel of spontaneously developing type 2 diabetes. In such an-
imals both telmisartan and the mineralocorticoid receptor antagonist
eplerenone similarly reduced the proteinuria developing over a
52 week period, and their combination brought it to levels observed in
a non-diabetic control strain (Nishiyama et al., 2010). As the combina-
tion did not lower BP more than either monotherapy, this
nephroprotective effect was apparently BP-independent. The idea of a
BP-independent effect was further supported by the observation that
both monotherapies and their combination similarly reduced
glomerulosclerosis, an effect not observed with hydralazine treatment.
Several studies have used another model of obesity and type 2 diabetes,
Zucker diabetic fatty rats. In these rats treatment with an ARB including
azilsartan (Hye Khan et al., 2014b), candesartan (Ecelbarger et al.,
2010), olmesartan (Koike et al., 2001; Pugsley, 2005) or telmisartan
Fig. 14. Reduction of systolic BP and urinary protein excretion in spontaneously
hypertensive/NIH-corpulent (SHR/NDmcr-cp) rats after 8 weeks of treatment. The
upper panel shows dose-dependency for both effects (proteinuria in mg/day, open
circles, left y-axis; systolic blood pressure in mm Hg, ﬁlled circles, right y-axis). The
lower panel shows the correlation between both parameters. Data are mean ± SD of 8
rats per group. Drawn based on data published by Tominaga et al. (2009)).
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irbesartan did not conﬁrm this (O'Donnell et al., 1997). In some of the
studies in this repeatedly used model beneﬁcial ARB effects were also
reported for other parameters of nephroprotection including serumcre-
atinine (Ecelbarger et al., 2010), glomerulosclerosis (O'Donnell et al.,
1997; Pugsley, 2005; Ohmura et al., 2012; Hye Khan et al., 2014b), tubu-
lar injury (O'Donnell et al., 1997; Koike et al., 2001; Pugsley, 2005;
Ohmura et al., 2012), renal ﬁbrosis (Ecelbarger et al., 2010; Ohmura
et al., 2012), inﬂammatory cytokines such as IL-1, IL-2, IL-4 IL-6, IL-10,
IL-18, TNF-α, TGF-β1 and MCP-1 (Ecelbarger et al., 2010). One of
these studies also included multiple telmisartan doses and a single
dose of enalapril; the two drug classes had comparable effects but the
chosen enalapril dose for most parameters including proteinuria was
weaker than than highest ARB dose (10 vs. 10 mg/kg/day) (Ohmura
et al., 2012). In Imai hyperlipidemic rats losartan and enalapril similarly
reduced proteinuria and glomerulosclerosis (SAkemi & Baba, 1993).
Similar data have been reported from mouse models of hereditary
obesity and type 2 diabetes. In db/db mice valsartan and aliskiren simi-
larly reduced proteinuria, but their combination had even greater ef-
fects; all three treatments also reduced mesangial matrix expression,
macrophage inﬁltration, proliferation, collagen disposition and TGF-β1
expression (Dong et al., 2010). Others have conﬁrmed the reduction of
proteinuria in db/db mice upon valsartan treatment (Gao et al., 2010).
In another study in db/db mice, treatment with the experimental
ACE2 inhibitor MLN-4760 increased proteinuria, and such increase
was prevented by concomitant telmisartan treatment; the effect of
ARB monotherapy was not reported in this study (Ye et al., 2006). In a
cross-over study, telmisartan and captopril similarly improved protein-
uria in db/db mice (Wysocki et al., 2013). In KK/Ta mice candesartan
similarly prevented albuminuria and lowered nitro-oxidative stress
whether treatment was started at an age of 6 or 12 weeks (Fan et al.,
2004).Among rodent models of acquired obesity a high-fat diet has been
used repeatedly to explore ARB effects on nephropathy. In one study,
normotensive rats or SHR on a high-fat diet did not exhibit major alter-
ations of urinary protein excretion or creatinine clearance; candesartan
treatmentwas reported to lower protein excretion in normotensive but
not hypertensive rats and did not affect GFR (Chung et al., 2010). Others
reported that a high-fat diet increased proteinuria in SHR, but that
telmisartan and valsartan lowered protein by a similarmargin irrespec-
tive of the rats being on a normal or high-fat diet (Khan & Imig, 2011).
The combined treatment of rats with nicotinamide and STZ is another
model of acquired type 2 diabetes. In this model treatment with
telmisartan lowered fasting blood glucose to a comparable extent as
either a metformin/pioglitazone/glimepiride combination or the
dipeptidylpeptidase IV inhibitor vildagliptin, and the telmisartan
vildagliptin combination exhibited the numerically largest glucose re-
duction; all four treatments lowered urinary albumin excretion, serum
creatinine and blood urea nitrogen and improved glomerulosclerosis
and interstitial ﬁbrosis (Sharma et al., 2014). Others used the nicotin-
amide + STZ model with additional unilateral nephrectomy, followed
by 2 week treatment with telmisartan or pioglitazone and then induc-
tion of ischemia/reperfusion injury in the remaining kidney and
follow-up for another 2 weeks (Tawﬁk, 2012). In samples obtained
24 h after the ischemia/reperfusion injury both treatments markedly
lowered glucose, creatinine and urea and ameliorated the histologically
assessed injury.
In conclusion ARBs as a class, probably to a similar extent as ACE in-
hibitors, prevent development or even reduce renal damage in a wide
variety of rodentmodels of diabetic nephropathy. This occurs largely in-
dependent of anti-diabetic or BP lowering effects. Accordingly, the
chance of reversal of albuminuria by an ARB was greater than by an
RAS-unrelated antihypertensive agent in clinical studies (Viberti &
Wheeldon, 2002).
7.2.7. Other models of impaired renal function
Potential nephroprotective effects of ARBs have also been explored
in multiple other models of renal disease, but within each of these
models only to a limited extent. Some of thesemodels related to pathol-
ogies in the cardiovascular system. For instance, in a rat model of con-
gestive heart failure with volume overload induced by creation of an
aorto-caval ﬁstula infusion of eprosartan reduced renovascular resis-
tance and increased RBF and GFR (Brodsky et al., 1998). Several groups
have explored ARB effects on ischemia/reperfusion injury in the kidney.
A 7-day pre-treatment of rats with a low dose of telmisartan attenuated
the ischemia/reperfusion injury-induced increases in blood urea nitro-
gen, serum creatinine, renal malondialdehyde, TNF-α, nitric oxide,
caspase-3 activity, and serum and renal homocysteine levels (Fouad
et al., 2010). Others reported that pre-treatment with fenoﬁbrate
prevented the ischemia/reperfusion injury-induced increase in serum
creatinine and attenuated that of serum urea; addition of telmisartan
to the pre-treatment did not further alter creatinine but led to normal-
ization of serum urea and homocysteine (Bhalodia et al., 2010). Within
that study, such experiments were also performed in rats on a high-
cholesterol diet, and also under these conditions addition of telmisartan
further improved the renoprotective effect of fenoﬁbrate. Others have
evaluated the effect of pre-treatment with telmisartan or pioglitazone
on renal ischemia/reperfusion injury in a ratmodel of type 2 diabetes in-
duced by a combination of nicotinamide + STZ, in which animals had
undergone unilateral nephrectomy prior to any treatment (Tawﬁk,
2012). Both treatments similarly prevented the increase in serum creat-
inine and urea and renal TNF-α levels. In a model of chronic renal allo-
graft failure bilaterally nephrectomized Lewis rats were transplanted
with a single kidney from Fisher 334 rats (Mackenzie et al., 1997). In
thismodel treatmentwith candesartan normalized glomerular capillary
pressure and reduced proteinuria and allograft glomerulosclerosis.
Another group of studies has explored protective effects of ARBs in
models of renal damage induced by anti-cancer chemotherapeutics or
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oral losartan treatment for 15 days starting concomitant with the injec-
tion dose-dependently lowered proteinuria and at the highest dose
prevented the increase in blood urea nitrogen (Yayama et al., 1993).
Beneﬁcial effects against puromycin injection-induced renal damage
in rats was also reported with irbesartan which exhibited a similar
degree of nephroprotection as enalapril (Zhou et al., 2012). Similarly,
in rats treated with daunorubicin a 6-week treatment with telmisartan
attenuated proteinuria, scores of histologically observed glomerular
congestion, tubular necrosis and renal ﬁbrosis and the increase in
serum creatinine and urea; furthermore, telmisartan treatment de-
creased the renal levels of ANG and AT1R but increased that of PPAR-γ
(Arozal et al., 2011). Importantly, 6 out of 12 daunorubicin-treated
rats died during the study, whereas no deaths were observed in the
12 rats receiving daunorubicin + telmisartan. In a rat model of
adriamycin-induced nephropathy, telmisartan reduced proteinuria,
glomerulosclerosis and podocyte apoptosis, and even more so when
combinedwith oxacalcitriol (Jeong et al., 2015). In a study not involving
an ARB, the PPAR-γ agonist pioglitazone provided a similar degree of
protection against adriamycin-induced renal damage as ramipril
(Ochodnicky et al., 2014), suggesting that both RAS inhibition and
PPAR-γ agonism may contribute to a beneﬁcial effect. Telmisartan at-
tenuated the increase in doxorubicin-induced increase in plasma creat-
inine and blood urea nitogen (Rashikh et al., 2014). In a rat model
telmisartan also attenuated cisplatin-induced nephropathy, as assessed
by serum creatinine and blood urea nitrogen, a tubular injury score
and tubular apoptosis (Maoik et al., 2015). In a rat model of
bromoethylamine-induced papillary necrosis, among irbesartan, enala-
pril, diltiazem and a cocktail of hydralazine, reserpine and hydrochloro-
thiazide in doses yielding similar BP lowering the two RAS inhibitors
reduced albuminuria whereas the two RAS-independent treatments
did not; attenuation of the decrease in creatinine clearance was ob-
served with enalapril but not irbesartan (Garber et al., 2001). Ochratox-
in A reduces GFR and renal plasma ﬂow in rats, and this was markedly
attenuated by pretreatment with losartan or enalapril (Gekle &
Silbernagl, 1993). To explore beneﬁcial ARB effects against renal dam-
age induced by X-ray contrast media, rats received a glycerine injection
follow by oral telmisartan and concomitantly an i.v. injection of a high
and a low osmolar contrast agent, diatrizoate and iohexol, respectively;
telmisartan prevented observed increases in serum creatinine, renal
ANG levels and caspase-3 activity (Duan et al., 2009). Finally, in a
mouse model of cadmium-induced nephrotoxicity pre-treatment with
telmisartan attenuated the increase in blood urea nitrogen and serum
creatinine and histologically assessed renal damage (Fouad & Jresat,
2011).
Taken together these data demonstrate that ARBs as a class provide
nephroprotection in a wide range of rodent models. A reduction in pro-
teinuria has also been reported in dogs upon telmisartan treatment
(Bugbee et al., 2014), indicating that it may apply to non-rodent species
aswell. Inmost cases such nephroprotectionwas similar to that provid-
ed by other RAS inhibitors but typically was not mimicked by agents
lowering BP independent of the RAS.
8. Conclusions
ARBs as a class are effective in the prevention of hypertension and in
reducing BP in established HT across a wide range of animal models
representing various types of underlying pathophysiology, except
those with a markedly suppressed RAS activity. They exhibit beneﬁcial
effects on possible sequelae of long-standing hypertension, which
typically exceed those exhibited by RAS-independent types of anti-
hypertensive medication. This includes effects on atherosclerosis,
cardiac and renal function. Such beneﬁcial effects were reported in pre-
ventive and treatment settings. They were often observed in doses
lower than those yielding appreciable BP lowering. Moreover, they
also were observed in vascular, cardiac and renal pathologies in non-hypertensivemodels, emphasizing an at least partly BP-independent ef-
fect that very often is shared by other types of RAS inhibitors.
ARBs typically have little effect on basal glucose and insulin levels,
particularly in lean animals, but nonetheless often (but not consistently)
improve glucose and insulin sensitivity, particularly in obese animals
and/or models of type 2 diabetes. Similarly, reports on lowering of tri-
glycerides and cholesterol were largely limited to rodents with obesity
and/or type 2 diabetes, and even within that group reported only incon-
sistently. However, ARBswere quite consistently reported to reduce liver
weight in animal models where that was increased and to reduce
adipose tissue mass, features also not shared by RAS-independent BP-
lowering drugs.
ARBs exhibiting additional properties including PPAR-γ partial
agonism such as telmisartan may mediate some of their effects at least
partly via this mechanism. However, AT1R antagonism and PPAR-γ
agonism inmost casesmodulate a given phenotype into the same direc-
tion, which makes it difﬁcult to interpret the relative importance of the
two pathways. This is particularly true when ARBs not exhibiting addi-
tional molecular targets and studied for comparison were administered
in doses not yielding maximum AT1R blockade. Therefore, the clinical
relevance of additional properties of some ARBs remains to be deter-
mined in dedicated clinical studies.
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